{
    "000004.SZ": {
        "short_name": "SHENZHEN GUOHUA NE",
        "long_name": "Shenzhen GuoHua Network Security Technology Co., Ltd.",
        "summary": "Shenzhen GuoHua Network Security Technology Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products in China. It offers products in the areas of cardiovascular, anti-infective, tumor immunity, nerve/analgesic, API, and gastrointestinal/reproductive. The company also provides clindamycin phosphate, adenosine triphosphate magnesium chloride, diisopropylamine dichloroacetate, cyclophosphamide, cytidine triphosphate disodium, urokinase, and other injection products. In addition, it engages in the development and sale of real estate properties, as well as housing property management activities. The company was formerly known as Shenzhen Cau Technology Co., Ltd and changed its name to Shenzhen GuoHua Network Security Technology Co., Ltd. in November 2020. Shenzhen GuoHua Network Security Technology Co., Ltd., was founded in 1990 and is based in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Shenzhen"
    },
    "000504.SZ": {
        "short_name": "NANHUA BIO-MEDICIN",
        "long_name": "NanHua Bio-medicine Co., Ltd",
        "summary": "NanHua Bio-medicine Co., Ltd. provides stem and immune cell storage, noninvasive genetic testing, and biological research and technical services. The company is based in Changsha, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Changsha"
    },
    "000518.SZ": {
        "short_name": "JIANGSU SIHUAN BIO",
        "long_name": "Jiangsu Sihuan Bioengineering Co., Ltd",
        "summary": "Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Jiangyin"
    },
    "000710.SZ": {
        "short_name": "BERRY GENOMICS CO",
        "long_name": "Berry Genomics Co.,Ltd",
        "summary": "Berry Genomics Co.,Ltd, a genomics company, develops and commercializes technologies for life sciences and clinical applications in China. The company offers sequencing-based genetic tests for genetic disease and cancer from preconception to adulthood. Its products include fetal chromosome aneuploidy detection kits; pre-implantation chromosome copy number anomaly detection kits; chromosome copy number variation detection kits; CSMART tumor gene mutation detection kit 1; BRCA 1/2, PTEN, and TP53 gene mutation detection kits; BRCA1/2 whole exon gene mutation detection sampling boxes; motor neuron survival gene 1 exon deletion detection kits; FMR1 gene regulatory region CGG repeat number detection kits; DNA preparation systems; and NextSeq CN500 sequencing supplies. The company also provides fetal chromosome aneuploidy data analysis and Keyongan data analysis software; and sells reagent equipment. It serves approximately 2,000 hospitals throughout Mainland China, Hong Kong, Macao, and Taiwan. Berry Genomics Co.,Ltd has a partnership with Personalis, Inc. The company was founded in 2010 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Beijing"
    },
    "001630.KS": {
        "short_name": "CHONGKUNDANG HOLDINGS",
        "long_name": "Chong Kun Dang Holdings Corp.",
        "summary": "Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. The company was founded in 1941 and is headquartered in Seoul, South Korea.",
        "currency": "KRW",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "KSC",
        "market": "kr_market",
        "country": "South Korea",
        "city": "Seoul"
    },
    "002007.SZ": {
        "short_name": "HUALAN BIOLOGICAL",
        "long_name": "Hualan Biological Engineering Inc.",
        "summary": "Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People's Republic of China. Its plasma products comprise surgical lyophilized fibrin sealant, human coagulation factor VIII, human albumin, human fibrinogen, human hepatitis B immunoglobulin, human tetanus immunoglobulin, human prothrombin complex, human immunoglobulin, human thrombin lyophilized for external use, human rabies immunoglobulin, and human immunoglobulin (PH4) for intravenous injection. The company's vaccines consist of meningococcal polysaccharide vaccine, inactivated influenza vaccine, recombinant hepatitis B vaccine, influenza A vaccine, and H7N9 inactivated influenza vaccine. It also offers gene products. Hualan Biological Engineering Inc. has strategic alliance with the Chinese Academy of Sciences. The company was founded in 1992 and is based in Xinxiang, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Xinxiang"
    },
    "002022.SZ": {
        "short_name": "SHANGHAI KEHUA BIO",
        "long_name": "Shanghai Kehua Bio-Engineering Co.,Ltd",
        "summary": "Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic products in China. The company offers HBV, hepatitis B, HCV antibody, alpha fetoprotein quantitative, and fecal occult blood test kits; carcino-embryonic antigen quantitative determination kits; test kits for antibody to treponema pallidum and human immunodeficiency virus, and the five serological markers of hepatitis B; and diagnostic kit for syphilis rapid plasma regain. It also provides automatic biochemical analysis systems for clinical laboratories and medical institutions; nucleic acid blood screening systems; automatic chemiluminescence measuring systems; microplate readers and plate washers; general and dedicated reagent packaging systems; and electrolyte analyzers. In addition, the company researches and develops diagnostic products in the field of renal disease that provides screening diagnosis and therapeutic effect monitoring solutions for patients with various types of kidney disease. Further, it offers single-part and multi-part nucleic acid detection, and enzyme immunoassay analysis systems; reagents for blood collection agencies and clinical diagnosis; and laboratory diagnostic instruments. Additionally, the company distributes automatic chemiluminescence, microbial, and blood and urine analysis systems, as well as their supporting supplies; and automatic biochemical analyzers and other products. It also establishes third-party medical laboratory centers; provides planning and designing, management consulting, equipment and reagent supplying, and supply chain optimization services for medical laboratories, as well as medical testing services. In addition, the company is involved in the social medical undertakings. It also exports its Kehua-branded products to 38 countries and regions. The company was founded in 1981 and is based in Shanghai, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Shanghai"
    },
    "002252.SZ": {
        "short_name": "S/H RAAS BLOOD PRO",
        "long_name": "Shanghai RAAS Blood Products Co., Ltd.",
        "summary": "Shanghai RAAS Blood Products Co., Ltd. manufactures and distributes blood products in China and internationally. It offers human albumin, human immunoglobulin, coagulation factor, and other products. The company was founded in 1988 and is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Shanghai"
    },
    "002275.SZ": {
        "short_name": "GUILIN SANJIN PHAR",
        "long_name": "Guilin Sanjin Pharmaceutical Co., Ltd.",
        "summary": "Guilin Sanjin Pharmaceutical Co., Ltd. researches, produces, and sells traditional Chinese and natural medicines in China. The company primarily offers Guilin watermelon frost and lozenge, and Sanjin tablets under the Chinese TCM brand, as well as Naomaitai capsules. It also produces contemporary TCM preparations. The company was founded in 1967 and is based in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. is a subsidiary of Guilin SanJin Group Co.,Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Guilin"
    },
    "002286.SZ": {
        "short_name": "BAOLINGBAO BIOLOGY",
        "long_name": "Baolingbao Biology Co.,Ltd.",
        "summary": "Baolingbao Biology Co.,Ltd. manufactures corn-based health and food ingredients in China and internationally. The company offers isomalto-oligosaccharide, galacto-oligosaccharides, fructose-oligosaccharides, and erythritol products; high fructose corn syrups, crystalline fructose products, sugar alcohols, and resistant dextrin-soluble corn fiber and polydextrose products; starch sugars, such as trehalose, maltodextrin, and glucose syrup products; terminal products; and corn steep liquors, corn husk sprayed products, and corn gluten meal products. It also provides agglomerated powder and organic products. The company's products are used in various food items, such as beverages, dairy, bakery, candy, meat, honey, seafood, canned food, condiment, health food, infant nutrition, fermentation, and animal nutrition, as well as in various fields, including daily chemicals, pharmaceuticals, cosmetics, etc. Baolingbao Biology Co.,Ltd. was founded in 1997 and is based in Yucheng, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Yucheng"
    },
    "002287.SZ": {
        "short_name": "TIBET CHEEZHENG TI",
        "long_name": "Tibet Cheezheng Tibetan Medicine Co., Ltd.",
        "summary": "Tibet Cheezheng Tibetan Medicine Co., Ltd. together with its subsidiaries, engages in the research, development, production, and sale of Tibetan medicine in China. It provides drug products in the areas of cardiovascular, respiratory, digestive, urinary and reproductive system, nervous system, musculoskeletal system, and gynecological disorders. The company was founded in 1995 and is based in Nyingchi, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Nyingchi"
    },
    "002566.SZ": {
        "short_name": "JILIN JIAN YISHENG",
        "long_name": "Jilin Jian Yisheng Pharmaceutical Co., Ltd.",
        "summary": "Jilin Jian Yisheng Pharmaceutical Co., Ltd. manufactures and sells medicine, Chinese herbal medicine, cosmetics, and food and health products in China. It offers capsules, injections, tablets, granules, and other products; and Ginseng medicinal and bee products. The company was founded in 1997 and is based in Ji'an, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Ji'an"
    },
    "002603.SZ": {
        "short_name": "SHIJIAZHUANG YILIN",
        "long_name": "Shijiazhuang Yiling Pharmaceutical Co., Ltd.",
        "summary": "Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceuticals primarily in China. It operates through three segments: Modern Chinese Medicine, Chemical Pharmaceutical, and Health Industry. The company offers drugs for cardiac and cerebral blood disease, influenza and respiratory disease, tumor, and diabetes mellitus. It sells its products through physical display, online product distribution, and join distribution parallels. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Shijiazhuang"
    },
    "002653.SZ": {
        "short_name": "HAISCO PHARMACEUTI",
        "long_name": "Haisco Pharmaceutical Group Co., Ltd.",
        "summary": "Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. The company offers capsules, tablets, granules, and bulk drugs in the fields of cardiovascular, anti-infection, digestive system, nervous and mental system, hepatopathy, diabetes mellitus, etc., as well as liver disease, parenteral nutrition, first-aid, antibiotics, anesthesia, and tumor adjuvant. It is also developing nalmefene hydrochloride injection, dolasetron mesylate injection, cefodizime sodium for injection, hydroxyethyl starch and sodium chloride injection, medium and long chain fat emulsion injection, and compound amino acids injection. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Chengdu"
    },
    "002821.SZ": {
        "short_name": "ASYMCHEM LABORATOR",
        "long_name": "Asymchem Laboratories (Tianjin) Co., Ltd.",
        "summary": "Asymchem Laboratories (Tianjin) Co., Ltd. researches, develops, and manufactures peptide API and drug products. It also provides analytical services. The company was founded in 1998 and is based in Tianjin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Tianjin"
    },
    "002868.SZ": {
        "short_name": "LIFECOME BIOCHEMIS",
        "long_name": "Lifecome Biochemistry Co., Ltd.",
        "summary": "Lifecome Biochemistry Co., Ltd. operates as a biopharmaceutical company in China. The company primarily offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, natamycin products, etc. Lifecome Biochemistry Co., Ltd. was founded in 2003 and is based in Pucheng, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Pucheng"
    },
    "002872.SZ": {
        "short_name": "TIANSHENG PHARMACE",
        "long_name": "Tiansheng Pharmaceutical Group Co., Ltd.",
        "summary": "Tiansheng Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and circulation activities. It offers products in various categories, including respiratory, digestive, cardiovascular and cerebrovascular, pediatric, gynecological, orthopedic, tumor, hepatobiliary, blood, surgery, diabetes, and other systems, as well as antipyretic, and analgesic and non-steroidal anti-inflammatory drugs. The company also provides antimicrobials, and vitamins and minerals. Tiansheng Pharmaceutical Group Co., Ltd. was founded in 2001 and is based in Chongqing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Chongqing"
    },
    "002873.SZ": {
        "short_name": "GUIYANG XINTIAN PH",
        "long_name": "Guiyang Xintian Pharmaceutical Co.,Ltd.",
        "summary": "Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of Chinese medicines for various diseases in China. The company offers formulation products, which include hard capsules, gels, mixtures, granules, and tablets. Its products are used for the treatment of antitumor, gynecological, urinary, breast thyroid, blood, heat, oral, anti-cold, and cardiovascular diseases. The company was founded in 1995 and is based in Guiyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Guiyang"
    },
    "002898.SZ": {
        "short_name": "ZHUHAI SAILONG PHA",
        "long_name": "Zhuhai Sailong Pharmaceutical Co.,Ltd.",
        "summary": "Zhuhai Sailong Pharmaceutical Co.,Ltd. principally engages in the fields of neuroprotective agents and treatment of diseases of the aged. The company is based in Zhuhai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Zhuhai"
    },
    "011000.KS": {
        "short_name": "GENEONE",
        "long_name": "GeneOne Life Science, Inc.",
        "summary": "GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.",
        "currency": "KRW",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "KSC",
        "market": "kr_market",
        "country": "South Korea",
        "city": "Seoul"
    },
    "015.F": {
        "short_name": "AILERON THERAP. DL-,001",
        "long_name": "Aileron Therapeutics, Inc.",
        "summary": "Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Watertown"
    },
    "041.SG": {
        "short_name": "ADL Bionatur Solutions S.A. Acc",
        "long_name": "ADL Bionatur Solutions, S.A.",
        "summary": "ADL Bionatur Solutions, S.A. engages in the research, development, manufacturing, and commercialization of products in biotech and pharmaceutical industry in Spain. It provides solutions in health, nutrition, cosmetics, and materials. The company was founded in 1954 and is headquartered in C\u00c3\u00a1diz, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Spain",
        "city": "C\u00c3\u00a1diz"
    },
    "04IC.F": {
        "short_name": "INVIVO THERAPEU.DL-,00001",
        "long_name": "InVivo Therapeutics Holdings Corp.",
        "summary": "InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "05Y.DE": {
        "short_name": "VIVORYON THERAPEUTICS",
        "long_name": "Vivoryon Therapeutics N.V.",
        "summary": "Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development products is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics AG has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Halle"
    },
    "05Y.F": {
        "short_name": "VIVORYON THERAPEUTICS",
        "long_name": "Vivoryon Therapeutics N.V.",
        "summary": "Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development products is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics AG has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Halle"
    },
    "068270.KS": {
        "short_name": "Celltrion",
        "long_name": "Celltrion, Inc.",
        "summary": "Celltrion, Inc. operates in the pharmaceutical industry in South Korea. It develops and provides biosimilars for auto-immune diseases and various cancers; generic pharmaceuticals; and covid-19 test kits. The company was founded in 2002 and is based in Incheon, South Korea.",
        "currency": "KRW",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "KSC",
        "market": "kr_market",
        "country": "South Korea",
        "city": "Incheon"
    },
    "0690.HK": {
        "short_name": "UNI-BIO GROUP",
        "long_name": "Uni-Bio Science Group Limited",
        "summary": "Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and distribution of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. It offers prescription drugs, including Uni-E4, a recombinant rExendin-4 injection for the treatment of Type 2 diabetes; and Uni-PTH, an injection form of recombinant human parathyroid hormone for the treatment of osteoporosis in postmenopausal women. The company also provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF-derivative eye drop for corneal damage and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. Uni-Bio Science Group Limited was founded in 2001 and is headquartered in Shatin, Hong Kong.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "Hong Kong",
        "city": "Shatin"
    },
    "07X.F": {
        "short_name": "ANNOVIS BIO INC. DL-,0001",
        "long_name": "Annovis Bio, Inc.",
        "summary": "Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Berwyn"
    },
    "0C1.F": {
        "short_name": "ATRECA INC.A SHS DL-,0001",
        "long_name": "Atreca, Inc.",
        "summary": "Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "0C1.MU": {
        "short_name": "ATRECA INC.A SHS DL-,0001",
        "long_name": "Atreca, Inc.",
        "summary": "Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "0ET.F": {
        "short_name": "ESPER.THERAP.(NEW) DL-001",
        "long_name": "Esperion Therapeutics, Inc.",
        "summary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Ann Arbor"
    },
    "0GT.F": {
        "short_name": "STOKE THERAPEUT.DL-,001",
        "long_name": "Stoke Therapeutics, Inc.",
        "summary": "Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Bedford"
    },
    "0IF.F": {
        "short_name": "LOGICBIO THERAP. DL-,0001",
        "long_name": "LogicBio Therapeutics, Inc.",
        "summary": "LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was founded in 2014 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Lexington"
    },
    "0IK.F": {
        "short_name": "NGM BIOPHARMAC.",
        "long_name": "NGM Biopharmaceuticals, Inc.",
        "summary": "NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "0JVN.F": {
        "short_name": "IBIO INC.  DL-,001",
        "long_name": "iBio, Inc.",
        "summary": "iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "0K3.F": {
        "short_name": "TFF PHARMAC.INC.  DL-,001",
        "long_name": "TFF Pharmaceuticals, Inc.",
        "summary": "TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company has a research collaboration with the University of Georgia's Center for Vaccines and Immunology (CVI), along with the University of Texas at Austin (UT Austin), to evaluate the immunogenicity of universal influenza vaccines; and cooperative research and development agreement with United States Army Medical Research Institute of Infectious Diseases for use of its thin film freezing technology platform. TFF Pharmaceuticals, Inc. also has a joint development and collaboration agreement with Augmenta Bioworks, Inc. to develop commercial products incorporating Augmenta's human-derived monoclonal antibodies for COVID-19 therapeutics. The company was founded in 2018 and is based in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Austin"
    },
    "0K4.F": {
        "short_name": "AKERO THEREP.INC.DL-,0001",
        "long_name": "Akero Therapeutics, Inc.",
        "summary": "Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "0LW.F": {
        "short_name": "NEOVACS NOM.  EO-,05",
        "long_name": "Neovacs S.A.",
        "summary": "Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "0M4.F": {
        "short_name": "MERSANA THERAP. DL-,0001",
        "long_name": "Mersana Therapeutics, Inc.",
        "summary": "Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "0N6.F": {
        "short_name": "NOXXON PH.CONF.IPO EO-,01",
        "long_name": "NOXXON Pharma N.V.",
        "summary": "NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. The company is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "0OT.F": {
        "short_name": "OCULAR THERAPEUT.DL-,0001",
        "long_name": "Ocular Therapeutix, Inc.",
        "summary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert), which has completed two Phase III clinical trials for the treatment of post-surgical ocular pain and inflammation, and allergic conjunctivitis; and DEXTENZA, which is in Phase III clinical trials for the treatment of dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert), which is in Phase III clinical trials for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant, which is in Phase I clinical trials for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant, which is in Phase I clinical trials for the treatment of wet age-related macular degeneration(AMD). Its various preclinical programs include OTX- BPI for the treatment of acute ocular pain; OTX-BDI to treat post-operative Pain, and inflammation and bacterial infection; OTX-CSI to treat dry-eye disease; and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Bedford"
    },
    "0PB.F": {
        "short_name": "PUMA BIOTECHNOLOG.DL-0001",
        "long_name": "Puma Biotechnology, Inc.",
        "summary": "Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "0PJ.F": {
        "short_name": "ALLENA PHARMAC. DL -,001",
        "long_name": "Allena Pharmaceuticals, Inc.",
        "summary": "Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Newton, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Newton"
    },
    "0PQ.F": {
        "short_name": "PROQR THERAPEUTICS EO-,04",
        "long_name": "ProQR Therapeutics N.V.",
        "summary": "ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Leiden"
    },
    "0PT.F": {
        "short_name": "PROTHENA CORP. PLC DL-,01",
        "long_name": "Prothena Corporation plc",
        "summary": "Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; A\u00c3\u009f, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "0RA.MU": {
        "short_name": "RAPT THERAP. INC.DL-,0001",
        "long_name": "RAPT Therapeutics, Inc.",
        "summary": "RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "0RX.F": {
        "short_name": "REDX PHARMA  LS -,01",
        "long_name": "Redx Pharma Plc",
        "summary": "Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company is developing RXC004, a porcupine inhibitor, which has completed Phase I clinical development for the treatment of colorectal, pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory intestinal fibrosis; RXC007, a Rho-associated protein kinase 2 inhibitors for the treatment of orphan disease, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, and other systemic fibrotic conditions; and Porcupine (RXC006), which is in Phase I for the treatment of lung fibrosis. Redx Pharma Plc has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. The company was founded in 2010 and is based in Macclesfield, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Macclesfield"
    },
    "0S9.F": {
        "short_name": "SYROS PHARMACEUT. DL-,001",
        "long_name": "Syros Pharmaceuticals, Inc.",
        "summary": "Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "0T22.F": {
        "short_name": "ONCONOVA THERAPEUT.DL-,01",
        "long_name": "Onconova Therapeutics, Inc.",
        "summary": "Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. The company has a license agreement with SymBio Pharmaceuticals Limited; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of ON 123300 in Greater China. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Newtown"
    },
    "0UC.F": {
        "short_name": "ANPAC BIO-MED SP.ADS/1  A",
        "long_name": "AnPac Bio-Medical Science Co., Ltd.",
        "summary": "Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "city": "Lishui"
    },
    "0VY.F": {
        "short_name": "I-MAB  SPONS.ADS/1 -,0001",
        "long_name": "I-Mab",
        "summary": "I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin (TJ101), a long-acting human growth hormone that has completed Phase II clinical trials to treat pediatric growth hormone deficiency; and Olamkicept (TJ301), a IL-6 blocker, which is in Phase II clinical trials for the treatment of ulcerative colitis and autoimmune diseases. The company's product candidates also include Enoblituzumab, a humanized B7-H3 antibody that has completed Phase I clinical trials to treat head and neck cancer and other oncology diseases; Efineptakin (TJ107), a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme (GBM) patients with lymphopenia; and Plonmarlimab (TJM2), a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies. In Addition, it is developing Lemzoparlimab (TJC4), a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Uliledlimab (TJD5), a CD73 antibody, which is in Phase I clinical trials for treating solid tumors and oncology. Its product candidates in pre-clinical development comprise TJ210, a monoclonal antibody against human C5aR1 for the treatment of cancers and potentially autoimmune diseases; TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM and TJ-CLDN4B antibodies for treating oncology diseases. I-Mab has a strategic collaboration agreement with AbbVie Ireland Unlimited Company to develop and commercialize Lemzoparlimab. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "city": "Shanghai"
    },
    "0X4.F": {
        "short_name": "AGEX THERAPEUTI. DL0,0001",
        "long_name": "AgeX Therapeutics, Inc.",
        "summary": "AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Alameda"
    },
    "1061.HK": {
        "short_name": "ESSEX BIO-TECH",
        "long_name": "Essex Bio-Technology Limited",
        "summary": "Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu eye drops for various corneal defects and punctate keratopathy, recurrent punctate keratopathy in the shallow layer, dry eye, corneal operation and poor corneal healing after the operation, geographic herpes simplex keratitis, and ballous keratitis, as well as for corneal abrasion, mild, and moderate chemical burns; and Beifushu eye gels to treat corneal transplantation and eye surface reconstruction, dry eye, cataract surgery, and corneal refractive surgery, as well as to treat various keratopathy, ocular traumas, and foreign body removal. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties; and eye health care products, including Beifu shuhui capsules to treat fundus ocular diseases, asthenopia, and visual impairments. Further, the company distributes Carisolv, a product for the treatment of root caries, deep cavities, and dental caries, as well as for removing carious dentin tissues. Essex Bio-Technology Limited has a research collaboration agreement with AC Immune SA to develop a biological therapeutic for the treatment of neurodegenerative diseases, such as Alzheimer's disease; and license agreement with Mitotech S.A. and Mitotech LLC. Essex Bio-Technology Limited was founded in 1999 and is headquartered in Central, Hong Kong.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "Hong Kong",
        "city": "Central"
    },
    "107.F": {
        "short_name": "BIOASIS TECHNOLOGIES INC.",
        "long_name": "Bioasis Technologies Inc.",
        "summary": "Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-002), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Bioasis Technologies Inc. was founded in 2007 and is headquartered in Guilford, Connecticut.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Guilford"
    },
    "1167.HK": {
        "short_name": "JACOBIO-B",
        "long_name": "Jacobio Pharmaceuticals Group Co., Ltd.",
        "summary": "Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. Its lead drug development programs include two clinical-stage allosteric SHP2 inhibitors, including JAB-3068, a SHP2 inhibitor for the treatment of patients with solid tumor; and JAB-3312, an oral small molecule anti-tumor agent. The company was founded in 2015 and is based in Beijing, China. Jacobio Pharmaceuticals Co., Ltd. is a subsidiary of Jacobio (HK) Pharmaceuticals Co., Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Beijing"
    },
    "12V.F": {
        "short_name": "VERACYTE INC.  DL-,001",
        "long_name": "Veracyte, Inc.",
        "summary": "Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and a collaboration with Johnson & Johnson Services, Inc. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "12X1.F": {
        "short_name": "ANAVEX LIFE SCI.  DL-,001",
        "long_name": "Anavex Life Sciences Corp.",
        "summary": "Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "137.F": {
        "short_name": "ALDEYRA THERAPEUT.DL-,001",
        "long_name": "Aldeyra Therapeutics, Inc.",
        "summary": "Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Lexington"
    },
    "1477.HK": {
        "short_name": "OCUMENSION-B",
        "long_name": "Ocumension Therapeutics",
        "summary": "Ocumension Therapeutics operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company researches and develops, manufactures, and commercializes ophthalmic drugs. It offers drugs for the treatment of blepharitis, infective conjunctivitis, allergic conjunctivitis, dry eye, cataract, glaucoma, uveitis, age-related macular degeneration, and myopia. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Suzhou"
    },
    "1548.HK": {
        "short_name": "GENSCRIPT BIO",
        "long_name": "Genscript Biotech Corporation",
        "summary": "Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life sciences research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. It operates in four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein production, peptide synthesis, and antibody development for use in basic biology studies, disease and pharmaceutical research, drug discovery, agriculture, environmental studies, and food industry; life sciences research catalogue products, such as pre-packaged, ready-to-use, and off-the-shelf products; and contractual research services, including protein engineering. The Biologics Development Services segment provides various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for antibody therapeutic antibodies and gene/cell therapy products. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops therapies for the treatment of liquid tumors. The company was founded in 2002 and is headquartered in Nanjing, China. Genscript Biotech Corporation is a subsidiary of GenScript Corporation.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Nanjing"
    },
    "1672.HK": {
        "short_name": "ASCLETIS-B",
        "long_name": "Ascletis Pharma Inc.",
        "summary": "Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a direct-acting anti-viral agent for the treatment of hepatitis C virus (HCV); Pegasys, a pegylated interferon for Hepatitis B and C virus; and Ravidasvir, a pan-genotypic NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B infection; ASC40, a Phase II-ready fatty acid synthase inhibitor for the treatment of non-alcoholic steatohepatitis (NASH); and ASC41, an oral THR-\u00c3\u009f agonist for the treatment of NASH. The company's products also comprise ASC09, a protease inhibitor that has completed Phase IIA clinical trial to treat human immunodeficiency virus type-1 infections; ASC06, which has completed Phase I clinical trial for treating liver cancer; and ASC21, a HCV NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of hepatitis B virus and NASH. The company was incorporated in 2014 and is headquartered in Hangzhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Hangzhou"
    },
    "1734.TW": {
        "short_name": "SINPHAR PHARMACEUTICAL CO LTD",
        "long_name": "Sinphar Pharmaceutical Co.,Ltd.",
        "summary": "Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. It produces anti-cancer pharmaceuticals, such as injections, solid reagents, and hormone reagents; and tablets, soft gel capsules and powder and canned special nutrient products. The company also provides shampoo, body wash, tonic water, lotions, moisturizers, sunscreen lotions, and serums; and pharmaceutical packaging products, such as eye drop bottles, dry canisters, tablet bottles, and various medical grade plastic containers. In addition, it offers plant extracts and functional foods; and OEM services, such as product design, manufacturing, etc. to manufacturers. Sinphar Pharmaceutical Co.,Ltd. was founded in 1977 and is headquartered in Yilan, Taiwan.",
        "currency": "TWD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TAI",
        "market": "tw_market",
        "country": "Taiwan",
        "city": "Yilan City"
    },
    "1760.TW": {
        "short_name": "PANION & BF BIOTECH INC",
        "long_name": "Panion & Bf Biotech Inc.",
        "summary": "Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, manufactures and sells various pharmaceutical products in Taiwan. The company offers products in the areas of medical beauty, kidney, respiratory tract, gastrointestinal tract, diagnosis, and delayed aging. It also provides oral drugs and external preparations; hand and mechanical disinfection, body lotion, and skin disinfection products; and pet health products, including surgical and skin prescriptions. Panion & Bf Biotech Inc. was founded in 1976 and is headquartered in Taipei City, Taiwan.",
        "currency": "TWD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TAI",
        "market": "tw_market",
        "country": "Taiwan",
        "city": "Taipei"
    },
    "1877.HK": {
        "short_name": "JUNSHI BIO",
        "long_name": "Shanghai Junshi Biosciences Co., Ltd.",
        "summary": "Shanghai Junshi Biosciences Co., Ltd., a bio-pharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, auto-immunity, and neurologic diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYIR for the indication of melanoma, mucosal melanoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophagus carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira that is in Phase I clinical trial for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for injection that is in Phase II clinical trial for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection; and JS001 that is in Phase Ib clinical trial in the United States. In addition, the company is developing JS501, a biosimilar of Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection, which are in Phase I clinical trials. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus; collaboration with Merck & Co., Inc. to explore new combination treatment for head and neck cancer patients; and a research collaboration and license agreement with Revitope Oncology Inc to explore immunotherapies with precision-targeted T-cell engaging antibodies. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Shanghai"
    },
    "18H.F": {
        "short_name": "PREVECEUTICAL MED.",
        "long_name": "PreveCeutical Medical Inc.",
        "summary": "PreveCeutical Medical Inc., a health sciences company, develops options for preventive and curative therapies utilizing organic and nature identical products in the United States and Canada. It has research and development programs, including dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a soluble gel drug delivery program, which provide relief from pain, inflammation, seizures, and neurological disorders; Nature Identical peptide therapeutic applications; non-addictive analgesic peptides as a replacement to the addictive analgesics, such as morphine, fentanyl, and oxycodone; and a therapeutic product for treating athletes who suffer from concussions. It also provides medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "1952.HK": {
        "short_name": "EVEREST MED-B",
        "long_name": "Everest Medicines Limited",
        "summary": "Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Shanghai"
    },
    "19KA.F": {
        "short_name": "CORMEDIX INC.  DL-,001",
        "long_name": "CorMedix Inc.",
        "summary": "CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Berkeley Heights"
    },
    "19X.F": {
        "short_name": "AXSOME THERAPEUT. DL-0001",
        "long_name": "Axsome Therapeutics, Inc.",
        "summary": "Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "1A1.SG": {
        "short_name": "Achaogen Inc. Registered Shares",
        "long_name": "Achaogen, Inc.",
        "summary": "Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "1AD.AX": {
        "short_name": "ADALTA FPO",
        "long_name": "AdAlta Limited",
        "summary": "AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has a collaborative partnership with GE Healthcare to discover i-bodies against granzyme B for use as a molecular imaging agent. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Bundoora"
    },
    "1AQ1.SG": {
        "short_name": "Evofem Biosciences Inc. Registe",
        "long_name": "Evofem Biosciences, Inc.",
        "summary": "Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "1B3.SG": {
        "short_name": "BIOSPECIFICS TECHNOLOGIES CORPR",
        "long_name": "BioSpecifics Technologies Corp.",
        "summary": "BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware. As of December 1, 2020, BioSpecifics Technologies Corp. operates as a subsidiary of Endo International plc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Wilmington"
    },
    "1BT.F": {
        "short_name": "ENLIVEX THERAP.LTD.IS-,01",
        "long_name": "Enlivex Therapeutics Ltd.",
        "summary": "Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "1C0S.F": {
        "short_name": "CELYAD ONCOLOGY SPONS.ADR",
        "long_name": "Celyad Oncology SA",
        "summary": "Celyad Oncology, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. The company's lead drug product candidates include CYAD-01 and CYAD-02 autologous cell therapies, which are in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an allogeneic cell therapy that is in Phase I clinical trial for the treatment of metastatic colorectal cancer; and CYAD-103, an allogeneic CAR-T product candidate that is in preclinical development for the treatment of solid tumors. The company's other preclinical candidates include CYAD-211, a CAR-T candidate targeting B-cell maturation antigen for the treatment of multiple myeloma; CYAD-221, a CAR-T candidate targeting CD19 for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. Celyad Oncology has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad Oncology was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Mont-Saint-Guibert"
    },
    "1C81.F": {
        "short_name": "CANCER GENET.INC DL-,0001",
        "long_name": "Cancer Genetics, Inc.",
        "summary": "Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Rutherford"
    },
    "1F6.F": {
        "short_name": "FERMENTALG  EO -,04",
        "long_name": "Fermentalg Soci\u00e9t\u00e9 Anonyme",
        "summary": "Fermentalg Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme develops, produces, and sells active ingredients extracted from microalgae for the food, health, and nutrition sectors in France and internationally. It offers DHA ORIGINS, a plant based DHA oil; PROTEALG, a vegetable protein; BLUE ORIGIN, a natural color substitutes for human health and nutrition; and Carbon sinks to capture CO2 in urban and industrial environments. The company was founded in 2009 and is based in Libourne, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Libourne"
    },
    "1FG.F": {
        "short_name": "FIBROGEN INC.  DL-,01",
        "long_name": "FibroGen, Inc.",
        "summary": "FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "1IJA.F": {
        "short_name": "ADICET BIO INC. DL -,0001",
        "long_name": "Adicet Bio, Inc.",
        "summary": "Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors or T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Its products pipeline includes ADI-001, which is in Phase 1 clinical study to treat non-Hodgkin's lymphoma; and ADI-002 that is in Phase 1 clinical study for the treatment of hepatocellular carcinoma and other solid tumors. The company is based in Menlo Park, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Menlo Park"
    },
    "1IY.F": {
        "short_name": "MONOPAR THERAP.  -,001",
        "long_name": "Monopar Therapeutics Inc.",
        "summary": "Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Espa\u00c3\u00b1ol de Investigaci\u00c3\u00b3n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Wilmette"
    },
    "1JA2.F": {
        "short_name": "JAGUAR HEALTH  DL-,0001",
        "long_name": "Jaguar Health, Inc.",
        "summary": "Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "1JK.F": {
        "short_name": "APELLIS PHARMACT.DL-,0001",
        "long_name": "Apellis Pharmaceuticals, Inc.",
        "summary": "Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Waltham"
    },
    "1KPA.F": {
        "short_name": "PROTARA THERAPEUT.DL-,001",
        "long_name": "Protara Therapeutics, Inc.",
        "summary": "Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "1LV.F": {
        "short_name": "SATSUMA PHARMACEUTICALS",
        "long_name": "Satsuma Pharmaceuticals, Inc.",
        "summary": "Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "1LV.MU": {
        "short_name": "SATSUMA PHARMACEUTICALS",
        "long_name": "Satsuma Pharmaceuticals, Inc.",
        "summary": "Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "1NE.F": {
        "short_name": "VERRICA PHARMAC. DL-,0001",
        "long_name": "Verrica Pharmaceuticals Inc.",
        "summary": "Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica Pharmaceuticals Inc. was founded in 2013 and is headquartered in West Chester, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "West Chester"
    },
    "1OT.F": {
        "short_name": "OVID THERAPEUTICS DL-,001",
        "long_name": "Ovid Therapeutics Inc.",
        "summary": "Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which is in a Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; and OV881 as a microRNA gene therapy for the treatment of angelman syndrome. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop, manufacture and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was founded in 2014 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "1RT.F": {
        "short_name": "NUFORMIX PLC  LS -,001",
        "long_name": "Nuformix plc",
        "summary": "Nuformix plc, a pharmaceutical development company, develops drugs using cocrystal technology in the United Kingdom. Its lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. The company is also developing NXP004, which is under the pre-clinical stage for the treatment of multiple forms of fibrosis in various human tissues. It has an agreement with VistaGen Therapeutics, Inc. to develop co-crystal-based formulations of AV-101 for the treatment of various central nervous system conditions. The company also has an option agreement with Oxilio Ltd. to provide consultancy services for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "1RV.F": {
        "short_name": "RHYTHM PHARMAC. DL-,001",
        "long_name": "Rhythm Pharmaceuticals, Inc.",
        "summary": "Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alstr\u00c3\u00b6m syndrome; and is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boston"
    },
    "1S1.F": {
        "short_name": null,
        "long_name": "Viridian Therapeutics, Inc.",
        "summary": "Viridian Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.",
        "currency": "None",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boulder"
    },
    "1S9.F": {
        "short_name": "SERES THERAPEUT. DL -,001",
        "long_name": "Seres Therapeutics, Inc.",
        "summary": "Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "1T3.F": {
        "short_name": "SYNDAX PHARMACEU.DL-,0001",
        "long_name": "Syndax Pharmaceuticals, Inc.",
        "summary": "Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Waltham"
    },
    "1VT.F": {
        "short_name": "VIKING THERAPEUT.DL -,005",
        "long_name": "Viking Therapeutics, Inc.",
        "summary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "1XT.F": {
        "short_name": "XINTELA AB",
        "long_name": "Xintela AB (publ)",
        "summary": "Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing Xintela Assay for Cell Therapy (XACT), an analytical test for cell therapy. It also offers XSTEM-OA, a stem cell-based product for the treatment of osteoarthritis in humans. In addition, the company develops stem cell-based products for animals. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "1XU1.F": {
        "short_name": "ENTHEON BIOMEDICAL CORP.",
        "long_name": "Entheon Biomedical Corp.",
        "summary": "Entheon Biomedical Corp., a biotechnology research and drug development company, engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company is based in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "207940.KS": {
        "short_name": "SAMSUNG BIOLOGICS",
        "long_name": "Samsung Biologics Co.,Ltd.",
        "summary": "Samsung Biologics Co., Ltd. engages in the contract manufacturing organization business for biopharmaceuticals products. The company is involved in the provision of contract development organization services, including cell line development, upstream and downstream processes, and analytical methods and formulations. It also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, the company engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. It has a manufacturing agreement with Vir Biotechnology, Inc. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. The company also has a partnership agreement with DiNonA Inc. to provide development services ranging from cell line development and process development to non-clinical and clinical material manufacturing. Samsung Biologics Co., Ltd. was founded in 2011 and is headquartered in Incheon, South Korea.",
        "currency": "KRW",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "KSC",
        "market": "kr_market",
        "country": "South Korea",
        "city": "Incheon"
    },
    "2096.HK": {
        "short_name": "SIMCERE PHARMA",
        "long_name": "Simcere Pharmaceutical Group Limited",
        "summary": "Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and distribution of pharmaceutical and vaccine products for pharmaceutical distributors and government in China. Its principal branded generic pharmaceuticals include Bicun, a prescription edaravone injection pharmaceutical for the treatment of strokes; Zailin, a line of generic prescription amoxicillin antibiotics; Yingtaiqing, an anti-inflammatory pain reliever and analgesic drug used to treat rheumatoid arthritis and osteoarthritis; Enlength, an oncology injection; and Sinofuan for the treatment of cancer. The company also offers generic anti-diarrhea pharmaceutical products under the Biqi brand; amoxicillin and clavulanate potassium tablets, granules, and injection for the treatment of infections under the Anqi brand name; cefaclor in dry suspension antibiotics for the treatment of infections under the Zaike brand; herbal medicines for the treatment of coughs under the Kechuanning name; Jiebaishu, which is primarily used for the treatment of head and neck cancers, small cell lung carcinoma, non-small-cell lung carcinoma, esophageal cancer, and other solid tumors; and biapenem for the treatment of severe infections under the Anxin brand. In addition, it offers cardiovascular products; autoimmune products; anti-infective drugs; and other pharmaceutical products, such as Biqi-branded diosmectite powder and anti-diarrhea products. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Nanjing"
    },
    "209A.F": {
        "short_name": "CATABAS.PHARM.INC. NEW",
        "long_name": "Catabasis Pharmaceuticals, Inc.",
        "summary": "Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boston"
    },
    "20D.F": {
        "short_name": "CIDARA THERAPEUT.DL-,0001",
        "long_name": "Cidara Therapeutics, Inc.",
        "summary": "Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "2126.HK": {
        "short_name": "JW THERAP-B",
        "long_name": "JW (Cayman) Therapeutics Co. Ltd",
        "summary": "JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is relmacabtagene autoleucel, an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Shanghai"
    },
    "2160.T": {
        "short_name": "GNI GROUP LTD",
        "long_name": "GNI Group Ltd.",
        "summary": "GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. The company was founded in 2001 and is headquartered in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "2181.HK": {
        "short_name": "MABPHARM-B",
        "long_name": "Mabpharm Limited",
        "summary": "Mabpharm Limited, a biopharmaceutical company, focuses on the research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in China. Its products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-IgE monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis. The company is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; and CMAB809 that is in Phase I clinical trial for the treatment of HER2 overexpressing breast cancer and metastatic gastric cancer. In addition, its products under the pre-clinical stage include CMAB810 for the treatment of breast cancer; CMAB813 for the treatment of severe lower respiratory tract disease in pediatric patients; CMAB816 for the treatment of periodic fever syndrome and systemic juvenile idiopathic arthritis; CMAB017 for the treatment of KRAS wild-type colorectal cancer; CMAB015, a biosimilar candidate for secukinumab to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis, as well as CMAB020, a recombinant bispecific fusion protein, which is in under development stage. The company was founded in 2018 and is headquartered in Taizhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Taizhou"
    },
    "2183.T": {
        "short_name": "LINICAL CO LTD",
        "long_name": "Linical Co., Ltd.",
        "summary": "Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. It offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. The company also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. Linical Co., Ltd. was founded in 2005 and is headquartered in Osaka, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Osaka"
    },
    "2191.T": {
        "short_name": "TELLA INC",
        "long_name": "tella, Inc.",
        "summary": "tella, Inc. researches and develops regenerative and cell medicines. The company offers techniques and operational knowhow associated with dendritic cell vaccine therapy to affiliated medical institutions for the treatment of cancer. It is also involved in the provision of consultation services on the establishment and maintenance of cell processing centers, and on introduction of management systems for cell cultivation; and lease of standard operating procedure and regular checks on manufacturing operation management and training of cell cultivation technicians. In addition, the company provides consultation services on training of expertise regarding treatment practice; and support services for the assessment of therapies, documentation required for treatment practice, and cognition and information providing activities for physicians and patients. tella, Inc. was founded in 2004 and is based in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "21J.F": {
        "short_name": "JOUNCE THERAP. DL-,001",
        "long_name": "Jounce Therapeutics, Inc.",
        "summary": "Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "2269.HK": {
        "short_name": "WUXI BIO",
        "long_name": "WuXi Biologics (Cayman) Inc.",
        "summary": "WuXi Biologics (Cayman) Inc., an investment holding company, operates as an open-access technology platform company that provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology; international sales contracting services; testing and development of testing technologies; provision of biologics clinical and manufacturing services provision of sales and marketing services in the United States; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. In addition, it provides clinical and commercial manufacturing, assay, formulation and process development, process validation, lot release testing, stability studies, drug product formulation, fill and finish, and regulatory support services for recombinant protein, monoclonal antibodies, and antibody drug conjugates. The company serves pharmaceutical and biotechnology companies. It has strategic partnerships with Amicus Therapeutics; ABL Bio; NBE-Therapeutics; I-Mab Biopharma; NovoCodex Biopharmaceuticals Co., Ltd.; Almirall; Antengene Corporation; and Arcus Biosciences, Inc. The company was founded in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Wuxi"
    },
    "22UA.F": {
        "short_name": "BIONTECH SE SPON. ADRS 1",
        "long_name": "BioNTech SE",
        "summary": "BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Mainz"
    },
    "2342.T": {
        "short_name": "TRANS GENIC INC",
        "long_name": "Trans Genic Inc.",
        "summary": "Trans Genic Inc. develops, distributes, and licenses genetically engineered animals and antibodies in Japan. The company provides information of approximately 750 knockout mouse strains; 2,000 knockout ES clones produced by the exchangeable gene-trap method; 900 knockout mouse strains, as well as 750 phenotypic data centering on target genes for drug discovery. It also engages in the custom production of genetically engineered mice comprising conventional, conditional, and knock-in mice, as well as transgenic mice; and customized mouse-related analysis, such as speed congenics and phenotype analysis, including blood examination, as well as cryopreservation of embryo and sperm, and housing and breeding activities. In addition, the company provides mouse-related products, such as circadian locomotor output cycles kaput mice used as disease models; frozen embryos used to produce genetically engineered mice; and electronic instruction manual of reproduction technology for embryo manipulation, as well as approximately 600 antibody products. Further, it offers contract services for drug efficiency and pharmacological, safety pharmacological, disposition, and pharmacokinetic studies. Additionally, the company provides drug discovery support services, such as clinical and nonclinical pharmacological tests for Parkinson's and Alzheimer's diseases; and high density human tissue microarrays for use in the assessment of drug target molecules. It is also involved in the custom production of high-affinity, monoclonal, and polyclonal antibodies; and protein hyper-producing cells, as well as the provision of antibody purification and labeling, and peptide synthesis services. The company was formerly known as Kumamoto Immunochemical Laboratories Inc. and changed its name to Trans Genic Inc. in April 2000. Trans Genic Inc. was founded in 1998 and is headquartered in Fukuoka, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Fukuoka"
    },
    "2370.T": {
        "short_name": "MEDINET CO LTD",
        "long_name": "MEDINET Co., Ltd.",
        "summary": "MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products. In addition, its value chain solutions include personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. The company supports medical institutions, research institutions, and biopharmaceutical companies to conduct immuno-cell therapy. MEDINET Co., Ltd. was founded in 1995 and is headquartered in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "2385.T": {
        "short_name": "SOIKEN HOLDINGS INC",
        "long_name": "Soiken Holdings Inc.",
        "summary": "Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives and other compounds. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for clinical research and epidemiology studies; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. The company was founded in 1994 and is headquartered in Toyonaka, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Toyonaka"
    },
    "23J.F": {
        "short_name": "PROMIS NEUROSCIENCES",
        "long_name": "ProMIS Neurosciences, Inc.",
        "summary": "ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform\u00c2\u0097ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (A\u00c3\u009fO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of A\u00c3\u009fO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company has a collaboration with BC Neuroimmunology to develop and commercialize proprietary diagnostic assays; and BC Neuroimmunology to develop and offer blood-based diagnostic tests for Alzheimer's diseases. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "25I.F": {
        "short_name": "IMMUPHARMA PLC  LS-,10",
        "long_name": "ImmuPharma plc",
        "summary": "ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "25K.F": {
        "short_name": "KARYOPHARM THERAP.DL-0001",
        "long_name": "Karyopharm Therapeutics Inc.",
        "summary": "Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma. The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of ow-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 2/3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration with PROMETRIKA, LLC to conduct the first randomized clinical trial for low-dose selinexor (XPOVIO\u00c3\u0082), an XPO1 inhibitor for hospitalized patients with COVID-19; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Newton"
    },
    "2616.HK": {
        "short_name": "CSTONE PHARMA-B",
        "long_name": "CStone Pharmaceuticals",
        "summary": "CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment worldwide. The company's late-stage clinical products include CS1001, a monoclonal antibody against programmed death ligand 1; CS1003, a monoclonal antibody against programmed death receptor; ivosidenib, a potent inhibitor of the mutated isocitrate dehydrogenase-1 enzyme for the treatment of cancer; avapritinib, an inhibitor for the treatment of gastrointestinal stromal tumors and systematic mastocytosis; and Pralsetinib for the treatment of medullary thyroid cancer and other advanced solid tumors. Its products also comprise CS1002, CS3002, CS3003, CS3005, and CS3006 for solid tumors; Fisogatinib that is used for the treatment of hepatocellular carcinoma; and CS3004, CS1009, and CS2004 for other indications. CStone Pharmaceuticals has a licensing agreement with Numab Therapeutics AG for the development and commercialization of NM21-1480, a potential monovalent tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin; a clinical collaboration with Bayer HealthCare LLC to evaluate CS1001 in combination with Bayer's oral multi-kinase inhibitor Stivarga, as a treatment for various types of cancer, including gastric cancer; and a strategic partnership with Burning Rock Biotech Limited to co-develop and commercialize companion diagnostics for pralsetinib, an investigational treatment for the detection of RET alterations in cancer patients. The company was founded in 2015 in Cayman Islands, and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Shanghai"
    },
    "2696.HK": {
        "short_name": "HENLIUS-B",
        "long_name": "Shanghai Henlius Biotech, Inc.",
        "summary": "Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologics with a focus on oncology and autoimmune diseases worldwide. The company offers HLX01, a monoclonal antibody biosimilar rituximab injection for the treatment of non-Hodgkin lymphoma. It is also developing 2 products, which are under new drug application (NDA) review; and 1 product that is under European medicines agency (EMA) review, as well as conducting approximately 20 clinical studies for 10 products and 8 combination therapies. Shanghai Henlius Biotech, Inc. Shanghai Henlius Biotech, Inc. has an agreement with Sanyou Biopharmaceuticals Co., Ltd. and Shanghai ZJ Bio-Tech Co., Ltd. to develop fully human antibody drug for COVID-19; and co-development and exclusive license agreement with Essex Bio-Investment Limited and Zhuhai Essex Bio-Pharmaceutical Company Limited to co-develop the HLX04, a recombinant humanized anti-VEGF monoclonal antibody as therapy for eye diseases, such as wet age-related macular degeneration. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Shanghai"
    },
    "26C.F": {
        "short_name": "NANTKWEST INC.  DL-,0001",
        "long_name": "NantKwest, Inc.",
        "summary": "NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "26M.F": {
        "short_name": "MIRATI THERAPEUTICS DL-01",
        "long_name": "Mirati Therapeutics, Inc.",
        "summary": "Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "27F.F": {
        "short_name": "KALA PHARMACEUT. DL-,001",
        "long_name": "Kala Pharmaceuticals, Inc.",
        "summary": "Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Watertown"
    },
    "290A.F": {
        "short_name": "CHINOOK THERAP.  DL-,0001",
        "long_name": "Chinook Therapeutics, Inc.",
        "summary": "Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Seattle"
    },
    "2B3.F": {
        "short_name": "XERIS PHARMAC.  DL-,0001",
        "long_name": "Xeris Pharmaceuticals, Inc.",
        "summary": "Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Chicago"
    },
    "2CB.F": {
        "short_name": "CALITHERA BIOSCIEN.DL-001",
        "long_name": "Calithera Biosciences, Inc.",
        "summary": "Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "2CX.F": {
        "short_name": "CHEMOCENTRYX INC.",
        "long_name": "ChemoCentryx, Inc.",
        "summary": "ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Mountain View"
    },
    "2DE.F": {
        "short_name": "GENPREX INC  DL-,001",
        "long_name": "Genprex, Inc.",
        "summary": "Genprex, Inc. operates as a clinical-stage gene therapy company that develops therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes. It develops drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company's lead product candidate REQORSA (quaratusugene ozeplasmid) for treatment for non-small cell lung cancer (NSCLC) has a multimodal mechanism of action to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis and programmed cell death in cancer cells; modulate immune response against cancer cells; and block mechanisms that create drug resistance. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Austin"
    },
    "2E4.F": {
        "short_name": "ERYTECH PHARMA SA  EO-,10",
        "long_name": "ERYTECH Pharma S.A.",
        "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lyon"
    },
    "2E4A.F": {
        "short_name": "ERYTECH PHARMA SP.ADR-,10",
        "long_name": "ERYTECH Pharma S.A.",
        "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lyon"
    },
    "2EM.DE": {
        "short_name": "ERGOMED PLC  LS -,01",
        "long_name": "Ergomed plc",
        "summary": "Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "2EM.F": {
        "short_name": "ERGOMED PLC  LS -,01",
        "long_name": "Ergomed plc",
        "summary": "Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "2F5.F": {
        "short_name": "BIOND.PHAR.S.ADS/40 IL-01",
        "long_name": "BiondVax Pharmaceuticals Ltd.",
        "summary": "BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "2GH.F": {
        "short_name": "MERUS N.V.  EO -,09",
        "long_name": "Merus N.V.",
        "summary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations with Caris Life Sciences to detect NRG1 fusions in cancer patients; and Loxo Oncology at Lilly to discover novel T-Cell Re-directing bispecific antibodies. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Utrecht"
    },
    "2H0.F": {
        "short_name": "EXICURE INC.  DL-,0001",
        "long_name": "Exicure, Inc.",
        "summary": "Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes AST-008 that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA\u00c2\u0096based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; and XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is based in Chicago, Illinois.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Chicago"
    },
    "2HA.F": {
        "short_name": "SPERO THERAP.INC. DL-,001",
        "long_name": "Spero Therapeutics, Inc.",
        "summary": "Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "2I9.F": {
        "short_name": "KAROLINSKA DEVELOP.AB",
        "long_name": "Karolinska Development AB (publ)",
        "summary": "Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "2JQ.F": {
        "short_name": "GRITSTONE ONCOL. DL-,0001",
        "long_name": "Gritstone Oncology, Inc.",
        "summary": "Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "EmeryVille"
    },
    "2JQ.SG": {
        "short_name": "Gritstone Oncology Inc. Registe",
        "long_name": "Gritstone Oncology, Inc.",
        "summary": "Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "EmeryVille"
    },
    "2K4.F": {
        "short_name": "PHASEBIO PHARMAC. DL-,001",
        "long_name": "PhaseBio Pharmaceuticals, Inc.",
        "summary": "PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Malvern"
    },
    "2KZ.F": {
        "short_name": "KEZAR LIFE SCIENC.DL-,001",
        "long_name": "Kezar Life Sciences, Inc.",
        "summary": "Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "2L9.F": {
        "short_name": "BLUEPRINT MED.CORP.DL-001",
        "long_name": "Blueprint Medicines Corporation",
        "summary": "Blueprint Medicines Corporation, a precision therapy company, develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "2LB.F": {
        "short_name": "IOVANCE BIOTHERAP.DL-,001",
        "long_name": "Iovance Biotherapeutics, Inc.",
        "summary": "Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Carlos"
    },
    "2PD.SG": {
        "short_name": "PeptiDream Inc. Registered Shar",
        "long_name": "PeptiDream Inc.",
        "summary": "PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company uses its Peptide Discovery Platform System platform for the development of peptides. PeptiDream Inc. has a collaboration with Merck & Co. Inc. for the discovery and development of peptide therapeutics capable of neutralizing the SARS-CoV-2 virus (COVID19) and potential coronavirus outbreaks; and a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was founded in 2006 and is headquartered in Kawasaki, Japan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Japan",
        "city": "Kawasaki"
    },
    "2PU1.F": {
        "short_name": "PULMATRIX INC.  DL-,0001",
        "long_name": "Pulmatrix, Inc.",
        "summary": "Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and Cipla Technologies LLC for the development and commercialization of Pulmazole. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Lexington"
    },
    "2Q3.F": {
        "short_name": "9 METERS BIOPHARM.DL-,001",
        "long_name": "9 Meters Biopharma, Inc.",
        "summary": "9 Meters Biopharma, Inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Raleigh"
    },
    "2Q5.SG": {
        "short_name": "Enochian Biosciences Inc Regist",
        "long_name": "Enochian Biosciences, Inc.",
        "summary": "Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "2QAA.F": {
        "short_name": "AURIS MEDICAL HLDG SF-,01",
        "long_name": "Auris Medical Holding Ltd.",
        "summary": "Auris Medical Holding Ltd., a development-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment and prevention of peripheral and central nervous disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; and AM-201, which is in Phase 1b clinical trial for the prevention of weight gain and drowsiness, which are side effects of various antipsychotic drugs, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Bermuda",
        "city": "Hamilton"
    },
    "2R3.F": {
        "short_name": "REATA PHARMA INC. 0,001",
        "long_name": "Reata Pharmaceuticals, Inc.",
        "summary": "Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Plano"
    },
    "2RZ.F": {
        "short_name": "POSEIDA THERAP.  DL-,0001",
        "long_name": "Poseida Therapeutics, Inc.",
        "summary": "Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "2SX.F": {
        "short_name": "SCPHARMACEUTIC. DL -,0001",
        "long_name": "scPharmaceuticals Inc.",
        "summary": "scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Burlington"
    },
    "2TK.F": {
        "short_name": "ELEDON PHARMACEUT.DL-,001",
        "long_name": "Eledon Pharmaceuticals, Inc.",
        "summary": "Eledon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. The company's lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). It also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Irvine"
    },
    "2US.F": {
        "short_name": "NEXTCURE INC.  DL-,001",
        "long_name": "NextCure, Inc.",
        "summary": "NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Beltsville"
    },
    "2US.MU": {
        "short_name": "NEXTCURE INC.  DL-,001",
        "long_name": "NextCure, Inc.",
        "summary": "NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "Beltsville"
    },
    "2VB.F": {
        "short_name": "PROVENTION BIO  DL-,0001",
        "long_name": "Provention Bio, Inc.",
        "summary": "Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Oldwick"
    },
    "2VJ.F": {
        "short_name": "ASCLETIS PHARMA  DL-,0001",
        "long_name": "Ascletis Pharma Inc.",
        "summary": "Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a direct-acting anti-viral agent for the treatment of hepatitis C virus (HCV); Pegasys, a pegylated interferon for Hepatitis B and C virus; and Ravidasvir, a pan-genotypic NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B infection; ASC40, a Phase II-ready fatty acid synthase inhibitor for the treatment of non-alcoholic steatohepatitis (NASH); and ASC41, an oral THR-\u00c3\u009f agonist for the treatment of NASH. The company's products also comprise ASC09, a protease inhibitor that has completed Phase IIA clinical trial to treat human immunodeficiency virus type-1 infections; ASC06, which has completed Phase I clinical trial for treating liver cancer; and ASC21, a HCV NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of hepatitis B virus and NASH. The company was incorporated in 2014 and is headquartered in Hangzhou, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "city": "Hangzhou"
    },
    "2VN.F": {
        "short_name": "BIOHAVEN PHARMAC.HLDG CO.",
        "long_name": "Biohaven Pharmaceutical Holding Company Ltd.",
        "summary": "Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New Haven"
    },
    "2VS.F": {
        "short_name": "VERASTEM INC.  DL-,0001",
        "long_name": "Verastem, Inc.",
        "summary": "Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is based in Needham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Needham"
    },
    "2VT.F": {
        "short_name": "LIPOCINE INC.NEW DL-,0001",
        "long_name": "Lipocine Inc.",
        "summary": "Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase 2b testing; LPCN 1148, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis cirrhosis (NASH); LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase 2 Clinical trial for the treatment of NASH. The company is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "2W6.SG": {
        "short_name": "Mustang Bio Inc. Registered Sha",
        "long_name": "Mustang Bio, Inc.",
        "summary": "Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase 1/2 clinical trials. The company also develops MB-102, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; MB-106 for immunotherapy of B-cell lymphomas; MB-104, an NK cell receptor regulating immune functions; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has a license agreement with Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center, Inc. to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Worcester"
    },
    "2X1.F": {
        "short_name": "ABIVAX SA  EO -,01",
        "long_name": "ABIVAX Soci\u00e9t\u00e9 Anonyme",
        "summary": "ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "300009.SZ": {
        "short_name": "ANHUI ANKE BIOTECH",
        "long_name": "Anhui Anke Biotechnology (Group) Co., Ltd.",
        "summary": "Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It also provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. The company was founded in 2000 and is based in Hefei, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Hefei"
    },
    "300049.SZ": {
        "short_name": "INNER MONGOLIA FUR",
        "long_name": "Inner Mongolia Furui Medical Science Co., Ltd.",
        "summary": "Inner Mongolia Furui Medical Science Co., Ltd. operates as a professional medical service platform company worldwide. The company provides disease diagnosis, drug treatment, and chronic disease management products in the liver disease field. It also offers health management center and medical care services. The company was formerly known as Inner Mongolia FuRui Pharmaceutical Limited Liability Company. Inner Mongolia Furui Medical Science Co., Ltd. was founded in 1998 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Beijing"
    },
    "300122.SZ": {
        "short_name": "CHONGQING ZHIFEI B",
        "long_name": "Chongqing Zhifei Biological Products Co., Ltd.",
        "summary": "Chongqing Zhifei Biological Products Co., Ltd. engages in the research, development, manufacture, and marketing of vaccines in China. It offers Meningococcal Group A&C Conjugate Vaccine and Meningococcal Polysaccharide Vaccine for the prevention of infectious and invasive meningococcal disease, including meningitis and pneumonia caused by Neisseria meningitidis serogroups A, C; Mycobacterium Vaccae for Injection, a bidirectional immune-modulator for disease like tuberculosis; Haemophilus Influenzae Type b Conjugate Vaccine for the prevention of invasive disease caused by Haemophilus influenzae type b, such as meningitis, pneumonia, sepsis, etc.; and Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine for the prevention of invasive disease caused by meningococcal groups A,C, as well as Haemophilus influenza type b comprising cerebrospinal meningitis, pneumonia, septicemia, epiglottitis, etc. The company also acts as agent for Hepatitis A vaccine; Pneumococcal vaccine; Human Papillomavirus Quadrivalent vaccine and Human Papillomavirus 9-valent vaccine for the prevention of cervical cancer, grade 1/2/3 cervical intraepithelial neoplasia, and cervical adenocarcinoma in situ caused by human papillomavirus; and Pentavalent Rotavirus vaccine for the prevention of rotavirus gastroenteritis in infants caused by the serotypes. In addition, it offers biologics for the prevention and treatment of TB and viral vaccines for the prevention of rabies, influenza, etc.; and sells generic drugs. Further, the company is involved in the marketing, import, export, and sale of biotechnologies; and provision of foreign investment and financing activities. Chongqing Zhifei Biological Products Co., Ltd. was founded in 2001 and is based in Chongqing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Chongqing"
    },
    "300147.SZ": {
        "short_name": "XIANGXUE PHARMACEU",
        "long_name": "Xiangxue Pharmaceutical Co.,Ltd.",
        "summary": "Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, procurement, manufacture, delivery, and distribution of pharmaceutical products in China. It offers antivirotic oral liquids under the Xiangxue brand name; and healthcare supplements, as well as health solutions, such as food and beverage. Xiangxue Pharmaceutical Co., Ltd. has strategic partnership agreement with 111, Inc. to develop the Internet + Medicine model for China's traditional Chinese medicine industry. The company was founded in 1997 and is based in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Guangzhou"
    },
    "300149.SZ": {
        "short_name": "CHEMPARTNER PHARMA",
        "long_name": "Chempartner Pharmatech Co., Ltd.",
        "summary": "Chempartner Pharmatech Co., Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company provides medical contract research organization, and contract development and manufacturing organization services for pre-clinical stages. It is also involved in the research, production, and sales of prebiotic fibers as a microecological fortification ingredient, ODM product, and food for special medical purposes product. The company was formerly known as Quantum Hi-Tech (China) Biological Co., Ltd. and changed its name to Quantum Hi-Tech (China) Biological Co., Ltd. in September 2020. Quantum Hi-Tech (China) Biological Co., Ltd. was founded in 2000 and is headquartered in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Guangzhou"
    },
    "300181.SZ": {
        "short_name": "ZHEJIANG JOLLY PHA",
        "long_name": "Zhejiang Jolly Pharmaceutical Co.,LTD",
        "summary": "Zhejiang Jolly Pharmaceutical Co., Ltd. engages in the research, production, and marketing of Chinese medicinal products in China and internationally. The company offers Wuling capsule that is used to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. It also provides Lingze tablet, which is used to treat frequent urination, dysuria, weak steam of urine, endless urine, and soreness and weakness of waist and knees caused by benign prostatic hyperplasia, kidney deficiency, and blood stasis; and Bailing tablet that is used as the adjuvant therapy to treat cough, asthma, back pain, and chronic bronchitis, which are caused by the deficiency of lungs and kidney. In addition, the company offers Linglianhua particles for the treatment of symptoms, including sweating, insomnia, dysphoria, heart palpitations, dreaminess, giddy tinnitus, lassitude in loin and legs, dry stool, and abnormal furred tongue, as well as weak pulse caused by perimenopausal syndrome, or disharmony of heart and kidney. Further, it provides azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside injections. Additionally, the company offers materials, such as cordyceps cephalosporin, fermented cordyceps, and Wuling powders. It also invests and participates in the medical services of Deqing No.3 People's Hospital. The company was formerly known as Zhejiang Jolly Pharmaceutical Health Products Co., LTD. and changed its name to Zhejiang Jolly Pharmaceutical Co., Ltd. in 1998. Zhejiang Jolly Pharmaceutical Co., Ltd. was founded in 2000 and is based in Huzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Huzhou"
    },
    "300204.SZ": {
        "short_name": "STAIDSON (BEIJING)",
        "long_name": "Staidson (Beijing) BioPharmaceuticals Co., Ltd.",
        "summary": "Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Beijing"
    },
    "300238.SZ": {
        "short_name": "GUANHAO BIOTECH CO",
        "long_name": "Guanhao Biotech Co.,Ltd.",
        "summary": "Guanhao Biotech Co.,Ltd. develops, manufactures, and markets regenerative medicine in China. It offers NormalGEN, a type of biological dura repair patch manufactured from animal tissue; GrandNeuro, an artificial dura patch for dura repairing; ThormalGEN, a biological surgical patch manufactured from animal tissue for surgical repairs; DermalGEN, a wound dressing product manufactured from animal tissue for use on burns, scalds, and wounds due to skin loss or trauma; and IREAL breast patch. The company was founded in 1999 and is based in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Guangzhou"
    },
    "300255.SZ": {
        "short_name": "HEBEI CHANGSHAN BI",
        "long_name": "Hebei Changshan Biochemical Pharmaceutical Co., Ltd.",
        "summary": "Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of heparin and related products in China. Its API products include heparin sodium injections, heparin calcium and lithium injections, heparinoid, LMW heparins, and sodium hyaluronate. The company also provides dalteparin and enoxaparin sodium injections, and nadroparin calcium injections, as well as sildenafil citrate tablets. It markets and sells its products to approximately 30 countries worldwide. Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000 and is based in Shijiazhuang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Shijiazhuang"
    },
    "300294.SZ": {
        "short_name": "BOYA BIO-PHARMACEU",
        "long_name": "Boya Bio-pharmaceutical Group Co.,Ltd",
        "summary": "Boya Bio-pharmaceutical Group Co., Ltd. develops, produces, and sells blood products and other related health products in China. Its products include human fibrinogen, intravenous human immunoglobulin, rabies patient immunoglobulin, and human albumin. The company also provides orthopedic medications, obstetrics and gynecology, gastrointestinal medication, enhanced immunological preparations, hepatic medication, cardiovascular and cerebral medicine, diabetes medication, anticoagulation hemostatic, API, and others products. In addition, it offers chemical raw materials, such as calcium hydroxybenzenesulfonate, glimepiride, azinamide, simvastatin, and repaglinide; biochemical drugs and chemical medicines; and other products in various categories, such as orthopedics, diabetes, hepatitis, gynecology, and gut and immunomodulatory agents. Further, the company focuses on the development of release preparations and compound preparations; and offers anti-diabetic products, such as metformin hydrochloride enteric-coated tablets, pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and glipizide tablets, as well as provides tablets and capsules for the treatment of diabetic retinopathy and glomerular lesions. The company was formerly known as Jiangxi Boya Bio-Pharmaceutical Co.,Ltd and changed its name to Boya Bio-pharmaceutical Group Co., Ltd. in August 2017. Boya Bio-pharmaceutical Group Co., Ltd. was founded in 1993 and is headquartered in Fuzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Fuzhou"
    },
    "300404.SZ": {
        "short_name": "GUANGZHOU BOJI MED",
        "long_name": "Guangzhou Boji Medical & Biotechnological Co., Ltd.",
        "summary": "Guangzhou Boji Medical & Biotechnological Co., Ltd. provides professional services in various medical study phases in China. It offers services on regulatory affairs, pre-clinical research, clinical trial phases, post marketing study, clinical trial for medical devices, data management and biostatistics, and SMO. Guangzhou Boji Medical & Biotechnological Co., Ltd. was founded in 1998 is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Beijing"
    },
    "300497.SZ": {
        "short_name": "JIANGXI FUSHINE PH",
        "long_name": "Jiangxi Fushine Pharmaceutical Co., Ltd.",
        "summary": "Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers penicillin, carbapenem, and other products. It also provides contract research, development, and manufacturing services. The company was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd and changed its name to Jiangxi Fushine Pharmaceutical Co., Ltd. in August 2012. The company was founded in 2002 and is based in Jingdezhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Jingdezhen"
    },
    "300583.SZ": {
        "short_name": "SHANDONG SITO BIO",
        "long_name": "Shandong Sito Bio-technology Co., Ltd.",
        "summary": "Shandong Sito Bio-technology Co., Ltd. researches and develops new steroid hormones, intermediates, and derivatives. Its products include cortisone acetate, ethylene deltenone, norandrostenedione, lactone, anecortave acetate, tetraene acetate, hydroxyprogesterone, and androstenedione. The company was founded in 2002 and is based in Heze, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Heze"
    },
    "300653.SZ": {
        "short_name": "YANTAI ZHENGHAI BI",
        "long_name": "Yantai Zhenghai Biotechnology Co., Ltd.",
        "summary": "Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and marketing of regenerative medical materials in China. It offers bone repair material, a partially deproteinised bone prepared from cancellous bones of calves after a series of treatment, such as decellularization and degreasing; oral cavity repair membrane line of products, which are used to treat defects of shallow oral cavity's soft tissue; and bio-membrane line of products that are used in neurosurgery to repair cerebral dura mater defect under the Heal-All brand name. The company also provides skin repair membrane line of products to repair wounds in dermal layer under the Heal-Full brand name. Yantai Zhenghai Biotechnology Co., Ltd. was founded in 2003 and is based in Yantai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Yantai"
    },
    "300705.SZ": {
        "short_name": "HUNAN JIUDIAN PHAR",
        "long_name": "Hunan Jiudian Pharmaceutical Co., Ltd.",
        "summary": "Hunan Jiudian Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers antiallergic, anti-infective, and anti-inflammatory drugs; analgosies and gynecological medication products; digestive system products; chemical and Chinese patent medicines; medical instruments; APIs; and other products. It also provides outsourcing services for tablets, capsules, granules, oral solutions, syrups, etc. Hunan Jiudian Pharmaceutical Co., Ltd. is based in Changsha, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Changsha"
    },
    "300841.SZ": {
        "short_name": "CHENGDU KANGHUA BI",
        "long_name": "Chengdu Kanghua Biological Products Co., Ltd.",
        "summary": "Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Chengdu"
    },
    "300858.SZ": {
        "short_name": "BEIJING SCITOP BIO",
        "long_name": "Beijing Scitop Bio-tech Co., Ltd.",
        "summary": "Beijing Scitop Bio-tech Co., Ltd. develops, produces, and sells doctors' lactic acid bacteria and related products. Its products have applications in the food industry, health care, animal husbandry, and agricultural planting. The company was founded in 2003 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Beijing"
    },
    "300871.SZ": {
        "short_name": "HVSEN BIOTECHNOLOG",
        "long_name": "Hvsen Biotechnology Co., Ltd.",
        "summary": "Hvsen Biotechnology Co., Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. Its products include tylvalosin raw materials, various tylvalosin preparations, florfenicol preparations, and other macrolides products. The company produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. is based in Wuhan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Wuhan"
    },
    "300878.SZ": {
        "short_name": "ZHEJIANG WECOME PH",
        "long_name": "Zhejiang Wecome Pharmaceutical Company Limited",
        "summary": "Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of pharmaceutical products. The company also offers healthcare products, OTC products, and Chinese medicines. It offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. The company was formerly known as Zhejiang Weikang Pharmaceutical Co., Ltd. Zhejiang Wecome Pharmaceutical Company Limited was founded in 2000 and is based in Lishui, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "city": "Lishui"
    },
    "30J.F": {
        "short_name": "IDEAYA BIOSCIENCE  DL-,01",
        "long_name": "IDEAYA Biosciences, Inc.",
        "summary": "IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase 1/2 clinical trial for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A for solid tumors with MTAP deletions; Pol-theta in tumors with homologous recombination deficiency, including BRCA mutations; PARG in tumors with BRCA2 mutations in base excision repair; and WRN in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase 1/2 study in metastatic uveal melanoma and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "30J.SG": {
        "short_name": "Ideaya Biosciences Inc. Registe",
        "long_name": "IDEAYA Biosciences, Inc.",
        "summary": "IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase 1/2 clinical trial for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A for solid tumors with MTAP deletions; Pol-theta in tumors with homologous recombination deficiency, including BRCA mutations; PARG in tumors with BRCA2 mutations in base excision repair; and WRN in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase 1/2 study in metastatic uveal melanoma and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "30O.F": {
        "short_name": "ONCOTHERAPY SCIENCE INC.",
        "long_name": "OncoTherapy Science, Inc.",
        "summary": "OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Japan",
        "city": "Kawasaki"
    },
    "30S.F": {
        "short_name": "SANIONA AB (PUBL)",
        "long_name": "Saniona AB (publ)",
        "summary": "Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The company's products include Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase III clinical trials to treat obesity; Tesomet, a fix-dose combination of tesofensine and metoprolol that is in Phase II clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; NS2359, a triple monoamine reuptake inhibitor that is in Phase II clinical trial for cocaine addiction; and CAD-1883 that is in Phase II clinical trial for tremor and spinocerebellar ataxia. It is also developing SAN711 for chronic itching and neuropathic pain; Boehringer Ingelheim program for schizophrenia; IK program for inflammatory bowel diseases; Nicotinic-a6 program for parkinson's diseases; Kv7 program for pain, epilepsy, and urinary incontinence; and SAN903 for autoimmune disorders. Saniona AB (publ) was founded in 2011 and is headquartered in Ballerup, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Ballerup"
    },
    "3164.TW": {
        "short_name": "GENMONT BIOTECH INC",
        "long_name": "GenMont Biotech Incorporation",
        "summary": "GenMont Biotech Incorporation engages in the research, development, and production of functional probiotics in Taiwan. The company offers functional probiotic raw materials and finished products. It also provides probiotics with special functions; and original formula design and manufacturing, and equipment manufacturing services on health care food, as well as cooperates in the research, production, and clinical trial of various products. GenMont Biotech Incorporation was founded in 2000 and is headquartered in Tainan, Taiwan.",
        "currency": "TWD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TAI",
        "market": "tw_market",
        "country": "Taiwan",
        "city": "Tainan City"
    },
    "328.F": {
        "short_name": "MEIRAGTX HLDGSDL-,0000388",
        "long_name": "MeiraGTx Holdings plc",
        "summary": "MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "335.F": {
        "short_name": "AERPIO PHARMAC.  DL-,0001",
        "long_name": "Aerpio Pharmaceuticals, Inc.",
        "summary": "Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cincinnati"
    },
    "335.SG": {
        "short_name": "Aerpio Pharmaceuticals Inc. Reg",
        "long_name": "Aerpio Pharmaceuticals, Inc.",
        "summary": "Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Cincinnati"
    },
    "336P.F": {
        "short_name": "HEPION PHARMACEUT. DL-,01",
        "long_name": "Hepion Pharmaceuticals, Inc.",
        "summary": "Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Edison"
    },
    "337.F": {
        "short_name": "CORBUS PHAR.HLDGS DL-0001",
        "long_name": "Corbus Pharmaceuticals Holdings, Inc.",
        "summary": "Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Norwood"
    },
    "34LA.F": {
        "short_name": "ALPINE IMMUNE SCI.DL-,001",
        "long_name": "Alpine Immune Sciences, Inc.",
        "summary": "Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Seattle"
    },
    "35H.F": {
        "short_name": "HOMOLOGY MED. DL-,0001",
        "long_name": "Homology Medicines, Inc.",
        "summary": "Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Bedford"
    },
    "366.F": {
        "short_name": "AZURRX BIOPHARMA DL-,0001",
        "long_name": "AzurRx BioPharma, Inc.",
        "summary": "AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients). It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida with scientific operations in Langlade, France and clinical operations in Hayward, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Delray Beach"
    },
    "3681.HK": {
        "short_name": "SINOMAB BIO-B",
        "long_name": "SinoMab BioScience Limited",
        "summary": "SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a BTK inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, NHL, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China and Hong Kong. SinoMab BioScience Limited was founded in 2001 and is headquartered in Pak Shek Kok, Hong Kong.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "Hong Kong",
        "city": "Tai Po"
    },
    "37Z.F": {
        "short_name": "ALLAKOS INC. DL-,001",
        "long_name": "Allakos Inc.",
        "summary": "Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "385.F": {
        "short_name": "CEAPRO INC.",
        "long_name": "Ceapro Inc.",
        "summary": "Ceapro Inc., a biotechnology company, engages in the development and commercialization of active ingredients in the United States, Germany, China, Canada, and internationally. It operates in two segments, The Active Ingredient Product Technology Industry and The Cosmeceutical Industry. The company is involved in the development and application of technology to the production of extracts and active ingredients from oats and other renewable plant resources. It adds value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company's products include natural active ingredients comprising beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides that are marketed to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; natural anti-aging skincare products; and veterinary therapeutic products, such as oat shampoos, ear cleansers, and dermal complexes/conditioners. Its products and technologies that are under research and development, or pre-commercial stage comprise a platform using its beta glucan formulations to deliver compounds for treatments in the personal and healthcare sectors; various novel enabling technologies, such as Pressurized Gas eXpanded drying technology; and technologies to enhance the content of avenanthramides. The company has a collaboration with the McMaster University to develop inhalable therapeutic for COVID-19. Ceapro Inc. was incorporated in 1997 and is headquartered in Edmonton, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Edmonton"
    },
    "397.F": {
        "short_name": "ELOXX PHARMACEUT.  DL-,01",
        "long_name": "Eloxx Pharmaceuticals, Inc.",
        "summary": "Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Waltham"
    },
    "3AC.F": {
        "short_name": "ACTINOGEN MEDICAL LTD.",
        "long_name": "Actinogen Medical Limited",
        "summary": "Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "3DM.F": {
        "short_name": "KINTARA THERAP.  DL-,001",
        "long_name": "Kintara Therapeutics, Inc.",
        "summary": "Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "3EE.F": {
        "short_name": "KANCERA AB",
        "long_name": "Kancera AB (publ)",
        "summary": "Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. It develops drugs for the treatment of inflammation and cancer. The company's drug development projects include ROR inhibitors for the treatment of leukemia and solid tumors; PFKFB3 inhibitors for reducing cancer's energy supply and inhibiting DNA repair; HDAC6 for the treatment of nerve inflammation and pain; and KAND567 and KAND145 that block the receptor for fractalkine and specific parts of the immune system, as well as for the treatment of heart injury after myocardial infarction. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "3G6.F": {
        "short_name": "GNI GROUP LTD.",
        "long_name": "GNI Group Ltd.",
        "summary": "GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. The company was founded in 2001 and is headquartered in Tokyo, Japan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "3HY.F": {
        "short_name": "ARIX BIOSCIENCE LS-,00001",
        "long_name": "Arix Bioscience plc",
        "summary": "Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "3MM.F": {
        "short_name": "ADVICENNE (PROM.) EO-,20",
        "long_name": "Advicenne S.A.",
        "summary": "Advicenne S.A., a late-stage biopharmaceutical company, develops pediatric therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its lead product is ADV7103, which has completed Phase III study for the treatment of distal renal tubular acidosis in children and adults, as well as in Phase III clinical studies for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility; Likozam to treat partial and generalized chronic refractory epilepsy in children and adults; and Levidcen, a granulated formulation of levetiracetam for the treatment of epilepsy in children and adults. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "3NQ.F": {
        "short_name": "NANOCARRIER CO. LTD",
        "long_name": "NanoCarrier Co., Ltd.",
        "summary": "NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan. Its product pipeline includes NC-6004 Cisplatin micelle for the treatment of pancreatic, head and neck, non-small cell lung, bladder, and biliary track cancers; and VB-111, a non-replicating Adeno 5 vector for the treatment of rGBM/ovarian cancer, etc. The company's product pipeline also comprise NC-6300 Epirubicin micelle for soft tissue sarcoma; NC-4016 Dach-platinum micelle for solid cancers; and NK105 Paclitaxel micella for the treatment of breast and gastric cancers. NanoCarrier Co., Ltd. was founded in 1996 and is headquartered in Kashiwa, Japan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Japan",
        "city": "Kashiwa"
    },
    "3O8.F": {
        "short_name": "OMEROS CORP. DL -,01",
        "long_name": "Omeros Corporation",
        "summary": "Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Seattle"
    },
    "4133.TW": {
        "short_name": "ABNOVA (TAIWAN) CORPORATION",
        "long_name": "Abnova (Taiwan) Corporation",
        "summary": "Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. It offers DNA and RNA, proteins/peptides, beads/dyes, lysates/slides, antibody pairs/kits, antibody and tissue arrays, in situ hydridization products, circulating rare cells, systems and automations, GMP and analyte specific reagents, and in vitro diagnostics. The company also provides MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, and IHC/pathology antibodies. In addition, the company's integrated solutions and services include gene synthesis and cytogenetics; peptide, protein expression, and conjugations; antibody production; and assay development services. Abnova (Taiwan) Corporation is headquartered in Taipei, Taiwan.",
        "currency": "TWD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TAI",
        "market": "tw_market",
        "country": "Taiwan",
        "city": "Taipei"
    },
    "4142.TW": {
        "short_name": "ADIMMUNE CORPORATION",
        "long_name": "Adimmune Corporation",
        "summary": "Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, an influenza vaccine; tetanus toxoid alum precipitated products used for prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent and Tetravalent influenza vaccines; Influenza A (H1N1) virus monovalent vaccines; and Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is based in Taichung City, Taiwan.",
        "currency": "TWD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TAI",
        "market": "tw_market",
        "country": "Taiwan",
        "city": "Taichung"
    },
    "41ON.F": {
        "short_name": "OUTLOOK THERAPEUT. DL-,01",
        "long_name": "Outlook Therapeutics, Inc.",
        "summary": "Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cranbury, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cranbury"
    },
    "41ON.SG": {
        "short_name": "Outlook Therapeutics Inc. Regis",
        "long_name": "Outlook Therapeutics, Inc.",
        "summary": "Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cranbury, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Cranbury"
    },
    "41X.F": {
        "short_name": "ARDELYX INC.  DL-,0001",
        "long_name": "Ardelyx, Inc.",
        "summary": "Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Fremont"
    },
    "44R3.F": {
        "short_name": "PHIO PHARMACEUT. DL-,0001",
        "long_name": "Phio Pharmaceuticals Corp.",
        "summary": "Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum M\u00c3\u00bcnchen. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Marlborough"
    },
    "4563.T": {
        "short_name": "ANGES INC",
        "long_name": "AnGes, Inc.",
        "summary": "AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; and Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan. It also has alliances with SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases; Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and Osaka University to develop a coronavirus vaccine. In addition, the company has a collaboration agreement with Brickell Biotech, Inc. to develop investigational plasmid DNA vaccine intended to prevent coronavirus in the United States, South America, and other markets. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Ibaraki"
    },
    "4564.T": {
        "short_name": "ONCOTHERAPY SCIENCE INC",
        "long_name": "OncoTherapy Science, Inc.",
        "summary": "OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Kawasaki"
    },
    "4565.T": {
        "short_name": "SOSEI GROUP CORP",
        "long_name": "Sosei Group Corporation",
        "summary": "Sosei Group Corporation discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of AZD4635, an adenosine A2a antagonist, which is in Phase II clinical trial for the treatment of solid tumors and metastatic castration resistant prostate cancer; HTL0016878, a muscarinic M4 agonist, which is in Phase I clinical trial for the treatment of Alzheimer's disease; and dual muscarinic M1/M4 agonist, which is in pre-clinical stage for the treatment of Alzheimer's disease. It also develops HTL0014242, a mGlu5 small molecule negative-allosteric modulator, which is in Phase I clinical trial for the treatment of certain neurological order; SSTR agonist, a novel somatostatin peptide agonist, which is in Phase I clinical trial for the treatment of endocrine disorders; HTL0022562, a calcitonin gene related peptide antagonist, which is in pre-clinical stage for the treatment of migraine and other severe headaches; GLP-1 antagonist, a potent glucagon-like peptide-1 antagonist, which is in pre-clinical stage for the treatment of severe hypoglycaemia in rare diseases; and GLP-2 agonist, a potent glucagon-like peptide-2 agonist, which is in pre-clinical stage for the treatment of intestinal disorders. In addition, the company's pipeline products include OX-1 antagonist to treat cocaine-use disorders; Apelin agonist for pulmonary arterial hypertension; GPR35 agonist to treat inflammatory bowel disease; H4 antagonist and PAR2 mAb for atopic dermatitis. Sosei Group Corporation has a strategic collaboration with Kymab, PeptiDream Inc., Pfizer, MorphoSys, Genentech, Takeda Pharmaceutical Company Limited, and Captor Therapeutics SA. The company was founded in 1990 and is headquartered in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "4571.T": {
        "short_name": "NANOCARRIER CO LTD",
        "long_name": "NanoCarrier Co., Ltd.",
        "summary": "NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan. Its product pipeline includes NC-6004 Cisplatin micelle for the treatment of pancreatic, head and neck, non-small cell lung, bladder, and biliary track cancers; and VB-111, a non-replicating Adeno 5 vector for the treatment of rGBM/ovarian cancer, etc. The company's product pipeline also comprise NC-6300 Epirubicin micelle for soft tissue sarcoma; NC-4016 Dach-platinum micelle for solid cancers; and NK105 Paclitaxel micella for the treatment of breast and gastric cancers. NanoCarrier Co., Ltd. was founded in 1996 and is headquartered in Kashiwa, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Kashiwa"
    },
    "4575.T": {
        "short_name": "CANBAS CO LTD",
        "long_name": "CanBas Co., Ltd.",
        "summary": "CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. The company develops CBP501, a calmodulin modulator for the treatment of tumors. It also develops CBS9106, a small molecule reversible inhibitor of Exportin-1 that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was founded in 2000 and is based in Numazu, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Numazu"
    },
    "4579.T": {
        "short_name": "RAQUALIA PHARMA INC",
        "long_name": "RaQualia Pharma Inc.",
        "summary": "RaQualia Pharma Inc. engages in the research and development of pharmaceutical and related businesses worldwide. The company offers Tegoprazan for gastroesophageal reflux diseases; Galliprant for pain management of pets; and ENTYCE for anorexia management of pets. It also provides Cyclooxygenase-2 Inhibitor that is in Phase I clinical trial for pain; Grapiprant, which is in Phase Ib clinical trial for the patients with colorectal cancer, Phase Ib/II clinical trial for the treatment of non-small cell lung cancer, and Phase I clinical trials for pain management and oncology field; and 5-HT2B Antagonist that has completed Phase I clinical trial for the treatment of irritable bowel syndrome. The company's products under development include 5-HT4 Partial Agonist for gastroparesis, functional dyspepsia, and chronic constipation; Motilin Receptor Agonist for gastroparesis, functional dyspepsia, and post-operative ileus; Ghrelin Receptor Agonist for the treatment of cancer-related anorexia/cachexia syndrome and spinal cord injury constipation; Selective Sodium Channel Blocker for pain and inflammation; Specific Ion Channels for gastrointestinal tract; Ziprasidone for the treatment of schizophrenia; P2X7 Receptor Antagonist for neuropathic pain; and TRPM8 Blocker Compounds for neuropathic pain. In addition, it licenses and sells intellectual property for pharmaceutical compounds and candidate compounds for clinical development. The company has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was founded in 2008 and is headquartered in Nagoya, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Nagoya"
    },
    "4583.T": {
        "short_name": "CHIOME BIOSCIENCE INC",
        "long_name": "Chiome Bioscience Inc.",
        "summary": "Chiome Bioscience Inc. engages in the research and development of drug discovery technology platform worldwide. The company provides drug discovery, development, and support services. It offers ADLib System, a monoclonal antibody generating technology for drug discovery and development. The company also provides protein expression and purification services; stable cell line generation services for recombinant protein and antibody production; and antibody generation services using ADLib system or B cell cloning techniques. Its product pipeline includes ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, neuroblastoma, etc.; CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, breast cancer (TNBC), etc.; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, colorectal cancer, etc.; and BMAA, an anti-semphorin3a antibody for treating diabetic macular edema. The company serves universities, research institutions, and pharmaceutical companies. It has a collaboration agreement with Velabs Therapeutics to discover modulatory and functional antibodies for its GPCR target genes. Chiome Bioscience Inc. was founded in 2005 and is headquartered in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "4587.T": {
        "short_name": "PEPTIDREAM INC",
        "long_name": "PeptiDream Inc.",
        "summary": "PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company uses its Peptide Discovery Platform System platform for the development of peptides. PeptiDream Inc. has a collaboration with Merck & Co. Inc. for the discovery and development of peptide therapeutics capable of neutralizing the SARS-CoV-2 virus (COVID19) and potential coronavirus outbreaks; and a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was founded in 2006 and is headquartered in Kawasaki, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Kawasaki"
    },
    "4591.T": {
        "short_name": "RIBOMIC INC",
        "long_name": "Ribomic Inc.",
        "summary": "Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. It develops drugs in the areas of pain, heart failure, achondroplasia, osteoarthritis, osteosclerosis, and fibrosis, as well as age-related macular degeneration. The company was founded in 2003 and is headquartered in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "4592.T": {
        "short_name": "SANBIO COMPANY LIMITED",
        "long_name": "SanBio Company Limited",
        "summary": "SanBio Company Limited develops, produces, and sells regenerative cell medicines for central nervous system. The company develops SB623, a therapeutic product that is in Phase II clinical trial for chronic motor deficit from traumatic brain injury. Its research pipeline products also comprise SB623 for strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618, a therapeutic agent for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease. SanBio Company Limited has an agreement with National University Corporation Asahikawa Medical University for the development of SB623 for the indication of retinal disease; Juntendo University to joint research into the production of pancreatic beta cells, as well as Ocumension (Hong Kong) Limited for the research, development, and commercialization of stem cell therapies for ophthalmic diseases; and Nippon Medical School to joint research into investigation of the efficacy of SB623 in the treatment of traumatic brain injury at subacute phase. The company was founded in 2001 and is headquartered in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "4593.T": {
        "short_name": "HEALIOS KK",
        "long_name": "Healios K.K.",
        "summary": "Healios K.K. engages in the research and development, and manufacture of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke. Healios K.K. has a license agreement with Athersys for the development of regenerative medicine products; and a research agreement with the National Cancer Center Japan to jointly research Healios' allogeneic iPS cell-derived gene-edited NK cells as an immune cell therapy for cancer. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was founded in 2011 and is headquartered in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "4596.T": {
        "short_name": "KUBOTA PHARMACEUTICAL HLDGS CO ",
        "long_name": "Kubota Pharmaceutical Holdings Co., Ltd.",
        "summary": "Kubota Pharmaceutical Holdings Co., Ltd. develops a portfolio of drugs and devices to preserve and restore vision worldwide. Its product pipeline comprises Emixustat hydrochloride, which is in Phase 3 clinical stage for the treatment of stargardt disease, and Phase 2 clinical stage for the treatment of proliferative diabetic retinopathy. The company is also developing human rhodopsin-based gene therapy for patients suffering from retinitis pigmentosa. In addition, it is developing home-based, patient self-monitoring optical coherence tomography devices. Kubota Pharmaceutical Holdings Co., Ltd. was founded in 2002 and is based in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "4599.T": {
        "short_name": "STEMRIM INC",
        "long_name": "StemRIM",
        "summary": "StemRIM, a biotechnology company, develops regeneration-guided medicines for the treatment of intractable diseases. The company focuses on the research and development of regeneration-inducing medicines that are applied to various diseases, such as epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, and stem cell gene therapy, as well as autologous cell collection devices for treatment. It also provides PJ1 regeneration induction medicine HMGB1 peptides, PJ2 regeneration induction drug new peptides, and PJ3 regeneration-inducing proteins derived from living bodies; PJ4 therapeutic autologous cell collection device; and PJ5 stem cell gene therapy technology. StemRIM was founded in 2006 and is headquartered in Ibaraki, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Ibaraki"
    },
    "471A.F": {
        "short_name": "ATYR PHARMA INC. DL -,001",
        "long_name": "aTyr Pharma, Inc.",
        "summary": "aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan; and a research collaboration with the Medical University of South Carolina to develop therapeutic antibodies that selectively target specific NRP2 isoforms. The company was founded in 2005 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "47M.F": {
        "short_name": "MEDMIRA INC.",
        "long_name": "MedMira Inc.",
        "summary": "MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America, the Caribbean, Europe, and the Asia Pacific. The company's research is focused on specific areas of the diagnostics market, such as rapid, point-of-care, and in vitro sectors. It offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. The company also provides Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis; and REVEALCOVID-19, an antibody test. In addition, it offers Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics. MedMira Inc. sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Halifax"
    },
    "4880.T": {
        "short_name": "CELLSOURCE CO LTD",
        "long_name": "CellSource Co., Ltd.",
        "summary": "CellSource Co., Ltd. manufactures regenerative medicines. The company was founded in 2015 and is based in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "4881.T": {
        "short_name": "FUNPEP COMPANY LTD",
        "long_name": "FunPep Company Limited",
        "summary": "FunPep Company Limited engages in the research and development of pharmaceuticals, cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, an intractable skin ulcer drug; FPP003, an antibody-inducing peptide that is in Phase I/IIa clinical study for the treatment of psoriasis in Australia, as well as is in preclinical studies for ankylosing spondylitis in Japan; and FPP004, an antibody-inducing peptide for pollinosis. The company was founded in 2013 and is based in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "4884.T": {
        "short_name": "KRINGLE PHARMA INC",
        "long_name": "Kringle Pharma, Inc.",
        "summary": "Kringle Pharma, Inc., a pharmaceutical biotechnology venture company, engages in the research and development of hepatocyte growth factor (HGF) protein medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis (ALS), ALS acute kidney injury, and vocal fold scar. Kringle Pharma, Inc. was founded in 2001 and is based in Ibaraki, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Ibaraki"
    },
    "4974.T": {
        "short_name": "TAKARA BIO INC",
        "long_name": "Takara Bio Inc.",
        "summary": "Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Kusatsu"
    },
    "4978.T": {
        "short_name": "REPROCELL INCORPORATED",
        "long_name": "ReproCELL Incorporated",
        "summary": "ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, and feeder cells; and 3D cell culture, labware, and drug discovery assays. The company also provides stem cell services, such as target cell isolation, iPSC reprogramming, and cell differentiation, as well as iPSC expansion, characterization, and banking services; and predictive drug discovery services in the areas of cardiac, vascular, respiratory, gastrointestinal, ADME/DMPK, skin/skin model, genitourinary, comparative pharmacology, and other assays. In addition, it offers human tissue samples, prospective collections, molecular, 3D cell, primary cell isolation, and DNA and RNA extraction services. ReproCELL Incorporated was founded in 2003 and is headquartered in Yokohama, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Yokohama"
    },
    "49B.F": {
        "short_name": "BEIGENE LTD",
        "long_name": "BeiGene, Ltd.",
        "summary": "BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; Hutchison China MediTech Limited; and Novartis. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "city": "Beijing"
    },
    "49BA.F": {
        "short_name": "BEIGENE LTD SP.ADR",
        "long_name": "BeiGene, Ltd.",
        "summary": "BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; Hutchison China MediTech Limited; and Novartis. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "city": "Beijing"
    },
    "4AJ.F": {
        "short_name": "ALK-ABELLO AS B  DK 10",
        "long_name": "ALK-Abell\u00f3 A/S",
        "summary": "ALK-Abell\u00c3\u00b3 A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, as well as sublingual drops and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company markets its products primarily under the ACARIZAX/ODACTRA, MITICURE, RAGWITEK, GRAZAX/GRASTEK, ITULAZAX, and CEDARCURE brand names. ALK-Abell\u00c3\u00b3 A/S was founded in 1923 and is headquartered in H\u00c3\u00b8rsholm, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Horsholm"
    },
    "4CX.F": {
        "short_name": "CYXONE AB  SK-,75",
        "long_name": "Cyxone AB (publ)",
        "summary": "Cyxone AB (publ), a clinical biotech company, develops immunomodulatory drugs for the treatment of autoimmune diseases. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and T20K that would enter clinical Phase I for multiple sclerosis. The company was founded in 2015 and is headquartered in Malm\u00c3\u00b6, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Malm\u00c3\u00b6"
    },
    "4DN.F": {
        "short_name": "DENALI THERAP.INC. DL-,01",
        "long_name": "Denali Therapeutics Inc.",
        "summary": "Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "4DN.MU": {
        "short_name": "DENALI THERAP.INC. DL-,01",
        "long_name": "Denali Therapeutics Inc.",
        "summary": "Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "4GB.F": {
        "short_name": "GOSSAMER BIO INC.",
        "long_name": "Gossamer Bio, Inc.",
        "summary": "Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "4GB.MU": {
        "short_name": "GOSSAMER BIO INC.",
        "long_name": "Gossamer Bio, Inc.",
        "summary": "Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "4K4.F": {
        "short_name": "STAYBLE THERAPEUTICS AB",
        "long_name": "Stayble Therapeutics AB (publ)",
        "summary": "Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) is based in Gothenburg, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Gothenburg"
    },
    "4KB.SG": {
        "short_name": "Krystal Biotech Inc. Registered",
        "long_name": "Krystal Biotech, Inc.",
        "summary": "Krystal Biotech, Inc., a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa. It is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in preclinical stage for treating aesthetic skin conditions; KB104 that is in preclinical stage for the treatment of Netherton Syndrome; and KB5xx for treating chronic skin diseases, which is in discovery stage. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Pittsburgh"
    },
    "4LS.F": {
        "short_name": "ATHERSYS INC. NEW DL-,001",
        "long_name": "Athersys, Inc.",
        "summary": "Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cleveland"
    },
    "4NX1.F": {
        "short_name": "LUMOS PHARMA  DL -,01",
        "long_name": "Lumos Pharma, Inc.",
        "summary": "Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Austin"
    },
    "4OD.F": {
        "short_name": "ODONATE TRERAPEUT. DL-,01",
        "long_name": "Odonate Therapeutics, Inc.",
        "summary": "Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "4OD.MU": {
        "short_name": "ODONATE TRERAPEUT. DL-,01",
        "long_name": "Odonate Therapeutics, Inc.",
        "summary": "Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "4QK.F": {
        "short_name": "CODEXIS INC.  DL-,01",
        "long_name": "Codexis, Inc.",
        "summary": "Codexis, Inc. discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "4RY.F": {
        "short_name": "AKESO INC.  O.N.",
        "long_name": "Akeso, Inc.",
        "summary": "Akeso, Inc., a clinical-stage biopharmaceutical company, engages in discovery, development and commercialization of therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody for tumor infiltrating lymphocytes, which is in Phase Ia/Ib trial in Australia, and five Phase Ib/II and Phase II trials in China; Penpulimab AK105, a monoclonal antibody that is in Phase III clinical trials for squamous and non-squamous NSCLC, as well as Phase II clinical trial for relapsed/refractory classical hodgkin's lymphoma; and AK112, a PD-1/VEGF bi-specific antibody that is in a Phase I clinical study for the treatment of solid tumors. It is also developing AK101, a monoclonal antibody, which is in Phase IIb clinical trial to treat severe psoriasis patients; AK111, a monoclonal antibody for autoimmune disease target IL-17; and Ebronucimab (AK102) for the treatment of cardiovascular diseases. The company has collaboration agreements with Merck; Sino Biopharm; Dawnrays Pharma; and Zhongshan Health Technology Industrial Base Development Co., Ltd. and Torch Development Zone Linhai Industry Park Development Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "city": "Zhongshan"
    },
    "4SG.F": {
        "short_name": "SOL-GEL TECHN. IS-,10",
        "long_name": "Sol-Gel Technologies Ltd.",
        "summary": "Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, which has completed Phase II clinical trials for the treatment of acne vulgaris; Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea; SGT-210, a epidermal growth factor receptor inhibitor, which is in development for the treatment of palmoplantar keratoderma and non-melanoma skin cancer; and tapinarof and roflumilast to treat psoriasis and other dermatological indications. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "4XB.F": {
        "short_name": "XBIOTECH INC.",
        "long_name": "XBiotech Inc.",
        "summary": "XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. Its product candidates include 514G3, an anti-infective antibody that is in Phase II clinical trial for the treatment of Staphylococcus Aureus infections; and other anti-infectious disease antibodies, which are in pre-clinical development to treat Clostridium Difficile, influenza, Ebola, and Herpes Varicella Zoster (Chickenpox). XBiotech Inc. has a collaboration with BioBridge Global for the development of potential COVID 19 treatment based on natural antibodies from recovered patients. The company was founded in 2005 and is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Austin"
    },
    "4XC1.F": {
        "short_name": "KALVISTA PHARMA.  DL-,001",
        "long_name": "KalVista Pharmaceuticals, Inc.",
        "summary": "KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "4YL.F": {
        "short_name": "NANOFORM FINLAND OYJ",
        "long_name": "Nanoform Finland Oyj",
        "summary": "Nanoform Finland Oy provides nanotechnology and drug particle engineering services for the pharmaceutical and biotechnology industries in Finland and internationally. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients in the creation of active pharmaceutical ingredients nanoparticles directly from solution. Its technology and services help in increasing the bioavailability of drug molecules and developing new drugs. The company was founded in 2015 and is headquartered in Helsinki, Finland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Finland",
        "city": "Helsinki"
    },
    "51B.F": {
        "short_name": "BIOVENTIX PLC  LS -,05",
        "long_name": "Bioventix PLC",
        "summary": "Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. The company was founded in 2003 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "51S.F": {
        "short_name": "CYNATA THERAPEUTICS",
        "long_name": "Cynata Therapeutics Limited",
        "summary": "Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Carlton"
    },
    "52X.F": {
        "short_name": "MAGLE CHEMOSWED HOLDING",
        "long_name": "Magle Chemoswed Holding AB (publ)",
        "summary": "Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacture of pharmaceutical products and technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); research, development, and production of products in the areas of wound care and diagnostics, with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical device technology products in the areas of advanced wound care, surgical and diagnostics, drug delivery, which include its marketed technology products comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; and SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company is headquartered in Malm\u00c3\u00b6, Sweden. Magle Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Malm\u00c3\u00b6"
    },
    "5CV.F": {
        "short_name": "CUREVAC N.V.  O.N.",
        "long_name": "CureVac N.V.",
        "summary": "CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in T\u00c3\u00bcbingen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "T\u00c3\u00bcbingen"
    },
    "5D8.F": {
        "short_name": "DEINOVE  EO-,40",
        "long_name": "Deinove SA",
        "summary": "DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME Ol\u00c3\u00a9oactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioM\u00c3\u00a9rieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Ol\u00c3\u00a9os-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Grabels"
    },
    "5DG.F": {
        "short_name": "OCUMENSION THER.DL-,00001",
        "long_name": "Ocumension Therapeutics",
        "summary": "Ocumension Therapeutics operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company researches and develops, manufactures, and commercializes ophthalmic drugs. It offers drugs for the treatment of blepharitis, infective conjunctivitis, allergic conjunctivitis, dry eye, cataract, glaucoma, uveitis, age-related macular degeneration, and myopia. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "city": "Suzhou"
    },
    "5GV.F": {
        "short_name": "GENOVIS AB  SE-,40",
        "long_name": "Genovis AB (publ.)",
        "summary": "Genovis AB (publ.) develops, produces, and sells tools for developing drugs for customers in the medical device and pharmaceutical industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1 at one specific site above the hinge and generating intact Fab and Fc fragments; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for producing a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues, including arginine linked to proline; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company was founded in 1999 and is based in Lund, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "5HB.F": {
        "short_name": "SHAGHAI HAOH.BI.TE.H YC 1",
        "long_name": "Shanghai Haohai Biological Technology Co., Ltd.",
        "summary": "Shanghai Haohai Biological Technology Co., Ltd. engages in the research and development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. The company offers ophthalmology, medical aesthetics and wound care, orthopedics, anti-adhesion, and homostasis products. It also provides medical sodium hyaluronate, medical chitosan, medical collagen sponge, and rhEGF, as well as biological reagents and materials. In addition, the company engages in the manufacture and sale of contact lens and intraocular lens materials, machines, and accessories; and investment and trading businesses. Further, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "city": "Shanghai"
    },
    "5HT.F": {
        "short_name": "HARPOON THERAPEUTICS",
        "long_name": "Harpoon Therapeutics, Inc.",
        "summary": "Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "5HU.F": {
        "short_name": "HEMOGENYX PHARM.PLC LS-01",
        "long_name": "Hemogenyx Pharmaceuticals Plc",
        "summary": "Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing products for bone marrow/hematopoietic stem cell BM/HSC transplant market, including CDX bi-specific antibody and CAR-T therapy for eliminating relapsed and/or refractory acute myeloid leukaemia, acute lymphoblastic leukaemia, and myelodysplastic syndrome; and Human Postnatal Hemogenic Endothelial Cells, a cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has collaboration with GlobalCo. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "5IU.F": {
        "short_name": "ISOFOL MEDICAL AB",
        "long_name": "Isofol Medical AB (publ)",
        "summary": "Isofol Medical AB (publ), a biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops Arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was founded in 2008 and is headquartered in Gothenburg, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Gothenburg"
    },
    "5IV1.F": {
        "short_name": "IMV INC.",
        "long_name": "IMV Inc.",
        "summary": "IMV Inc. operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma). DPX-Survivac is evaluated in multiple Phase 2 clinical trials across six cancer indications and also in combination with Merck's Keytruda in two clinical trials. The company is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts. In addition, it is developing DPX-RSV, a DPX-based vaccine candidate targeting the respiratory syncytial virus strain A. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Dartmouth"
    },
    "5J9.F": {
        "short_name": "FLUICELL AB",
        "long_name": "Fluicell AB (publ)",
        "summary": "Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Gothenburg"
    },
    "5KW.F": {
        "short_name": "SKINBIO THERAP  LS-,01",
        "long_name": "SkinBioTherapeutics Plc",
        "summary": "SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. The company focuses on the development of SkinBiotix technology for use in cosmetic, infection control, and eczema applications. It has an agreement with Croda International Plc for the design and manufacture of a new active cosmetic skincare ingredient based on its SkinBiotix skin microbiome technology. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Macclesfield, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Macclesfield"
    },
    "5LB.F": {
        "short_name": "BIOVAXYS TECHNOLOGY CORP.",
        "long_name": "BioVaxys Technology Corp.",
        "summary": "BioVaxys LLC, a clinical stage company that develops immunotherapeutic vaccines for antiviral and individualized cancer therapy. The company was founded in 2018 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "5LU.F": {
        "short_name": "SIMRIS ALG AB  B",
        "long_name": "Simris Alg AB (publ)",
        "summary": "Simris Alg AB (publ) manufactures and sells dietary supplements and algae-based foods in Sweden and internationally. It offers Simris Algae Omega-3, a plant-based marine omega-3 EPA and DHA line; and a line of algae-based products, such as finest chlorella, spirulina sprinkles, boosting astaxanthin, flower power algae tea, and sun candy algae tea under the Simris Select brand. The company was founded in 2010 and is headquartered in Hammenh\u00c3\u00b6g, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Hammenh\u00c3\u00b6g"
    },
    "5MC1.F": {
        "short_name": "LEAP THERAPEUTICS DL-,001",
        "long_name": "Leap Therapeutics, Inc.",
        "summary": "Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. Its clinical stage programs also include TRX518, a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "5MPA.F": {
        "short_name": "MIDATECH PHARMA LS-,001",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "5MPD.F": {
        "short_name": "MIDATECH PHARMA SP.ADR/5",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "5NP.F": {
        "short_name": "HAVN LIFE SCIENCES INC.",
        "long_name": "HAVN Life Sciences Inc.",
        "summary": "HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The company was founded in 2020 and is headquartered in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "5NR.F": {
        "short_name": "NANOBIOTIX INH.  EO-,03",
        "long_name": "Nanobiotix S.A.",
        "summary": "Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "5RT.F": {
        "short_name": "RUBIUS THERAPEUT. DL-,001",
        "long_name": "Rubius Therapeutics, Inc.",
        "summary": "Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "5VA.MU": {
        "short_name": "VAXCYTE INC.  DL -,001",
        "long_name": "Vaxcyte, Inc.",
        "summary": "Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "Foster City"
    },
    "5VT.F": {
        "short_name": "VTV THERAPEUTICS A DL-,01",
        "long_name": "vTv Therapeutics Inc.",
        "summary": "vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "High Point"
    },
    "600161.SS": {
        "short_name": "BEIJING TIANTAN BIOLOGICAL PROD",
        "long_name": "Beijing Tiantan Biological Products Co., Ltd.",
        "summary": "Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, and sale and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood injection immunoglobulin; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; and human immunoglobulin. The company was founded in 1998 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Beijing"
    },
    "600200.SS": {
        "short_name": "JIANGSU WUZHONG INDUSTRIAL",
        "long_name": "Jiangsu Wuzhong Industrial Co., Ltd",
        "summary": "Jiangsu Wuzhong Industrial Co., Ltd, together with its subsidiaries, engages in pharmaceutical, real estate, and chemical businesses in China. It develops, produces, and sells anti-infective, digestive system, cardiovascular, cerebrovascular, antiviral, vitamin, and hemostatic drugs; and immunomodulations, including biopharmaceuticals, chemical drugs, and modern Chinese medicines. The company offers its products in various forms, such as infusion solutions, water and powder injections, capsules, granules, tablets, emulsions, and oral liquids. It also engages in the research, development, production, and sale of dyes and dye intermediates; and the fields of commercial housing and affordable housing development. Jiangsu Wuzhong Industrial Co., Ltd was founded in 1994 and is based in Suzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Suzhou"
    },
    "600201.SS": {
        "short_name": "JINYU BIO-TECHNOLOGY CO LTD",
        "long_name": "Jinyu Bio-technology Co., Ltd.",
        "summary": "Jinyu Bio-technology Co., Ltd. engages in the development, production, and sale of veterinary vaccines in China. The company was formerly known as Inner Mongolia Jinyu Group Co., Ltd. and changed its name to Jinyu Bio-technology Co., Ltd. in December 2015. Jinyu Bio-technology Co., Ltd. was founded in 1992 and is based in Hohhot, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Hohhot"
    },
    "600645.SS": {
        "short_name": "ZHONGYUAN UNION CELL & GENE ENG",
        "long_name": "Vcanbio Cell & Gene Engineering Corp., Ltd",
        "summary": "Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the detection and storage of stem cell sources in the People's Republic of China. The company is involved in the storage of newborns and adults cells; and preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, and adipose-derived stem cells and immune cells. It also provides genetic testing services related to children's genes, non-invasive prenatal genes, oncology and cardiovascular genes, and adult susceptibility genes. In addition, the company produces and sells biochemical diagnostic reagents; and beauty and make-up products. Vcanbio Cell & Gene Engineering Corp., Ltd is based in Tianjin, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Tianjin"
    },
    "603229.SS": {
        "short_name": "ZHEJIANG AUSUN PHARMACEUTICAL C",
        "long_name": "Zhejiang Ausun Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Ausun Pharmaceutical Co., Ltd. develops, produces, and sells specialty drug substances and pharmaceutical intermediates. The company offers prostaglandins and its intermediates; APIs; fluorine and antibacterial products; and intermediates. It also provides products for liver disease, respiratory system, and cardiovascular and cerebrovascular, as well as entecavir for the treatment of hepatitis B. In addition, the company is involved in the customized processing, and research and development business. Zhejiang Ausun Pharmaceutical Co., Ltd. was founded in 2010 is headquartered in Linhai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Linhai"
    },
    "603233.SS": {
        "short_name": "DASHENLIN PHARMACEUTICAL GROUP ",
        "long_name": "DaShenLin Pharmaceutical Group Co., Ltd.",
        "summary": "DaShenLin Pharmaceutical Group Co., Ltd. manufactures, wholesales, and retails pharmaceutical products in China. The company was founded in 1999 and is based in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Guangzhou"
    },
    "603392.SS": {
        "short_name": "BEIJING WANTAI BIOLOGICAL PHARM",
        "long_name": "Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.",
        "summary": "Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. researches, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides COVID 19, HIV and HTLV, Hepatitis, EV-71, and Tuberculosis diagnostics test kits; Hepatitis C and Syphilis detection reagents; automated immunoassays; ELISA kits and rapid tests for infectious disease diagnostics; chemiluminescence and clinical chemistry reagents; immunodiagnostic reagents; and Hepatitis E and human papillomavirus vaccines. It serves blood banks, hospitals and clinics, reference laboratories, border inspection centers, blood-processing companies, and research institutes. The company was founded in 1991 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Beijing"
    },
    "603439.SS": {
        "short_name": "GUIZHOU SANLI PHARMACEUTICAL CO",
        "long_name": "GuiZhou SanLi Pharmaceutical Co., Ltd.",
        "summary": "GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Guiyang"
    },
    "603566.SS": {
        "short_name": "PULIKE BIOLOGICAL",
        "long_name": "Pulike Biological Engineering, Inc.",
        "summary": "Pulike Biological Engineering, Inc. engages in the research and development, production, and operation of veterinary biological products and drugs. It offers vaccines and antibodies for poultry; and poultry and pig medicines, as well as other medicines. The company is headquartered in Luoyang City, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Luoyang City"
    },
    "603590.SS": {
        "short_name": "BEIJING KONRUNS PHARMACEUTICAL ",
        "long_name": "Beijing Konruns Pharmaceutical Co.,Ltd.",
        "summary": "Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research, production, and sale of various drugs. The company offers Haemocoagulase Agkistrodon used in auxiliary stopping of capillary hemorrhage on superficial wound in surgical operation; GuShuKang Keli and GuShuKang Jiaonang products for osteoporosis; Fangshen Zhiyang Keli for acute hives of wind-heat syndrome; Siyu Yangxue Yishen to alleviate waist/knee soreness, listlessness, palpitation, and dyspnea in climacteric women; Qingxuan Zhitan Wan for symptoms caused by liver-yang hyperactivity and liver-fire flaming; Xiaoaiping Pian for esophagus, stomach, and lung cancer; and Guchi Xiaotong Jiaonang for hyperosteogeny rheumarthritis, and rheumatalgia. It also provides Liganlong Keli for acute/chronic, persistent, and chronic active hepatitis; Naoluotong Jiaonang for various cerebrovascular diseases and symptoms caused by qi deficiency and blood stasis; Compound Bismuth Aluminate Tablet for chronic gastritis, and the symptoms caused by hyperacidity; Shenshi Tong Keli for stones in kidney, renal pelvis, urinary bladder, and ureter; Naoxueshuan Pian to prevent and treat the stroke; and Kanggan Jiedu Keli for wind-heat cold. In addition, the company offers calcium carbonate capsules; Fosfomycin Calcium Capsule to lower urinary tract infection and intestinal infection; Yansheqing Keli for respiratory tract inflammation, bronchitis, pneumonia, acute tonsillitis, urinary system infection, and biliary tract infection; Sanqi Zhixue Pian to disperse blood stasis, stop bleeding, subside swelling, and relieve pain; Da Feng Wan for waist/leg soreness, limb numbness, and tendon/bone soreness; Yankening Pian to clear away heat, purge intense fire, diminish inflammation and relieve dysentery; Kudancao Jiaonang to eliminate dampness, and purge fire in liver and gallbladder; and Tongmai Pian to invigorate blood circulation and dredge channels. The company was founded in 1999 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Beijing"
    },
    "603718.SS": {
        "short_name": "SHANGHAI HILE BIO-",
        "long_name": "Shanghai Hile Bio-Technology Co., Ltd.",
        "summary": "Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers porcine parvovirus oil emulsion inactivated vaccines, Pseudorabies live vaccines, Streptococcus suis disease inactivated vaccines, Trivalent live vaccines, swine blast vaccines, porcine reproductive and respiratory syndrome vaccines, Piglet Escherichia coli K88/K99 Bivalent gene engineering inactivated vaccines, swine atrophic rhinitis inactivated vaccines, pig infectious gastroenteritis and porcine epidemic diarrhea inactivated vaccines, porcine circovirus type 2 inactivated vaccines, and porcine encephalitis live vaccines. It also provides newcastle disease low virulent live vaccines; newcastle disease, infectious bronchitis, and Avian Influenza triple inactivated vaccines; newcastle disease, infectious bronchitis, and egg drop syndrome triple inactivated oil emulsion vaccines; avian infectious bronchitis live vaccines; newcastle disease and avian infectious bronchitis combined living vaccines; newcastle disease inactivated vaccines; newcastle disease low virulent live vaccines; chicken Marek's disease turkey herpes virus live vaccines; chicken pox live vaccines; duck plague live vaccines; chicken newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; newcastle disease and Avian Influenza inactivated vaccines; chicken infectious rhinitis inactivated vaccines; chicken infectious bursal disease live vaccines; and chicken infectious rhinitis and newcastle disease inactivated vaccines, as well as various other live and inactivated vaccines. The company was founded in 1981 and is based in Shanghai, China. Shanghai Hile Bio-Technology Co., Ltd. is a subsidiary of Shanghai Haoyuan Science And Technology Development Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Shanghai"
    },
    "603739.SS": {
        "short_name": "QINGDAO VLAND BIOTECH CO LTD",
        "long_name": "Qingdao Vland Biotech INC.",
        "summary": "Qingdao Vland Biotech INC. engages in the research and development of enzymes, probiotics, and animal vaccines and health products. It offers animal feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological products, such as live and inactivated poultry, and swine vaccines, as well as antibodies; poultry drugs comprising anti-parastic, antiviral, and nutritional drugs, as well as disinfectants; and traditional Chinese veterinary medicines for scale and avian breeding, livestock, and laying hens. It serves agriculture, animal husbandry, textile, paper making, household cleaning and detergents, food, biofuel, environmental protection, and other industries. The company was founded in 2005 and is headquartered in Qingdao, China. Qingdao Vland Biotech INC. is a subsidiary of Qingdao Kangdien Industrial Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Qingdao"
    },
    "603896.SS": {
        "short_name": "ZHEJIANG SHOUXIANGU PHARMACEUTI",
        "long_name": "Zhejiang Shouxiangu Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Shouxiangu Pharmaceutical Co., Ltd. researches, develops, and sells Chinese medicine products. It offers ganoderma lucidum spore powder, dendrobium officinale, crocus sativus, and other health products. The company was founded in 1997 and is based in Jinhua, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Jinhua"
    },
    "605116.SS": {
        "short_name": "AURISCO PHARMACEUTICAL CO LTD",
        "long_name": "Aurisco Pharmaceutical Co.,Ltd.",
        "summary": "Aurisco Pharmaceutical Co.,Ltd. engages in research, manufacturing, and marketing of intermediates, specialty active pharmaceutical ingredients (API's), and formulations catering to the pharmaceutical market worldwide. The company offers steroids, oncology, antiretroviral, and other APIs and intermediates. It also provides contract manufacturing services and related development works for chemicals, intermediates, and API's. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Tiantai"
    },
    "605199.SS": {
        "short_name": "HAINAN HULUWA PHARMACEUTICAL GR",
        "long_name": "Hainan Huluwa Pharmaceutical Group Co., Ltd.",
        "summary": "Hainan Huluwa Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of drugs in the areas of Children's respiratory and digestive systems in China. Its primary products include 4 grams of pediatric lung heat cough granules and capsules. The company was founded in 2005 and is based in Haikou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Haikou"
    },
    "609.F": {
        "short_name": "ABIONYX PHARMA SA  EO-,05",
        "long_name": "ABIONYX Pharma SA",
        "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Labege"
    },
    "609.SG": {
        "short_name": "ABIONYX PHARMA",
        "long_name": "ABIONYX Pharma SA",
        "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "France",
        "city": "Labege"
    },
    "6090.T": {
        "short_name": "HUMAN METABOLOME TECHNOLOGIES I",
        "long_name": "Human Metabolome Technologies, Inc.",
        "summary": "Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solution for cancer metabolism, metabolic flux analysis, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was founded in 2003 and is headquartered in Tsuruoka, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tsuruoka"
    },
    "6160.HK": {
        "short_name": "BEIGENE",
        "long_name": "BeiGene, Ltd.",
        "summary": "BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; Hutchison China MediTech Limited; and Novartis. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Beijing"
    },
    "6541.TW": {
        "short_name": "TANVEX BIOPHARMA INC",
        "long_name": "Tanvex BioPharma, Inc.",
        "summary": "Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. Its products pipeline include TX01, which has completed phase III clinical trials; TX05, which is in phase III clinical trials for the treatment of cancer; TX16 which is in phase I; and other products. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.",
        "currency": "TWD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TAI",
        "market": "tw_market",
        "country": "Cayman Islands",
        "city": "George Town"
    },
    "65G.F": {
        "short_name": "NEXTCELL PHARMA AB",
        "long_name": "NextCell Pharma AB",
        "summary": "NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases, as well as for use in kidney transplants. It also provides a service under the Cellaviva brand name, which is a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. The company has a partnership with Bonzun Health Information AB. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Huddinge"
    },
    "6826.HK": {
        "short_name": "HAOHAI BIOTEC",
        "long_name": "Shanghai Haohai Biological Technology Co., Ltd.",
        "summary": "Shanghai Haohai Biological Technology Co., Ltd. engages in the research and development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. The company offers ophthalmology, medical aesthetics and wound care, orthopedics, anti-adhesion, and homostasis products. It also provides medical sodium hyaluronate, medical chitosan, medical collagen sponge, and rhEGF, as well as biological reagents and materials. In addition, the company engages in the manufacture and sale of contact lens and intraocular lens materials, machines, and accessories; and investment and trading businesses. Further, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Shanghai"
    },
    "688068.SS": {
        "short_name": "BEIJING HOTGEN BIOTECH CO LTD",
        "long_name": "Beijing Hotgen Biotech Co., Ltd.",
        "summary": "Beijing Hotgen Biotech Co., Ltd. develops, manufactures, and sells in-vitro diagnostic (IVD), point-of-care-testing (POCT) and biodefense products worldwide. Its IVD products include instruments and kits for aiding diagnosis in cardiovascular diseases, chronic liver diseases, tumor screening and risk stratification, kidney injury, rheumatoid arthritis, infection, infectious diseases, and risk assessment of preterm labor. The company's biodefense and food safety product line covers various bioterrorist agents, including Yersinia pestis, Anthrax, Brucella, Ricin, Abrin, etc.; and various food borne pathogenic bacteria, such as cholera, E. coli, salmonella, etc. Its biodefense products are used for military anti-bioterrorism campaign, customs inspection and quarantine, on-site inspection in centers for disease control, mobile bio-emergency inspection, on-site detection of food-borne pathogenic microorganisms, etc. Beijing Hotgen Biotech Co., Ltd. was founded in 2005 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Beijing"
    },
    "688166.SS": {
        "short_name": "BRIGHTGENE BIO-MEDICAL TECHNOLO",
        "long_name": "BrightGene Bio-Medical Technology Co., Ltd.",
        "summary": "BrightGene Bio-Medical Technology Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of medicines, and generic APIs and FDFs in China. Its product pipeline includes immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumor, and novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastasis. The company also develops Eribulin, Trabectedin, Fondaparinux, Caspofungin, and non-biological molecules; macromolecules, such as Ferumoxytol and Ferric pyrophosphate citrate; and ADC cytotoxic payloads comprising Maytansinoids, Auristatins, and Calicheamicin. It offers cardiovascular, antibacterial, ADC, oncology, antifungal, iron supplement, anti-HBV, veterinary, and immuno products. The company was founded in 2001 and is based in Suzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Suzhou"
    },
    "688177.SS": {
        "short_name": "BIO THERA SOLUTIONS LTD",
        "long_name": "Bio-Thera Solutions,Ltd.",
        "summary": "Bio-Thera Solutions, Ltd engages in the research and development of biosimilar therapeutics for the treatment of cancer, autoimmune, cardiovascular, and other serious medical conditions. It develops antibody therapeutics, such as BAT8001, BAT1306, BAT4306F, BAT5906, BAT8003, and BAT2094; and biosimilars, including BAT1406, BAT1706, BAT1806, and BAT2506. The company is based in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Guangzhou"
    },
    "688180.SS": {
        "short_name": "SHANGHAI JUNSHI BIOSCIENCES CO ",
        "long_name": "Shanghai Junshi Biosciences Co., Ltd.",
        "summary": "Shanghai Junshi Biosciences Co., Ltd., a bio-pharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, auto-immunity, and neurologic diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYIR for the indication of melanoma, mucosal melanoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophagus carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira that is in Phase I clinical trial for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for injection that is in Phase II clinical trial for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection; and JS001 that is in Phase Ib clinical trial in the United States. In addition, the company is developing JS501, a biosimilar of Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection, which are in Phase I clinical trials. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus; collaboration with Merck & Co., Inc. to explore new combination treatment for head and neck cancer patients; and a research collaboration and license agreement with Revitope Oncology Inc to explore immunotherapies with precision-targeted T-cell engaging antibodies. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Shanghai"
    },
    "688222.SS": {
        "short_name": "HITGEN INC",
        "long_name": "HitGen Inc.",
        "summary": "HitGen Inc. operates a platform for early-stage drug discovery research focusing on DNA encoded chemical libraries (DELs). Its DELs include encoded syntheses for diverse, drug-likesmall molecule, and macrocycle compounds. The company has internal projects in research, with Phase I, PCC generation, and in lead generation stages that focus on oncology, CVD, inflammation/respiratory, metabolism, and ophthalmology therapeutic areas. HitGen Inc. has a drug discovery research collaboration with Gilead Sciences, Galapagos NV, Kymera Therapeutics, Inc., and Morphic Therapeutic to identify potential small molecule leads; and a strategic partnership with Oncodesign Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme for the identification and progression of new chemical entities. The company was founded in 2012 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Chengdu"
    },
    "688278.SS": {
        "short_name": "XIAMEN AMOYTOP BIOTECH CO LTD",
        "long_name": "Xiamen Amoytop Biotech Co., Ltd.",
        "summary": "Xiamen Amoytop Biotech Co., Ltd. engages in the manufacture, marketing, and sale of recombinant protein drugs using genetic engineering technology in China. It offers formulations, reagents, and APIs, as well as custom-manufacturing services. The company was founded in 1996 and is based in Xiamen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Xiamen"
    },
    "688366.SS": {
        "short_name": "SHANGHAI HAOHAI BIOLOGICAL TECH",
        "long_name": "Shanghai Haohai Biological Technology Co., Ltd.",
        "summary": "Shanghai Haohai Biological Technology Co., Ltd. engages in the research and development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. The company offers ophthalmology, medical aesthetics and wound care, orthopedics, anti-adhesion, and homostasis products. It also provides medical sodium hyaluronate, medical chitosan, medical collagen sponge, and rhEGF, as well as biological reagents and materials. In addition, the company engages in the manufacture and sale of contact lens and intraocular lens materials, machines, and accessories; and investment and trading businesses. Further, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Shanghai"
    },
    "688488.SS": {
        "short_name": "JIANGSU AIDEA PHARMACEUTICAL CO",
        "long_name": "Jiangsu Aidea Pharmaceutical Co., Ltd.",
        "summary": "Jiangsu Aidea Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products. It offers folium sennae granules, powdered bacillus tablets, clindamycin hydrochloride capsules, sodium bicarbonate tablets, nitrendipine tablets, metronidazole tablets, compound gentamycin sulfate and procaine hydrochloride sulfate granules, and cefradine capsules, as well as raw materials. The company was founded in 2009 and is based in Yangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Yangzhou"
    },
    "688513.SS": {
        "short_name": "CHENGDU EASTON BIO PHARMACEUTIC",
        "long_name": "Chengdu Easton Biopharmaceuticals Co., Ltd.",
        "summary": "Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry , and urinary system therapeutic categories. The company was founded in 2009 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Chengdu"
    },
    "688520.SS": {
        "short_name": "SINOCELLTECH GROUP LTD",
        "long_name": "Sinocelltech Group Limited",
        "summary": "Sinocelltech Group Limited, a biotech company, focuses on the development of technologies for the development and manufacturing of recombinant proteins, monoclonal antibodies, and vaccines in China. The company is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Beijing"
    },
    "688526.SS": {
        "short_name": "WUHAN KEQIAN BIOLOGY CO LTD",
        "long_name": "Wuhan Keqian Biology Co.,Ltd",
        "summary": "Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. It offers vaccines for swine, poultry, and pets, as well as diagnostic reagents. The company was founded in 2001 and is based in Wuhan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "city": "Wuhan"
    },
    "6996.HK": {
        "short_name": "ANTENGENE-B",
        "long_name": "Antengene Corporation Limited",
        "summary": "Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-010 (selinexor), a SINE compound targeting XPO1, a key nuclear export protein for the treatment of hematologic malignancies, such as multiple myeloma and DLBCL. The company's products in pipeline include ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of various advanced solid tumors and hematological malignancies; ATG-016 (eltanexor), a SINE compound; ATG-527 (verdinexor), which is in Phase I clinical trial primarily for oncology; ATG-019, an oral dual PAK4/NAMPT inhibitor for the treatment of NHL and advanced solid tumors; and ATG-017, an oral selective ERK1/2 inhibitor for the treatment of various solid tumors and hematological malignancies. Its products in pre-clinical stage include ATG-101, a PD-L1/CD137 (4-1BB) bi-specific antibody for the treatment of hematological malignancies and solid tumors; ATG-018, a small molecule inhibitor targeting ataxia telangiectasia and Rad3 related (ATR) kinase for the treatment of hematological malignancies and solid tumors; ATG-022, a humanized IgG1 monoclonal antibody against human Claudin 18.2 (CLDN18.2) antigen for the treatment of solid tumors; and ATG-012, a KRAS G12C inhibitor against KRAS oncoprotein for the treatment of solid tumors. The company was founded in 2016 and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Shanghai"
    },
    "6998.HK": {
        "short_name": "JHBP-B",
        "long_name": "JHBP (CY) Holdings Limited",
        "summary": "JHBP (CY) Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer; GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors; GB242, an infliximab (Remicade) biosimilar; and GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate. JHBP (CY) Holdings Limited was founded in 2007 and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Shanghai"
    },
    "6A3A.F": {
        "short_name": "AUTOLUS THERAP. SP.ADR/1",
        "long_name": "Autolus Therapeutics plc",
        "summary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "6C1.F": {
        "short_name": "CYTOMX THERAPEUTICS INC.",
        "long_name": "CytomX Therapeutics, Inc.",
        "summary": "CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "6KB.MU": {
        "short_name": "KINNATE BIOPHARMA -,0001",
        "long_name": "Kinnate Biopharma Inc.",
        "summary": "Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. The company's lead product candidate is KIN002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. Its other products in preclinical stage include KIN003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. Kinnate Biopharma Inc. was founded in 2018 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "6LJ.F": {
        "short_name": "MATINAS BIOPH.HLD.DL-,001",
        "long_name": "Matinas BioPharma Holdings, Inc.",
        "summary": "Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Bedminster"
    },
    "6LU.F": {
        "short_name": "NOVAN INC.  DL-,0001",
        "long_name": "Novan, Inc.",
        "summary": "Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, a topical anti-viral product candidate. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was founded in 2006 and is headquartered in Morrisville, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Morrisville"
    },
    "6MX.F": {
        "short_name": "EIDOS THERAPEUT.  DL-,001",
        "long_name": "Eidos Therapeutics, Inc.",
        "summary": "Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "6NQ.F": {
        "short_name": "BIOMED-LUBLIN WYT.SUR.",
        "long_name": "BIOMED-LUBLIN Wytw\u00f3rnia Surowic i Szczepionek S.A.",
        "summary": "BIOMED-LUBLIN Wytw\u00c3\u00b3rnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50, a product used in treating superficial (non-muscle invasive) bladder tumour; GAMMA anty HBs 200 and Gamma anty-HBs 1000 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; L\u00c3\u00b6wenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; L\u00c3\u00b6wenstein-Jensen medium containing glycerol is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, RPMI 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was founded in 1944 and is based in Lublin, Poland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Poland",
        "city": "Lublin"
    },
    "6PB.F": {
        "short_name": "PASCAL BIOSCIENCES INC.",
        "long_name": "Pascal Biosciences Inc.",
        "summary": "Pascal Biosciences Inc., a biopharmaceutical company, researches and develops products for the treatment of cancer, and for the enhancement of immune system. Its development portfolio includes PAS-403, a small molecule therapeutic advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory molecule to enhance the efficacy of checkpoint inhibitors. The company is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was founded in 2013 and is headquartered in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "6RC.F": {
        "short_name": "REPROCELL INC.",
        "long_name": "ReproCELL Incorporated",
        "summary": "ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, and feeder cells; and 3D cell culture, labware, and drug discovery assays. The company also provides stem cell services, such as target cell isolation, iPSC reprogramming, and cell differentiation, as well as iPSC expansion, characterization, and banking services; and predictive drug discovery services in the areas of cardiac, vascular, respiratory, gastrointestinal, ADME/DMPK, skin/skin model, genitourinary, comparative pharmacology, and other assays. In addition, it offers human tissue samples, prospective collections, molecular, 3D cell, primary cell isolation, and DNA and RNA extraction services. ReproCELL Incorporated was founded in 2003 and is headquartered in Yokohama, Japan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Japan",
        "city": "Yokohama"
    },
    "6T4.F": {
        "short_name": "TREVENA INC.  DL-,001",
        "long_name": "Trevena, Inc.",
        "summary": "Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Chesterbrook"
    },
    "6UF.F": {
        "short_name": "NEONMIND BIOSCIENCES INC.",
        "long_name": "NeonMind Biosciences Inc.",
        "summary": "NeonMind Biosciences Inc. engages in the discovery, development, and commercialization of medicinal and psychedelic mushrooms for mental illnesses. It is developing psilocybin based products comprising mushroom-infused beverages and other mushroom-infused products to treat weight loss and management, depression, cardiovascular, obesity, diabetes, and heart diseases. The company was formerly known as Flourish Mushroom Labs Inc. and changed its name to NeonMind Biosciences Inc. in April 2020. NeonMind Biosciences Inc. was incorporated in 2019 and is headquartered in Vancouver, Canada. NeonMind Biosciences Inc. is a subsidiary of The Yield Growth Corp.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "6VX.F": {
        "short_name": "HEALIOS K.K.",
        "long_name": "Healios K.K.",
        "summary": "Healios K.K. engages in the research and development, and manufacture of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke. Healios K.K. has a license agreement with Athersys for the development of regenerative medicine products; and a research agreement with the National Cancer Center Japan to jointly research Healios' allogeneic iPS cell-derived gene-edited NK cells as an immune cell therapy for cancer. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was founded in 2011 and is headquartered in Tokyo, Japan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "6XP.SG": {
        "short_name": "XSpray Pharma AB Namn-Aktier o.",
        "long_name": "Xspray Pharma AB (publ)",
        "summary": "Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was founded in 2003 and is based in Solna, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "6Y4.F": {
        "short_name": "VICORE PHARMA HOLDING AB",
        "long_name": "Vicore Pharma Holding AB (publ)",
        "summary": "Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), diffuse systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; and license agreement with Nanologica AB (publ). The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Gothenburg"
    },
    "6Z4.F": {
        "short_name": "CRINETICS PHARM. DL-,001",
        "long_name": "Crinetics Pharmaceuticals, Inc.",
        "summary": "Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "6ZD.F": {
        "short_name": "ONENESS B.GDR REGS/5 TA10",
        "long_name": "Oneness Biotech Co., Ltd.",
        "summary": "Oneness Biotech Co., Ltd. operates as a biopharmaceutical company in Taiwan. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti- liver cancer drug that completed Phase I clinical trials. It is also developing SNS01, SNA02, and SNA03 that are in pre-clinical stage for the treatment of cancer; FB704A that is in Phase I clinical trial for the treatment of rheumatoid arthritis, cancer, and cytokine storms; and FB825, which is in Phase II clinical trial for treating allergic diseases and asthma. The company was founded in 2008 and is based in Taipei City, Taiwan. Oneness Biotech Co., Ltd. operates as a subsidiary of Microbio Co., Ltd.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Taiwan",
        "city": "Taipei"
    },
    "71M.F": {
        "short_name": "MYOVANT SCIENC. DL-,00001",
        "long_name": "Myovant Sciences Ltd.",
        "summary": "Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "72C1.F": {
        "short_name": "EIGER BIOPHARM. DL -,0001",
        "long_name": "Eiger BioPharmaceuticals, Inc.",
        "summary": "Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Palo Alto"
    },
    "7774.T": {
        "short_name": "JAPAN TISSUE ENGINEERING CO LTD",
        "long_name": "Japan Tissue Engineering Co., Ltd.",
        "summary": "Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company offers autologous cultured epidermis and cartilage to medical institutions for the purpose of medical treatment. It also provides tissue-engineered medical products, which are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured, and then transplanted back to the same patient. In addition, the company researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, it offers regenerative medical products contract development and manufacturing, and contract research services. Japan Tissue Engineering Co., Ltd. was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. operates as a subsidiary of Fujifilm Corporation.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Gamagori"
    },
    "7776.T": {
        "short_name": "CELLSEED INC",
        "long_name": "CellSeed Inc.",
        "summary": "CellSeed Inc. develops regenerative medicine products primarily in Japan and internationally. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides contract development and manufacturing services. The company was founded in 2001 and is headquartered in Tokyo, Japan.",
        "currency": "JPY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "JPX",
        "market": "jp_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "78D.F": {
        "short_name": "ALZINOVA AB",
        "long_name": "Alzinova AB",
        "summary": "Alzinova AB, a biotechnology company, engages in the discovery and development of therapeutics for the treatment of Alzheimer's disease in Sweden. It focuses on developing ALZ-101, an oligomer-directed vaccine; and ALZ-201, a monoclonal antibody that is used for the treatment of oligomeric A\u00c3\u009f. The company was founded in 2011 and is based in M\u00c3\u00b6lndal, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "M\u00c3\u00b6lndal"
    },
    "7AL.F": {
        "short_name": "ALLIGATOR BIOSC. AB O.N.",
        "long_name": "Alligator Bioscience AB (publ)",
        "summary": "Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. It develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and bispecific antibody formats for the development of novel dual-action antibodies. The company develops ADC-1013, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial for tumor-directed treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB (CD137) in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer; and ATOR-1144, a bispecific antibody to treat solid tumors and hematologic cancers. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has operations in the United States, Sweden, Asia, and internationally. The company has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527. Alligator Bioscience AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "7AY1.F": {
        "short_name": "ACTINIUM PHARMAC. DL-,001",
        "long_name": "Actinium Pharmaceuticals, Inc.",
        "summary": "Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, developing Antibody Radiation-Conjugates (ARCs). The ARCs selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. It also offers Iomab-B (I-131 apamistamab), which is in a phase III study for Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company is also developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "7BG.F": {
        "short_name": "BERGENBIO ASA",
        "long_name": "BerGenBio ASA",
        "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Bergen"
    },
    "7CA.F": {
        "short_name": "CAMURUS AB",
        "long_name": "Camurus AB (publ)",
        "summary": "Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, North America, and Asia. It offers Buvidal, an injection solution for the treatment of opioid dependence; and episil oral liquid is a medical device for the treatment of inflammatory and painful conditions in the oral cavity. The company's products pipeline also includes CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment acromegaly and in phase II clinical trials for the treatment neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension. In addition, it develops CAM2032 for the treatment of prostate cancer; CAM4071, which has completed Phase I clinical trials for the treatment of Endocrine disorder; CAM4072 that is in phase III clinical trials for the treatment of rare genetic obesity disorders; and CAM4083, a pre-clinical stage product for treatment of myasthenia gravis, immune-mediated necrotizing myopathy, and other tissue disorders, as well as CAM2047, CAM2048, and CAM2058 for the treatment of chemotherapy induced nausea and vomiting, postoperative pain, and postoperative nausea and vomiting. The company was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB (publ) is a subsidiary of Sandberg Development AB.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "7CB1.F": {
        "short_name": "CLEVELAND BIOLABS DL-,005",
        "long_name": "Cleveland BioLabs, Inc.",
        "summary": "Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Buffalo"
    },
    "7DC.F": {
        "short_name": "DIACEUTICS PLC  LS-,002",
        "long_name": "Diaceutics PLC",
        "summary": "Diaceutics Plc provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic regulation, turnaround time, and sample availability analysis services; diagnostic tracking services, including lab tracking, patient insights, and physician segmentation services; and diagnostic payers research, diagnostic clinical landscape, integrated mapping research, buying process research, and testers/non-testers research services. The company also provides diagnostic planning services consisting of strategic and tactical planning, launch planning, diagnostic partner selection, and financial forecast services; commercialization services comprising content creation; LabEd/workshops, diagnostic adboards, conference support, and proficiency testing services; and Diagnostic reimbursement services. Diaceutics Plc was founded in 2005 and is headquartered in Belfast, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Belfast"
    },
    "7EYA.F": {
        "short_name": "EYEGATE PHARMACEUT.DL-,01",
        "long_name": "EyeGate Pharmaceuticals, Inc.",
        "summary": "EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Waltham"
    },
    "7OC.F": {
        "short_name": "ONCOCYTE CORP.",
        "long_name": "OncoCyte Corporation",
        "summary": "OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Irvine"
    },
    "7OT.F": {
        "short_name": "OTONOMY INC.  DL-,001",
        "long_name": "Otonomy, Inc.",
        "summary": "Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of M\u00c3\u00a9ni\u00c3\u00a8re's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "7PO.F": {
        "short_name": "POXEL S.A.  EO -,02",
        "long_name": "Poxel S.A.",
        "summary": "Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lyon"
    },
    "7TLA.F": {
        "short_name": "TAIWAN LIPOSOME SP.ADR/2",
        "long_name": "Taiwan Liposome Company, Ltd.",
        "summary": "Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III trial for knee osteoarthritis pain. The company's product candidates also comprises TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that is in Phase II clinical trial for post-surgical pain management; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; and TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Taiwan",
        "city": "Taipei"
    },
    "7UM.F": {
        "short_name": "ULTIMOVACS AS  DK1",
        "long_name": "Ultimovacs ASA",
        "summary": "Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company engages in performing a clinical development program with clinical trials in Europe and the United States. Its lead product candidate is UV1, a peptide-based vaccine, which completed Phase I clinical trial that induces T cell response against the universal cancer antigen telomerase. The company was founded in 2011 and is headquartered in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "7V3.F": {
        "short_name": "CANTARGIA AB",
        "long_name": "Cantargia AB (publ)",
        "summary": "Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases. It specializes in antibody-based treatment aimed at the molecular target Interleukin-1 Receptor Accessory Protein (IL1RAP), which has the potential to be used against various forms of cancer, as well as for autoimmune and inflammatory diseases. The company is developing CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system. It is also developing CANxx antibodies against IL1RAP for the treatment of autoimmune and inflammatory diseases. Cantargia AB (publ) has a collaboration agreement with BioWa. The company was founded in 2010 and is based in Lund, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "82C.F": {
        "short_name": "CIRCASSIA GROUP PLC",
        "long_name": "Circassia Group Plc",
        "summary": "Circassia Group Plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through three segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; Tudorza for the treatment of COPD; and Duaklir, a fixed-dose combination of the long-acting muscarinic antagonist aclidinium bromide and long-acting beta agonist formoterol fumarate, which is administered twice-daily through the breath actuated Pressair inhaler for the maintenance treatment of COPD. It is also developing LungFit, a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. The company markets its products directly to specialists in the United States, the United Kingdom, China, Italy, and Germany, as well as through a network of partners internationally. Circassia Group Plc has a collaboration agreement with AstraZeneca to promote Tudorza and Duaklir for COPD treatment; and the United States and Chinese commercial rights to LungFit. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "84C.F": {
        "short_name": "CLENE INC.",
        "long_name": "Clene Inc.",
        "summary": "Clene Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The company has a nanotechnology drug platform for the development of orally administered neurotherapeutic drugs. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; and NM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc. is based in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "8AP.F": {
        "short_name": "AGIOS PHARMACEUT. DL-,001",
        "long_name": "Agios Pharmaceuticals, Inc.",
        "summary": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "8AT.F": {
        "short_name": "ACLARIS THERAPEUTICS DL 1",
        "long_name": "Aclaris Therapeutics, Inc.",
        "summary": "Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Wayne"
    },
    "8BTA.F": {
        "short_name": "BRIACELL THERAPEUTICS",
        "long_name": "BriaCell Therapeutics Corp.",
        "summary": "BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "West Vancouver"
    },
    "8EM.F": {
        "short_name": "EDITAS MEDICINE  DL-,0001",
        "long_name": "Editas Medicine, Inc.",
        "summary": "Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "8EV.F": {
        "short_name": "EVGEN PHARMA PLC LS-,0025",
        "long_name": "Evgen Pharma plc",
        "summary": "Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Wilmslow"
    },
    "8FW.F": {
        "short_name": "TRYP THERAPEUTICS INC.",
        "long_name": "Tryp Therapeutics Inc.",
        "summary": "Tryp Therapeutics Inc., a pharmaceutical company, focuses on developing compounds with known activity and/or safety profiles for the treatment of rare or orphan diseases and other diseases with high unmet medical needs. The company's lead development program is psilocybin-for-neuropsychiatry, or PFN, which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its program candidates include TRP-8802 that has indication for fibromyalgia, a condition characterized by pain that is chronic and widespread; and TRP-1001, an oral formulation of razoxane evaluating for the treatment of soft tissue sarcoma. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was founded in 2019 and is headquartered in Kelowna, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Kelowna"
    },
    "8IY.F": {
        "short_name": "YUMANITY THERAPEUTICS INC",
        "long_name": "Yumanity Therapeutics, Inc.",
        "summary": "Yumanity Therapeutics Inc. discovers and develops disease-modifying therapies for neurodegenerative diseases. It focuses on discovering disease-modifying therapies for patients with Parkinson's, amyotrophic lateral sclerosis, and Alzheimer's diseases. The company concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding. Yumanity Therapeutics Inc. has a strategic research collaboration and license agreement with Merck. The company was founded in 2014 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boston"
    },
    "8NE2.F": {
        "short_name": "CALADRIUS BIOSC.  DL-,001",
        "long_name": "Caladrius Biosciences, Inc.",
        "summary": "Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Basking Ridge"
    },
    "8NN.F": {
        "short_name": "NORDIC NANOVECTOR NK 0,20",
        "long_name": "Nordic Nanovector ASA",
        "summary": "Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for haematological cancers. The company's lead product candidate is Betalutin, an antibody-radionuclide-conjugate, which has completed Phase I/IIa clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChemBio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was founded in 2009 and is headquartered in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "8OP.SG": {
        "short_name": "Opiant Pharmaceuticals Inc. Reg",
        "long_name": "Opiant Pharmaceuticals, Inc.",
        "summary": "Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Santa Monica"
    },
    "8QQ.F": {
        "short_name": "ABCELLERA BIOLOGICS",
        "long_name": "AbCellera Biologics Inc.",
        "summary": "AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "8STN.F": {
        "short_name": "SORRENTO THER.NEW DL-0001",
        "long_name": "Sorrento Therapeutics, Inc.",
        "summary": "Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "8SV1.F": {
        "short_name": "WPD PHARMACEUTICALS",
        "long_name": "WPD Pharmaceuticals Inc.",
        "summary": "WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious disease. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat CNS tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of GBM, melanoma, and other cancers that is in the pre-clinical trial; and Annamycin to treat AML and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is based in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "9926.HK": {
        "short_name": "AKESO-B",
        "long_name": "Akeso, Inc.",
        "summary": "Akeso, Inc., a clinical-stage biopharmaceutical company, engages in discovery, development and commercialization of therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody for tumor infiltrating lymphocytes, which is in Phase Ia/Ib trial in Australia, and five Phase Ib/II and Phase II trials in China; Penpulimab AK105, a monoclonal antibody that is in Phase III clinical trials for squamous and non-squamous NSCLC, as well as Phase II clinical trial for relapsed/refractory classical hodgkin's lymphoma; and AK112, a PD-1/VEGF bi-specific antibody that is in a Phase I clinical study for the treatment of solid tumors. It is also developing AK101, a monoclonal antibody, which is in Phase IIb clinical trial to treat severe psoriasis patients; AK111, a monoclonal antibody for autoimmune disease target IL-17; and Ebronucimab (AK102) for the treatment of cardiovascular diseases. The company has collaboration agreements with Merck; Sino Biopharm; Dawnrays Pharma; and Zhongshan Health Technology Industrial Base Development Co., Ltd. and Torch Development Zone Linhai Industry Park Development Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Zhongshan"
    },
    "9939.HK": {
        "short_name": "KINTOR PHARMA-B",
        "long_name": "Kintor Pharmaceutical Limited",
        "summary": "Kintor Pharmaceutical Limited, a biopharmaceutical company, engages in the research and development of drugs for the treatment of various cancers and other androgen receptor (AR) - related diseases in China, the United States, and Taiwan. The company's lead drug candidates include Proxalutamide, a small molecule second generation AR antagonist that is in various clinical trials for metastatic castration-resistant prostate cancer and breast cancer; and Pyrilutamide, which is in various clinical trials for androgenetic alopecia and acne vulgaris. It also develops ALK-1 for the treatment of metastatic hepatocellular carcinoma and liver cancer; Detorsertib, a second-generation mTOR inhibitor for the treatment of metastatic solid tumours; and GT1708F, for the treatment of leukaemia and basal-cell carcinoma. The company was founded in 2009 and is headquartered in Suzhou, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Suzhou"
    },
    "9969.HK": {
        "short_name": "INNOCARE-B",
        "long_name": "InnoCare Pharma Limited",
        "summary": "InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It is developing Orelabrutinib (ICP-022), a Bruton's tyrosine kinase that is in registrational trials for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed and refractory mantle cell lymphoma; in Phase II studies for patients with relapsed and refractory marginal zone lymphoma, relapsed and refractory central nervous system lymphoma, and relapsed and refractory Waldenstrom's macroglobulinemia; and in a Phase I clinical trial for follicular lymphoma patients, as well as Phase I basket trial for B-cell malignancies. The company is also developing ICP-192, a pan-inhibitor of fibroblast growth factor receptor (FGFR) that is in Phase I/IIa clinical trial to define its maximum tolerated dose and/or optimal biological dose, and pharmacokinetics/ pharmacodynamics in patients with solid tumors; and ICP-105, a FGFR4 inhibitor, which is in Phase I dose escalation trial for the treatment of advanced hepatocellular carcinoma. Its preclinical stage products include ICP-723, a pan-inhibitor of tropomyosin-related kinase family to treat patients with neurotrophic tyrosine receptor kinase fusion-positive cancers; and ICP-330, a small-molecule inhibitor of tyrosine kinase 2 for the treatment of various T-cell mediated autoimmune disorders, such as psoriasis, inflammatory bowel disease, and systemic lupus erythematosus. The company was founded in 2015 and is headquartered in Wanchai, Hong Kong.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "Hong Kong",
        "city": "Wanchai"
    },
    "9995.HK": {
        "short_name": "REMEGEN-B",
        "long_name": "RemeGen Co., Ltd.",
        "summary": "RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in the People's Republic of China and internationally. The company's products in various stages of development include Telitacicept (RC18) for use in the treatment of autoimmune diseases, such as systemic lupus erythematosus, neuromyelitis optica spectrum disorder, rheumatoid arthritis, IgA nephritis, Sj\u00c3\u00b6gren's syndrome, multiple sclerosis, and myasthenia gravis; and Disitamab Vedotin (RC48) and RC98 for use in the treatment of various cancers. It is also developing RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; and RC88, which is in Phase 1 clinical trials for use in the treatment of diabetic macular edema, as well as pre-clinical products, such as RC108, RC118, RC138, RC148, and RC158 to treat various solid tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "city": "Yantai"
    },
    "99B.F": {
        "short_name": "QUIAPEG PHARMAC.H.SK-1,20",
        "long_name": "QuiaPEG Pharmaceuticals Holding AB (publ)",
        "summary": "QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "9EP.F": {
        "short_name": "ENANTA PHARMA.INC. DL-,01",
        "long_name": "Enanta Pharmaceuticals, Inc.",
        "summary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Watertown"
    },
    "9IB.SG": {
        "short_name": "Infant Bacterial Therapeutics N",
        "long_name": "Infant Bacterial Therapeutics AB (publ)",
        "summary": "Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "9PT.MU": {
        "short_name": "PLIANT THERA.INC.DL-,0001",
        "long_name": "Pliant Therapeutics, Inc.",
        "summary": "Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of av\u00c3\u009f6 and av\u00c3\u009f1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of av\u00c3\u009f1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "9U9.F": {
        "short_name": "UNITY BIOTECHN.  DL-,0001",
        "long_name": "Unity Biotechnology, Inc.",
        "summary": "Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase II clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee; UBX1325, which is Phase I clinical trial for the treatment of diabetic macular edema; and UBX1967 for the treatment of ophthalmologic diseases. It is also developing programs in pulmonary disorders and neurological disorders, as well as kidney and liver diseases. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "A1LN34.SA": {
        "short_name": "ALNYLAM PHARDRN",
        "long_name": "Alnylam Pharmaceuticals, Inc.",
        "summary": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "A1LX34.SA": {
        "short_name": "ALEXION PHARDRN",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "city": "Boston"
    },
    "A1PA.F": {
        "short_name": "ACASTI PHARMA INC.",
        "long_name": "Acasti Pharma Inc.",
        "summary": "Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Laval"
    },
    "A1V.F": {
        "short_name": "APTORUM GROUP LTD A DL1",
        "long_name": "Aptorum Group Limited",
        "summary": "Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "A28.F": {
        "short_name": "AFFIMED N.V.  EO-,01",
        "long_name": "Affimed N.V.",
        "summary": "Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; Genentech; and Roivant Sciences. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Heidelberg"
    },
    "A6X.F": {
        "short_name": "AXICHEM AB A",
        "long_name": "aXichem AB",
        "summary": "aXichem AB develops, patents, and markets natural-analogue industrial compounds for the marine, pest control, feed ingredient, and medical application markets in Sweden and internationally. It offers aXiphen-repellent, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; aXiphen-feed ingredient for pig and poultry diets; and aXiphen for use in various foods and dietary supplements, as well as in the pharmaceutical industry. The company is based in Malm\u00c3\u00b6, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Malm\u00c3\u00b6"
    },
    "A89.F": {
        "short_name": "ADOCIA SAS  EO -,10",
        "long_name": "Adocia SA",
        "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lyon"
    },
    "A8C1.F": {
        "short_name": "ABCAM PLC  LS -,002",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "A8C3.F": {
        "short_name": "ABCAM PLC SP.ADR 1 LS-002",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "AAVXF": {
        "short_name": "ABIVAX",
        "long_name": "ABIVAX Soci\u00e9t\u00e9 Anonyme",
        "summary": "ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "AB3A.F": {
        "short_name": "SAREPTA THERAP.  DL-,0001",
        "long_name": "Sarepta Therapeutics, Inc.",
        "summary": "Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "ABC.L": {
        "short_name": "ABCAM PLC ORD 0.2P",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "ABCL": {
        "short_name": "AbCellera Biologics Inc.",
        "long_name": "AbCellera Biologics Inc.",
        "summary": "AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "ABCM": {
        "short_name": "Abcam plc",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "ABCZF": {
        "short_name": "ABCAM PLC",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "ABEO": {
        "short_name": "Abeona Therapeutics Inc.",
        "long_name": "Abeona Therapeutics Inc.",
        "summary": "Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "ABIO": {
        "short_name": "ARCA biopharma, Inc.",
        "long_name": "ARCA biopharma, Inc.",
        "summary": "ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Westminster"
    },
    "ABNX.PA": {
        "short_name": "ABIONYX PHARMA",
        "long_name": "ABIONYX Pharma SA",
        "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Labege"
    },
    "ABS.MI": {
        "short_name": "ARTERRA BIOSCIENCE",
        "long_name": "Arterra Bioscience S.p.A.",
        "summary": "Arterra Bioscience S.p.A., a research-based biotech company, engages in the research and development of various ingredients and natural solutions. It develops technological platforms, extraction processes, and raw materials for use in the cosmetics, agriculture, and nutraceutics sectors. The company was founded in 2003 and is based in Naples, Italy.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MIL",
        "market": "it_market",
        "country": "Italy",
        "city": "Napoli"
    },
    "ABUS": {
        "short_name": "Arbutus Biopharma Corporation",
        "long_name": "Arbutus Biopharma Corporation",
        "summary": "Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Warminster"
    },
    "ABVC": {
        "short_name": "AMERICAN BRIVISION HOLDING CORP",
        "long_name": "American BriVision (Holding) Corporation",
        "summary": "American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; and ABV-1601 for treating depression in cancer patients. It has a co-development agreement with Rgene Corporation; collaboration agreement with BioHopeKing Corporation to develop ABV-1501; and collaborative agreement with BioFirst Corporation to co-develop BFC-1401 vitreous substitute for Vitrectom; and license with BioFirst Corporation to research and develop a medical device, ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. The company was founded in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Fremont"
    },
    "ABVX.PA": {
        "short_name": "ABIVAX",
        "long_name": "ABIVAX Soci\u00e9t\u00e9 Anonyme",
        "summary": "ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ACAD": {
        "short_name": "ACADIA Pharmaceuticals Inc.",
        "long_name": "ACADIA Pharmaceuticals Inc.",
        "summary": "ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ACBM": {
        "short_name": "ACRO BIOMEDICAL CO LTD",
        "long_name": "Acro Biomedical Co., Ltd.",
        "summary": "Acro Biomedical Co., Ltd. develops and markets nutritional products. It sells cordycepin and cordyceps powder, a fungus used in traditional Chinese medicine; and metallothionein MT-3 elizer, a protein powder used in health supplements. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd. in January 2017. Acro Biomedical Co., Ltd. was founded in 2014 and is based in Fishers, Indiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Fishers"
    },
    "ACE.ST": {
        "short_name": "Ascelia Pharma AB",
        "long_name": "Ascelia Pharma AB (publ)",
        "summary": "Ascelia Pharma AB (publ) operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase III for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase II for the treatment of gastric cancer. The company was founded in 2000 and is headquartered in Malm\u00c3\u00b6, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Malm\u00c3\u00b6"
    },
    "ACER": {
        "short_name": "Acer Therapeutics Inc.",
        "long_name": "Acer Therapeutics Inc.",
        "summary": "Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of induced Vasomotor Symptoms. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Newton"
    },
    "ACET": {
        "short_name": "Adicet Bio, Inc.",
        "long_name": "Adicet Bio, Inc.",
        "summary": "Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors or T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Its products pipeline includes ADI-001, which is in Phase 1 clinical study to treat non-Hodgkin's lymphoma; and ADI-002 that is in Phase 1 clinical study for the treatment of hepatocellular carcinoma and other solid tumors. The company is based in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Menlo Park"
    },
    "ACHFF": {
        "short_name": "ARCH BIOPARTNERS INC",
        "long_name": "Arch Biopartners Inc.",
        "summary": "Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant bacterial infections, primarily in the lungs and wounds, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "ACHV": {
        "short_name": "Achieve Life Sciences, Inc.",
        "long_name": "Achieve Life Sciences, Inc.",
        "summary": "Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "ACIU": {
        "short_name": "AC Immune SA",
        "long_name": "AC Immune SA",
        "summary": "AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Lausanne"
    },
    "ACOR": {
        "short_name": "Acorda Therapeutics, Inc.",
        "long_name": "Acorda Therapeutics, Inc.",
        "summary": "Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Ardsley"
    },
    "ACOU.ST": {
        "short_name": "AcouSort AB",
        "long_name": "AcouSort AB (publ)",
        "summary": "AcouSort AB (publ), a biotech company, develops proprietary bioanalytical and clinical applications based on acoustophoresis. It offers AcouTrap, a tabletop research platform for acoustic trapping; AcouPlasma, a blood-plasma separation module that enables analysis of blood plasma from whole blood samples; and AcouWash, a stand-alone table top research tool, which applies acoustic forces to focus cells. The company was founded in 2010 and is based in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "ACPH.BR": {
        "short_name": "ACACIA PHARMA",
        "long_name": "Acacia Pharma Group plc",
        "summary": "Acacia Pharma Group plc, a hospital pharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, other invasive procedures, or cancer chemotherapy treatments in the United States and internationally. The company's lead product is BAREMSIS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also comprise APD403, an intravenous and oral amisulpride that has completed Phase II clinical trials for the chemotherapy-induced nausea and vomiting treatment; and BYFAVO, an ultra-short-acting and reversible intravenous benzodiazepine sedative/anesthetic, which has completed Phase III clinical trials for the use in invasive medical procedures, such as colonoscopy and bronchoscopy. The company's products are primarily serves anesthesiologists and oncologists. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "ACR.AX": {
        "short_name": "ACRUX FPO",
        "long_name": "Acrux Limited",
        "summary": "Acrux Limited, together with its subsidiaries, develops and commercializes generic and specialty topical pharmaceuticals in Australia, Germany, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. Acrux Limited was founded in 1998 and is based in West Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "West Melbourne"
    },
    "ACRS": {
        "short_name": "Aclaris Therapeutics, Inc.",
        "long_name": "Aclaris Therapeutics, Inc.",
        "summary": "Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Wayne"
    },
    "ACST": {
        "short_name": "Acasti Pharma, Inc.",
        "long_name": "Acasti Pharma Inc.",
        "summary": "Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Canada",
        "city": "Laval"
    },
    "ACST.V": {
        "short_name": "ACASTI PHARMA INC",
        "long_name": "Acasti Pharma Inc.",
        "summary": "Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Laval"
    },
    "ACW.AX": {
        "short_name": "ACTINOGEN FPO",
        "long_name": "Actinogen Medical Limited",
        "summary": "Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "ADAP": {
        "short_name": "Adaptimmune Therapeutics plc",
        "long_name": "Adaptimmune Therapeutics plc",
        "summary": "Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Abingdon"
    },
    "ADCT": {
        "short_name": "ADC Therapeutics SA",
        "long_name": "ADC Therapeutics SA",
        "summary": "ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are ADCT-402, an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and ADCT-301, an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 and ADCT-602, as well as preclinical product candidates, including ADCT-701 and ADCT-901. ADC Therapeutics SA has a collaboration and license agreement with Genmab A/S. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Epalinges"
    },
    "ADIL": {
        "short_name": "Adial Pharmaceuticals, Inc",
        "long_name": "Adial Pharmaceuticals, Inc.",
        "summary": "Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of treatment for addictions. Its lead product is AD04, a selective serotonin-3 antagonist for the treatment of alcohol use disorder. The company was founded in 2010 and is based in Charlottesville, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Charlottesville"
    },
    "ADL.MC": {
        "short_name": "ADL BIONATUR SOLUTIONS, S.A.",
        "long_name": "ADL Bionatur Solutions, S.A.",
        "summary": "ADL Bionatur Solutions, S.A. engages in the research, development, manufacturing, and commercialization of products in biotech and pharmaceutical industry in Spain. It provides solutions in health, nutrition, cosmetics, and materials. The company was founded in 1954 and is headquartered in C\u00c3\u00a1diz, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MCE",
        "market": "es_market",
        "country": "Spain",
        "city": "C\u00c3\u00a1diz"
    },
    "ADMA": {
        "short_name": "ADMA Biologics Inc",
        "long_name": "ADMA Biologics, Inc.",
        "summary": "ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Ramsey"
    },
    "ADO.AX": {
        "short_name": "ANTEO TECH FPO",
        "long_name": "AnteoTech Limited",
        "summary": "AnteoTech Limited engages in developing, commercializing, manufacturing, and distributing products for the life sciences research, vitro diagnostics, energy, and medical device markets primarily in Australia. Its principal technology products include AnteoCoat, which is applicable to the energy sector in lithium-ion batteries; AnteoBind that is applicable to point of care, in vitro, and life science diagnostic sectors. The company also manufactures and sells COVID-19 antigen testing kits. AnteoTech Limited has collaboration agreements with Axxin for for COVID-19 anigen test. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited was incorporated in 1995 and is headquartered in Eight Mile Plains, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Eight Mile Plains"
    },
    "ADOC.PA": {
        "short_name": "ADOCIA",
        "long_name": "Adocia SA",
        "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lyon"
    },
    "ADOCY": {
        "short_name": "ADOCIA",
        "long_name": "Adocia SA",
        "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Lyon"
    },
    "ADPT": {
        "short_name": "Adaptive Biotechnologies Corpor",
        "long_name": "Adaptive Biotechnologies Corporation",
        "summary": "Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "ADTX": {
        "short_name": "ADiTx Therapeutics, Inc.",
        "long_name": "ADiTx Therapeutics, Inc.",
        "summary": "ADiTx Therapeutics, Inc., a life sciences company, focuses on developing nucleic acid-based technologies for addressing the rejection of transplanted organs, autoimmune diseases, and allergies. The company is developing Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology that utilizes an approach, which mimics the way the body naturally induces tolerance to its own tissues. It also develops ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was founded in 2017 and is headquartered in Loma Linda, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Loma Linda"
    },
    "ADVIC.PA": {
        "short_name": "ADVICENNE",
        "long_name": "Advicenne S.A.",
        "summary": "Advicenne S.A., a late-stage biopharmaceutical company, develops pediatric therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its lead product is ADV7103, which has completed Phase III study for the treatment of distal renal tubular acidosis in children and adults, as well as in Phase III clinical studies for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility; Likozam to treat partial and generalized chronic refractory epilepsy in children and adults; and Levidcen, a granulated formulation of levetiracetam for the treatment of epilepsy in children and adults. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ADVM": {
        "short_name": "Adverum Biotechnologies, Inc.",
        "long_name": "Adverum Biotechnologies, Inc.",
        "summary": "Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "ADXN": {
        "short_name": "Addex Therapeutics Ltd",
        "long_name": "Addex Therapeutics Ltd",
        "summary": "Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Geneva"
    },
    "ADXN.SW": {
        "short_name": "ADDEX N",
        "long_name": "Addex Therapeutics Ltd",
        "summary": "Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Geneva"
    },
    "ADXS": {
        "short_name": "Advaxis, Inc.",
        "long_name": "Advaxis, Inc.",
        "summary": "Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Princeton"
    },
    "ADYX": {
        "short_name": "ADYNXX INC",
        "long_name": "Adynxx, Inc.",
        "summary": "Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "AEZS": {
        "short_name": "Aeterna Zentaris Inc.",
        "long_name": "Aeterna Zentaris Inc.",
        "summary": "Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Summerville"
    },
    "AEZS.TO": {
        "short_name": "AETERNA ZENTARIS INC",
        "long_name": "Aeterna Zentaris Inc.",
        "summary": "Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "United States",
        "city": "Summerville"
    },
    "AFFY": {
        "short_name": "AFFYMAX INC",
        "long_name": "Affymax, Inc.",
        "summary": "Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "AFMD": {
        "short_name": "Affimed N.V.",
        "long_name": "Affimed N.V.",
        "summary": "Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; Genentech; and Roivant Sciences. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Germany",
        "city": "Heidelberg"
    },
    "AGE": {
        "short_name": "AgeX Therapeutics, Inc.",
        "long_name": "AgeX Therapeutics, Inc.",
        "summary": "AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Alameda"
    },
    "AGEN": {
        "short_name": "Agenus Inc.",
        "long_name": "Agenus Inc.",
        "summary": "Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGF\u00c3\u009f TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Lexington"
    },
    "AGIO": {
        "short_name": "Agios Pharmaceuticals, Inc.",
        "long_name": "Agios Pharmaceuticals, Inc.",
        "summary": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "AGIO.MX": {
        "short_name": "AGIOS PHARMACEUTICALS INC",
        "long_name": "Agios Pharmaceuticals, Inc.",
        "summary": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "AGLE": {
        "short_name": "Aeglea BioTherapeutics, Inc.",
        "long_name": "Aeglea BioTherapeutics, Inc.",
        "summary": "Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "AGNPF": {
        "short_name": "ALGERNON PHARMACEUTICALS INC",
        "long_name": "Algernon Pharmaceuticals Inc.",
        "summary": "Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of non\u00c2\u0096alcoholic steatohepatitis, liver disease, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury. The company's lead candidate is NP-120, a N-methyl-D-aspartate (NMDA) receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB) and prevents glutamate signalling. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "AGTC": {
        "short_name": "Applied Genetic Technologies Co",
        "long_name": "Applied Genetic Technologies Corporation",
        "summary": "Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Alachua"
    },
    "AGTX": {
        "short_name": "AGENTIX CORP",
        "long_name": "Agentix Corp.",
        "summary": "Agentix Corp. develops and commercializes therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. The company was incorporated in 2013 and is based in Dana Point, California. Agentix Corp. is a subsidiary of Applied Biosciences Corp.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Dana Point"
    },
    "AHROQ": {
        "short_name": "ATHERONOVA INC",
        "long_name": "AtheroNova Inc.",
        "summary": "AtheroNova Inc., a development stage company, is engaged in the research, development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. The company develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases. Its lead compound includes AHRO-001, an active pharmaceutical ingredient. The company also focuses on developing various applications for its patented and patents-pending therapies in market sectors that comprise cardiovascular disease, stroke, and peripheral artery disease. AtheroNova Inc. was founded in 2006 and is based in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Irvine"
    },
    "AIKI": {
        "short_name": "AIkido Pharma Inc.",
        "long_name": "AIkido Pharma Inc.",
        "summary": "Spherix Incorporated, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company's platform consists of patented technology from leading universities and researchers and in the process of developing an innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer. Spherix Incorporated was founded in 1967 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "AIM": {
        "short_name": "AIM ImmunoTech Inc.",
        "long_name": "AIM ImmunoTech Inc.",
        "summary": "AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Ocala"
    },
    "AJ81.F": {
        "short_name": "AGENUS INC.  DL-,01",
        "long_name": "Agenus Inc.",
        "summary": "Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGF\u00c3\u009f TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Lexington"
    },
    "AJW.F": {
        "short_name": "ANGES, INC.",
        "long_name": "AnGes, Inc.",
        "summary": "AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; and Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan. It also has alliances with SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases; Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and Osaka University to develop a coronavirus vaccine. In addition, the company has a collaboration agreement with Brickell Biotech, Inc. to develop investigational plasmid DNA vaccine intended to prevent coronavirus in the United States, South America, and other markets. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Japan",
        "city": "Ibaraki"
    },
    "AKABY": {
        "short_name": "ALK-ABELLO A/S",
        "long_name": "ALK-Abell\u00f3 A/S",
        "summary": "ALK-Abell\u00c3\u00b3 A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, as well as sublingual drops and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company markets its products primarily under the ACARIZAX/ODACTRA, MITICURE, RAGWITEK, GRAZAX/GRASTEK, ITULAZAX, and CEDARCURE brand names. ALK-Abell\u00c3\u00b3 A/S was founded in 1923 and is headquartered in H\u00c3\u00b8rsholm, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Horsholm"
    },
    "AKAOQ": {
        "short_name": "ACHAOGEN INC",
        "long_name": "Achaogen, Inc.",
        "summary": "Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "AKBA": {
        "short_name": "Akebia Therapeutics, Inc.",
        "long_name": "Akebia Therapeutics, Inc.",
        "summary": "Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "AKP.F": {
        "short_name": "ANIKA THERAPEUTICS DL-,01",
        "long_name": "Anika Therapeutics, Inc.",
        "summary": "Anika Therapeutics, Inc., together with its subsidiaries, operates as an integrated joint preservation, restoration, and regenerative solutions company in the United States, Europe, and internationally. The company's lead products include HYALOMATRIX for the treatment of skin wounds, such as pressure ulcers, diabetic foot ulcers, and deep second-degree burns; and MEROGEL, a woven fleece nasal packing. Its joint pain management products comprise MONOVISC, ORTHOVISC, and CINGAL that are used as hyaluronic acid (HA) based viscosupplements to treat osteoarthritis pain in humans; and HYVISC, a HA-based treatment for equine osteoarthritis pain. In addition, the company offers HYALOFAST, a HYAFF-based support for human bone marrow mesenchymal stem cells used for cartilage regeneration and adjunct for microfracture surgery; and Tactoset, a HA-enhanced bone repair therapy to treat insufficiency fractures. Further, it provides ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; joint surface implant and preservation solutions for knee, shoulder, hip, ankle, wrist, and toe to treat upper and lower orthopedic conditions caused by trauma, injury, and arthritic disease; and surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Bedford"
    },
    "AKRO": {
        "short_name": "Akero Therapeutics, Inc.",
        "long_name": "Akero Therapeutics, Inc.",
        "summary": "Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "AKTX": {
        "short_name": "Akari Therapeutics Plc",
        "long_name": "Akari Therapeutics, Plc",
        "summary": "Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barr\u00c3\u00a9 syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "AKUS": {
        "short_name": "Akouos, Inc.",
        "long_name": "Akouos, Inc.",
        "summary": "Akouos, Inc., a precision genetic medicine company, develops gene therapies to restore, improve, and preserve physiologic hearing for people worldwide. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. The company was founded in 2016 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "ALBO": {
        "short_name": "Albireo Pharma, Inc.",
        "long_name": "Albireo Pharma, Inc.",
        "summary": "Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of gastrointestinal diseases. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "ALBPS.PA": {
        "short_name": "BIOPHYTIS",
        "long_name": "Biophytis SA",
        "summary": "Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101). The company was founded in 2006 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALCLS.PA": {
        "short_name": "CELLECTIS",
        "long_name": "Cellectis S.A.",
        "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALDEI.PA": {
        "short_name": "DEINOVE",
        "long_name": "Deinove SA",
        "summary": "DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME Ol\u00c3\u00a9oactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioM\u00c3\u00a9rieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Ol\u00c3\u00a9os-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Grabels"
    },
    "ALDX": {
        "short_name": "Aldeyra Therapeutics, Inc.",
        "long_name": "Aldeyra Therapeutics, Inc.",
        "summary": "Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Lexington"
    },
    "ALEC": {
        "short_name": "Alector, Inc.",
        "long_name": "Alector, Inc.",
        "summary": "Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "ALGEN.PA": {
        "short_name": "GENOWAY",
        "long_name": "genOway Soci\u00e9t\u00e9 anonyme",
        "summary": "genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company provides technological solutions for transgenesis and model design. It produces custom mouse models, such as knockout (KO) and knockin (KI) mouse models; custom rat models; custom cell models; catalog models; and phenotyping for in vivo or in vitro studies. The company also provides patented homologous recombination technology for the generation of genetically modified rodent models; CRISPR/Cas9 nuclease systems for the KO and KI model creation; and FLEx, an inducible point mutation technology that allows scientists to induce the expression of a mutated gene or a reporter gene during the lifetime of the animal model. In addition, it offers tetracycline on/off systems to control gene expression; and internal ribosome entry site technology to generate multigenic-based disease models, reporter models, cell lineage tracking models, and tissue-specific Cre driver lines, as well as to monitor cell expression patterns in KO models. Further, the company provides recombinase-mediated cassette exchange technology to enable the swapping of genomic regions; and Quick Knockin technology, such as Rosa26, Hprt, and AAVS1. It serves pharmaceutical and life science companies, and academic institutes. genOway S.A. has a strategic alliance with Merck to develop and validate new CRISPR/Cas9-related products and solutions. The company was founded in 1999 and is based in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lyon"
    },
    "ALGS": {
        "short_name": "Aligos Therapeutics, Inc.",
        "long_name": "Aligos Therapeutics, Inc.",
        "summary": "Aligos Therapeutics, Inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR-\u00c3\u009f agonist for the treatment of non-alcoholic steatohepatitis. Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "ALHYG.PA": {
        "short_name": "HYBRIGENICS",
        "long_name": "Hybrigenics Soci\u00e9t\u00e9 Anonyme",
        "summary": "Hybrigenics Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme comprises biopharmaceutical company. Hybrigenics Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme is located in France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "None"
    },
    "ALIMM.BR": {
        "short_name": "IMMUPHARMA",
        "long_name": "ImmuPharma plc",
        "summary": "ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "ALINT.PA": {
        "short_name": "INTEGRAGEN",
        "long_name": "IntegraGen SA",
        "summary": "As of October 21, 2020, IntegraGen SA operates as a subsidiary of OncoDNA SA.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Evry"
    },
    "ALK-B.CO": {
        "short_name": "ALK-Abell B A/S",
        "long_name": "ALK-Abell\u00f3 A/S",
        "summary": "ALK-Abell\u00c3\u00b3 A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, as well as sublingual drops and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company markets its products primarily under the ACARIZAX/ODACTRA, MITICURE, RAGWITEK, GRAZAX/GRASTEK, ITULAZAX, and CEDARCURE brand names. ALK-Abell\u00c3\u00b3 A/S was founded in 1923 and is headquartered in H\u00c3\u00b8rsholm, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Horsholm"
    },
    "ALKS": {
        "short_name": "Alkermes plc",
        "long_name": "Alkermes plc",
        "summary": "Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also ALKS 3831 to treat schizophrenia; and ALKS 4230, an engineered fusion protein to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "ALLK": {
        "short_name": "Allakos Inc.",
        "long_name": "Allakos Inc.",
        "summary": "Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "ALLO": {
        "short_name": "Allogene Therapeutics, Inc.",
        "long_name": "Allogene Therapeutics, Inc.",
        "summary": "Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "ALLR.ST": {
        "short_name": "Allarity Therapeutics A/S",
        "long_name": "Allarity Therapeutics A/S",
        "summary": "Allarity Therapeutics A/S develops drugs for the treatment of cancer using drug-specific companion diagnostics. Its product pipeline includes 2X-121, a PARP and tankyrase inhibitor in Phase II clinical trials for the treatment of ovarian cancer; Dovitinib, a pan-tyrosine kinase inhibitor in post-Phase III clinical trials for treatment renal cell carcinoma; and IXEMPRA, a microtublin inhibitor for treatment of metastatic breast cancer. The company is also developing LiPlaCis, a liposomal formulation of cisplatin in Phase II clinical trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin in Phase II clinical trials in breast cancer; and Irofulven, a DNA damaging agent in Phase II clinical trials for prostate cancer. The company was formerly known as Oncology Venture A/S and changed its name to Allarity Therapeutics A/S in October 2020. Allarity Therapeutics A/S was founded in 2004 and is headquartered in H\u00c3\u00b8rsholm, Denmark.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Denmark",
        "city": "Horsholm"
    },
    "ALNA": {
        "short_name": "Allena Pharmaceuticals, Inc.",
        "long_name": "Allena Pharmaceuticals, Inc.",
        "summary": "Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Newton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Newton"
    },
    "ALNEV.PA": {
        "short_name": "NEOVACS",
        "long_name": "Neovacs S.A.",
        "summary": "Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALNOX.PA": {
        "short_name": "NOXXON",
        "long_name": "NOXXON Pharma N.V.",
        "summary": "NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. The company is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "ALNY": {
        "short_name": "Alnylam Pharmaceuticals, Inc.",
        "long_name": "Alnylam Pharmaceuticals, Inc.",
        "summary": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "ALNY.MX": {
        "short_name": "ALNYLAM PHARMACEUTICALS INC",
        "long_name": "Alnylam Pharmaceuticals, Inc.",
        "summary": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "ALONC.PA": {
        "short_name": "ONCODESIGN",
        "long_name": "Oncodesign Soci\u00e9t\u00e9 Anonyme",
        "summary": "Oncodesign Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. The company was founded in 1995 and is headquartered in Dijon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Dijon"
    },
    "ALONX.PA": {
        "short_name": "ONXEO",
        "long_name": "Onxeo SA",
        "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALPAT.PA": {
        "short_name": "PLANT ADVANCED",
        "long_name": "Plant Advanced Technologies SA",
        "summary": "Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. The company's technologies include PAT Plant Milking that produces active extracts through plant stimulation and living-root exudation while preserving plants; PAT Target Binding, which finds the ligands that bind to the protein targets of interest, such as enzymes; and PAT Friday, a recombinant protein expression system using natural protein excretion system of genetically modified carnivorous plants to produce outside their leaf in a sterile closed pitcher. Plant Advanced Technologies SA was founded in 2005 and is headquartered in Vand\u00c2\u009cuvre-l\u00c3\u00a8s-Nancy, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Vand\u00c5\u0093uvre-l\u00c3\u00a8s-Nancy"
    },
    "ALPHA.PA": {
        "short_name": "PHARNEXT",
        "long_name": "Pharnext SA",
        "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Issy-les-Moulineaux"
    },
    "ALPN": {
        "short_name": "Alpine Immune Sciences, Inc.",
        "long_name": "Alpine Immune Sciences, Inc.",
        "summary": "Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "ALQGC.PA": {
        "short_name": "QUANTUM GENOMICS",
        "long_name": "Quantum Genomics Soci\u00e9t\u00e9 Anonyme",
        "summary": "Quantum Genomics Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug for the treatment of hypertension and heart failure, as well as acts on the inhibition of Aminopeptidase A in the brain. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy; and QGC006 to optimize the treatment of hypertension with a monotherapy drug. The company is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALRN": {
        "short_name": "Aileron Therapeutics, Inc.",
        "long_name": "Aileron Therapeutics, Inc.",
        "summary": "Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Watertown"
    },
    "ALSE": {
        "short_name": "ALSERES PHARMACEUTICALS INC",
        "long_name": "Alseres Pharmaceuticals, Inc.",
        "summary": "Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Auburndale"
    },
    "ALSEN.PA": {
        "short_name": "SENSORION",
        "long_name": "Sensorion SA",
        "summary": "Sensorion SA, a biopharmaceutical company, develops therapies for the treatment of inner ear disorders. The company develops SENS-111, which is in phase II clinical trials to treat acute unilateral vestibulopathy; and SENS-401 that is in phase I clinical trials to treat sudden sensorineural hearing loss. It also develops SENS-300, which is under the pre-clinical stage for use in inner ear toxicity treatment. The company has a strategic collaboration with Cochlear Limited to study combination therapies for cochlear implant patients. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Montpellier"
    },
    "ALT": {
        "short_name": "Altimmune, Inc.",
        "long_name": "Altimmune, Inc.",
        "summary": "Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Gaithersburg"
    },
    "ALTHX.PA": {
        "short_name": "THERANEXUS",
        "long_name": "Theranexus Soci\u00e9t\u00e9 Anonyme",
        "summary": "Theranexus soci\u00c3\u00a9t\u00c3\u00a9 anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lyon"
    },
    "ALVAL.PA": {
        "short_name": "VALBIOTIS",
        "long_name": "Valbiotis SA",
        "summary": "Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. The company develops Valedia, a product that is in Phase II clinical trial for the treatment of type 2 diabetes. The company also develops VAL-63, a health supplement that is used for the prevention of non-alcoholic fatty liver disease; and VAL-630, a medical nutrition product for providing nutritional support for patients with non-alcoholic steatohepatitis and type 2 diabetes. In addition, the company's products under clinical development comprise Lipidrive that regulates body weight by acting specifically on body fat mass; and VAL-070, which reduces lipid dysfunctions cholesterol, a risk factor for cardiovascular disease. Valbiotis SA was founded in 2014 and is based in P\u00c3\u00a9rigny, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "P\u00c3\u00a9rigny"
    },
    "ALVR": {
        "short_name": "AlloVir, Inc.",
        "long_name": "AlloVir, Inc.",
        "summary": "Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "ALXN": {
        "short_name": "Alexion Pharmaceuticals, Inc.",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "ALXN.MX": {
        "short_name": "ALEXION PHARMACEUTICAL INC",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Boston"
    },
    "ALXN.VI": {
        "short_name": "ALEXION PHARMACEUTICALS INC",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "city": "Boston"
    },
    "ALXO": {
        "short_name": "ALX Oncology Holdings Inc.",
        "long_name": "ALX Oncology Holdings Inc.",
        "summary": "ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Burlingame"
    },
    "ALZ.ST": {
        "short_name": "Alzinova AB",
        "long_name": "Alzinova AB",
        "summary": "Alzinova AB, a biotechnology company, engages in the discovery and development of therapeutics for the treatment of Alzheimer's disease in Sweden. It focuses on developing ALZ-101, an oligomer-directed vaccine; and ALZ-201, a monoclonal antibody that is used for the treatment of oligomeric A\u00c3\u009f. The company was founded in 2011 and is based in M\u00c3\u00b6lndal, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "M\u00c3\u00b6lndal"
    },
    "AM6.F": {
        "short_name": "AMICUS THERAPEUTICS INC.",
        "long_name": "Amicus Therapeutics, Inc.",
        "summary": "Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cranbury"
    },
    "AMAR": {
        "short_name": "AMARILLO BIOSCIENCES",
        "long_name": "Amarillo Biosciences, Inc.",
        "summary": "Amarillo Biosciences, Inc., a healthcare company, discovers and develops biologics for the treatment of human and animal diseases. The company owns or licenses six issued patents related to the low-dose oral delivery of interferon; and one patent associated with a dietary supplement, Maxisal. It focuses on research for the treatment of human disease indications primarily influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha. Amarillo Biosciences, Inc. was founded in 1984 and is based in Amarillo, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Amarillo"
    },
    "AMBS": {
        "short_name": "AMARANTUS BIOSCIENCE HLDGS INC",
        "long_name": "Amarantus BioScience Holdings, Inc.",
        "summary": "Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "AMHV": {
        "short_name": "AMERICAN HEMP VENTURES INC",
        "long_name": "American Hemp Ventures Inc.",
        "summary": "ASC Biosciences, Inc., a biotechnology company, develops products that restore, maintain, and improve tissue function in humans. It offers Chondrofelt, a medical device to repair articular cartilage defects caused by trauma/osteoarthritis; PeriGen, a product that regenerates peritoneum following abdominal surgery to prevent surgical adhesions; ChondroGen, a product to regenerate articular cartilage and subchondral bone in patients with cartilage damage resulting from sports injury, traumatic injury, and osteoarthritis; and RhytiGen, a product that utilizes MASCs to form connective tissue when injected under the skin. The company also provides MeniGen, a product that incorporates MASCs into a matrix for use as a universal allogeneic meniscus graft; OsteoGen, a product that utilizes MASCs in polylactic acid polymers/purchased porous bone substitutes as three-dimensional scaffolds for the healing of fractures, non-union fractures, and craniofacial defects; and DermiGen, a product that utilizes MASCs to form the cell types in skin, fibroblasts in the dermis, and keratinocytes in the epidermis. ASC Biosciences, Inc. was founded in 2015 and is based in Palm Desert, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Palm Desert"
    },
    "AMPE": {
        "short_name": "Ampio Pharmaceuticals, Inc.",
        "long_name": "Ampio Pharmaceuticals, Inc.",
        "summary": "Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. has collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion. The company is headquartered in Englewood, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Englewood"
    },
    "AMRN": {
        "short_name": "Amarin Corporation plc",
        "long_name": "Amarin Corporation plc",
        "summary": "Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "AMTI": {
        "short_name": "Applied Molecular Transport Inc",
        "long_name": "Applied Molecular Transport Inc.",
        "summary": "Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its lead product candidate is AMT-101, an oral gastrointestinal (GI) selective interleukin 10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The company, through its technology platform designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and RNA therapeutics. In addition, it engages in the development of AMT-126, a GI-selective oral fusion of rhIL-22 for diseases related to intestinal epithelium barrier function defects. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "AN6.F": {
        "short_name": "ANAPTYSBIO INC.  DL-,001",
        "long_name": "AnaptysBio, Inc.",
        "summary": "AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; collaboration with Celgene Corporation; and immuno-oncology collaboration agreement with GlaxoSmithKline plc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ANAB": {
        "short_name": "AnaptysBio, Inc.",
        "long_name": "AnaptysBio, Inc.",
        "summary": "AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; collaboration with Celgene Corporation; and immuno-oncology collaboration agreement with GlaxoSmithKline plc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ANCN": {
        "short_name": "Anchiano Therapeutics Ltd.",
        "long_name": "Anchiano Therapeutics Ltd.",
        "summary": "Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/\u00c3\u009f-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/\u00c3\u009f-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/\u00c3\u009f-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "ANIC.L": {
        "short_name": "AGRONOMICS LIMITED  ORD 0.0001P",
        "long_name": "Agronomics Limited",
        "summary": "Agronomics Limited, formerly known as Port Erin Biopharma Investments Limited, is a principal investment firm specializing in investments in funds, equity and equity related products. The firm invests in quoted and unquoted companies. It prefers to invest in the nascent industry of modern foods, biopharma sector and will establish a portfolio of investments in biotechnology and biopharmaceutical companies. The firm may also invest in shares of collective investment schemes with exposure to the biopharma sector and in long-term equity anticipation securities the underlying securities of which will be based on biopharma sector securities and/or indices relating to the biopharma Sector. It may invest in biopharma sector debt, where investments shall not exceed 15 per cent of the net asset value of the company. Agronomics Limited was founded on May 3, 2011 and is based in Douglas, Isle of Man.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "Isle of Man",
        "city": "Douglas"
    },
    "ANIK": {
        "short_name": "Anika Therapeutics Inc.",
        "long_name": "Anika Therapeutics, Inc.",
        "summary": "Anika Therapeutics, Inc., together with its subsidiaries, operates as an integrated joint preservation, restoration, and regenerative solutions company in the United States, Europe, and internationally. The company's lead products include HYALOMATRIX for the treatment of skin wounds, such as pressure ulcers, diabetic foot ulcers, and deep second-degree burns; and MEROGEL, a woven fleece nasal packing. Its joint pain management products comprise MONOVISC, ORTHOVISC, and CINGAL that are used as hyaluronic acid (HA) based viscosupplements to treat osteoarthritis pain in humans; and HYVISC, a HA-based treatment for equine osteoarthritis pain. In addition, the company offers HYALOFAST, a HYAFF-based support for human bone marrow mesenchymal stem cells used for cartilage regeneration and adjunct for microfracture surgery; and Tactoset, a HA-enhanced bone repair therapy to treat insufficiency fractures. Further, it provides ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; joint surface implant and preservation solutions for knee, shoulder, hip, ankle, wrist, and toe to treat upper and lower orthopedic conditions caused by trauma, injury, and arthritic disease; and surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Bedford"
    },
    "ANNX": {
        "short_name": "Annexon, Inc.",
        "long_name": "Annexon, Inc.",
        "summary": "Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barr\u00c3\u00a9 syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "ANNX.ST": {
        "short_name": "Annexin Pharmaceuticals AB",
        "long_name": "Annexin Pharmaceuticals AB (publ)",
        "summary": "Annexin Pharmaceuticals AB (publ), a biotechnology company, engages in developing drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "ANPC": {
        "short_name": "AnPac Bio-Medical Science Co., ",
        "long_name": "AnPac Bio-Medical Science Co., Ltd.",
        "summary": "Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "city": "Lishui"
    },
    "ANR.AX": {
        "short_name": "ANATARA LS FPO",
        "long_name": "Anatara Lifesciences Limited",
        "summary": "Anatara Lifesciences Limited engages in the research and development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans in Australia. Its lead product candidate includes Detach, a non-antibiotic therapy that prevents and treats diarrhea disease in piglets. The company is also developing bromelain formulations for gastrointestinal health in humans, as well as for piglets and poultry. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Carlton"
    },
    "ANTH": {
        "short_name": "ANTHERA PHARMACEUTICALS INC",
        "long_name": "Anthera Pharmaceuticals, Inc.",
        "summary": "Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Houston"
    },
    "ANTI": {
        "short_name": "ANTIGENICS INC",
        "long_name": "Antigenics, Inc.",
        "summary": "Antigenics, Inc. is based in Huntingdon Valley, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Huntingdon Valley"
    },
    "ANU1.F": {
        "short_name": "XORTX THERAPEUTICS",
        "long_name": "XORTX Therapeutics Inc.",
        "summary": "XORTX Therapeutics Inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. It has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. The company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. In addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. The company has a strategic alliance with Teijin Pharma Limited to develop TMX-049, a xanthine oxidoreductase; and a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Calgary, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Calgary"
    },
    "ANVS": {
        "short_name": "Annovis Bio, Inc.",
        "long_name": "Annovis Bio, Inc.",
        "summary": "Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Berwyn"
    },
    "ANW.F": {
        "short_name": "IMMURON LTD",
        "long_name": "Immuron Limited",
        "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Carlton"
    },
    "ANWA.F": {
        "short_name": "IMMURON LTD SPON.ADR 40",
        "long_name": "Immuron Limited",
        "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Carlton"
    },
    "AOBI": {
        "short_name": "AMERICAN ORIENTAL BIOENGINEERIN",
        "long_name": "American Oriental Bioengineering, Inc.",
        "summary": "American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. In addition, the company provides various nutraceutical products, such as soybean peptide based drinks, tablets, powder, and instant coffee. Further, it is involved in the wholesale and retail of pharmaceutical and nutraceutical products. The company sells its products directly and through distributors to hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical stores, and other retail outlets in the People's Republic of China. American Oriental Bioengineering, Inc. is headquartered in Beijing, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Beijing"
    },
    "AP8N.F": {
        "short_name": "APTEVO THERAP.INC.DL-,001",
        "long_name": "Aptevo Therapeutics Inc.",
        "summary": "Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Seattle"
    },
    "APC.V": {
        "short_name": "ADVANCED PROTEOME THERAPEUTICS ",
        "long_name": "Advanced Proteome Therapeutics Corporation",
        "summary": "Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics, primarily antibody-drug conjugates. Its proprietary technology targets delivery of anti-cancer drugs to cancerous tumors. The company is headquartered in Burnaby, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Burnaby"
    },
    "APH.F": {
        "short_name": "AMPIO PHARMACEUTIC.DL-,01",
        "long_name": "Ampio Pharmaceuticals, Inc.",
        "summary": "Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. has collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion. The company is headquartered in Englewood, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Englewood"
    },
    "APLI.TO": {
        "short_name": "APPILI THERAPEUTICS INC",
        "long_name": "Appili Therapeutics Inc.",
        "summary": "Appili Therapeutics Inc., a biopharmaceutical company, acquires, develops, and commercializes novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1501, a taste-masked oral liquid suspension formulation of an antibiotic, metronidazole; ATI-1503 that develops a class of gram-negative targeting antibiotics; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was founded in 2015 and is headquartered in Halifax, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Halifax"
    },
    "APLIF": {
        "short_name": "APPILI THERAPEUTICS INC",
        "long_name": "Appili Therapeutics Inc.",
        "summary": "Appili Therapeutics Inc., a biopharmaceutical company, acquires, develops, and commercializes novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1501, a taste-masked oral liquid suspension formulation of an antibiotic, metronidazole; ATI-1503 that develops a class of gram-negative targeting antibiotics; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was founded in 2015 and is headquartered in Halifax, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Halifax"
    },
    "APLS": {
        "short_name": "Apellis Pharmaceuticals, Inc.",
        "long_name": "Apellis Pharmaceuticals, Inc.",
        "summary": "Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "APLT": {
        "short_name": "Applied Therapeutics, Inc.",
        "long_name": "Applied Therapeutics, Inc.",
        "summary": "Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company's preclinical stage products include AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "APM": {
        "short_name": "Aptorum Group Limited",
        "long_name": "Aptorum Group Limited",
        "summary": "Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "APM.PA": {
        "short_name": "APTORUM GROUP CL A",
        "long_name": "Aptorum Group Limited",
        "summary": "Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "APOP": {
        "short_name": "Cellect Biotechnology Ltd.",
        "long_name": "Cellect Biotechnology Ltd.",
        "summary": "Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company has collaborations with the denovoMATRIX group of the Technische Universit\u00c3\u00a4t Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; and Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state. It also has a collaboration with the Washington University School of Medicine to determine the safety and tolerability of ApoGraft for bone marrow transplantations in the United States. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was founded in 2011 and is headquartered in Kfar Saba, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Israel",
        "city": "Kfar Saba"
    },
    "APRE": {
        "short_name": "Aprea Therapeutics, Inc.",
        "long_name": "Aprea Therapeutics, Inc.",
        "summary": "Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "APS.TO": {
        "short_name": "APTOSE BIOSCIENCES INC",
        "long_name": "Aptose Biosciences Inc.",
        "summary": "Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "APTO": {
        "short_name": "Aptose Biosciences, Inc.",
        "long_name": "Aptose Biosciences Inc.",
        "summary": "Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "APTX": {
        "short_name": "Aptinyx Inc.",
        "long_name": "Aptinyx Inc.",
        "summary": "Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Evanston"
    },
    "APVO": {
        "short_name": "Aptevo Therapeutics Inc.",
        "long_name": "Aptevo Therapeutics Inc.",
        "summary": "Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "AQST": {
        "short_name": "Aquestive Therapeutics, Inc.",
        "long_name": "Aquestive Therapeutics, Inc.",
        "summary": "Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. It also develops APL-130277, a sublingual film formulation of apomorphine to treat Parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Warren"
    },
    "ARAV": {
        "short_name": "Aravive, Inc.",
        "long_name": "Aravive, Inc.",
        "summary": "Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Houston"
    },
    "ARCH.V": {
        "short_name": "ARCH BIOPARTNERS INC",
        "long_name": "Arch Biopartners Inc.",
        "summary": "Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. It focuses on developing its lead drug candidate MetaBlok, which is in Phase II for the treatment or prevention of dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver, or kidneys. The company also develops AB569, a drug candidate for the treatment of antibiotic resistant bacterial infections, primarily in the lungs and wounds, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. In addition, the company develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "ARCT": {
        "short_name": "Arcturus Therapeutics Holdings ",
        "long_name": "Arcturus Therapeutics Holdings Inc.",
        "summary": "Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ARDS": {
        "short_name": "Aridis Pharmaceuticals Inc.",
        "long_name": "Aridis Pharmaceuticals, Inc.",
        "summary": "Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase II clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "San Jose"
    },
    "ARDX": {
        "short_name": "Ardelyx, Inc.",
        "long_name": "Ardelyx, Inc.",
        "summary": "Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Fremont"
    },
    "ARFXF": {
        "short_name": "PROMIS NEUROSCIENCES INC",
        "long_name": "ProMIS Neurosciences, Inc.",
        "summary": "ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform\u00c2\u0097ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (A\u00c3\u009fO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of A\u00c3\u009fO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company has a collaboration with BC Neuroimmunology to develop and commercialize proprietary diagnostic assays; and BC Neuroimmunology to develop and offer blood-based diagnostic tests for Alzheimer's diseases. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "ARGX": {
        "short_name": "argenx SE",
        "long_name": "argenx SE",
        "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.\u00c3\u0080.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Breda"
    },
    "ARGX.BR": {
        "short_name": "ARGENX SE",
        "long_name": "argenx SE",
        "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.\u00c3\u0080.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Netherlands",
        "city": "Breda"
    },
    "ARGX.VI": {
        "short_name": "ARGENX SE",
        "long_name": "argenx SE",
        "summary": "argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.\u00c3\u0080.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Netherlands",
        "city": "Breda"
    },
    "ARIX.L": {
        "short_name": "ARIX BIOSCIENCE PLC ORD 0.001P",
        "long_name": "Arix Bioscience plc",
        "summary": "Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "ARMP": {
        "short_name": "Armata Pharmaceuticals, Inc.",
        "long_name": "Armata Pharmaceuticals Inc.",
        "summary": "Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Marina del Rey"
    },
    "ARNA": {
        "short_name": "Arena Pharmaceuticals, Inc.",
        "long_name": "Arena Pharmaceuticals, Inc.",
        "summary": "Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ARNA.MX": {
        "short_name": "ARENA PHARMACEUTICALS INC",
        "long_name": "Arena Pharmaceuticals, Inc.",
        "summary": "Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ARNI": {
        "short_name": "ARNO THERAPEUTICS INC",
        "long_name": "Arno Therapeutics, Inc.",
        "summary": "Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Flemington"
    },
    "ARPO": {
        "short_name": "Aerpio Pharmaceuticals, Inc.",
        "long_name": "Aerpio Pharmaceuticals, Inc.",
        "summary": "Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cincinnati"
    },
    "ARQT": {
        "short_name": "Arcutis Biotherapeutics, Inc.",
        "long_name": "Arcutis Biotherapeutics, Inc.",
        "summary": "Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Westlake Village"
    },
    "ARTH": {
        "short_name": "ARCH THERAPEUTICS INC",
        "long_name": "Arch Therapeutics, Inc.",
        "summary": "Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Framingham"
    },
    "ARTL": {
        "short_name": "Artelo Biosciences, Inc.",
        "long_name": "Artelo Biosciences, Inc.",
        "summary": "Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "La Jolla"
    },
    "ARUXF": {
        "short_name": "ACRUX",
        "long_name": "Acrux Limited",
        "summary": "Acrux Limited, together with its subsidiaries, develops and commercializes generic and specialty topical pharmaceuticals in Australia, Germany, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. Acrux Limited was founded in 1998 and is based in West Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "West Melbourne"
    },
    "ARVN": {
        "short_name": "Arvinas, Inc.",
        "long_name": "Arvinas, Inc.",
        "summary": "Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New Haven"
    },
    "ARWR": {
        "short_name": "Arrowhead Pharmaceuticals, Inc.",
        "long_name": "Arrowhead Pharmaceuticals, Inc.",
        "summary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Pasadena"
    },
    "ARWR.MX": {
        "short_name": "ARROWHEAD PHARMACEUTICALS INC",
        "long_name": "Arrowhead Pharmaceuticals, Inc.",
        "summary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Pasadena"
    },
    "ASAP.ST": {
        "short_name": "Asarina Pharma AB",
        "long_name": "Asarina Pharma AB (publ)",
        "summary": "Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "ASCLF": {
        "short_name": "ASCLETIS PHARMA INC",
        "long_name": "Ascletis Pharma Inc.",
        "summary": "Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a direct-acting anti-viral agent for the treatment of hepatitis C virus (HCV); Pegasys, a pegylated interferon for Hepatitis B and C virus; and Ravidasvir, a pan-genotypic NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B infection; ASC40, a Phase II-ready fatty acid synthase inhibitor for the treatment of non-alcoholic steatohepatitis (NASH); and ASC41, an oral THR-\u00c3\u009f agonist for the treatment of NASH. The company's products also comprise ASC09, a protease inhibitor that has completed Phase IIA clinical trial to treat human immunodeficiency virus type-1 infections; ASC06, which has completed Phase I clinical trial for treating liver cancer; and ASC21, a HCV NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of hepatitis B virus and NASH. The company was incorporated in 2014 and is headquartered in Hangzhou, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Hangzhou"
    },
    "ASIT.BR": {
        "short_name": "ASIT",
        "long_name": "ASIT Biotech S.A.",
        "summary": "ASIT Biotech S.A., a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium and internationally. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen rhinitis. The company is also developing hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as BioTech Tools SA and changed its name to ASIT Biotech S.A. in August 2015. ASIT Biotech S.A. was founded in 1997 and is based in Li\u00c3\u00a8ge, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Belgium",
        "city": "Li\u00c3\u00a8ge"
    },
    "ASLN": {
        "short_name": "ASLAN Pharmaceuticals Limited",
        "long_name": "ASLAN Pharmaceuticals Limited",
        "summary": "ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Singapore",
        "city": "Singapore"
    },
    "ASMB": {
        "short_name": "Assembly Biosciences, Inc.",
        "long_name": "Assembly Biosciences, Inc.",
        "summary": "Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs; and a collaboration and option agreement with Door Pharmaceuticals, LLC focused on the development of a hepatitis B virus core protein modulators. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "ASND": {
        "short_name": "Ascendis Pharma A/S",
        "long_name": "Ascendis Pharma A/S",
        "summary": "Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "ASNHF": {
        "short_name": "AVIDUS MANAGEMENT GROUP",
        "long_name": "Avidus Management Group Inc.",
        "summary": "Avidus Management Group Inc. develops, acquires, and operates direct sales and network marketing companies in the consumer health and wellness market in the United States. The company also offers nutraceuticals and health aids; customized nutritional, diet, and exercise plans; and various supplements comprising natural ingredients. The company's principal products include RealW8, a weight loss supplement; and IS2, a functional beverage that supports the body's natural ability to protect, fight, and rebuild against the effects of injuries, illnesses, and diseases. Avidus Management Group Inc. provides its products to various retail vendors, individuals, and businesses. The company was formerly known as Asantae Holdings International Inc. and changed its name to Avidus Management Group Inc. in May 2013. Avidus Management Group Inc. was incorporated in 2006 and is headquartered in Mesa, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Mesa"
    },
    "AT2.F": {
        "short_name": "ATARA BIOTHERAP. DL-,0001",
        "long_name": "Atara Biotherapeutics, Inc.",
        "summary": "Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms Tumor 1; and ATA621 for BK and JCV. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was founded in 2012 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "ATBPF": {
        "short_name": "ANTIBE THERAPEUTICS INC",
        "long_name": "Antibe Therapeutics Inc.",
        "summary": "Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "ATHA": {
        "short_name": "Athira Pharma, Inc.",
        "long_name": "Athira Pharma, Inc.",
        "summary": "Athira Pharma, Inc., a clinical-stage biopharmaceutical company, develops small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. The company also develops product candidates, which are in preclinical stage, including ATH-1019 for depression; and ATH-1018 for peripheral neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is based in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "ATHE": {
        "short_name": "Alterity Therapeutics Limited",
        "long_name": "Alterity Therapeutics Limited",
        "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "ATHX": {
        "short_name": "Athersys, Inc.",
        "long_name": "Athersys, Inc.",
        "summary": "Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cleveland"
    },
    "ATMS": {
        "short_name": "ARTEMIS THERAPEUTICS INC",
        "long_name": "Artemis Therapeutics Inc.",
        "summary": "Artemis Therapeutics Inc. does not have significant operations. Previously, it was engaged in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company was incorporated in 1997 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "ATNF": {
        "short_name": "180 Life Sciences Corp.",
        "long_name": "180 Life Sciences Corp.",
        "summary": "180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Menlo Park"
    },
    "ATNM": {
        "short_name": "Actinium Pharmaceuticals, Inc. ",
        "long_name": "Actinium Pharmaceuticals, Inc.",
        "summary": "Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, developing Antibody Radiation-Conjugates (ARCs). The ARCs selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. It also offers Iomab-B (I-131 apamistamab), which is in a phase III study for Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company is also developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "ATORX.ST": {
        "short_name": "Alligator Bioscience AB",
        "long_name": "Alligator Bioscience AB (publ)",
        "summary": "Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. It develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and bispecific antibody formats for the development of novel dual-action antibodies. The company develops ADC-1013, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial for tumor-directed treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB (CD137) in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer; and ATOR-1144, a bispecific antibody to treat solid tumors and hematologic cancers. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has operations in the United States, Sweden, Asia, and internationally. The company has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527. Alligator Bioscience AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "ATOS": {
        "short_name": "Atossa Therapeutics, Inc.",
        "long_name": "Atossa Therapeutics, Inc.",
        "summary": "Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "ATQP.F": {
        "short_name": "VERICEL CORP.",
        "long_name": "Vericel Corporation",
        "summary": "Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "ATRA": {
        "short_name": "Atara Biotherapeutics, Inc.",
        "long_name": "Atara Biotherapeutics, Inc.",
        "summary": "Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms Tumor 1; and ATA621 for BK and JCV. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was founded in 2012 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "ATRX": {
        "short_name": "ADHERA THERAPEUTICS INC",
        "long_name": "Adhera Therapeutics, Inc.",
        "summary": "Adhera Therapeutics, Inc. does not have significant operations. Previously, it was involved in the development and commercialization of drug therapeutics for chronic and acute diseases in the United States. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is headquartered in Wake Forest, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Wake Forest"
    },
    "ATRY.MC": {
        "short_name": "ATRYS HEALTH, S.A.",
        "long_name": "Atrys Health, S.A.",
        "summary": "Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology. The company also provides radiotherapy; and develops therapeutic modalities and diagnostic tools. Atrys Health, S.A. was founded in 2007 and is based in Barcelona, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MCE",
        "market": "es_market",
        "country": "Spain",
        "city": "Barcelona"
    },
    "ATX.AX": {
        "short_name": "AMPLIA FPO",
        "long_name": "Amplia Therapeutics Limited",
        "summary": "Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "ATXI": {
        "short_name": "Avenue Therapeutics, Inc.",
        "long_name": "Avenue Therapeutics, Inc.",
        "summary": "Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019,  Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "AUP.TO": {
        "short_name": "AURINIA PHARMACEUTICALS INC",
        "long_name": "Aurinia Pharmaceuticals Inc.",
        "summary": "Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Victoria"
    },
    "AUPH": {
        "short_name": "Aurinia Pharmaceuticals Inc",
        "long_name": "Aurinia Pharmaceuticals Inc.",
        "summary": "Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Victoria"
    },
    "AURX": {
        "short_name": "NUO THERAPEUTICS INC",
        "long_name": "Nuo Therapeutics, Inc.",
        "summary": "Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Gaithersburg, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Gaithersburg"
    },
    "AUTL": {
        "short_name": "Autolus Therapeutics plc",
        "long_name": "Autolus Therapeutics plc",
        "summary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "AVCT.L": {
        "short_name": "AVACTA GROUP PLC ORD 10P",
        "long_name": "Avacta Group Plc",
        "summary": "Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in Diagnostics, Therapeutics, and Animal Health segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Wetherby"
    },
    "AVE.AX": {
        "short_name": "AVECHO FPO",
        "long_name": "Avecho Biotechnology Limited",
        "summary": "Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. The company operates through Production, Human Health, and Animal Health and Nutrition segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company serves customers in Australia, Switzerland, the United States, India, Japan, China, Singapore, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited is based in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "AVEO": {
        "short_name": "AVEO Pharmaceuticals, Inc.",
        "long_name": "AVEO Pharmaceuticals, Inc.",
        "summary": "AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. AVEO Pharmaceuticals, Inc. has collaboration and license agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Kirin Co., Ltd. It has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "AVIR": {
        "short_name": "Atea Pharmaceuticals, Inc.",
        "long_name": "Atea Pharmaceuticals, Inc.",
        "summary": "Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. It also develops AT-787 which is under phase 2 clinical for the treatment of hepatitis C virus; AT-752 which is under phase 2 clinical trial for the treatment of dengue; and AT-889, AT-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. The company was incorporated in 2012 and is based in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "AVRO": {
        "short_name": "AVROBIO, Inc.",
        "long_name": "AVROBIO, Inc.",
        "summary": "AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "AVXL": {
        "short_name": "Anavex Life Sciences Corp.",
        "long_name": "Anavex Life Sciences Corp.",
        "summary": "Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "AVXT": {
        "short_name": "AVAX TECHNOLOGIES INC",
        "long_name": "AVAX Technologies, Inc.",
        "summary": "AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Philadelphia"
    },
    "AX9.F": {
        "short_name": "AKEBIA THERAPEUT.DL-00001",
        "long_name": "Akebia Therapeutics, Inc.",
        "summary": "Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "AXD2.F": {
        "short_name": "HERON THERAPEUTICS DL-,01",
        "long_name": "Heron Therapeutics, Inc.",
        "summary": "Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam that is in Phase III clinical trial for pain management; and HTX-034, a product candidate for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "AXIC-A.ST": {
        "short_name": "aXichem AB ser. A",
        "long_name": "aXichem AB",
        "summary": "aXichem AB develops, patents, and markets natural-analogue industrial compounds for the marine, pest control, feed ingredient, and medical application markets in Sweden and internationally. It offers aXiphen-repellent, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; aXiphen-feed ingredient for pig and poultry diets; and aXiphen for use in various foods and dietary supplements, as well as in the pharmaceutical industry. The company is based in Malm\u00c3\u00b6, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Malm\u00c3\u00b6"
    },
    "AXIM": {
        "short_name": "AXIM BIOTECHNOLOGIES INC",
        "long_name": "AXIM Biotechnologies, Inc.",
        "summary": "AXIM Biotechnologies, Inc. is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). The company's NeuCovix is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. It is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was founded in 2010 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "AXLA": {
        "short_name": "Axcella Health Inc.",
        "long_name": "Axcella Health Inc.",
        "summary": "Axcella Health Inc., a clinical-stage biotechnology company, researches and develops endogenous metabolic modulators (EMMs) for the treatment of complex diseases and improving health in the United States. It offers AXA1665 for use in treating overt hepatic encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic steatohepatitis; AXA2678 for use in treating muscle atrophy; and AXA4010 to target multiple biological pathways to support normal structures and functions of the blood. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was founded in 2008 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "AXP.DE": {
        "short_name": "ALEXION PHARMAC. DL-,0001",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "city": "Boston"
    },
    "AXP.F": {
        "short_name": "ALEXION PHARMAC. DL-,0001",
        "long_name": "Alexion Pharmaceuticals, Inc.",
        "summary": "Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boston"
    },
    "AXSM": {
        "short_name": "Axsome Therapeutics, Inc.",
        "long_name": "Axsome Therapeutics, Inc.",
        "summary": "Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "AYJ.F": {
        "short_name": "VALNEVA SE  EO -,15",
        "long_name": "Valneva SE",
        "summary": "Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease and single-shot vaccine against chikungunya. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company has collaboration with Dynavax Technologies Corporation to advance vaccine development for COVID-19. Valneva SE was incorporated in 1999 and is headquartered in Nantes, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Nantes"
    },
    "AYLA": {
        "short_name": "Ayala Pharmaceuticals, Inc.",
        "long_name": "Ayala Pharmaceuticals, Inc.",
        "summary": "Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "AYTU": {
        "short_name": "Aytu BioScience, Inc.",
        "long_name": "Aytu BioScience, Inc.",
        "summary": "Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. Aytu BioScience, Inc. is based in Englewood, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Englewood"
    },
    "AZRX": {
        "short_name": "AzurRx BioPharma, Inc.",
        "long_name": "AzurRx BioPharma, Inc.",
        "summary": "AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, engages in the research and development of non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company focuses on developing a pipeline of three gut-restricted GI clinical programs. Its lead therapeutic candidate is MS1819, a recombinant lipase that is in two Phase 2 clinical trials for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is also launching two new clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor comprising FW-420, for grade 1 immune checkpoint inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. was incorporated in 2014 and is headquartered in Delray Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Delray Beach"
    },
    "B1N.F": {
        "short_name": "BIONOMICS LTD.",
        "long_name": "Bionomics Limited",
        "summary": "Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Thebarton"
    },
    "B4V.F": {
        "short_name": "ARCTICZYMES TECH ASA NK 1",
        "long_name": "ArcticZymes Technologies ASA",
        "summary": "ArcticZymes Technologies ASA develops, manufactures, and markets immunomodulating beta-glucans and recombinant enzymes in Norway, Europe, Asia, Australia, Africa, and the Americas. It operates through two segments, Enzymes and Beta-Glucans. The company provides recombinant enzymes that are primarily derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics, and therapeutics. It offers shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing (NGS) processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of DNA from RNA samples; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; salt active nuclease for the removal of nucleic acids during manufacturing of vaccines, viruses, recombinant proteins, and other reagents; and ligases for joining DNA fragments. The company also provides immunomodulating beta-glucans products for the wound care, animal and consumer health, and adjuvants markets. It offers Woulgan wound gel; M-Glucan, a natural immune-stimulating product for fish and animal feed; and M-Gard, a natural immune-stimulating ingredients to enhance physical health. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Troms\u00c3\u00b8, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Troms\u00c3\u00b8"
    },
    "B8F.DE": {
        "short_name": "BIOFRONTERA AG NA O.N.",
        "long_name": "Biofrontera AG",
        "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "B8F.F": {
        "short_name": "BIOFRONTERA AG NA O.N.",
        "long_name": "Biofrontera AG",
        "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "B8FE.SG": {
        "short_name": "Biofrontera AG (Spons.ADRs)/2 o",
        "long_name": "Biofrontera AG",
        "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "B9A.F": {
        "short_name": "BIOARCTIC AB B",
        "long_name": "BioArctic AB (publ)",
        "summary": "BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops BAN0805, an anti-alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "BAVA.CO": {
        "short_name": "Bavarian Nordic A/S",
        "long_name": "Bavarian Nordic A/S",
        "summary": "Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "BBI": {
        "short_name": "Brickell Biotech, Inc.",
        "long_name": "Brickell Biotech, Inc.",
        "summary": "Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Boulder"
    },
    "BBIO": {
        "short_name": "BridgeBio Pharma, Inc.",
        "long_name": "BridgeBio Pharma, Inc.",
        "summary": "BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; strategic collaboration agreements with Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; and UC San Francisco. The company was founded in 2015 and is headquartered in Palo Alto, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Palo Alto"
    },
    "BBIXF": {
        "short_name": "BONUS BIOGROUP LTD",
        "long_name": "Bonus BioGroup Ltd.",
        "summary": "Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. It develops tissue-regenerating bone grafts from cells derived from the patient's own cells for the treatment of skeletal disorders, such as bone and cartilage related arthritis, as well as various types of bone and joint trauma. The company's products include BonoFill injectable bone graft that is suitable for bone repair applications, including jaw bone cysts; and BonoFill pre-designed bone graft, which is used to repair large/segmental bone defects. Its products in pipeline comprise bone grafts for maxillofacial and orthopedic applications; novel nanomaterials technology for tissue regeneration; and large vascularized bone grafts. The company was formerly known as Oceana Advanced Industries Ltd. and changed its name to Bonus BioGroup Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Haifa"
    },
    "BCAB": {
        "short_name": "BioAtla, Inc.",
        "long_name": "BioAtla, Inc.",
        "summary": "BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "BCDA": {
        "short_name": "BioCardia, Inc.",
        "long_name": "BioCardia, Inc.",
        "summary": "BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "San Carlos"
    },
    "BCEL": {
        "short_name": "Atreca, Inc.",
        "long_name": "Atreca, Inc.",
        "summary": "Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "BCLI": {
        "short_name": "Brainstorm Cell Therapeutics In",
        "long_name": "Brainstorm Cell Therapeutics Inc.",
        "summary": "Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company has a partnership with Catalent for the manufacture of NurOwn, an autologous cellular therapy. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "BCRX": {
        "short_name": "BioCryst Pharmaceuticals, Inc.",
        "long_name": "BioCryst Pharmaceuticals, Inc.",
        "summary": "BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Durham"
    },
    "BCRX.MX": {
        "short_name": "BIOCRYST PHARMACEUTICALS INC",
        "long_name": "BioCryst Pharmaceuticals, Inc.",
        "summary": "BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Durham"
    },
    "BCT.V": {
        "short_name": "BRIACELL THERAPEUTICS CORP",
        "long_name": "BriaCell Therapeutics Corp.",
        "summary": "BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "West Vancouver"
    },
    "BCTXF": {
        "short_name": "BRIACELL THERAPEUTICS CORP",
        "long_name": "BriaCell Therapeutics Corp.",
        "summary": "BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "West Vancouver"
    },
    "BCYC": {
        "short_name": "Bicycle Therapeutics plc",
        "long_name": "Bicycle Therapeutics plc",
        "summary": "Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics plc has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "BD5.F": {
        "short_name": "BIODELIVERY SCIE. DL-,001",
        "long_name": "BioDelivery Sciences International, Inc.",
        "summary": "BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Raleigh"
    },
    "BDQM.F": {
        "short_name": "ALBIREO PHARMA  DL -,01",
        "long_name": "Albireo Pharma, Inc.",
        "summary": "Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of gastrointestinal diseases. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boston"
    },
    "BDSI": {
        "short_name": "BioDelivery Sciences Internatio",
        "long_name": "BioDelivery Sciences International, Inc.",
        "summary": "BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Raleigh"
    },
    "BDTX": {
        "short_name": "Black Diamond Therapeutics, Inc",
        "long_name": "Black Diamond Therapeutics, Inc.",
        "summary": "Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "BEAM": {
        "short_name": "Beam Therapeutics Inc.",
        "long_name": "Beam Therapeutics Inc.",
        "summary": "Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "BETR.CN": {
        "short_name": "BetterLifePhar",
        "long_name": "BetterLife Pharma Inc.",
        "summary": "BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumours to treat various types of cancer. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was founded in 2002 and is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "BETRF": {
        "short_name": "BETTERLIFE PHARMA INC",
        "long_name": "BetterLife Pharma Inc.",
        "summary": "BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumours to treat various types of cancer. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was founded in 2002 and is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "BFRA": {
        "short_name": "Biofrontera AG American Deposit",
        "long_name": "Biofrontera AG",
        "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "BGBIO.OL": {
        "short_name": "BERGENBIO ASA",
        "long_name": "BerGenBio ASA",
        "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Bergen"
    },
    "BGNE": {
        "short_name": "BeiGene, Ltd.",
        "long_name": "BeiGene, Ltd.",
        "summary": "BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; Hutchison China MediTech Limited; and Novartis. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "city": "Beijing"
    },
    "BGT.AX": {
        "short_name": "BIOGENETEC FPO",
        "long_name": "Bio-Gene Technology Limited",
        "summary": "Bio-Gene Technology Limited, a biotechnology company, engages in developing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. It is involved in developing Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from the leaves of rare eucalyptus trees. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has collaborations with Pacific Discovery Services for studying Flavocide's mode of action; and the Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "BHN0.F": {
        "short_name": "BELLUS HEALTH INC.",
        "long_name": "BELLUS Health Inc.",
        "summary": "BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Laval"
    },
    "BHVN": {
        "short_name": "Biohaven Pharmaceutical Holding",
        "long_name": "Biohaven Pharmaceutical Holding Company Ltd.",
        "summary": "Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "New Haven"
    },
    "BICB": {
        "short_name": "BIO CUBE INC",
        "long_name": "BioCube, Inc.",
        "summary": "BioCube, Inc., a development stage company, focuses on the development and marketing of lithium ion batteries in North America. The company was formerly known as Alliance Network Communications Holdings, Inc. and changed its name to BioCube, Inc. in December 2010. BioCube, Inc. is based in Bohemia, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Bohemia"
    },
    "BICTF": {
        "short_name": "BIOCURE TECHNOLOGY INC",
        "long_name": "Biocure Technology Inc.",
        "summary": "Biocure Technology Inc. develops and commercializes biopharmaceutical technologies for uses in recombinant and ranibizumab. The company is developing Interferons- \u00c3\u009f for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It is also developing CAR T Cell Therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and a hair growth production product. Biocure Technology Inc. is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "BINV.ST": {
        "short_name": "BioInvent International AB",
        "long_name": "BioInvent International AB (publ)",
        "summary": "BioInvent International AB (publ) focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It has a collaboration agreement with Oncurious to develop TB-403, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma. The company is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells for modulating the immune system and BI-1808, an antibody candidate. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; and partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors. The company also has an agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was founded in 1996 and is based in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "BIO.MC": {
        "short_name": "BIOSEARCH, S.A.",
        "long_name": "Biosearch, S.A.",
        "summary": "Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MCE",
        "market": "es_market",
        "country": "Spain",
        "city": "Granada"
    },
    "BIOA-B.ST": {
        "short_name": "BioArctic AB ser. B",
        "long_name": "BioArctic AB (publ)",
        "summary": "BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops BAN0805, an anti-alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "BIOAF": {
        "short_name": "BIOASIS TECHNOLOGIES INC",
        "long_name": "Bioasis Technologies Inc.",
        "summary": "Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-002), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Bioasis Technologies Inc. was founded in 2007 and is headquartered in Guilford, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Guilford"
    },
    "BIOBV.HE": {
        "short_name": "Biohit Oyj B",
        "long_name": "Biohit Oyj",
        "summary": "Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. Its diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; Lactose Intolerance Quick Test; Celiac Disease Quick Test; and The GA-map Dysbiosis test, a gut microbiota DNA analysis tool. The company also provides monoclonal antibodies for use in cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, it provides acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Additionally, it provides microplate readers and strip washers, quick test readers, and ThunderBolt, an automated immunoassay analyzer; and products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies, and service laboratory services. The company was founded in 1988 and is headquartered in Helsinki, Finland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HEL",
        "market": "fi_market",
        "country": "Finland",
        "city": "Helsinki"
    },
    "BIOCON.NS": {
        "short_name": "BIOCON LTD",
        "long_name": "Biocon Limited",
        "summary": "Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Small Molecules, Biologics, Branded Formulations, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology, and inflammatory diseases. The company provides biosimilars comprising recombinant human insulin, insulin glargine, biosimilar trastuzumab, and other biopharmaceuticals; small molecules, such as active pharmaceutical ingredients and generic formulations; and branded formulation products under the Insugen, Basalog, BIOMAb EGFR, CANMAb, and ALZUMAb brands. It is also involved in the integrated discovery, development, and manufacturing services for small and large molecules, antibody-drug conjugates, and oligonucleotides. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.",
        "currency": "INR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NSI",
        "market": "in_market",
        "country": "India",
        "city": "Bengaluru"
    },
    "BIOM3.SA": {
        "short_name": "BIOMM       ON      MA",
        "long_name": "Biomm S.A.",
        "summary": "Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in S\u00c3\u00a3o Paulo, Brazil.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "Brazil",
        "city": "S\u00c3\u00a3o Paulo"
    },
    "BIOV.CN": {
        "short_name": "BioVaxysTech",
        "long_name": "BioVaxys Technology Corp.",
        "summary": "BioVaxys LLC, a clinical stage company that develops immunotherapeutic vaccines for antiviral and individualized cancer therapy. The company was founded in 2018 and is based in New York, New York.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "United States",
        "city": "New York"
    },
    "BIOVIC-B.ST": {
        "short_name": "Biovica International AB ser. B",
        "long_name": "Biovica International AB (publ)",
        "summary": "Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome in Europe, the United States, and Asia. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves pharmaceutical companies and contract research organizations. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Uppsala"
    },
    "BIOWKS.ST": {
        "short_name": "Bio-Works Technologies AB",
        "long_name": "Bio-Works Technologies AB (publ)",
        "summary": "Bio-Works Technologies AB (publ) researches, develops, manufactures, and supplies agarose based resins used to separate proteins and other biomolecules. It offers activated and affinity resins; BabyBio columns; immobilized metal-ion affinity chromatography (IMAC) resins; ion exchange resins; OptioBio glass columns; and size exclusion chromatography (SEC) resins. The company's products are used in antibody, His-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines purification process. Bio-Works Technologies AB (publ) founded in 2006 and is based in Uppsala, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Uppsala"
    },
    "BIT.AX": {
        "short_name": "BIOTRON FPO",
        "long_name": "Biotron Limited",
        "summary": "Biotron Limited, a biotechnology company, engages in the developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also develops a portfolio of preclinical antiviral drugs. Biotron Limited was incorporated in 1999 and is based in North Ryde, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "North Ryde"
    },
    "BITRF": {
        "short_name": "BIOTRON",
        "long_name": "Biotron Limited",
        "summary": "Biotron Limited, a biotechnology company, engages in the developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also develops a portfolio of preclinical antiviral drugs. Biotron Limited was incorporated in 1999 and is based in North Ryde, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "North Ryde"
    },
    "BIVI": {
        "short_name": "BioVie Inc.",
        "long_name": "BioVie Inc.",
        "summary": "BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Santa Monica"
    },
    "BIX0.F": {
        "short_name": "BIOINVENT INTERN.  SK 2",
        "long_name": "BioInvent International AB (publ)",
        "summary": "BioInvent International AB (publ) focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It has a collaboration agreement with Oncurious to develop TB-403, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma. The company is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells for modulating the immune system and BI-1808, an antibody candidate. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; and partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors. The company also has an agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was founded in 1996 and is based in Lund, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "BJ93.F": {
        "short_name": "BENITEC BIOPHARMA INC.",
        "long_name": "Benitec Biopharma Inc.",
        "summary": "Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Hayward"
    },
    "BLCM": {
        "short_name": "Bellicum Pharmaceuticals, Inc.",
        "long_name": "Bellicum Pharmaceuticals, Inc.",
        "summary": "Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. It has collaboration and license agreements with Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Houston"
    },
    "BLI": {
        "short_name": "Berkeley Lights, Inc.",
        "long_name": "Berkeley Lights, Inc.",
        "summary": "Berkeley Lights, Inc., a digital cell biology company that focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. It offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. The company was incorporated in 2011 and is based in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "EmeryVille"
    },
    "BLPH": {
        "short_name": "Bellerophon Therapeutics, Inc.",
        "long_name": "Bellerophon Therapeutics, Inc.",
        "summary": "Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Warren"
    },
    "BLRX": {
        "short_name": "BioLineRx Ltd.",
        "long_name": "BioLineRx Ltd.",
        "summary": "BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's TECENTRIQ (Atezolizumab) in Phase 1b/2 studies for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Hevel Modi'in"
    },
    "BLRX.TA": {
        "short_name": "BIOLINE RX LTD",
        "long_name": "BioLineRx Ltd.",
        "summary": "BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's TECENTRIQ (Atezolizumab) in Phase 1b/2 studies for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Hevel Modi'in"
    },
    "BLT.NZ": {
        "short_name": "Blis Technologies Limited Ordin",
        "long_name": "BLIS Technologies Limited",
        "summary": "BLIS Technologies Limited develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity in New Zealand and internationally. The company markets two strains of probiotic bacteria, which include BLIS K12, a probiotic supplement to support ear, nose, and throat health of infants and children, as well as for improving bad breath; and BLIS M18 for promoting the bacterial balance for dental health. Its product portfolio consists of DailyDefence, a daily probiotic to support throat immunity; DailyDefence Junior, a daily powder formulation to support ear, nose, and throat health of infants and small children; ThroatGuard PRO to give immunity support to help protect against winter ills; and TravelProtect to help support the immune system when travelling. The company also offers FreshBreath Kit, a regime that re-populates the mouth, thereby replacing the bad smelly bacteria in the mouth; HoneyBlis, a tasting honey lozenge to soothe and protect a scratchy or a sore throat; and ToothGuard and ToothGuard Junior probiotics for the health of teeth and gums helping to prevent cavities in children and gum disease in adults. It has operations in Asia Pacific, Europe, the Middle East, Africa, North America, and internationally. BLIS Technologies Limited was incorporated in 2000 and is headquartered in Dunedin, New Zealand.",
        "currency": "NZD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NZE",
        "market": "nz_market",
        "country": "New Zealand",
        "city": "Dunedin"
    },
    "BLU": {
        "short_name": "BELLUS Health Inc.",
        "long_name": "BELLUS Health Inc.",
        "summary": "BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Laval"
    },
    "BLU.TO": {
        "short_name": "BELLUS HEALTH INC.",
        "long_name": "BELLUS Health Inc.",
        "summary": "BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Laval"
    },
    "BLUE": {
        "short_name": "bluebird bio, Inc.",
        "long_name": "bluebird bio, Inc.",
        "summary": "bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of \u00c3\u009f-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases, as well as clinical trial collaboration with Magenta Therapeutics. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "BMMX": {
        "short_name": "BIOMIMIX INC",
        "long_name": "Biomimix, Inc.",
        "summary": "Biomimix, Inc. operates in the life science tools and services market covering genomics, proteomics, cell biology, analytical chemistry, bioprocess development, and bioinformatics in the United States. It develops and commercializes products based on processes and systems found in nature, known as biomimicry. The company's product portfolio includes Bonegrafix products, which are bioactive substances to produce graft attributes for bone replacement and filling defects or holes in bone, or stabilizing bone during the healing process; and ocean water based skin care products to supplement skin health. It also engages in the research and development of Medusa technology, an electro-chemical process that focuses on ballast water treatment, remote potable water treatment, and hydrogen production for use with portable renewable energy platforms. The company was formerly known as C'watre International, Inc. and changed its name to Biomimix, Inc. in April 2009. Biomimix, Inc. was founded in 1986 and is based in Ashburn, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Ashburn"
    },
    "BMRN": {
        "short_name": "BioMarin Pharmaceutical Inc.",
        "long_name": "BioMarin Pharmaceutical Inc.",
        "summary": "BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Rafael"
    },
    "BMRN.VI": {
        "short_name": "BIOMARIN PHARMACEUTICAL INC",
        "long_name": "BioMarin Pharmaceutical Inc.",
        "summary": "BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "city": "San Rafael"
    },
    "BNN.DE": {
        "short_name": "B.R.A.I.N. NA",
        "long_name": "B.R.A.I.N. Biotechnology Research and Information Network AG",
        "summary": "B.R.A.I.N. Biotechnology Research and Information Network AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom. The company operates through BioScience and BioIndustrial segments. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and natural-source substances for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was founded in 1993 and is headquartered in Zwingenberg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Zwingenberg"
    },
    "BNN.F": {
        "short_name": "B.R.A.I.N. NA",
        "long_name": "B.R.A.I.N. Biotechnology Research and Information Network AG",
        "summary": "B.R.A.I.N. Biotechnology Research and Information Network AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom. The company operates through BioScience and BioIndustrial segments. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and natural-source substances for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was founded in 1993 and is headquartered in Zwingenberg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Zwingenberg"
    },
    "BNO.AX": {
        "short_name": "BIONOMICS FPO",
        "long_name": "Bionomics Limited",
        "summary": "Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Thebarton"
    },
    "BNOEF": {
        "short_name": "BIONOMICS LTD",
        "long_name": "Bionomics Limited",
        "summary": "Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Thebarton"
    },
    "BNTC": {
        "short_name": "Benitec Biopharma Inc.",
        "long_name": "Benitec Biopharma Inc.",
        "summary": "Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Hayward"
    },
    "BNTX": {
        "short_name": "BioNTech SE",
        "long_name": "BioNTech SE",
        "summary": "BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "Mainz"
    },
    "BNTX.VI": {
        "short_name": "BIONTECH SE ADR",
        "long_name": "BioNTech SE",
        "summary": "BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "Mainz"
    },
    "BO1.F": {
        "short_name": "BIOCRYST PHARMAC.  DL-,01",
        "long_name": "BioCryst Pharmaceuticals, Inc.",
        "summary": "BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Durham"
    },
    "BOAA": {
        "short_name": "BIO AMERICA INC",
        "long_name": "Bio-America Inc.",
        "summary": "Bio-America Inc. operates as a biotechnology company that researches and develops drug- screening technologies for manufacturing anti-obesity, anti-infective, and oncology products. The company was founded in 1999 and is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "BOLT.TA": {
        "short_name": "BIOLIGHT LIFE SCI",
        "long_name": "BioLight Life Sciences Ltd.",
        "summary": "BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions comprising glaucoma, dry eye syndrome, and age-related macular degeneration. The company's ophthalmic product offering and pipeline of product candidates include IOPtiMate, a laser-based surgical treatment for glaucoma; TeaRx, a point-of-care multi-parameter diagnostic test for DES; Eye-D, a controlled release drug-delivery insert platform; OphRx, a non-invasive topical drug delivery technology; and LipiTear, a micro-emulsion vehicle for the dry eye treatment, as well as for the treatment of other ocular diseases. It also invests in cancer diagnostics technologies, including proprietary tests that are designated for bladder, cervical, multiple myeloma, and other cancers. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was founded in 2005 and is based in Tel Aviv, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "BOTHE.BR": {
        "short_name": "BONE THERAPEUTICS",
        "long_name": "Bone Therapeutics SA",
        "summary": "Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases. Its products include ALLOB, an allogeneic cell therapy product, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. Bone Therapeutics SA has collaborations with Cerhum, 3D-Side, mSKIL, and IREC to develop personalized, tissue engineered bone implants. The company was founded in 2006 and is based in Gosselies, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Belgium",
        "city": "Gosselies"
    },
    "BP2M.F": {
        "short_name": "AIKIDO PHARMA  DL-,01",
        "long_name": "AIkido Pharma Inc.",
        "summary": "Spherix Incorporated, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company's platform consists of patented technology from leading universities and researchers and in the process of developing an innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer. Spherix Incorporated was founded in 1967 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "BPMC": {
        "short_name": "Blueprint Medicines Corporation",
        "long_name": "Blueprint Medicines Corporation",
        "summary": "Blueprint Medicines Corporation, a precision therapy company, develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "BPMUF": {
        "short_name": "BASILEA PHARMACEUTICA AG",
        "long_name": "Basilea Pharmaceutica AG",
        "summary": "Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers isavuconazole, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally under the Cresemba brand. The company also provides ceftobiprole, an intravenous antibiotic for the treatment of adult patients with community and hospital-acquired pneumonia, as well as Ceftobiprole, which is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia under the Zevtera name in European and various non-European countries. In addition, it engages in developing Derazantinib, an orally administered small molecule inhibitor, which is in a clinical study for the treatment intrahepatic cholangiocarcinoma, a form of biliary tract cancer; BAL101553, a tumor checkpoint controller drug for tumor types unresponsive to standard therapeutics; and BAL3833, an orally available small-molecule drug candidate for use as a panRAF/SRC kinase inhibitor. The company was founded in 2000 and is headquartered in Basel, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "BPSR": {
        "short_name": "BIOTECH PROD SVCS & RESEARCH IN",
        "long_name": "Organicell Regenerative Medicine, Inc.",
        "summary": "Organicell Regenerative Medicine, Inc. processes, distributes, and supplies biologically processed cellular and tissue-based products in the United States. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. has an agreement with Regenerative Care Network to study potential therapeutic benefits of Zofin for patients with heart failure. Organicell Regenerative Medicine, Inc. was founded in 2011 and is headquartered in Miami, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Miami"
    },
    "BPTH": {
        "short_name": "Bio-Path Holdings, Inc.",
        "long_name": "Bio-Path Holdings, Inc.",
        "summary": "Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome; and in Phase IIa clinical trials for the treatment of chronic myeloid leukemia, as well as to treat solid tumors. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Bellaire"
    },
    "BPXA.F": {
        "short_name": "BELLICUM PHARMA.INC.DL-01",
        "long_name": "Bellicum Pharmaceuticals, Inc.",
        "summary": "Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. It has collaboration and license agreements with Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Houston"
    },
    "BRRGF": {
        "short_name": "BERGENBIO ASA",
        "long_name": "BerGenBio ASA",
        "summary": "BerGenBio ASA, a clinical-stage biopharmaceutical company, develops medicines to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bioavailable small molecule AXL inhibitor, which is in Phase II clinical development in two major cancer indications. The Phase II clinical trial program focuses on lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer. In addition, it is developing tilvestamab, a function blocking antibody that is in Phase I clinical trial; and BGB601, a Phase I clinical trial antibody drug conjugate against human AXL that is linked to a cytotoxin. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was founded in 2007 and is headquartered in Bergen, Norway.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Norway",
        "city": "Bergen"
    },
    "BRTX": {
        "short_name": "BIORESTORATIVE THERAPIES INC",
        "long_name": "BioRestorative Therapies, Inc.",
        "summary": "BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Melville"
    },
    "BSEM": {
        "short_name": "BIOSTEM TECHNOLOGIES INC",
        "long_name": "BioStem Technologies, Inc.",
        "summary": "BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Pompano Beach"
    },
    "BSLN.SW": {
        "short_name": "BASILEA N",
        "long_name": "Basilea Pharmaceutica AG",
        "summary": "Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers isavuconazole, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally under the Cresemba brand. The company also provides ceftobiprole, an intravenous antibiotic for the treatment of adult patients with community and hospital-acquired pneumonia, as well as Ceftobiprole, which is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia under the Zevtera name in European and various non-European countries. In addition, it engages in developing Derazantinib, an orally administered small molecule inhibitor, which is in a clinical study for the treatment intrahepatic cholangiocarcinoma, a form of biliary tract cancer; BAL101553, a tumor checkpoint controller drug for tumor types unresponsive to standard therapeutics; and BAL3833, an orally available small-molecule drug candidate for use as a panRAF/SRC kinase inhibitor. The company was founded in 2000 and is headquartered in Basel, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Basel"
    },
    "BSSP": {
        "short_name": "BASSLINE PRODUCTIONS INC",
        "long_name": "Reve Technologies, Inc.",
        "summary": "Reve Technologies, Inc., a drug development company, provides advanced therapeutics for the treatment of cancer. It offers irreversible pepsin fraction (IPF), a therapeutic platform technology that is used to facilitate a range of applications. The company's solution is also used for the treatment of autoimmune diseases, such as cirrhosis and Hepatitis C. The company was founded in 2010 and is based in San Clemente, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Clemente"
    },
    "BSTC": {
        "short_name": "BioSpecifics Technologies Corp",
        "long_name": "BioSpecifics Technologies Corp.",
        "summary": "BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware. As of December 1, 2020, BioSpecifics Technologies Corp. operates as a subsidiary of Endo International plc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Wilmington"
    },
    "BSTG": {
        "short_name": "Biostage, Inc.",
        "long_name": "Biostage, Inc.",
        "summary": "Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Holliston"
    },
    "BSYI": {
        "short_name": "BIOSYNTECH INC",
        "long_name": "BioSyntech, Inc.",
        "summary": "BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. Its lead products in development include BST-CarGel, a biodegradable gel for cartilage repair; BST-InPod for heel pain relief; BST-DermOn for chronic wound healing; BST-Ossifil for bone filling; BST-Ossifix for bone structural support; and BST-Disc for intervertebral disc restoration. The company's products also comprise BST-Gel-based injectable products that deliver biotherapeutics to their targeted site of action; Arthro-BST, an arthroscopic device used for the non-destructive evaluation of cartilage degradation and/or repair; and Mach-1, a micromechanical testing system for evaluating the mechanical properties of tissues and materials. In addition, it manufactures ultra pure chitosans under the Ultrasan name; and offers manufacturing and analytical services. The company was incorporated in 1994 and is based in Laval, Canada. On May 12, 2010, Biosyntech Inc. filed for administration under the Bankruptcy and Insolvency Act. Biosyntech Inc. is in reorganization.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Laval"
    },
    "BT1.F": {
        "short_name": "BONE THERAPEUTICS S.A.",
        "long_name": "Bone Therapeutics SA",
        "summary": "Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases. Its products include ALLOB, an allogeneic cell therapy product, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. Bone Therapeutics SA has collaborations with Cerhum, 3D-Side, mSKIL, and IREC to develop personalized, tissue engineered bone implants. The company was founded in 2006 and is based in Gosselies, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Gosselies"
    },
    "BTAI": {
        "short_name": "BioXcel Therapeutics, Inc.",
        "long_name": "BioXcel Therapeutics, Inc.",
        "summary": "BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "New Haven"
    },
    "BTHE": {
        "short_name": "BOSTON THERAPEUTICS INC",
        "long_name": "Boston Therapeutics, Inc.",
        "summary": "Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Lawrence"
    },
    "BTI.V": {
        "short_name": "BIOASIS TECHNOLOGIES INC.",
        "long_name": "Bioasis Technologies Inc.",
        "summary": "Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-002), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). Bioasis Technologies Inc. was founded in 2007 and is headquartered in Guilford, Connecticut.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "city": "Guilford"
    },
    "BTPC.F": {
        "short_name": "ACTIVE BIOTECH  SK 10",
        "long_name": "Active Biotech AB (publ)",
        "summary": "Active Biotech AB (publ), a biotechnology company, together with its subsidiaries, develops pharmaceuticals for the treatment of cancer and inflammatory diseases in Sweden. The company is involved in developing Naptumomab, an immunotherapy that is in Phase Ib/II clinical trial for treatment of solid tumors; and Tasquinimod, an immunomodulator to treat multiple myeloma. It is also developing Laquinimod, an immunomodulator or the treatment of eye disorders; wet age-related macular degeneration and uveitis; and Crohn's disease, an inflammatory bowels disease. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "BV3.F": {
        "short_name": "BAVARIAN NOR  NAM.  DK 10",
        "long_name": "Bavarian Nordic A/S",
        "summary": "Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "BVNKF": {
        "short_name": "BAVARIAN NORDIC",
        "long_name": "Bavarian Nordic A/S",
        "summary": "Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "BVNRY": {
        "short_name": "BAVARIAN NORDIC",
        "long_name": "Bavarian Nordic A/S",
        "summary": "Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Hellerup"
    },
    "BVXP.L": {
        "short_name": "BIOVENTIX PLC ORD 5P",
        "long_name": "Bioventix PLC",
        "summary": "Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. The company was founded in 2003 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "BVXV": {
        "short_name": "BiondVax Pharmaceuticals Ltd.",
        "long_name": "BiondVax Pharmaceuticals Ltd.",
        "summary": "BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "BX2.F": {
        "short_name": "BIOXCEL THERAPEUT DL-,001",
        "long_name": "BioXcel Therapeutics, Inc.",
        "summary": "BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New Haven"
    },
    "BXN.AX": {
        "short_name": "BIOXYNE FPO",
        "long_name": "Bioxyne Limited",
        "summary": "Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. The company operates in two segments, Wholesale Sales and Direct Sales segments. It also engages in developing a range of functional foods and beauty products. The company's products portfolio include BK18, a dairy based food supplement; Allura, a beauty drink for women's weight management; Mustang, a nutritional shake for men's weight management; Mymana, a colostrum and fortified milk formula for nutrition and immune support; and BEssence, an anti-ageing serum. In addition, it offers its probiotic products under the Progastrim and proTract names. The company provides its products online, as well as through retail channels in Australia, the United States, New Zealand, and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "BXPHF": {
        "short_name": "BOTANIX PHARMACEUTICALS LTD",
        "long_name": "Botanix Pharmaceuticals Limited",
        "summary": "Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which is in Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; and BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea. The company was incorporated in 1984 and is based in North Perth, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "North Perth"
    },
    "BXRX": {
        "short_name": "Baudax Bio, Inc.",
        "long_name": "Baudax Bio, Inc.",
        "summary": "Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Malvern"
    },
    "BYSI": {
        "short_name": "BeyondSpring, Inc.",
        "long_name": "BeyondSpring Inc.",
        "summary": "BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "BZYR": {
        "short_name": "BURZYNSKI RESEARCH INSTITUTE IN",
        "long_name": "Burzynski Research Institute, Inc.",
        "summary": "Burzynski Research Institute, Inc. operates a research and development facility of drugs for use in the treatment of cancer in the United States. The company focuses on the research, development, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also provides consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Houston"
    },
    "C0I.F": {
        "short_name": "CYMABAY THERAPEUT.DL-0001",
        "long_name": "CymaBay Therapeutics, Inc.",
        "summary": "CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Newark"
    },
    "C4X.F": {
        "short_name": "ONXEO S.A. AC.PORT.EO-,25",
        "long_name": "Onxeo SA",
        "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "C6K.F": {
        "short_name": "CERECOR INC.  DL-,001",
        "long_name": "Cerecor Inc.",
        "summary": "Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Rockville"
    },
    "C6O.DE": {
        "short_name": "CLOVIS ONCOLOGY  DL-,001",
        "long_name": "Clovis Oncology, Inc.",
        "summary": "Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "city": "Boulder"
    },
    "C6O.F": {
        "short_name": "CLOVIS ONCOLOGY  DL-,001",
        "long_name": "Clovis Oncology, Inc.",
        "summary": "Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boulder"
    },
    "CABA": {
        "short_name": "Cabaletta Bio, Inc.",
        "long_name": "Cabaletta Bio, Inc.",
        "summary": "Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Philadelphia"
    },
    "CALA": {
        "short_name": "Calithera Biosciences, Inc.",
        "long_name": "Calithera Biosciences, Inc.",
        "summary": "Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "CALZF": {
        "short_name": "POLYNOVO LIMITED",
        "long_name": "PolyNovo Limited",
        "summary": "Polynovo Limited develops medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; breast devices in partnership with Establishment Labs; NovoSorb dermal beta cell implant in collaboration with BetaCell Technologies Pty Ltd; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is based in Port Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Port Melbourne"
    },
    "CAMX.ST": {
        "short_name": "Camurus AB",
        "long_name": "Camurus AB (publ)",
        "summary": "Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, North America, and Asia. It offers Buvidal, an injection solution for the treatment of opioid dependence; and episil oral liquid is a medical device for the treatment of inflammatory and painful conditions in the oral cavity. The company's products pipeline also includes CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment acromegaly and in phase II clinical trials for the treatment neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension. In addition, it develops CAM2032 for the treatment of prostate cancer; CAM4071, which has completed Phase I clinical trials for the treatment of Endocrine disorder; CAM4072 that is in phase III clinical trials for the treatment of rare genetic obesity disorders; and CAM4083, a pre-clinical stage product for treatment of myasthenia gravis, immune-mediated necrotizing myopathy, and other tissue disorders, as well as CAM2047, CAM2048, and CAM2058 for the treatment of chemotherapy induced nausea and vomiting, postoperative pain, and postoperative nausea and vomiting. The company was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB (publ) is a subsidiary of Sandberg Development AB.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "CANF": {
        "short_name": "Can-Fite Biopharma Ltd Sponsore",
        "long_name": "Can-Fite BioPharma Ltd.",
        "summary": "Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "CANF.TA": {
        "short_name": "CAN FITE BIOPHARMA",
        "long_name": "Can-Fite BioPharma Ltd.",
        "summary": "Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "CANTA.ST": {
        "short_name": "Cantargia AB",
        "long_name": "Cantargia AB (publ)",
        "summary": "Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases. It specializes in antibody-based treatment aimed at the molecular target Interleukin-1 Receptor Accessory Protein (IL1RAP), which has the potential to be used against various forms of cancer, as well as for autoimmune and inflammatory diseases. The company is developing CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system. It is also developing CANxx antibodies against IL1RAP for the treatment of autoimmune and inflammatory diseases. Cantargia AB (publ) has a collaboration agreement with BioWa. The company was founded in 2010 and is based in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "CAPR": {
        "short_name": "Capricor Therapeutics, Inc.",
        "long_name": "Capricor Therapeutics, Inc.",
        "summary": "Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. Capricor collaborates with Lonza for the development of CAP-1002, its cell therapy candidate for the treatment of Duchenne muscular dystrophy and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Beverly Hills"
    },
    "CAPS": {
        "short_name": "CAPSTONE THERAPEUTICS CORPORATI",
        "long_name": "Capstone Therapeutics Corp.",
        "summary": "Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Tempe"
    },
    "CARA": {
        "short_name": "Cara Therapeutics, Inc.",
        "long_name": "Cara Therapeutics, Inc.",
        "summary": "Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Stamford"
    },
    "CASI": {
        "short_name": "CASI Pharmaceuticals, Inc.",
        "long_name": "CASI Pharmaceuticals, Inc.",
        "summary": "CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Rockville"
    },
    "CATB": {
        "short_name": "Catabasis Pharmaceuticals, Inc.",
        "long_name": "Catabasis Pharmaceuticals, Inc.",
        "summary": "Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "CBAY": {
        "short_name": "CymaBay Therapeutics Inc.",
        "long_name": "CymaBay Therapeutics, Inc.",
        "summary": "CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Newark"
    },
    "CBBT": {
        "short_name": "CEREBAIN BIOTECH CORP",
        "long_name": "Cerebain Biotech Corp.",
        "summary": "Cerebain Biotech Corp., a biomedical company, focuses on the discovery of products for the treatment of Alzheimer's disease. Its products would include medical device solutions, as well as synthetic drug solutions. The company was formerly known as Discount Dental Materials, Inc. and changed its name to Cerebain Biotech Corp. in June 2014. Cerebain Biotech Corp. was incorporated in 2007 and is headquartered in Costa Mesa, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Costa Mesa"
    },
    "CBDC": {
        "short_name": "APOTHECA BIOSCIENCES INC",
        "long_name": "Apotheca Biosciences, Inc.",
        "summary": "Apotheca Biosciences, Inc. develops cutting-edge medical products, nutraceuticals, formulations, and delivery technologies for the healthcare and consumer care industry in the United States. The company's products include transdermal, sublingual, and nasal delivery devices for dosing of cannabinoids. It also provides CBD pain cream, gel capsules, patches, and sleep tablets; and Promed, anti-aging and cosmetic products. The company was incorporated in 2014 and is based in Saint Petersburg, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Saint Petersburg"
    },
    "CBI.TA": {
        "short_name": "CLAL BIOTECHNOLOGY",
        "long_name": "Clal Biotechnology Industries Ltd.",
        "summary": "Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to invest in companies based in United States, and Israel. It invests between $0.5 million and $10 million per company. It takes a seat on the board of directors of the companies it invests in. It invests through personal capital of its management. The firm acts as a lead investor and major shareholder in its portfolio companies. Clal Biotechnology Industries Ltd. was founded in July, 1998 and is based in Tel Aviv, Israel with an additional office in Cambridge, Massachusetts. It operates as a former subsidiary of Clal Industries and Investments Ltd.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "CBIO": {
        "short_name": "Catalyst Biosciences, Inc.",
        "long_name": "Catalyst Biosciences, Inc.",
        "summary": "Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase II development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation engineered coagulation Factor IX therapy that has completed Phase IIb clinical trials for the treatment of hemophilia B. The company also develops CB 2679d-GT, an early stage Factor IX gene therapy construct for Hemophilia B; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (AMD); and SQ systemic complement inhibitors pipeline. The company has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "CBLI": {
        "short_name": "Cleveland BioLabs, Inc.",
        "long_name": "Cleveland BioLabs, Inc.",
        "summary": "Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Buffalo"
    },
    "CBMG": {
        "short_name": "Cellular Biomedicine Group, Inc",
        "long_name": "Cellular Biomedicine Group, Inc.",
        "summary": "Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "CBOC.F": {
        "short_name": "CELSION CORP.  DL-,01",
        "long_name": "Celsion Corporation",
        "summary": "Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Lawrenceville"
    },
    "CBPI": {
        "short_name": "CHINA BOTANIC PHARMACEUTICAL",
        "long_name": "China Botanic Pharmaceutical Inc.",
        "summary": "China Botanic Pharmaceutical Inc. researches, develops, manufactures, and distributes of botanical products, bio-pharmaceutical products, and traditional Chinese medicines in the People's Republic of China. It offers botanical anti-depression and nerve-regulation products, including Acanthopanax, a Siberian ginseng that regulates the nervous system, delays aging process, strengthens the body, and treats neurasthenia, insomnia, cerebrovascular and cardiovascular diseases, and fatigue; Tianma tablets and compound Yangjiao tablets, which are botanic drugs for treating headaches and regulate nerves; and compound Schisandra tablets, a botanic drug used to regulate central nervous system, generate body fluids and alleviate thirst, nourish the kidneys, and cure insomnia and palpitations, as well as to cure neurasthenia. The company's biopharmaceutical products consist of Ginseng and Venison Extract, which comprises nutrients that nourish the blood and kidneys, and restore body's energy; and Badger oil expels that treats water and fire burns, scalds, and skin pain. Its botanical antibiotics and traditional over the counter Chinese medicines include Banlangen antiviral and broad-spectrum antibiotic granules; compound Honeysuckle antiviral, antibacterial, and anti-inflammatory granules; Shengmai granules, which regulate blood flow, strengthen heart beat, and improve the immune system and blood quality; and Qing Re Jie Du Oral Liquid that treats flu, upper respiratory infections, and sore throats. The company distributes its products through a network of approximately 3,000 distributors and approximately 70 sales centers. The company was formerly known as Renhuang Pharmaceuticals, Inc. and changed its name to China Botanic Pharmaceutical Inc. in November 2010. China Botanic Pharmaceutical Inc. was founded in 1996 and is headquartered in Harbin, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Harbin"
    },
    "CBPO": {
        "short_name": "China Biologic Products Holding",
        "long_name": "China Biologic Products Holdings, Inc.",
        "summary": "China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "city": "Beijing"
    },
    "CCAN": {
        "short_name": "CANADIAN CANNABIS CORP",
        "long_name": "Canadian Cannabis Corp.",
        "summary": "Canadian Cannabis Corp. focuses on the manufacture and marketing of medical marijuana products in Canada and internationally. The company intends to offer 15 different strains of dried marijuana, as well as the constituents to produce edible and elixir products for medicinal use. The company was founded in 2014 and is based in Brampton, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Brampton"
    },
    "CCCC": {
        "short_name": "C4 Therapeutics, Inc.",
        "long_name": "C4 Therapeutics, Inc.",
        "summary": "C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E and RET programs for genetically defined resistant solid tumors. It has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. C4 Therapeutics, Inc. was founded in 2015 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Watertown"
    },
    "CCXI": {
        "short_name": "ChemoCentryx, Inc.",
        "long_name": "ChemoCentryx, Inc.",
        "summary": "ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Mountain View"
    },
    "CDAK": {
        "short_name": "Codiak BioSciences, Inc.",
        "long_name": "Codiak BioSciences, Inc.",
        "summary": "Codiak BioSciences, Inc. is harnessing exosomes\u00c2\u0097natural intercellular messengers\u00c2\u0097to pioneer a new class of biologic medicines, exosome therapeutics. It develops the engEx Platform, versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company's two lead engEx product candidates, exoSTING and exoIL-12. Its engEx Platform has the potential to produce a broad pipeline of product candidates for the treatment of diseases with high unmet medical need, including in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurodegenerative disorders, and rare diseases. Codiak BioSciences, Inc. has a strategic collaboration with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of exoVACC vaccine platform for SARS-CoV-2 and human immunodeficiency virus. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "CDG0.F": {
        "short_name": "ACORDA THERAP.NEW DL-,001",
        "long_name": "Acorda Therapeutics, Inc.",
        "summary": "Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Ardsley"
    },
    "CDMO": {
        "short_name": "Avid Bioservices, Inc.",
        "long_name": "Avid Bioservices, Inc.",
        "summary": "Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Tustin"
    },
    "CDMOP": {
        "short_name": "Avid Bioservices, Inc. - 10.50%",
        "long_name": "Avid Bioservices, Inc.",
        "summary": "Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Tustin"
    },
    "CDTX": {
        "short_name": "Cidara Therapeutics, Inc.",
        "long_name": "Cidara Therapeutics, Inc.",
        "summary": "Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "CDXC": {
        "short_name": "ChromaDex Corporation",
        "long_name": "ChromaDex Corporation",
        "summary": "ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "CDXI": {
        "short_name": "CARDAX INC",
        "long_name": "Cardax, Inc.",
        "summary": "Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an anti-inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate; and CDX-301, a zeaxanthin pharmaceutical candidate for pharmaceutical applications. The company has a joint development and supply agreement with BASF SE, as well as a collaboration agreement with Capsugel US, LLC for the development of astaxanthin products for the consumer health market. Cardax, Inc. is based in Honolulu, Hawaii.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Honolulu"
    },
    "CDXS": {
        "short_name": "Codexis, Inc.",
        "long_name": "Codexis, Inc.",
        "summary": "Codexis, Inc. discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "CDY.AX": {
        "short_name": "CELLMID FPO",
        "long_name": "Cellmid Limited",
        "summary": "Cellmid Limited, a life sciences company, researches, develops, and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers midkine, a driver and modulator of inflammatory diseases, including chronic inflammatory diseases and cancer; and focuses on blocking midkine, a protein for autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer, and neurodegenerative diseases. It also develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company sells SARS-CoV-2 antibody kits and PCR tests. It markets its products through retailers and wholesalers, as well as through a direct-to-consumer e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "CELZ": {
        "short_name": "CREATIVE MEDICAL TECH HOLDING I",
        "long_name": "Creative Medical Technology Holdings, Inc.",
        "summary": "Creative Medical Technology Holdings, Inc., through its subsidiaries, engages in the stem cell research and developing applications to treat male sexual dysfunction and related issues. The company markets its erectile dysfunction (ED) treatment under the Caverstem name to physicians for use with their patients suffering from ED. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona. Creative Medical Technology Holdings, Inc. is a subsidiary of Creative Medical Health, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Phoenix"
    },
    "CEPS.F": {
        "short_name": "CTI BIOPHARMA CORP.",
        "long_name": "CTI BioPharma Corp.",
        "summary": "CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Seattle"
    },
    "CERC": {
        "short_name": "Cerecor Inc.",
        "long_name": "Cerecor Inc.",
        "summary": "Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Rockville"
    },
    "CERE": {
        "short_name": "Cerevel Therapeutics Holdings, ",
        "long_name": "Cerevel Therapeutics Holdings, Inc.",
        "summary": "Cerevel Therapeutics Holdings, Inc. operates as a clinical-stage biopharmaceutical company that engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in an ongoing Phase Ib multiple ascending dose and pharmacokinetic/pharmacodynamic trials for the treatment of patients with schizophrenia; and CVL-865, a PAM that is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as intends to initiate a Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III program for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "CERS": {
        "short_name": "Cerus Corporation",
        "long_name": "Cerus Corporation",
        "summary": "Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Concord"
    },
    "CERT": {
        "short_name": "Certara, Inc.",
        "long_name": "Certara, Inc.",
        "summary": "Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies and academic institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Princeton"
    },
    "CFRX": {
        "short_name": "ContraFect Corporation",
        "long_name": "ContraFect Corporation",
        "summary": "ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. ContraFect Corporation has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. The company also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Yonkers"
    },
    "CGEM": {
        "short_name": "Cullinan Management, Inc.",
        "long_name": "Cullinan Management, Inc.",
        "summary": "Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell acute lymphoblastic leukemia; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. Cullinan Management, Inc. has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was founded in 2016 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "CGEN": {
        "short_name": "Compugen Ltd.",
        "long_name": "Compugen Ltd.",
        "summary": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Holon"
    },
    "CGEN.TA": {
        "short_name": "COMPUGEN",
        "long_name": "Compugen Ltd.",
        "summary": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Holon"
    },
    "CGIX": {
        "short_name": "Cancer Genetics, Inc.",
        "long_name": "Cancer Genetics, Inc.",
        "summary": "Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Rutherford"
    },
    "CHMA": {
        "short_name": "Chiasma, Inc.",
        "long_name": "Chiasma, Inc.",
        "summary": "Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Needham"
    },
    "CHRS": {
        "short_name": "Coherus BioSciences, Inc.",
        "long_name": "Coherus BioSciences, Inc.",
        "summary": "Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "CIR.L": {
        "short_name": "CIRCASSIA GROUP PLC ORD 0.08P",
        "long_name": "Circassia Group Plc",
        "summary": "Circassia Group Plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through three segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; Tudorza for the treatment of COPD; and Duaklir, a fixed-dose combination of the long-acting muscarinic antagonist aclidinium bromide and long-acting beta agonist formoterol fumarate, which is administered twice-daily through the breath actuated Pressair inhaler for the maintenance treatment of COPD. It is also developing LungFit, a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. The company markets its products directly to specialists in the United States, the United Kingdom, China, Italy, and Germany, as well as through a network of partners internationally. Circassia Group Plc has a collaboration agreement with AstraZeneca to promote Tudorza and Duaklir for COPD treatment; and the United States and Chinese commercial rights to LungFit. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "CKPT": {
        "short_name": "Checkpoint Therapeutics, Inc.",
        "long_name": "Checkpoint Therapeutics, Inc.",
        "summary": "Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was founded in 2014 and is headquartered in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "CLBIO.ST": {
        "short_name": "Corline Biomedical AB",
        "long_name": "Corline Biomedical AB",
        "summary": "Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Uppsala"
    },
    "CLBS": {
        "short_name": "Caladrius Biosciences, Inc.",
        "long_name": "Caladrius Biosciences, Inc.",
        "summary": "Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Its product candidates include developmental treatments for cardiovascular diseases, such as CLBS12 for the treatment of critical limb ischemia; CLBS16, which is in Phase II clinical trial for the treatment of coronary microvascular dysfunction; CLBS14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in Basking Ridge, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Basking Ridge"
    },
    "CLCS": {
        "short_name": "CELL SOURCE INC",
        "long_name": "Cell Source, Inc.",
        "summary": "Cell Source, Inc., a cell therapy company, focuses on developing and commercializing immunotherapy medicines in Israel. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, such as treatment of lymphoma, leukemia, and multiple myeloma; and facilitating the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. The company was founded in 2011 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "CLDX": {
        "short_name": "Celldex Therapeutics, Inc.",
        "long_name": "Celldex Therapeutics, Inc.",
        "summary": "Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Hampton"
    },
    "CLGN": {
        "short_name": "CollPlant Biotechnologies Ltd.",
        "long_name": "CollPlant Biotechnologies Ltd.",
        "summary": "CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "CLLS": {
        "short_name": "Cellectis S.A.",
        "long_name": "Cellectis S.A.",
        "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "CLNN": {
        "short_name": "Clene Inc.",
        "long_name": "Clene Inc.",
        "summary": "Clene Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The company has a nanotechnology drug platform for the development of orally administered neurotherapeutic drugs. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; and NM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc. is based in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "CLRB": {
        "short_name": "Cellectar Biosciences, Inc.",
        "long_name": "Cellectar Biosciences, Inc.",
        "summary": "Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Florham Park"
    },
    "CLSD": {
        "short_name": "Clearside Biomedical, Inc.",
        "long_name": "Clearside Biomedical, Inc.",
        "summary": "Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Alpharetta"
    },
    "CLSN": {
        "short_name": "Celsion Corporation",
        "long_name": "Celsion Corporation",
        "summary": "Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Lawrenceville"
    },
    "CLVLF": {
        "short_name": "CLINUVEL PHARMACEUTICALS LTD",
        "long_name": "Clinuvel Pharmaceuticals Limited",
        "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PR\u00c3\u0089NUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "CLVLY": {
        "short_name": "CLINUVEL PHARMACEUTICALS LTD",
        "long_name": "Clinuvel Pharmaceuticals Limited",
        "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PR\u00c3\u0089NUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "CLVS": {
        "short_name": "Clovis Oncology, Inc.",
        "long_name": "Clovis Oncology, Inc.",
        "summary": "Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boulder"
    },
    "CLXPF": {
        "short_name": "CYBIN INC",
        "long_name": "Cybin Inc.",
        "summary": "Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "CMOTEC-B.ST": {
        "short_name": "Scandinavian ChemoTech AB B",
        "long_name": "Scandinavian ChemoTech AB (publ)",
        "summary": "Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "CMPI": {
        "short_name": "Checkmate Pharmaceuticals, Inc.",
        "long_name": "Checkmate Pharmaceuticals, Inc.",
        "summary": "Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor's ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "CMRX": {
        "short_name": "Chimerix, Inc.",
        "long_name": "Chimerix, Inc.",
        "summary": "Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Durham"
    },
    "CMVLF": {
        "short_name": "CELLECTIS",
        "long_name": "Cellectis S.A.",
        "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "CMXHF": {
        "short_name": "CSL LTD",
        "long_name": "CSL Limited",
        "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Parkville"
    },
    "CNBX": {
        "short_name": "CANNABICS PHARMACEUTICALS INC",
        "long_name": "Cannabics Pharmaceuticals Inc.",
        "summary": "Cannabics Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The company focuses on developing and marketing bioinformatic delivery systems for cannabinoids, personalized medicine therapies, and procedures based on cannabis originated compounds and bioinformatics tools. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, a drug sensitivity test for cannabinoid-based cancer therapies. The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. was founded in 2004 and is based in Bethesda, Maryland. Cannabics Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Bethesda"
    },
    "CNCE": {
        "short_name": "Concert Pharmaceuticals, Inc.",
        "long_name": "Concert Pharmaceuticals, Inc.",
        "summary": "Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for the treatment of autoimmune and central nervous system disorders. Its product candidates include CTP-543, which is in Phase III clinical trials for the treatment of alopecia areata; CTP-692, a selective deuterium-modified analog of the endogenous amino acid and D-serine that is in Phase II trials for the treatment of schizophrenia; and AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease. The company has strategic collaborations with Avanir Pharmaceuticals, Inc.; Cipla Technologies; Processa Pharmaceuticals; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Lexington"
    },
    "CNMD.TA": {
        "short_name": "CANNOMED MEDICAL",
        "long_name": "Cannomed Medical Cannabis Industries LTD",
        "summary": "Cannomed Medical Cannabis Industries Ltd, a biopharmaceutical company, discovers and develops novel therapeutics. It focuses on discovering inhibitors for E3 ubiquitin ligases for the treatment of cancer, metabolic diseases, viral infection, and CNS related disorders. The company was founded in 1999 and is based in Rehovot, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "CNSP": {
        "short_name": "CNS Pharmaceuticals, Inc.",
        "long_name": "CNS Pharmaceuticals, Inc.",
        "summary": "CNS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. CNS Pharmaceuticals, Inc. was founded in 2017 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Houston"
    },
    "CNST": {
        "short_name": "Constellation Pharmaceuticals, ",
        "long_name": "Constellation Pharmaceuticals, Inc.",
        "summary": "Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "CNWK.DE": {
        "short_name": "CO.DON AG  INH. O.N.",
        "long_name": "co.don AG",
        "summary": "co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The company develops, produces, and markets autologous cell therapies for the minimally invasive repair of cartilage damage to knee joints following traumatic or degenerative defects. Its therapies include matrix-associated autologous cartilage transplantation, a biological therapy for the treatment of damaged articular cartilage with the body's own cells; and autologous chondrocyte transplantation for the regeneration of biomechanical load-bearing and pressure-resistant cartilage tissue. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Teltow"
    },
    "CNWK.F": {
        "short_name": "CO.DON AG  INH. O.N.",
        "long_name": "co.don AG",
        "summary": "co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The company develops, produces, and markets autologous cell therapies for the minimally invasive repair of cartilage damage to knee joints following traumatic or degenerative defects. Its therapies include matrix-associated autologous cartilage transplantation, a biological therapy for the treatment of damaged articular cartilage with the body's own cells; and autologous chondrocyte transplantation for the regeneration of biomechanical load-bearing and pressure-resistant cartilage tissue. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Teltow"
    },
    "COCP": {
        "short_name": "Cocrystal Pharma, Inc.",
        "long_name": "Cocrystal Pharma, Inc.",
        "summary": "Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Bothell"
    },
    "COGT": {
        "short_name": "Cogent Biosciences, Inc.",
        "long_name": "Cogent Biosciences, Inc.",
        "summary": "Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a \u00c2\u0091bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "CORT": {
        "short_name": "Corcept Therapeutics Incorporat",
        "long_name": "Corcept Therapeutics Incorporated",
        "summary": "Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator that is in Phase II for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Menlo Park"
    },
    "COTQF": {
        "short_name": "COTINGA PHARMACEUTICALS INC",
        "long_name": "Cotinga Pharmaceuticals Inc.",
        "summary": "Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "COV.V": {
        "short_name": "COVALON TECHNOLOGIES LTD",
        "long_name": "Covalon Technologies Ltd.",
        "summary": "Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has three platform technologies, including collagen matrix platform that is used to manufacture a family of products that treat chronic and infected wounds, such as diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform, which is used in a family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. It sells wound care dressing, surgical and peri-operative, and infection management products under the Covalon brand name. The company also offers development contracts, licensing agreements, and distribution contracts services. It provides its technologies, products, and services to various health care providers, such as hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Mississauga"
    },
    "COX.PA": {
        "short_name": "NICOX",
        "long_name": "Nicox S.A.",
        "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Valbonne"
    },
    "CPH1.F": {
        "short_name": "HISTOGEN INC. DL-,0001",
        "long_name": "Histogen Inc.",
        "summary": "Histogen Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. It offers human multipotent cell conditioned media (CCM); human extracellular matrix (hECM); and hair stimulating complex (HSC). The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. Histogen Inc. is headquartered San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "CPMV": {
        "short_name": "MOSAIC IMMUNOENGINEERING INC",
        "long_name": "Mosaic ImmunoEngineering Inc.",
        "summary": "Patriot Scientific Corporation operates as an intellectual-property licensing company. The company's Moore Microprocessor Patent portfolio that includes U.S. patents, as well as European and Japanese counterparts, which cover techniques that enable consumer and commercial digital systems ranging from PCs, cell phones, portable music players, communications infrastructure, medical equipment, and automobiles. Patriot Scientific Corporation is headquartered in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "None"
    },
    "CPRX": {
        "short_name": "Catalyst Pharmaceuticals, Inc.",
        "long_name": "Catalyst Pharmaceuticals, Inc.",
        "summary": "Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Coral Gables"
    },
    "CPTA.F": {
        "short_name": "COLL.BIO. SP.ADR/1 -,01",
        "long_name": "CollPlant Biotechnologies Ltd.",
        "summary": "CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "CRBP": {
        "short_name": "Corbus Pharmaceuticals Holdings",
        "long_name": "Corbus Pharmaceuticals Holdings, Inc.",
        "summary": "Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Norwood"
    },
    "CRDF": {
        "short_name": "Cardiff Oncology, Inc.",
        "long_name": "Cardiff Oncology, Inc.",
        "summary": "Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "CRIS": {
        "short_name": "Curis, Inc.",
        "long_name": "Curis, Inc.",
        "summary": "Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors. The company's products in pipeline include CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments to identify therapeutic opportunities. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Lexington"
    },
    "CRMD": {
        "short_name": "CorMedix Inc.",
        "long_name": "CorMedix Inc.",
        "summary": "CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Berkeley Heights"
    },
    "CRNX": {
        "short_name": "Crinetics Pharmaceuticals, Inc.",
        "long_name": "Crinetics Pharmaceuticals, Inc.",
        "summary": "Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "CRO.F": {
        "short_name": "OPEN ORPHAN PLC  LS-,001",
        "long_name": "Open Orphan plc",
        "summary": "Open Orphan plc operates as a clinical research organization pharmaceutical services company with a focus on virology, vaccine studies, and orphan drugs in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. It operates a virtual rep, a pharmaceutical commercialization platform for rare/orphan disease space; and develops Genomic Health Data platform, a collection of infectious disease progression data. The company also provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations. In addition, it offers hVIVO COVID Clear Test, an antibody test for employers in the United Kingdom and Ireland. The company is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "CRPOF": {
        "short_name": "CEAPRO INC",
        "long_name": "Ceapro Inc.",
        "summary": "Ceapro Inc., a biotechnology company, engages in the development and commercialization of active ingredients in the United States, Germany, China, Canada, and internationally. It operates in two segments, The Active Ingredient Product Technology Industry and The Cosmeceutical Industry. The company is involved in the development and application of technology to the production of extracts and active ingredients from oats and other renewable plant resources. It adds value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company's products include natural active ingredients comprising beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides that are marketed to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; natural anti-aging skincare products; and veterinary therapeutic products, such as oat shampoos, ear cleansers, and dermal complexes/conditioners. Its products and technologies that are under research and development, or pre-commercial stage comprise a platform using its beta glucan formulations to deliver compounds for treatments in the personal and healthcare sectors; various novel enabling technologies, such as Pressurized Gas eXpanded drying technology; and technologies to enhance the content of avenanthramides. The company has a collaboration with the McMaster University to develop inhalable therapeutic for COVID-19. Ceapro Inc. was incorporated in 1997 and is headquartered in Edmonton, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Edmonton"
    },
    "CRSP": {
        "short_name": "CRISPR Therapeutics AG",
        "long_name": "CRISPR Therapeutics AG",
        "summary": "CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Zug"
    },
    "CRTX": {
        "short_name": "Cortexyme, Inc.",
        "long_name": "Cortexyme, Inc.",
        "summary": "Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "CRVS": {
        "short_name": "Corvus Pharmaceuticals, Inc.",
        "long_name": "Corvus Pharmaceuticals, Inc.",
        "summary": "Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Burlingame"
    },
    "CRXM": {
        "short_name": "TAXUS CARDIUM PHARMACEUTICALS G",
        "long_name": "Gene Biotherapeutics, Inc.",
        "summary": "Gene Biotherapeutics, Inc. manages a portfolio of medical technologies in the United States. It focuses on acquiring and developing gene-based therapeutics. The company, through its subsidiary, Angionetics, Inc., focuses on the clinical advancement and commercialization of Generx, an interventional cardiology, angiogenic gene therapy Phase 3 product candidate designed for the potential treatment of patients with refractory angina due to advanced coronary artery disease. It also holds royalties on the commercialization of Excellagen technology platform for advanced wound care in Eurasian countries. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was founded in 2003 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "CRYO": {
        "short_name": "AMERICAN CRYOSTEM CORPORATION",
        "long_name": "American CryoStem Corporation",
        "summary": "American CryoStem Corporation develops, markets, and licenses tissue-based cellular technologies with a focus on processing, commercial bio-banking, and application development for adipose tissue and autologous adipose-derived regenerative cells. The company's products include CELLECT collection, transportation, and storage system, which is a solution for physicians to collect and deliver tissue samples; ATGRAFT adipose tissue storage service, a fat storage solution that enables physicians to provide their patients with tissue products and cell storage options; and ATCELL adipose derived stem cells. It also offers ACSelerat cell culture media products for growing human stromal cells. In addition, the company, through its ACS Laboratories division, operate human tissue processing, cryopreservation and cell culture and differentiation media development facility. Further, it provides contract manufacturing services for Autokine-CM, an anti-aging topical formulation; and autologous skin care product line. The company was founded in 1987 and is based in Eatontown, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Eatontown"
    },
    "CSBR": {
        "short_name": "Champions Oncology, Inc.",
        "long_name": "Champions Oncology, Inc.",
        "summary": "Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Hackensack"
    },
    "CSBTF": {
        "short_name": "KUROS BIOSCIENCES AG",
        "long_name": "Kuros Biosciences AG",
        "summary": "Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company's orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Schlieren"
    },
    "CSJ.F": {
        "short_name": "CSL LTD",
        "long_name": "CSL Limited",
        "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Parkville"
    },
    "CSJA.F": {
        "short_name": "CSL LTD  SPON.ADR 2",
        "long_name": "CSL Limited",
        "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Parkville"
    },
    "CSLLY": {
        "short_name": "CSL LTD",
        "long_name": "CSL Limited",
        "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Parkville"
    },
    "CSP.F": {
        "short_name": "CASSIOPEA S.P.A.  EO 1",
        "long_name": "Cassiopea S.p.A.",
        "summary": "Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Italy",
        "city": "Lainate"
    },
    "CSPHF": {
        "short_name": "CSTONE PHARMACEUTICALS",
        "long_name": "CStone Pharmaceuticals",
        "summary": "CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment worldwide. The company's late-stage clinical products include CS1001, a monoclonal antibody against programmed death ligand 1; CS1003, a monoclonal antibody against programmed death receptor; ivosidenib, a potent inhibitor of the mutated isocitrate dehydrogenase-1 enzyme for the treatment of cancer; avapritinib, an inhibitor for the treatment of gastrointestinal stromal tumors and systematic mastocytosis; and Pralsetinib for the treatment of medullary thyroid cancer and other advanced solid tumors. Its products also comprise CS1002, CS3002, CS3003, CS3005, and CS3006 for solid tumors; Fisogatinib that is used for the treatment of hepatocellular carcinoma; and CS3004, CS1009, and CS2004 for other indications. CStone Pharmaceuticals has a licensing agreement with Numab Therapeutics AG for the development and commercialization of NM21-1480, a potential monovalent tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin; a clinical collaboration with Bayer HealthCare LLC to evaluate CS1001 in combination with Bayer's oral multi-kinase inhibitor Stivarga, as a treatment for various types of cancer, including gastric cancer; and a strategic partnership with Burning Rock Biotech Limited to co-develop and commercialize companion diagnostics for pralsetinib, an investigational treatment for the detection of RET alterations in cancer patients. The company was founded in 2015 in Cayman Islands, and is headquartered in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Shanghai"
    },
    "CTIC": {
        "short_name": "CTI BioPharma Corp.",
        "long_name": "CTI BioPharma Corp.",
        "summary": "CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "CTMX": {
        "short_name": "CytomX Therapeutics, Inc.",
        "long_name": "CytomX Therapeutics, Inc.",
        "summary": "CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "CTXR": {
        "short_name": "Citius Pharmaceuticals, Inc.",
        "long_name": "Citius Pharmaceuticals, Inc.",
        "summary": "Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cranford"
    },
    "CU2.F": {
        "short_name": "CERUS CORP.  DL-,001",
        "long_name": "Cerus Corporation",
        "summary": "Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Concord"
    },
    "CUE": {
        "short_name": "Cue Biopharma, Inc.",
        "long_name": "Cue Biopharma, Inc.",
        "summary": "Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, an onco-fetal viral antigen for cancers, including solid tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases, as well as a strategic research collaboration with Dr. Michael Dustin and Oxford University. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "CURE.CN": {
        "short_name": "BiocureTechInc",
        "long_name": "Biocure Technology Inc.",
        "summary": "Biocure Technology Inc. develops and commercializes biopharmaceutical technologies for uses in recombinant and ranibizumab. The company is developing Interferons- \u00c3\u009f for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It is also developing CAR T Cell Therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and a hair growth production product. Biocure Technology Inc. is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "CUSA.F": {
        "short_name": "CURIS INC.  DL-,01",
        "long_name": "Curis, Inc.",
        "summary": "Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors. The company's products in pipeline include CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments to identify therapeutic opportunities. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Lexington"
    },
    "CUV.AX": {
        "short_name": "CLINUVEL FPO",
        "long_name": "Clinuvel Pharmaceuticals Limited",
        "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PR\u00c3\u0089NUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "CVAC": {
        "short_name": "CureVac N.V.",
        "long_name": "CureVac N.V.",
        "summary": "CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in T\u00c3\u00bcbingen, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "T\u00c3\u00bcbingen"
    },
    "CVAC.VI": {
        "short_name": "CUREVAC NV",
        "long_name": "CureVac N.V.",
        "summary": "CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in T\u00c3\u00bcbingen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "T\u00c3\u00bcbingen"
    },
    "CVALF": {
        "short_name": "COVALON TECHNOLOGIES LTD",
        "long_name": "Covalon Technologies Ltd.",
        "summary": "Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has three platform technologies, including collagen matrix platform that is used to manufacture a family of products that treat chronic and infected wounds, such as diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform, which is used in a family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. It sells wound care dressing, surgical and peri-operative, and infection management products under the Covalon brand name. The company also offers development contracts, licensing agreements, and distribution contracts services. It provides its technologies, products, and services to various health care providers, such as hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Mississauga"
    },
    "CVM": {
        "short_name": "Cel-Sci Corporation",
        "long_name": "CEL-SCI Corporation",
        "summary": "CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Vienna"
    },
    "CWBR": {
        "short_name": "CohBar, Inc.",
        "long_name": "CohBar, Inc.",
        "summary": "CohBar, Inc., a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. The company was founded in 2007 and is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Menlo Park"
    },
    "CXF.F": {
        "short_name": "CHIMERIX INC.  DL -,001",
        "long_name": "Chimerix, Inc.",
        "summary": "Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Durham"
    },
    "CXS.F": {
        "short_name": "CHIASMA INC.DL-,01",
        "long_name": "Chiasma, Inc.",
        "summary": "Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Needham"
    },
    "CYAD": {
        "short_name": "Celyad Oncology SA",
        "long_name": "Celyad Oncology SA",
        "summary": "Celyad Oncology, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. The company's lead drug product candidates include CYAD-01 and CYAD-02 autologous cell therapies, which are in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an allogeneic cell therapy that is in Phase I clinical trial for the treatment of metastatic colorectal cancer; and CYAD-103, an allogeneic CAR-T product candidate that is in preclinical development for the treatment of solid tumors. The company's other preclinical candidates include CYAD-211, a CAR-T candidate targeting B-cell maturation antigen for the treatment of multiple myeloma; CYAD-221, a CAR-T candidate targeting CD19 for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. Celyad Oncology has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad Oncology was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Belgium",
        "city": "Mont-Saint-Guibert"
    },
    "CYAD.BR": {
        "short_name": "CELYAD ONCOLOGY",
        "long_name": "Celyad Oncology SA",
        "summary": "Celyad Oncology, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. The company's lead drug product candidates include CYAD-01 and CYAD-02 autologous cell therapies, which are in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an allogeneic cell therapy that is in Phase I clinical trial for the treatment of metastatic colorectal cancer; and CYAD-103, an allogeneic CAR-T product candidate that is in preclinical development for the treatment of solid tumors. The company's other preclinical candidates include CYAD-211, a CAR-T candidate targeting B-cell maturation antigen for the treatment of multiple myeloma; CYAD-221, a CAR-T candidate targeting CD19 for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. Celyad Oncology has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad Oncology was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Belgium",
        "city": "Mont-Saint-Guibert"
    },
    "CYBN.NE": {
        "short_name": "CYBIN INC.",
        "long_name": "Cybin Inc.",
        "summary": "Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NEO",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "CYCC": {
        "short_name": "Cyclacel Pharmaceuticals, Inc.",
        "long_name": "Cyclacel Pharmaceuticals, Inc.",
        "summary": "Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Berkeley Heights"
    },
    "CYCCP": {
        "short_name": "Cyclacel Pharmaceuticals, Inc. ",
        "long_name": "Cyclacel Pharmaceuticals, Inc.",
        "summary": "Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Berkeley Heights"
    },
    "CYCN": {
        "short_name": "Cyclerion Therapeutics, Inc.",
        "long_name": "Cyclerion Therapeutics, Inc.",
        "summary": "Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "CYDY": {
        "short_name": "CYTODYN INC",
        "long_name": "CytoDyn Inc.",
        "summary": "CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Vancouver"
    },
    "CYP.AX": {
        "short_name": "CYNATA THR FPO",
        "long_name": "Cynata Therapeutics Limited",
        "summary": "Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Carlton"
    },
    "CYTH": {
        "short_name": "Cyclo Therapeutics, Inc.",
        "long_name": "Cyclo Therapeutics, Inc.",
        "summary": "Cyclo Therapeutics, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in October 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Gainesville"
    },
    "CYTK": {
        "short_name": "Cytokinetics, Incorporated",
        "long_name": "Cytokinetics, Incorporated",
        "summary": "Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "CYTR": {
        "short_name": "CYTRX CORP",
        "long_name": "CytRx Corporation",
        "summary": "CytRx Corporation, a biopharmaceutical company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "CYXO.ST": {
        "short_name": "Cyxone AB",
        "long_name": "Cyxone AB (publ)",
        "summary": "Cyxone AB (publ), a clinical biotech company, develops immunomodulatory drugs for the treatment of autoimmune diseases. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and T20K that would enter clinical Phase I for multiple sclerosis. The company was founded in 2015 and is headquartered in Malm\u00c3\u00b6, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Malm\u00c3\u00b6"
    },
    "CZO.V": {
        "short_name": "Ceapro Inc",
        "long_name": "Ceapro Inc.",
        "summary": "Ceapro Inc., a biotechnology company, engages in the development and commercialization of active ingredients in the United States, Germany, China, Canada, and internationally. It operates in two segments, The Active Ingredient Product Technology Industry and The Cosmeceutical Industry. The company is involved in the development and application of technology to the production of extracts and active ingredients from oats and other renewable plant resources. It adds value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company's products include natural active ingredients comprising beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides that are marketed to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; natural anti-aging skincare products; and veterinary therapeutic products, such as oat shampoos, ear cleansers, and dermal complexes/conditioners. Its products and technologies that are under research and development, or pre-commercial stage comprise a platform using its beta glucan formulations to deliver compounds for treatments in the personal and healthcare sectors; various novel enabling technologies, such as Pressurized Gas eXpanded drying technology; and technologies to enhance the content of avenanthramides. The company has a collaboration with the McMaster University to develop inhalable therapeutic for COVID-19. Ceapro Inc. was incorporated in 1997 and is headquartered in Edmonton, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Edmonton"
    },
    "D05.F": {
        "short_name": "DECIPHERA PHARMAC. DL-,01",
        "long_name": "Deciphera Pharmaceuticals, Inc.",
        "summary": "Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Waltham"
    },
    "DARE": {
        "short_name": "Dare Bioscience, Inc.",
        "long_name": "Dar\u00e9 Bioscience, Inc.",
        "summary": "Dar\u00c3\u00a9 Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214 injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "DBV.F": {
        "short_name": "DBV TECHNOLOGIES  EO -,10",
        "long_name": "DBV Technologies S.A.",
        "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Montrouge"
    },
    "DBV.PA": {
        "short_name": "DBV TECHNOLOGIES",
        "long_name": "DBV Technologies S.A.",
        "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Montrouge"
    },
    "DBVA.F": {
        "short_name": "DBV TECH.SP.ADR 1/2 EO-10",
        "long_name": "DBV Technologies S.A.",
        "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Montrouge"
    },
    "DBVT": {
        "short_name": "DBV Technologies S.A.",
        "long_name": "DBV Technologies S.A.",
        "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Montrouge"
    },
    "DCAL.NS": {
        "short_name": "DISHMAN CARBOGEN",
        "long_name": "Dishman Carbogen Amcis Limited",
        "summary": "Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide. It also manufactures and supplies marketable molecules, such as bulk drugs, intermediates, quaternary ammonium compounds, specialty chemicals, vitamins and chemicals, and disinfectants. The company was incorporated in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.",
        "currency": "INR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NSI",
        "market": "in_market",
        "country": "India",
        "city": "Ahmedabad"
    },
    "DCPH": {
        "short_name": "Deciphera Pharmaceuticals, Inc.",
        "long_name": "Deciphera Pharmaceuticals, Inc.",
        "summary": "Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "DDDD.L": {
        "short_name": "4D PHARMA PLC ORD 0.25P",
        "long_name": "4D pharma plc",
        "summary": "4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Leeds"
    },
    "DFFN": {
        "short_name": "Diffusion Pharmaceuticals Inc.",
        "long_name": "Diffusion Pharmaceuticals Inc.",
        "summary": "Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Charlottesville"
    },
    "DMAC": {
        "short_name": "DiaMedica Therapeutics Inc.",
        "long_name": "DiaMedica Therapeutics Inc.",
        "summary": "DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Minneapolis"
    },
    "DMN.F": {
        "short_name": "DIAMYD MEDICAL B",
        "long_name": "Diamyd Medical AB (publ)",
        "summary": "Diamyd Medical AB (publ) engages in developing therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunomodulating diabetes vaccine for the treatment of type 1 diabetes and latent autoimmune diabetes, which is in Phase IIb clinical development; and Remygen, an oral regenerative and immunomodulatory drug candidate for the treatment of autoimmune and type 2 diabetes, which is in Phase I/II clinical development. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is based in Stockholm, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "DMYD-B.ST": {
        "short_name": "Diamyd Medical AB ser. B",
        "long_name": "Diamyd Medical AB (publ)",
        "summary": "Diamyd Medical AB (publ) engages in developing therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunomodulating diabetes vaccine for the treatment of type 1 diabetes and latent autoimmune diabetes, which is in Phase IIb clinical development; and Remygen, an oral regenerative and immunomodulatory drug candidate for the treatment of autoimmune and type 2 diabetes, which is in Phase I/II clinical development. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is based in Stockholm, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "DNLI": {
        "short_name": "Denali Therapeutics Inc.",
        "long_name": "Denali Therapeutics Inc.",
        "summary": "Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "DOSE.CN": {
        "short_name": "RapidDose",
        "long_name": "Rapid Dose Therapeutics Corp.",
        "summary": "Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. It also offers PharmaStrip delivery system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Burlington"
    },
    "DP81.F": {
        "short_name": "DIFFUSION PHARMA. DL-,001",
        "long_name": "Diffusion Pharmaceuticals Inc.",
        "summary": "Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Charlottesville"
    },
    "DP81.SG": {
        "short_name": "Diffusion Pharmaceuticals Inc.R",
        "long_name": "Diffusion Pharmaceuticals Inc.",
        "summary": "Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Charlottesville"
    },
    "DPL.F": {
        "short_name": "DICERNA PHARMAC.DL -,0001",
        "long_name": "Dicerna Pharmaceuticals, Inc.",
        "summary": "Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Lexington"
    },
    "DRNA": {
        "short_name": "Dicerna Pharmaceuticals, Inc.",
        "long_name": "Dicerna Pharmaceuticals, Inc.",
        "summary": "Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Lexington"
    },
    "DROP": {
        "short_name": "FUSE SCIENCE INC",
        "long_name": "Fuse Science, Inc.",
        "summary": "Fuse Science, Inc. focuses on the development and commercialization of proprietary delivery technology for delivering energy, nutrition, and medications to humans in the United States. The company also produces and sells sports nutrition and performance products. Its products include SkyPorts, a drone support technology and energy demand network that enables long distance flight required for drone-based commerce without the need for drones to return every 15 minutes to recharge; and XTRAX, a remote monitoring system designed to measure the production of solar and other renewable energy systems, as well as transmit the data via the cellular and radio frequency, and microwave transmission network or satellite. The company was formerly known as Double Eagle Holdings, Ltd. and changed its name to Fuse Science, Inc. in December 2011. Fuse Science, Inc. was founded in 1985 and is based in Massapequa, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Massapequa"
    },
    "DTHR": {
        "short_name": "DTHERA SCIENCES",
        "long_name": "Dthera Sciences",
        "summary": "Dthera Sciences operates as a digital therapeutic company in neurodegenerative diseases. It is developing DTHR-ALZ, a medical device for the mitigation of the symptoms of agitation and depression associated with Alzheimer's disease. The company is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "DTIL": {
        "short_name": "Precision BioSciences, Inc.",
        "long_name": "Precision BioSciences, Inc.",
        "summary": "Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Durham"
    },
    "DUL.DE": {
        "short_name": "ALNYLAM PHARMACE.DL-,0001",
        "long_name": "Alnylam Pharmaceuticals, Inc.",
        "summary": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "DUL.F": {
        "short_name": "ALNYLAM PHARMACE.DL-,0001",
        "long_name": "Alnylam Pharmaceuticals, Inc.",
        "summary": "Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "DVAX": {
        "short_name": "Dynavax Technologies Corporatio",
        "long_name": "Dynavax Technologies Corporation",
        "summary": "Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "EmeryVille"
    },
    "DXB.AX": {
        "short_name": "DIMERIX FPO",
        "long_name": "Dimerix Limited",
        "summary": "Dimerix Limited, a biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. It offers DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis; and DMX-700, which is in pre-clinical stage for the treatment of chronic obstructive pulmonary disease, as well as proprietary ReceptorHIT assay technology. The company was incorporated in 1975 and is headquartered in Fitzroy, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Fitzroy"
    },
    "DXRX.L": {
        "short_name": "DIACEUTICS PLC ORD GBP0.002",
        "long_name": "Diaceutics PLC",
        "summary": "Diaceutics Plc provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic regulation, turnaround time, and sample availability analysis services; diagnostic tracking services, including lab tracking, patient insights, and physician segmentation services; and diagnostic payers research, diagnostic clinical landscape, integrated mapping research, buying process research, and testers/non-testers research services. The company also provides diagnostic planning services consisting of strategic and tactical planning, launch planning, diagnostic partner selection, and financial forecast services; commercialization services comprising content creation; LabEd/workshops, diagnostic adboards, conference support, and proficiency testing services; and Diagnostic reimbursement services. Diaceutics Plc was founded in 2005 and is headquartered in Belfast, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Belfast"
    },
    "DYAI": {
        "short_name": "Dyadic International, Inc.",
        "long_name": "Dyadic International, Inc.",
        "summary": "Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd., as well as with the Israel Institute for Biological Research; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; research collaboration with Sanofi-Aventis Deutschland GmbH; research and commercialization collaboration with Serum Institute of India Pvt.; and nonexclusive research collaboration with WuXi Biologics. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Jupiter"
    },
    "DYF1.F": {
        "short_name": "DYNAVAX TECHS  DL-,001",
        "long_name": "Dynavax Technologies Corporation",
        "summary": "Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "EmeryVille"
    },
    "DYN": {
        "short_name": "Dynegy Inc.",
        "long_name": "Dyne Therapeutics, Inc.",
        "summary": "Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "E031.F": {
        "short_name": "ESSA PHARMA INC.",
        "long_name": "ESSA Pharma Inc.",
        "summary": "ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "E4N.F": {
        "short_name": "SUDA PHARMACEUTICALS LTD.",
        "long_name": "Suda Pharmaceuticals Ltd",
        "summary": "Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Osborne Park"
    },
    "E8L.F": {
        "short_name": "GEOVAX LABS NEW  DL -,001",
        "long_name": "GeoVax Labs, Inc.",
        "summary": "GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Vaxeal Holding SA; Virometix AG; Geneva Foundation; Enesi Pharma; UCSF; BravoVax; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Smyrna"
    },
    "EAJF.F": {
        "short_name": "VALIRX PLC  LS-,001",
        "long_name": "ValiRx plc",
        "summary": "ValiRx plc, a biotechnology oncology focused company, engages in developing novel therapeutics and associated biomarkers for cancer in the United Kingdom. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the treatment of women with endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a candidate produced by GeneICE technology platform to modulate BCl2 expression \u00c2\u0096 implicated in cancers. ValiRx plc has collaboration agreement with Oncolytika Limited and Black Cat Bio Limited to develop and evaluate BC201 for patients suffering a hyperimmune response to Coronavirus SARS-CoV2 infection. The company was incorporated in 2000 and is based in Hatfield, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Hatfield"
    },
    "EARS": {
        "short_name": "Auris Medical Holding Ltd.",
        "long_name": "Auris Medical Holding Ltd.",
        "summary": "Auris Medical Holding Ltd., a development-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment and prevention of peripheral and central nervous disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; and AM-201, which is in Phase 1b clinical trial for the prevention of weight gain and drowsiness, which are side effects of various antipsychotic drugs, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Bermuda",
        "city": "Hamilton"
    },
    "EBM.V": {
        "short_name": "EASTWOOD BIO MEDICAL CANADA INC",
        "long_name": "Eastwood Bio-Medical Canada Inc.",
        "summary": "Eastwood Bio-Medical Canada Inc. distributes natural health supplements in North America and Asia. The company distributes Eleotin products and related products. Its Eleotin brand of products provides natural sourced solutions for metabolic syndromes, such as blood glucose disorders, obesity, and hypertension. The company's licensed products include Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for development and maintenance of bones and teeth; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. Its product also include Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. The company was incorporated in 2010 and is based in Richmond, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Richmond"
    },
    "ECQ.F": {
        "short_name": "PHARMAUST LTD.",
        "long_name": "PharmAust Limited",
        "summary": "PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for human and animal healthcare. The company develops drug discovery intellectual property for the treatment of various cancers in humans and animals. Its lead candidate is Monepantel, which are in Phase II clinical trials for the treatment of cancer. The company also provides highly specialized medicinal and synthetic chemistry services on a contract basis to clients to the drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Bentley"
    },
    "EDIT": {
        "short_name": "Editas Medicine, Inc.",
        "long_name": "Editas Medicine, Inc.",
        "summary": "Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "EDSA": {
        "short_name": "Edesa Biotech, Inc.",
        "long_name": "Edesa Biotech, Inc.",
        "summary": "Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Markham"
    },
    "EGTX.ST": {
        "short_name": "Egetis Therapeutics AB",
        "long_name": "Egetis Therapeutics AB (publ)",
        "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. It engages in developing PledOx, which is in Phase III clinical trial to protect patients from nerve damage caused by chemotherapy without reducing its anticancer effects; Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling; and Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. The company was founded in 2006 and is headquartered in Stockholm, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "EH3A.F": {
        "short_name": "AMARIN CORP.ADR LS-50",
        "long_name": "Amarin Corporation plc",
        "summary": "Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "EIDX": {
        "short_name": "Eidos Therapeutics, Inc.",
        "long_name": "Eidos Therapeutics, Inc.",
        "summary": "Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "EIGR": {
        "short_name": "Eiger BioPharmaceuticals, Inc.",
        "long_name": "Eiger BioPharmaceuticals, Inc.",
        "summary": "Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Palo Alto"
    },
    "ELDN": {
        "short_name": "Eledon Pharmaceuticals, Inc.",
        "long_name": "Eledon Pharmaceuticals, Inc.",
        "summary": "Eledon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. The company's lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). It also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Irvine"
    },
    "ELOX": {
        "short_name": "Eloxx Pharmaceuticals, Inc.",
        "long_name": "Eloxx Pharmaceuticals, Inc.",
        "summary": "Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "ELVAF": {
        "short_name": "EVOLVA HOLDING SA",
        "long_name": "Evolva Holding SA",
        "summary": "Evolva Holding SA discovers, develops, and commercializes ingredients for use in food, nutrition, personal healthcare, agriculture, and other sectors in Switzerland, the United States, and internationally. It offers branded ingredients, such as Veri-te Resveratrol, a natural ingredient in grapes, as well as other plants, including peanuts, cranberries, and Japanese knotweed for use in age-related health conditions; Nootkashield for pest control applications; EverSweet Stevia, a sweetener use in food, beverages, and table-top sweeteners; EveNootkatone, an ingredient for flavour and fragrance applications; and EveValencene, a citrus flavor. The company also develops and sells own products. It serves the nutrition, flavors and fragrances, animal health, personal care, and pharmaceutical markets. The company was founded in 2004 and is headquartered in Reinach, Switzerla.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Reinach"
    },
    "EMBT": {
        "short_name": "EMBER THERAPEUTICS INC",
        "long_name": "Ember Therapeutics, Inc.",
        "summary": "Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport's syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease. The company also holds approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "EMMA": {
        "short_name": "EMMAUS LIFE SCIENCES INC NEW",
        "long_name": "Emmaus Life Sciences, Inc.",
        "summary": "Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. is headquartered in Torrance, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Torrance"
    },
    "EMMLF": {
        "short_name": "OKYO PHARMA LTD",
        "long_name": "OKYO Pharma Limited",
        "summary": "OKYO Pharma Limited operates as a life sciences and biopharmaceutical company in the United Kingdom. Its pre-clinical development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM8, a non-opioid analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "ENBI.CN": {
        "short_name": "Entheon Biomed",
        "long_name": "Entheon Biomedical Corp.",
        "summary": "Entheon Biomedical Corp., a biotechnology research and drug development company, engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company is based in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "ENDV": {
        "short_name": "ENDONOVO THERAPEUTICS INC",
        "long_name": "Endonovo Therapeutics, Inc.",
        "summary": "Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive electrocuetical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its electrocuetical medical devices are also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for the treatment central nervous system disorders, such as traumatic brain injury, acute concussions, post- concussion syndrome, and multiple sclerosis. The company has a collaboration with the Stanford University sponsored Orthopedic Shoulder and Knee Study to determine the benefits of Endonovo's tPEMF SofPulse on pain, medication levels, and physical function post-operatively. The company was founded in 2008 and is based in Woodland Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Woodland Hills"
    },
    "ENLV": {
        "short_name": "Enlivex Therapeutics Ltd.",
        "long_name": "Enlivex Therapeutics Ltd.",
        "summary": "Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "ENLV.TA": {
        "short_name": "ENLIVEX THERAPEUTI",
        "long_name": "Enlivex Therapeutics Ltd.",
        "summary": "Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "ENMN.F": {
        "short_name": "CASI PHARMAC. NEW  DL-,01",
        "long_name": "CASI Pharmaceuticals, Inc.",
        "summary": "CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Rockville"
    },
    "ENOB": {
        "short_name": "Enochian Biosciences, Inc.",
        "long_name": "Enochian Biosciences, Inc.",
        "summary": "Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "ENTA": {
        "short_name": "Enanta Pharmaceuticals, Inc.",
        "long_name": "Enanta Pharmaceuticals, Inc.",
        "summary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Watertown"
    },
    "ENTX": {
        "short_name": "Entera Bio Ltd.",
        "long_name": "Entera Bio Ltd.",
        "summary": "Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase II clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. The company was founded in 2009 and is based in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "ENVB": {
        "short_name": "Enveric Biosciences, Inc.",
        "long_name": "Enveric Biosciences, Inc.",
        "summary": "Jay Pharma Inc. develops evidence-based cannabinoid products and combination therapies cure effects of cancer treatment. The company was incorporated in 2017 and is based in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "ENZC": {
        "short_name": "ENZOLYTICS INC",
        "long_name": "Enzolytics Inc.\t",
        "summary": "Enzolytics Inc., through its subsidiary, Extreme Mobile Coatings, Inc., provides coating solutions in the United States. The company offers franchise opportunities to operate a mobile business that provides painting or coating on various surfaces utilizing specialized proprietary material. It offers products, including anti-microbial protected surface coatings to prevent growth of mold, mildew, and fungus on the surface of the coating, as well as to inhibit growth of microorganisms; marine vessel hull protection coatings that stop barnacles from attaching and does not leach metals into the sea; and general construction coatings for use in various applications, such as architectural, glow in the dark, corrosion protection for iron and steel bridges and beams, epoxy spray for welding projects, blast system for fire restoration, anti-slip, epoxy concrete floors, mold remediation, and blasting and coating guard rails. Enzolytics Inc. was founded in 2007 and is based in Bohemia, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Bohemia"
    },
    "ENZN": {
        "short_name": "ENZON PHARMACEUTICALS INC",
        "long_name": "Enzon Pharmaceuticals, Inc.",
        "summary": "Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. The company was founded in 1981 and is headquartered in Cranford, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Cranford"
    },
    "EPE.F": {
        "short_name": "EPIZYME INC.  DL -,0001",
        "long_name": "Epizyme, Inc.",
        "summary": "Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "EPIX": {
        "short_name": "ESSA Pharma Inc.",
        "long_name": "ESSA Pharma Inc.",
        "summary": "ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "EPRSQ": {
        "short_name": "EPIRUS BIOPHARMACEUTICALS INC",
        "long_name": "EPIRUS Biopharmaceuticals, Inc.",
        "summary": "EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "EPZM": {
        "short_name": "Epizyme, Inc.",
        "long_name": "Epizyme, Inc.",
        "summary": "Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "EQ": {
        "short_name": "Equillium, Inc.",
        "long_name": "Equillium, Inc.",
        "summary": "Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "La Jolla"
    },
    "ERGO": {
        "short_name": "ENTIA BIOSCIENCES INC",
        "long_name": "Entia Biosciences, Inc.",
        "summary": "Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Sherwood"
    },
    "ERGO.L": {
        "short_name": "ERGOMED PLC ORD 1P",
        "long_name": "Ergomed plc",
        "summary": "Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "ERYP": {
        "short_name": "Erytech Pharma S.A.",
        "long_name": "ERYTECH Pharma S.A.",
        "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Lyon"
    },
    "ERYP.PA": {
        "short_name": "ERYTECH PHARMA",
        "long_name": "ERYTECH Pharma S.A.",
        "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lyon"
    },
    "ESPR": {
        "short_name": "Esperion Therapeutics, Inc.",
        "long_name": "Esperion Therapeutics, Inc.",
        "summary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Ann Arbor"
    },
    "ETNB": {
        "short_name": "89bio, Inc.",
        "long_name": "89bio, Inc.",
        "summary": "89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "ETON": {
        "short_name": "Eton Pharmaceuticals, Inc.",
        "long_name": "Eton Pharmaceuticals, Inc.",
        "summary": "Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. The company offers Biorphen, a phenylephrine hydrochloride injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. It also develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-203, which is injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101 and ET-104, which are oral liquid product candidates for neurological indications; DS-300 and DS-100, which are injectable product candidates; and ET-105, a lamotrigine for oral suspension. Eton Pharmaceuticals, Inc. was founded in 2017 and is based in Deer Park, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Deer Park"
    },
    "ETTX": {
        "short_name": "Entasis Therapeutics Holdings I",
        "long_name": "Entasis Therapeutics Holdings Inc.",
        "summary": "Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "ETX.L": {
        "short_name": "E-THERAPEUTICS PLC ORD 0.1P",
        "long_name": "e-therapeutics plc",
        "summary": "e-Therapeutics plc engages in the discovery of drugs through its proprietary network-driven drug discovery platform in the United Kingdom. It is developing two NDD-derived immuno-oncology programs, including tryptophan catabolism and immune checkpoint modulation. The company, through its subsidiary, Searchbolt Limited, develops search engine technology. The company has collaborations with C4X Holdings PLC, Intellegens, Biorelate, Novo Nordisk, and Galapagos NV. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Long Hanborough"
    },
    "EVFM": {
        "short_name": "Evofem Biosciences, Inc.",
        "long_name": "Evofem Biosciences, Inc.",
        "summary": "Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "EVG.L": {
        "short_name": "EVGEN PHARMA PLC ORD 0.25P",
        "long_name": "Evgen Pharma plc",
        "summary": "Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Wilmslow"
    },
    "EVGN": {
        "short_name": "Evogene Ltd.",
        "long_name": "Evogene Ltd.",
        "summary": "Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "EVGN.TA": {
        "short_name": "EVOGENE LTD",
        "long_name": "Evogene Ltd.",
        "summary": "Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "EVLO": {
        "short_name": "Evelo Biosciences, Inc.",
        "long_name": "Evelo Biosciences, Inc.",
        "summary": "Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a monoclonal microbial candidate, which is in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of psoriasis or atopic dermatitis. The company is also developing monoclonal microbial candidates, which are in pre-clinical development stage include EDP1815 for treating psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis; EDP1867 for asthma; EDP2939 for inflammatory disease; and EDP1632 for neuro-inflammatory diseases. In addition, it is developing EDP1503, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "EWOOF": {
        "short_name": "EASTWOOD BIO-MED CDA INC",
        "long_name": "Eastwood Bio-Medical Canada Inc.",
        "summary": "Eastwood Bio-Medical Canada Inc. distributes natural health supplements in North America and Asia. The company distributes Eleotin products and related products. Its Eleotin brand of products provides natural sourced solutions for metabolic syndromes, such as blood glucose disorders, obesity, and hypertension. The company's licensed products include Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for development and maintenance of bones and teeth; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. Its product also include Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. The company was incorporated in 2010 and is based in Richmond, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Richmond"
    },
    "EX1.AX": {
        "short_name": "EXOPHARM FPO",
        "long_name": "Exopharm Limited",
        "summary": "Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. The company is developing Na\u00c3\u00afve EVs as regenerative medicines, including Plexaris for wound healing; and Cevaris used in inflammatory, immunomodulatory, and tissue remodeling activities. Its Engineered EVs products comprise Fortrexo CoV, an engineered EV product that reduce the duration and severity of SARS-CoV-2 infection in the early phase of a patient's exposure to COVID-19; and Plexodox, a platelet derived EV loaded with the approved anti-cancer drug doxorubicin as a novel and improved anticancer drug. The company was founded in 2013 and is headquartered in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "EX9.DE": {
        "short_name": "EXELIXIS INC.  DL-,01",
        "long_name": "Exelixis, Inc.",
        "summary": "Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Daiichi Sankyo Company, Limited, and clinical collaboration with Ipsen. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "city": "Alameda"
    },
    "EX9.F": {
        "short_name": "EXELIXIS INC.  DL-,01",
        "long_name": "Exelixis, Inc.",
        "summary": "Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Daiichi Sankyo Company, Limited, and clinical collaboration with Ipsen. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Alameda"
    },
    "EXEL": {
        "short_name": "Exelixis, Inc.",
        "long_name": "Exelixis, Inc.",
        "summary": "Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Daiichi Sankyo Company, Limited, and clinical collaboration with Ipsen. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Alameda"
    },
    "EXPRS2.ST": {
        "short_name": "ExpreS2ion Biotech Holding AB",
        "long_name": "ExpreS2ion Biotech Holding AB (publ)",
        "summary": "ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops a platform technology that enables the production of complex proteins for new vaccines and diagnostics of malaria. The company develops ExpreS2 platform, an S2 cell that produce proteins. Its ExpreS2 kit include ExpreS2 plasmids, ExpreS2 cells, ExpreS2 transfection reagents, culture media for S2 cells, and plasmid maps and protocols for use. The company also offers ExpreS2 TR, a transfection reagent, which is formulated and optimized for insect cell transfection; placental malaria vaccine; and blood stage malaria vaccine. In addition, it provides upstream process development and a range of products and services related to ExpreS2 protein expression platform. ExpreS2ion Biotech Holding AB (publ) is based in Horsholm, Denmark.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Denmark",
        "city": "Horsholm"
    },
    "EXTX.OL": {
        "short_name": "EXACT THERAPEUTICS",
        "long_name": "EXACT Therapeutics AS",
        "summary": "EXACT Therapeutics AS, a clinical stage biotech company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology (chemotherapy and immunotherapy), infectious diseases, and neurological conditions. EXACT Therapeutics AS has a collaboration with GE Healthcare to develop an ultrasound probe to be used in studies using acoustic cluster therapy across various disease conditions. The company was founded in 2012 and is based in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "EYEG": {
        "short_name": "Eyegate Pharmaceuticals, Inc.",
        "long_name": "EyeGate Pharmaceuticals, Inc.",
        "summary": "EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "EYEN": {
        "short_name": "Eyenovia, Inc.",
        "long_name": "Eyenovia, Inc.",
        "summary": "Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. The company, through its proprietary delivery technology, is developing smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration. Eyenovia, Inc. focuses on advancing its MicroLine program for the improvement in near vision in patients with presbyopia in Phase III development. Its other product candidates include MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension; MicroStat, which has completed Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of red eye and itch relief lubrication; and MicroPine for the treatment of progressive myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "EYPT": {
        "short_name": "EyePoint Pharmaceuticals, Inc.",
        "long_name": "EyePoint Pharmaceuticals, Inc.",
        "summary": "EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Watertown"
    },
    "EZ1.F": {
        "short_name": "ENZON PHARMACEUT.  DL-,01",
        "long_name": "Enzon Pharmaceuticals, Inc.",
        "summary": "Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. The company was founded in 1981 and is headquartered in Cranford, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cranford"
    },
    "F2KA.F": {
        "short_name": "DIAMEDICA THERAPEUT.",
        "long_name": "DiaMedica Therapeutics Inc.",
        "summary": "DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Minneapolis"
    },
    "F6T.F": {
        "short_name": "FATE THERAPEUTICS DL-,001",
        "long_name": "Fate Therapeutics, Inc.",
        "summary": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "FAB.L": {
        "short_name": "FUSION ANTIBODIES PLC ORD 4P",
        "long_name": "Fusion Antibodies plc",
        "summary": "Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development services; and a range of antibody engineering services for various stages of therapeutic and diagnostic antibody development. It also engages in the humanization of antibodies, antibody developability, affinity maturation, and antibody reformatting activities. In addition, the company provides antibody sequencing services; custom expression and purification of recombinant proteins; transient protein expression; and cell line development services, as well as antibody analysis services. It serves pharmaceuticals, biotech, and diagnostic companies. The company has a collaboration partnership with Celonic AG for the development of high yield stable cell lines. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Belfast"
    },
    "FAD2.F": {
        "short_name": "ADVAXIS INC.  DL-,01",
        "long_name": "Advaxis, Inc.",
        "summary": "Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Princeton"
    },
    "FALG.PA": {
        "short_name": "FERMENTALG",
        "long_name": "Fermentalg Soci\u00e9t\u00e9 Anonyme",
        "summary": "Fermentalg Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme develops, produces, and sells active ingredients extracted from microalgae for the food, health, and nutrition sectors in France and internationally. It offers DHA ORIGINS, a plant based DHA oil; PROTEALG, a vegetable protein; BLUE ORIGIN, a natural color substitutes for human health and nutrition; and Carbon sinks to capture CO2 in urban and industrial environments. The company was founded in 2009 and is based in Libourne, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Libourne"
    },
    "FARN.L": {
        "short_name": "FARON PHARMACEUTICALS OY ORD NP",
        "long_name": "Faron Pharmaceuticals Oy",
        "summary": "Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "Finland",
        "city": "Turku"
    },
    "FARON.HE": {
        "short_name": "Faron Pharmaceuticals Oy",
        "long_name": "Faron Pharmaceuticals Oy",
        "summary": "Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HEL",
        "market": "fi_market",
        "country": "Finland",
        "city": "Turku"
    },
    "FATE": {
        "short_name": "Fate Therapeutics, Inc.",
        "long_name": "Fate Therapeutics, Inc.",
        "summary": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "FBIO": {
        "short_name": "Fortress Biotech, Inc.",
        "long_name": "Fortress Biotech, Inc.",
        "summary": "Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial product that reduces amyloid deposits in the tissues and organs; MB-102, a chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; MB-106, a CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101 that is in Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; AVTS-001, an adeno-associated virus gene therapy; CUTX-101, a copper histidinate injection for the treatment of Menkes disease; CK-103 for metastatic solid tumor cancers; CK-302 for oncology indications; and CK-303 to treat renal cell carcinoma. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "FBIOP": {
        "short_name": "Fortress Biotech, Inc. - 9.375%",
        "long_name": "Fortress Biotech, Inc.",
        "summary": "Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial product that reduces amyloid deposits in the tissues and organs; MB-102, a chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; MB-106, a CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101 that is in Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; AVTS-001, an adeno-associated virus gene therapy; CUTX-101, a copper histidinate injection for the treatment of Menkes disease; CK-103 for metastatic solid tumor cancers; CK-302 for oncology indications; and CK-303 to treat renal cell carcinoma. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "FBRX": {
        "short_name": "Forte Biosciences, Inc.",
        "long_name": "Forte Biosciences, Inc.",
        "summary": "Forte Biosciences Inc. operates as a clinical-stage dermatology company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company is based in Torrance, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Torrance"
    },
    "FDMT": {
        "short_name": "4D Molecular Therapeutics, Inc.",
        "long_name": "4D Molecular Therapeutics, Inc.",
        "summary": "4D Molecular Therapeutics, Inc. operates as a clinical-stage gene therapy company that develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology, and pulmonology therapeutic areas. The company engages in developing 4D-125, which is in a Phase I/II clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase I clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase I/II clinical trial for the treatment of fabry disease. It also focuses on developing two investigational new drug candidates, which include 4D-150 for the treatment of wet age-related macular degeneration; and 4D-710 for the treatment of cystic fibrosis lung disease. The company was founded in 2013 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "EmeryVille"
    },
    "FENC": {
        "short_name": "Fennec Pharmaceuticals Inc.",
        "long_name": "Fennec Pharmaceuticals Inc.",
        "summary": "Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Research Triangle Park"
    },
    "FGEN": {
        "short_name": "FibroGen, Inc",
        "long_name": "FibroGen, Inc.",
        "summary": "FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "FGEN.MX": {
        "short_name": "FIBROGEN INC",
        "long_name": "FibroGen, Inc.",
        "summary": "FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "FHTX": {
        "short_name": "Foghorn Therapeutics Inc.",
        "long_name": "Foghorn Therapeutics Inc.",
        "summary": "Foghorn Therapeutics Inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small-molecule enzymatic inhibitor of BRG1 and BRM for the treatment of acute myeloid leukemia and uveal melanoma; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing preclinical and discovery programs, including selective BRM targeting non-small-cell lung cancer; and selective ARID1B modulators for bladder, ovarian, and endometrial cancer. It has a collaboration with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "FIXX": {
        "short_name": "Homology Medicines, Inc.",
        "long_name": "Homology Medicines, Inc.",
        "summary": "Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Bedford"
    },
    "FJY.F": {
        "short_name": "ACRUX LTD.",
        "long_name": "Acrux Limited",
        "summary": "Acrux Limited, together with its subsidiaries, develops and commercializes generic and specialty topical pharmaceuticals in Australia, Germany, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. Acrux Limited was founded in 1998 and is based in West Melbourne, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "West Melbourne"
    },
    "FLUI.ST": {
        "short_name": "Fluicell AB",
        "long_name": "Fluicell AB (publ)",
        "summary": "Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Gothenburg"
    },
    "FMTX": {
        "short_name": "Forma Therapeutics Holdings, In",
        "long_name": "Forma Therapeutics Holdings, Inc.",
        "summary": "Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Watertown"
    },
    "FMW.F": {
        "short_name": "VERU INC.  DL-,01",
        "long_name": "Veru Inc.",
        "summary": "Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. In addition, the company's drug candidates include Enobosarm, an oral selective androgen receptor agonist that targets the androgen receptor positive, estrogen receptor positive, and human epidermal growth factor receptor 2 metastatic breast cancer without the unwanted virilizing side effects. Further, it is advancing a new drug formulation in its specialty pharmaceutical pipeline addressing unmet medical needs in urology, such as Tadalafil and Finasteride Combination. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Miami"
    },
    "FNAM": {
        "short_name": "EVOLUTIONARY GENOMICS INC",
        "long_name": "Evolutionary Genomics, Inc.",
        "summary": "Evolutionary Genomics, Inc. engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities. The company was incorporated in 1990 and is based in Castle Rock, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Castle Rock"
    },
    "FOLD": {
        "short_name": "Amicus Therapeutics, Inc.",
        "long_name": "Amicus Therapeutics, Inc.",
        "summary": "Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cranbury"
    },
    "FOLD.MX": {
        "short_name": "AMICUS THERAPEUTICS INC",
        "long_name": "Amicus Therapeutics, Inc.",
        "summary": "Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Cranbury"
    },
    "FORU": {
        "short_name": "FORU HOLDINGS INC",
        "long_name": "ForU Holdings, Inc.",
        "summary": "ForU Holdings, Inc., a wellness solutions company, through its subsidiaries, provides nutritional products and healthcare services. The company engages in researching and developing branded consumer products in the health and wellness space, including functional food and beverages; providing a suite of in-home non-medical and medical staffing and services, including light housekeeping and transportation, nurse and doctor visits, occupational and physical therapy, and other clinical services; and operating Wish Upon A Hero (WUAH), an online community that connects people in need with people who can help. It is also involved in the development of an orally administered product for the treatment of pediatric diarrhea in India; and provision of DNA customized nutritional supplements, skin care, and gene modulating weight management products through self-directed businesses. The company was formerly known as Capsalus Corp. and changed its name to ForU Holdings, Inc. in July 2014. ForU Holdings, Inc. is headquartered in Barrington, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Barrington"
    },
    "FP11.F": {
        "short_name": "SALARIUM PHARMA. DL-,0001",
        "long_name": "Salarius Pharmaceuticals, Inc.",
        "summary": "Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Houston"
    },
    "FPHAF": {
        "short_name": "FARON PHARMACEUTICALS OY",
        "long_name": "Faron Pharmaceuticals Oy",
        "summary": "Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Finland",
        "city": "Turku"
    },
    "FPMI": {
        "short_name": "FLUOROPHARMA MEDICAL INC",
        "long_name": "FluoroPharma Medical, Inc.",
        "summary": "FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Montclair"
    },
    "FPRX": {
        "short_name": "Five Prime Therapeutics, Inc.",
        "long_name": "Five Prime Therapeutics, Inc.",
        "summary": "Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "FREQ": {
        "short_name": "Frequency Therapeutics, Inc.",
        "long_name": "Frequency Therapeutics, Inc.",
        "summary": "Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Woburn"
    },
    "FRLN": {
        "short_name": "Freeline Therapeutics Holdings ",
        "long_name": "Freeline Therapeutics Holdings plc",
        "summary": "Freeline Therapeutics Holdings plc operates as a clinical-stage systemic adeno-associated virus (AAV)-based gene therapy company. Its advanced product candidate is FLT180a, a gene therapy product candidate that is being evaluated in a Phase 1/2 dose-finding clinical trials in adult males for the treatment of patients with moderate or severe hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Stevenage"
    },
    "FRPRF": {
        "short_name": "4D PHARMA PLC",
        "long_name": "4D pharma plc",
        "summary": "4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Leeds"
    },
    "FRX.TO": {
        "short_name": "FENNEC PHARMACEUTICALS INC",
        "long_name": "Fennec Pharmaceuticals Inc.",
        "summary": "Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "United States",
        "city": "Research Triangle Park"
    },
    "FSTX": {
        "short_name": "F-star Therapeutics, Inc.",
        "long_name": "F-star Therapeutics, Inc.",
        "summary": "F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "FTD.F": {
        "short_name": "FIN.DE TUBIZE ACT.NOUV.",
        "long_name": "Financi\u00e8re de Tubize SA",
        "summary": "Financi\u00c3\u00a8re de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financi\u00c3\u00a8re de Tubize S.A. is based in Brussels, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Brussels"
    },
    "FTD.SG": {
        "short_name": "Financire de Tubize S.A. Action",
        "long_name": "Financi\u00e8re de Tubize SA",
        "summary": "Financi\u00c3\u00a8re de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financi\u00c3\u00a8re de Tubize S.A. is based in Brussels, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Brussels"
    },
    "FULC": {
        "short_name": "Fulcrum Therapeutics, Inc.",
        "long_name": "Fulcrum Therapeutics, Inc.",
        "summary": "Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and \u00c3\u009f-thalassemia. The company is also discovering drug targets for the treatments of duchenne muscular dystrophy, friedreich ataxia, myotonic dystrophy 1, and a-synucleinopathies, as well as neurological and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "FUSN": {
        "short_name": "Fusion Pharmaceuticals Inc.",
        "long_name": "Fusion Pharmaceuticals Inc.",
        "summary": "Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Hamilton"
    },
    "FWP": {
        "short_name": "Forward Pharma A/S",
        "long_name": "Forward Pharma A/S",
        "summary": "Forward Pharma A/S, a biopharmaceutical company, focuses on developing proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. The company was founded in 2005 and is headquartered in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "FYB.DE": {
        "short_name": "FORMYCON AG",
        "long_name": "Formycon AG",
        "summary": "Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis 1, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that has completed Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase I clinical trial; and FYB203, a biosimilar candidate for Eylea 3, like Lucentis, Eylea, used to treat neovascular age-related macular degeneration and other eye diseases. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "FYB.F": {
        "short_name": "FORMYCON AG",
        "long_name": "Formycon AG",
        "summary": "Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis 1, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that has completed Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase I clinical trial; and FYB203, a biosimilar candidate for Eylea 3, like Lucentis, Eylea, used to treat neovascular age-related macular degeneration and other eye diseases. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "FZRQ.F": {
        "short_name": "IMMUNE PHARMAC.  DL-,0001",
        "long_name": "Immune Pharmaceuticals, Inc.",
        "summary": "Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Fort Lee"
    },
    "G061.F": {
        "short_name": "GENKYOTEX S.A. EO 1,-",
        "long_name": "Genkyotex SA",
        "summary": "Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Lab\u00c3\u00a8ge, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lab\u00c3\u00a8ge"
    },
    "G49N.F": {
        "short_name": "GENSIGHT BIOLOG. EO -,025",
        "long_name": "GenSight Biologics S.A.",
        "summary": "GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery and development of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial target sequence and optogenetics technology platforms. Its lead product candidates include GS010, an AAV2 based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by mutation of the ND4 gene; and GS030 that is in Phase I/II trial for the treatment of retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "G51.F": {
        "short_name": "GENSCRIPT BIOT. DL-,001",
        "long_name": "Genscript Biotech Corporation",
        "summary": "Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life sciences research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. It operates in four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein production, peptide synthesis, and antibody development for use in basic biology studies, disease and pharmaceutical research, drug discovery, agriculture, environmental studies, and food industry; life sciences research catalogue products, such as pre-packaged, ready-to-use, and off-the-shelf products; and contractual research services, including protein engineering. The Biologics Development Services segment provides various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for antibody therapeutic antibodies and gene/cell therapy products. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops therapies for the treatment of liquid tumors. The company was founded in 2002 and is headquartered in Nanjing, China. Genscript Biotech Corporation is a subsidiary of GenScript Corporation.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "city": "Nanjing"
    },
    "G5B.F": {
        "short_name": "GLOBAL BL.THERAP.  DL-,01",
        "long_name": "Global Blood Therapeutics, Inc.",
        "summary": "Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "GALT": {
        "short_name": "Galectin Therapeutics Inc.",
        "long_name": "Galectin Therapeutics, Inc.",
        "summary": "Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate is GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. The company was founded in 2000 and is based in Norcross, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Norcross"
    },
    "GBE.F": {
        "short_name": "GENUS PLC  LS-,1",
        "long_name": "Genus plc",
        "summary": "Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Basingstoke"
    },
    "GBI1.F": {
        "short_name": "GENOCEA BIOSCIENC.DL-,001",
        "long_name": "Genocea Biosciences, Inc.",
        "summary": "Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient's CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "GBIM": {
        "short_name": "GLOBEIMMUNE INC",
        "long_name": "GlobeImmune, Inc.",
        "summary": "GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Louisville"
    },
    "GBIO": {
        "short_name": "Generation Bio Co.",
        "long_name": "Generation Bio Co.",
        "summary": "Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "GBLX": {
        "short_name": "GB SCIENCES INC",
        "long_name": "GB Sciences, Inc.",
        "summary": "GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Las Vegas"
    },
    "GBMB.F": {
        "short_name": "INOVIO PHARMACEUTICAL INC",
        "long_name": "Inovio Pharmaceuticals, Inc.",
        "summary": "Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Plymouth Meeting"
    },
    "GBT": {
        "short_name": "Global Blood Therapeutics, Inc.",
        "long_name": "Global Blood Therapeutics, Inc.",
        "summary": "Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "GBY.DE": {
        "short_name": "SANGAMO THERAP.INC.DL-,01",
        "long_name": "Sangamo Therapeutics, Inc.",
        "summary": "Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression. Its therapeutic products that are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; ST-920 gene therapy for Fabry disease; ST-101 gene therapy for phenylketonuria; ST-400 and BIVV-003 for the treatment of hemoglobinopathies; SB-913 for the treatment of Mucopolysaccharidosis type II; SB-318 for the treatment of Mucopolysaccharidosis type I; and SB-FIX for the treatment of hemophilia B. The company has collaborative and strategic partnerships with Biogen Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "city": "Brisbane"
    },
    "GBY.F": {
        "short_name": "SANGAMO THERAP.INC.DL-,01",
        "long_name": "Sangamo Therapeutics, Inc.",
        "summary": "Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression. Its therapeutic products that are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; ST-920 gene therapy for Fabry disease; ST-101 gene therapy for phenylketonuria; ST-400 and BIVV-003 for the treatment of hemoglobinopathies; SB-913 for the treatment of Mucopolysaccharidosis type II; SB-318 for the treatment of Mucopolysaccharidosis type I; and SB-FIX for the treatment of hemophilia B. The company has collaborative and strategic partnerships with Biogen Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Brisbane"
    },
    "GEM.F": {
        "short_name": "GENEURO SA  SF-,05",
        "long_name": "GeNeuro SA",
        "summary": "GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. Its lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for the treatment of multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. The company has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis. GeNeuro SA was founded in 2006 and is headquartered in Plan-les-Ouates, Switzerland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Switzerland",
        "city": "Plan-les-Ouates"
    },
    "GENO.ST": {
        "short_name": "Genovis AB",
        "long_name": "Genovis AB (publ.)",
        "summary": "Genovis AB (publ.) develops, produces, and sells tools for developing drugs for customers in the medical device and pharmaceutical industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1 at one specific site above the hinge and generating intact Fab and Fc fragments; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for producing a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues, including arginine linked to proline; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company was founded in 1999 and is based in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "GENSF": {
        "short_name": "GENUS",
        "long_name": "Genus plc",
        "summary": "Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Basingstoke"
    },
    "GENX.V": {
        "short_name": "GENIX PHARMACEUTICALS CORPORATI",
        "long_name": "Genix Pharmaceuticals Corporation",
        "summary": "Genix Pharmaceuticals Corporation research, development, manufacturing, sales, and distribution of novel, evidence-based, and branded ophthalmic drugs and ophthalmic over the counter products in Canada and the United States. The company develops Flu-X, an anti-viral spray; Renochlor, dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that lowers blood sugar by increasing the muscle, fat, and liver's sensitivity to insulin. It also offers nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and powders. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "GERN": {
        "short_name": "Geron Corporation",
        "long_name": "Geron Corporation",
        "summary": "Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Menlo Park"
    },
    "GHDN.F": {
        "short_name": "BRAINSTORM C.NEW DL-,0001",
        "long_name": "Brainstorm Cell Therapeutics Inc.",
        "summary": "Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company has a partnership with Catalent for the manufacture of NurOwn, an autologous cellular therapy. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "GKO.F": {
        "short_name": "GLYCOMIMETICS INC. DL-001",
        "long_name": "GlycoMimetics, Inc.",
        "summary": "GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist, which has completed Phase III clinical trial for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Rockville"
    },
    "GKTX.PA": {
        "short_name": "GENKYOTEX",
        "long_name": "Genkyotex SA",
        "summary": "Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Lab\u00c3\u00a8ge, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lab\u00c3\u00a8ge"
    },
    "GLMD": {
        "short_name": "Galmed Pharmaceuticals Ltd.",
        "long_name": "Galmed Pharmaceuticals Ltd.",
        "summary": "Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST Phase III pivotal study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity, and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; and a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol. The company was founded in 2000 and is headquartered in Tel Aviv-Yafo, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "GLPG": {
        "short_name": "Galapagos NV",
        "long_name": "Galapagos NV",
        "summary": "Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sj\u00c3\u00b6gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.\u00c3\u00a0 r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Belgium",
        "city": "Mechelen"
    },
    "GLPG.AS": {
        "short_name": "GALAPAGOS",
        "long_name": "Galapagos NV",
        "summary": "Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sj\u00c3\u00b6gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.\u00c3\u00a0 r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "AMS",
        "market": "nl_market",
        "country": "Belgium",
        "city": "Mechelen"
    },
    "GLPG.VI": {
        "short_name": "GALAPAGOS NV",
        "long_name": "Galapagos NV",
        "summary": "Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sj\u00c3\u00b6gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.\u00c3\u00a0 r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Belgium",
        "city": "Mechelen"
    },
    "GLPH": {
        "short_name": "GALA PHARMACEUTICAL INC",
        "long_name": "Gala Pharmaceutical, Inc.",
        "summary": "Gala Pharmaceutical, Inc. focuses on the research, development, and commercialization of products derived from the hemp and cannabis plant. The company also provides genetic fingerprinting and sequencing services for various crop species. In addition, it offers consulting services on testing and manufacturing lab designs and SOPs, as well as services to customers for building turnkey labs, drug formulations, and troubleshooting. The company was formerly known as Gala Global Inc. and changed its name to Gala Pharmaceutical, Inc. in January 2018. Gala Pharmaceutical, Inc. was founded in 2010 and is based in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Irvine"
    },
    "GLSI": {
        "short_name": "Greenwich LifeSciences, Inc.",
        "long_name": "Greenwich LifeSciences, Inc.",
        "summary": "Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other human epidermal growth factor receptor 2/neu-expressing (HER2/neu) cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was founded in 2006 and is headquartered in Stafford, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Stafford"
    },
    "GLTO": {
        "short_name": "Galecto, Inc.",
        "long_name": "Galecto, Inc.",
        "summary": "Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "GLYC": {
        "short_name": "GlycoMimetics, Inc.",
        "long_name": "GlycoMimetics, Inc.",
        "summary": "GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist, which has completed Phase III clinical trial for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Rockville"
    },
    "GMAB": {
        "short_name": "Genmab A/S",
        "long_name": "Genmab A/S",
        "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "GMAB.CO": {
        "short_name": "Genmab A/S",
        "long_name": "Genmab A/S",
        "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "GMAB.VI": {
        "short_name": "GENMAB AS",
        "long_name": "Genmab A/S",
        "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "GMDA": {
        "short_name": "Gamida Cell Ltd.",
        "long_name": "Gamida Cell Ltd.",
        "summary": "Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a nicotinamide expanded hematopoietic stem cells and differentiated immune cells, including T cells that is in Phase 3 studies in patients with high-risk hematologic malignancies, as well as in Phase 1/2 clinical trial in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "GNBT": {
        "short_name": "GENEREX BIOTECHNOLOGY CORP",
        "long_name": "Generex Biotechnology Corporation",
        "summary": "Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Miramar"
    },
    "GNCA": {
        "short_name": "Genocea Biosciences, Inc.",
        "long_name": "Genocea Biosciences, Inc.",
        "summary": "Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient's CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "GNFT": {
        "short_name": "GENFIT S.A.",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Loos"
    },
    "GNFT.PA": {
        "short_name": "GENFIT",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Loos"
    },
    "GNFTF": {
        "short_name": "GENFIT",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Loos"
    },
    "GNLKQ": {
        "short_name": "GENELINK INC",
        "long_name": "GeneLink, Inc.",
        "summary": "GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Orlando"
    },
    "GNMSF": {
        "short_name": "GENMAB AS",
        "long_name": "Genmab A/S",
        "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "GNPX": {
        "short_name": "Genprex, Inc.",
        "long_name": "Genprex, Inc.",
        "summary": "Genprex, Inc. operates as a clinical-stage gene therapy company that develops therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes. It develops drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company's lead product candidate REQORSA (quaratusugene ozeplasmid) for treatment for non-small cell lung cancer (NSCLC) has a multimodal mechanism of action to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis and programmed cell death in cancer cells; modulate immune response against cancer cells; and block mechanisms that create drug resistance. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "GNRO.PA": {
        "short_name": "GENEURO",
        "long_name": "GeNeuro SA",
        "summary": "GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. Its lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for the treatment of multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. The company has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis. GeNeuro SA was founded in 2006 and is headquartered in Plan-les-Ouates, Switzerland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "Switzerland",
        "city": "Plan-les-Ouates"
    },
    "GNS.L": {
        "short_name": "GENUS PLC ORD 10P",
        "long_name": "Genus plc",
        "summary": "Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Basingstoke"
    },
    "GON.F": {
        "short_name": "GERON CORP. (DEL.) DL-001",
        "long_name": "Geron Corporation",
        "summary": "Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Menlo Park"
    },
    "GOSS": {
        "short_name": "Gossamer Bio, Inc.",
        "long_name": "Gossamer Bio, Inc.",
        "summary": "Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "GOVX": {
        "short_name": "GeoVax Labs, Inc.",
        "long_name": "GeoVax Labs, Inc.",
        "summary": "GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Vaxeal Holding SA; Virometix AG; Geneva Foundation; Enesi Pharma; UCSF; BravoVax; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Smyrna"
    },
    "GRAY": {
        "short_name": "Graybug Vision, Inc.",
        "long_name": "Graybug Vision, Inc.",
        "summary": "Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "GRCL": {
        "short_name": "Gracell Biotechnologies Inc.",
        "long_name": "Gracell Biotechnologies Inc.",
        "summary": "Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC007F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate that is in Phase I clinical trial for the treatment of B-NHL. The company's product candidates also comprise GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is based in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "city": "Suzhou"
    },
    "GRTS": {
        "short_name": "Gritstone Oncology, Inc.",
        "long_name": "Gritstone Oncology, Inc.",
        "summary": "Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "EmeryVille"
    },
    "GRTX": {
        "short_name": "Galera Therapeutics, Inc.",
        "long_name": "Galera Therapeutics, Inc.",
        "summary": "Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer. It is also involved in developing GC4711, which is in Phase I/II clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Malvern"
    },
    "GSD.V": {
        "short_name": "DEVONIAN HEALTH GROUP INC",
        "long_name": "Devonian Health Group Inc.",
        "summary": "Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses, as well as distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Qu\u00c3\u00a9bec, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Qu\u00c3\u00a9bec"
    },
    "GTBP": {
        "short_name": "GT BIOPHARMA INC",
        "long_name": "GT Biopharma, Inc.",
        "summary": "GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase 1 clinical trial; GTB-C3550, a next-generation follow-on to its lead candidates TriKE, GTB-3550, and GTB-C3550, which contains a modified CD16 moiety; and GTB-1615, a single-chain fusion protein for the treatment of solid tumors. Its central nervous system portfolio consists of GTP-004 for the treatment of myasthenia gravis, PainBrake to treat chronic neuropathic pain, and GTP-011 for the treatment of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is headquartered in Westlake Village, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Westlake Village"
    },
    "GTBP.PA": {
        "short_name": "GT BIOPHARMA INC",
        "long_name": "GT Biopharma, Inc.",
        "summary": "GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase 1 clinical trial; GTB-C3550, a next-generation follow-on to its lead candidates TriKE, GTB-3550, and GTB-C3550, which contains a modified CD16 moiety; and GTB-1615, a single-chain fusion protein for the treatment of solid tumors. Its central nervous system portfolio consists of GTP-004 for the treatment of myasthenia gravis, PainBrake to treat chronic neuropathic pain, and GTP-011 for the treatment of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is headquartered in Westlake Village, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "United States",
        "city": "Westlake Village"
    },
    "GTHR": {
        "short_name": "GENETHERA INC",
        "long_name": "GeneThera, Inc.",
        "summary": "GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of COVID-19 and other zoonotic diseases. It offers specific assays for chronic wasting disease in elk and deer, and mad cow disease in cattle; diagnostics for E. coli disease for cattle; and Johne's disease for cattle and bison. The company is based in Westminster, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Westminster"
    },
    "GTHX": {
        "short_name": "G1 Therapeutics, Inc.",
        "long_name": "G1 Therapeutics, Inc.",
        "summary": "G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Research Triangle Park"
    },
    "GTU2.F": {
        "short_name": "ONCTERNAL THERAP.  DL-,01",
        "long_name": "Oncternal Therapeutics, Inc.",
        "summary": "Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ROR1) that is in Phase I/II clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in Phase Ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. It also develops TK-216, a small-molecule that is designed to inhibit E26 transformation specific family of oncoproteins, which is in Phase I clinical trial to treat patients with Ewing sarcoma and in combination with vincristine chemotherapy. In addition, the company develops a chimeric antigen receptor-T product candidate that targets ROR1, which is in preclinical development for treating hematologic cancers and solid tumors. Oncternal Therapeutics, Inc. has a research and development collaboration with Karolinska Institutet to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK cells. The company is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "GXE.DE": {
        "short_name": "GALAPAGOS N.V.",
        "long_name": "Galapagos NV",
        "summary": "Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sj\u00c3\u00b6gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.\u00c3\u00a0 r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Belgium",
        "city": "Mechelen"
    },
    "GXE.F": {
        "short_name": "GALAPAGOS N.V.",
        "long_name": "Galapagos NV",
        "summary": "Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sj\u00c3\u00b6gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.\u00c3\u00a0 r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Mechelen"
    },
    "GXEA.F": {
        "short_name": "GALAPAGOS N.V. ADR 1",
        "long_name": "Galapagos NV",
        "summary": "Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sj\u00c3\u00b6gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.\u00c3\u00a0 r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Mechelen"
    },
    "GYX.F": {
        "short_name": "FUTURA MEDICAL  LS-,002",
        "long_name": "Futura Medical plc",
        "summary": "Futura Medical plc, a pharmaceutical company, researches and develops pharmaceutical drugs and medical devices for the consumer healthcare markets focusing on sexual health and pain relief management. The company offers CSD500, a condom that contains erectogenic gel. It is also developing MED3000, a topical gel for the treatment of erectile dysfunction that has completed Phase III clinical trials. In addition, the company develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "H3AA.SG": {
        "short_name": "Biostage Inc. Registered Shares",
        "long_name": "Biostage, Inc.",
        "summary": "Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Holliston"
    },
    "H3D.F": {
        "short_name": "SONNET BIOTH.H.I.DL-,0001",
        "long_name": "Sonnet BioTherapeutics Holdings, Inc.",
        "summary": "Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Princeton"
    },
    "HALB": {
        "short_name": "HALBERD CORP",
        "long_name": "Alaric Corporation",
        "summary": "Alaric Corporation, formerly known as Halberd Corporation is out of business. It is a venture capital firm specializing in incubation, early stage, and seed investments. The firm invests in the United States. It invests up to $2 million. The firm prefers to take equity stakes between 15 percent to 80 percent. Tykhe Corporation was founded in January 26, 2009 and is based in Sherman Oaks, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Sherman Oaks"
    },
    "HALO": {
        "short_name": "Halozyme Therapeutics, Inc.",
        "long_name": "Halozyme Therapeutics, Inc.",
        "summary": "Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "HARP": {
        "short_name": "Harpoon Therapeutics, Inc.",
        "long_name": "Harpoon Therapeutics, Inc.",
        "summary": "Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "HAVLF": {
        "short_name": "HAVN LIFE SCIENCES INC",
        "long_name": "HAVN Life Sciences Inc.",
        "summary": "HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The company was founded in 2020 and is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "HAVN.CN": {
        "short_name": "HAVNLifeSci",
        "long_name": "HAVN Life Sciences Inc.",
        "summary": "HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The company was founded in 2020 and is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "HBC.OL": {
        "short_name": "HOFSETH BIOCARE AS",
        "long_name": "Hofseth BioCare ASA",
        "summary": "Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for the human nutrition, and pet and feed markets in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company has a research agreement with Stanford University School of Medicine to investigate the gastro-intestinal-protective properties of HBC's salmon protein hydrolysate peptides in children and adults with GI tract disorders. The company was founded in 2000 and is headquartered in \u00c3\u0085lesund, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "\u00c3\u0085lesund"
    },
    "HBP.F": {
        "short_name": "HELIX BIOPHARMA CORP.",
        "long_name": "Helix BioPharma Corp.",
        "summary": "Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Richmond Hill"
    },
    "HBP.TO": {
        "short_name": "HELIX BIOPHARM",
        "long_name": "Helix BioPharma Corp.",
        "summary": "Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Richmond Hill"
    },
    "HBQ.F": {
        "short_name": "HOFSETH BIOCARE  NK 0,01",
        "long_name": "Hofseth BioCare ASA",
        "summary": "Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for the human nutrition, and pet and feed markets in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company has a research agreement with Stanford University School of Medicine to investigate the gastro-intestinal-protective properties of HBC's salmon protein hydrolysate peptides in children and adults with GI tract disorders. The company was founded in 2000 and is headquartered in \u00c3\u0085lesund, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "\u00c3\u0085lesund"
    },
    "HCM": {
        "short_name": "Hutchison China MediTech Limite",
        "long_name": "Hutchison China MediTech Limited",
        "summary": "Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Hong Kong",
        "city": "Central"
    },
    "HCM.L": {
        "short_name": "HUTCHISON CHINA MEDITECH LIMITE",
        "long_name": "Hutchison China MediTech Limited",
        "summary": "Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "Hong Kong",
        "city": "Central"
    },
    "HDP1.F": {
        "short_name": "ARROWHEAD PHARMAC. DL-,01",
        "long_name": "Arrowhead Pharmaceuticals, Inc.",
        "summary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Pasadena"
    },
    "HDST.TA": {
        "short_name": "HBL-HADASIT BIO",
        "long_name": "Hadasit Bio-Holdings Ltd",
        "summary": "Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. The company primarily focuses on the therapeutic areas, such as oncology, regenerative medicine, and inflammatory disease. The company was founded in 2005 and is based in Jerusalem, Israel. Hadasit Bio-Holdings Ltd is a subsidiary of Hadasit Ltd.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "HEM.V": {
        "short_name": "HEMOSTEMIX INC",
        "long_name": "Hemostemix Inc.",
        "summary": "Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, peripheral arterial disease, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and other conditions of ischemia that is in Phase II clinical trial in Canada and the United States. It also offers various types of synergetic cell populations, such as angiogenic cell precursors, myocardial cell precursors, neural cell precursors, and bone cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Calgary"
    },
    "HEMO.L": {
        "short_name": "HEMOGENYX PHARMACEUTICALS PLC O",
        "long_name": "Hemogenyx Pharmaceuticals Plc",
        "summary": "Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing products for bone marrow/hematopoietic stem cell BM/HSC transplant market, including CDX bi-specific antibody and CAR-T therapy for eliminating relapsed and/or refractory acute myeloid leukaemia, acute lymphoblastic leukaemia, and myelodysplastic syndrome; and Human Postnatal Hemogenic Endothelial Cells, a cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has collaboration with GlobalCo. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "HEPA": {
        "short_name": "Hepion Pharmaceuticals, Inc.",
        "long_name": "Hepion Pharmaceuticals, Inc.",
        "summary": "Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Edison"
    },
    "HESG": {
        "short_name": "HEALTH SCIENCES GROUP INC",
        "long_name": "Health Sciences Group, Inc.",
        "summary": "Health Sciences Group Inc., through its subsidiaries, provides various products used in nutritional supplements and functional foods and beverages in the United States. It primarily offers Shugr, a zero-calorie sugar substitute that tastes and bakes like cane sugar; and Sequesterol Advance Cardio Formula, a proprietary blend of clinically studied ingredients for the maintenance of cardiovascular health and a free-flowing circulatory system. The company also offers Aplevia, an antioxidant derived from apple peels; and Edible Sponges, an open-cell hydrocolloid product. It sells its products primarily through mass market retailers, such as mass merchandisers, drug stores, supermarkets, and discount stores, as well as through healthcare professionals and practitioners, and other media. Health Sciences Group was founded in 1996 as Centurion Properties Development Corporation and changed its name to iGoHealthy.com in 2000. It changed its name to Health Sciences Group, Inc. in 2001. The company is based in Newport Beach, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Newport Beach"
    },
    "HGEN": {
        "short_name": "Humanigen, Inc.",
        "long_name": "Humanigen, Inc.",
        "summary": "Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Burlingame"
    },
    "HGF2.F": {
        "short_name": "CATALYST BIOSC.  DL -,01",
        "long_name": "Catalyst Biosciences, Inc.",
        "summary": "Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing. Its products include Marzeptacog alfa (activated), a subcutaneously administered next-generation engineered coagulation Factor VIIa that has completed Phase II development for individuals with hemophilia A or B with inhibitors; and Dalcinonacog alfa, a next-generation engineered coagulation Factor IX therapy that has completed Phase IIb clinical trials for the treatment of hemophilia B. The company also develops CB 2679d-GT, an early stage Factor IX gene therapy construct for Hemophilia B; CB 2782-PEG, a long acting anti-C3 protease for the treatment of dry age-related macular degeneration (AMD); and SQ systemic complement inhibitors pipeline. The company has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other serious inflammatory retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "HIRU": {
        "short_name": "HIRU CORPORATION",
        "long_name": "Hiru Corporation",
        "summary": "Hiru Corporation, through its subsidiary, produces Chinese herbs for the naturopathic industry in China. It manufactures herbal supplements containing ginseng. The company sells and distributes pharmaceuticals, health and beauty products, dietary and herbal supplements, and other healthcare products. It manufactures approximately 120 extracts used in traditional Chinese medicine. Hiru Corporation sells its products through regional distributors, as well as directly to the hospitals, clinics, and pharmacies in China. Hiru Corporation was formerly known as Phoenix Restaurant Group, Inc. and changed its name to Hiru Corporation in November 2008. The company is based in Henderson, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Henderson"
    },
    "HMGN": {
        "short_name": "HEMAGEN DIAGNOSTICS INC",
        "long_name": "Hemagen Diagnostics, Inc.",
        "summary": "Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and specialty assays, including Chagas, acute phase proteins, and cytokines. In addition, the company provides veterinary diagnostic products, such as equipment, reagents, supplies, accessories, and electrodes in chemistry, hematology, and electrolyte areas. It sells its products directly, as well as through distributors to various laboratories, hospitals, and blood banks. The company was founded in 1985 and is based in Columbia, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Columbia"
    },
    "HNSA.ST": {
        "short_name": "Hansa Biopharma AB",
        "long_name": "Hansa Biopharma AB (publ)",
        "summary": "Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), an antibody cleaving enzyme for enabling kidney transplantations in sensitized patients, as well as for anti-GBM antibody disease and Guillain Barr\u00c3\u00a9 syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company also has licensing agreement with Axis-Shield Diagnostics Limited for Heparin Binding Protein (HBP)-assay, a method that predicts severe sepsis in emergency clinics. Hansa Biopharma AB (publ) is headquartered in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "HOFBF": {
        "short_name": "HOFSETH BIOCARE AS",
        "long_name": "Hofseth BioCare ASA",
        "summary": "Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for the human nutrition, and pet and feed markets in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company has a research agreement with Stanford University School of Medicine to investigate the gastro-intestinal-protective properties of HBC's salmon protein hydrolysate peptides in children and adults with GI tract disorders. The company was founded in 2000 and is headquartered in \u00c3\u0085lesund, Norway.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Norway",
        "city": "\u00c3\u0085lesund"
    },
    "HOOK": {
        "short_name": "HOOKIPA Pharma Inc.",
        "long_name": "HOOKIPA Pharma Inc.",
        "summary": "HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "HOPHF": {
        "short_name": "HEMOGENYX PHARMACEUTICALS PLC",
        "long_name": "Hemogenyx Pharmaceuticals Plc",
        "summary": "Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing products for bone marrow/hematopoietic stem cell BM/HSC transplant market, including CDX bi-specific antibody and CAR-T therapy for eliminating relapsed and/or refractory acute myeloid leukaemia, acute lymphoblastic leukaemia, and myelodysplastic syndrome; and Human Postnatal Hemogenic Endothelial Cells, a cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has collaboration with GlobalCo. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "HOTH": {
        "short_name": "Hoth Therapeutics, Inc.",
        "long_name": "Hoth Therapeutics, Inc.",
        "summary": "Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. It intends to use the BioLexa Platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company has license agreements with the George Washington University; the University of Maryland Baltimore; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zyl\u00c3\u00b6 Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. Hoth Therapeutics has research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was founded in 2017 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "HPHA.DE": {
        "short_name": "HEIDELBERG PHARMA AG O.N.",
        "long_name": "Heidelberg Pharma AG",
        "summary": "Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibodies, and specializes in antibody drug conjugates in Germany. It is developing HDP-101 for the treatment of multiple myeloma; PSMA, an ATAC candidate to treat prostate cancer; and CDXX, an ATAC candidate for the treatment of Non-Hodgkin lymphoma and solid/hematological tumors. The company is also developing MGTA-XX-ATACs for HSCs, Conditioning programs for blood cancers, and genetic diseases. In addition, it provides preclinical research services in the field of cancer, as well as inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Ladenburg"
    },
    "HPHA.F": {
        "short_name": "HEIDELBERG PHARMA AG O.N.",
        "long_name": "Heidelberg Pharma AG",
        "summary": "Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibodies, and specializes in antibody drug conjugates in Germany. It is developing HDP-101 for the treatment of multiple myeloma; PSMA, an ATAC candidate to treat prostate cancer; and CDXX, an ATAC candidate for the treatment of Non-Hodgkin lymphoma and solid/hematological tumors. The company is also developing MGTA-XX-ATACs for HSCs, Conditioning programs for blood cancers, and genetic diseases. In addition, it provides preclinical research services in the field of cancer, as well as inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Ladenburg"
    },
    "HRMY": {
        "short_name": "Harmony Biosciences Holdings, I",
        "long_name": "Harmony Biosciences Holdings, Inc.",
        "summary": "Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Plymouth Meeting"
    },
    "HRNTS.ST": {
        "short_name": "Herantis Pharma Oyj",
        "long_name": "Herantis Pharma Oyj",
        "summary": "Herantis Pharma Oyj, a drug development company, focuses on developing regenerative medicine. Its products in pipeline includes CDNF, which is in Phase I-II clinical trial for the treatment of Parkinson's disease, as well as in preclinical stage for the treatment of amyotrophic lateral sclerosis; and Lymfactin, which is in Phase II clinical trial for the treatment of breast cancer associated lymphedema. The company was founded in 2008 and is based in Espoo, Finland.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Finland",
        "city": "Espoo"
    },
    "HRTIS.HE": {
        "short_name": "Herantis Pharma Oyj",
        "long_name": "Herantis Pharma Oyj",
        "summary": "Herantis Pharma Oyj, a drug development company, focuses on developing regenerative medicine. Its products in pipeline includes CDNF, which is in Phase I-II clinical trial for the treatment of Parkinson's disease, as well as in preclinical stage for the treatment of amyotrophic lateral sclerosis; and Lymfactin, which is in Phase II clinical trial for the treatment of breast cancer associated lymphedema. The company was founded in 2008 and is based in Espoo, Finland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HEL",
        "market": "fi_market",
        "country": "Finland",
        "city": "Espoo"
    },
    "HRTX": {
        "short_name": "Heron Therapeutics, Inc.",
        "long_name": "Heron Therapeutics, Inc.",
        "summary": "Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam that is in Phase III clinical trial for pain management; and HTX-034, a product candidate for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "HSITF": {
        "short_name": "HBL - HADASIT BIO HOLDINGS LTD",
        "long_name": "Hadasit Bio-Holdings Ltd",
        "summary": "Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. The company primarily focuses on the therapeutic areas, such as oncology, regenerative medicine, and inflammatory disease. The company was founded in 2005 and is based in Jerusalem, Israel. Hadasit Bio-Holdings Ltd is a subsidiary of Hadasit Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "HSTC": {
        "short_name": "HST GLOBAL INC",
        "long_name": "HST Global, Inc.",
        "summary": "HST Global, Inc., an integrated health and wellness biotechnology company, develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer worldwide. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancers and other life threatening diseases. The company also intends to acquire products for the treatment of individual health challenges. HST Global, Inc. is headquartered in Hampton, Virginia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Hampton"
    },
    "HSTO": {
        "short_name": "Histogen Inc.",
        "long_name": "Histogen Inc.",
        "summary": "Histogen Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. It offers human multipotent cell conditioned media (CCM); human extracellular matrix (hECM); and hair stimulating complex (HSC). The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. Histogen Inc. is headquartered San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "HTBX": {
        "short_name": "Heat Biologics, Inc.",
        "long_name": "Heat Biologics, Inc.",
        "summary": "Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Morrisville"
    },
    "HTD.F": {
        "short_name": "CORCEPT THERAPEUTICS INC.",
        "long_name": "Corcept Therapeutics Incorporated",
        "summary": "Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator that is in Phase II for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Menlo Park"
    },
    "HTDS": {
        "short_name": "HARD TO TREAT DISEASES INC",
        "long_name": "Hard to Treat Diseases Inc.",
        "summary": "Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Shenzhen"
    },
    "HXB2.F": {
        "short_name": "AIM IMMUNOTECH INC.",
        "long_name": "AIM ImmunoTech Inc.",
        "summary": "AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Ocala"
    },
    "HXBM": {
        "short_name": "HELIX BIOMEDIX INC",
        "long_name": "Helix BioMedix, Inc.",
        "summary": "Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Bothell"
    },
    "HXL.AX": {
        "short_name": "HEXIMA FPO",
        "long_name": "Hexima Limited",
        "summary": "Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is HXP124, which is in a phase IIb clinical trial for the treatment of fungal toenail infections. It operates in the topical antifungal sector of the pharmaceutical product development industry worldwide. The company was founded in 1997 and is headquartered in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "HXXB.F": {
        "short_name": "IDERA PHARMAC.  DL-,001",
        "long_name": "Idera Pharmaceuticals, Inc.",
        "summary": "Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Exton, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Exton"
    },
    "HYL.BR": {
        "short_name": "HYLORIS",
        "long_name": "Hyloris Pharmaceuticals SA",
        "summary": "Hyloris Pharmaceuticals SA manufactures pharmaceutical products. The company offers cardiovascular products for atrial fibrillation, congestive heart failure, and coronary heart disease; intravenous ready-to-use and oral liquid formulations; and topical gel and cream products. Hyloris Pharmaceuticals SA was founded in 2013 and is based in Liege, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Belgium",
        "city": "Li\u00c3\u00a8ge"
    },
    "I9DN.F": {
        "short_name": "ARBUTUS BIOPHARMA",
        "long_name": "Arbutus Biopharma Corporation",
        "summary": "Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Warminster"
    },
    "I9SA.F": {
        "short_name": "VERONA PHARMA SP.ADR 8",
        "long_name": "Verona Pharma plc",
        "summary": "Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "IBIO": {
        "short_name": "iBio, Inc.",
        "long_name": "iBio, Inc.",
        "summary": "iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "IBPB.F": {
        "short_name": "BIO-PATH HLDGS INC.",
        "long_name": "Bio-Path Holdings, Inc.",
        "summary": "Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome; and in Phase IIa clinical trials for the treatment of chronic myeloid leukemia, as well as to treat solid tumors. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Bellaire"
    },
    "IBT-B.ST": {
        "short_name": "Infant Bacterial Therapeutics A",
        "long_name": "Infant Bacterial Therapeutics AB (publ)",
        "summary": "Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "ICCC": {
        "short_name": "ImmuCell Corporation",
        "long_name": "ImmuCell Corporation",
        "summary": "ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Portland"
    },
    "ICOTF": {
        "short_name": "ICO THERAPEUTICS INC",
        "long_name": "iCo Therapeutics Inc.",
        "summary": "iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "ICPT": {
        "short_name": "Intercept Pharmaceuticals, Inc.",
        "long_name": "Intercept Pharmaceuticals, Inc.",
        "summary": "Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "ICY.F": {
        "short_name": "INCYTE  DL-,001",
        "long_name": "Incyte Corporation",
        "summary": "Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat na\u00c3\u00afve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Wilmington"
    },
    "IDD.F": {
        "short_name": "INNATE PHARMA  EO -,05",
        "long_name": "Innate Pharma S.A.",
        "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Marseille"
    },
    "IDDA.MU": {
        "short_name": "INNATE PHARMA SP.ADR/1",
        "long_name": "Innate Pharma S.A.",
        "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "France",
        "city": "Marseille"
    },
    "IDIA.SW": {
        "short_name": "IDORSIA N",
        "long_name": "Idorsia Ltd",
        "summary": "Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Allschwil"
    },
    "IDOGEN.ST": {
        "short_name": "Idogen AB",
        "long_name": "Idogen AB (publ)",
        "summary": "Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, or the body's own cells or tissues in Sweden. Its advanced product candidate is IDO 8, designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII. The company also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection, primarily kidney transplant rejection; and IDO AID for severe and rare autoimmune diseases. The company was founded in 2008 and is headquartered in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "IDRA": {
        "short_name": "Idera Pharmaceuticals, Inc.",
        "long_name": "Idera Pharmaceuticals, Inc.",
        "summary": "Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Exton, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Exton"
    },
    "IDRSF": {
        "short_name": "IDORSIA LTD",
        "long_name": "Idorsia Ltd",
        "summary": "Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Allschwil"
    },
    "IDYA": {
        "short_name": "IDEAYA Biosciences, Inc.",
        "long_name": "IDEAYA Biosciences, Inc.",
        "summary": "IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase 1/2 clinical trial for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A for solid tumors with MTAP deletions; Pol-theta in tumors with homologous recombination deficiency, including BRCA mutations; PARG in tumors with BRCA2 mutations in base excision repair; and WRN in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase 1/2 study in metastatic uveal melanoma and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "IFRX": {
        "short_name": "InflaRx N.V.",
        "long_name": "InflaRx N.V.",
        "summary": "InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "Jena"
    },
    "IG7.F": {
        "short_name": "MEMPHASYS LTD",
        "long_name": "Memphasys Limited",
        "summary": "Memphasys Limited, a bio-separations company, develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that uses high quality sperm cells from semen samples for human assisted reproductive technologies for treating male factor infertility; hydrogels; and other polymer membranes to separate cells from fluids. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited was incorporated in 2006 and is headquartered in Homebush, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Homebush"
    },
    "IGMS": {
        "short_name": "IGM Biosciences, Inc.",
        "long_name": "IGM Biosciences, Inc.",
        "summary": "IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19; and strategic research collaboration and license agreement with AbCellera to discover and develop IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Mountain View"
    },
    "IGX.V": {
        "short_name": "INTELGENX TECHNOLOGIES CORP.",
        "long_name": "IntelGenx Technologies Corp.",
        "summary": "IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral thin film products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, and INT0040/2014. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Insud Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Montreal"
    },
    "IGXT": {
        "short_name": "INTELGENX TECHNOLOGIES CORPORAT",
        "long_name": "IntelGenx Technologies Corp.",
        "summary": "IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral thin film products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, and INT0040/2014. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Insud Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Montreal"
    },
    "IKAP.F": {
        "short_name": "AURINIA PHARMACEUT.",
        "long_name": "Aurinia Pharmaceuticals Inc.",
        "summary": "Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Victoria"
    },
    "IKT": {
        "short_name": "Inhibikase Therapeutics, Inc.",
        "long_name": "Inhibikase Therapeutics, Inc.",
        "summary": "Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It offers products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Atlanta"
    },
    "IM8N.F": {
        "short_name": "INSMED INC.  DL-,01",
        "long_name": "Insmed Incorporated",
        "summary": "Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Bridgewater"
    },
    "IM8N.SG": {
        "short_name": "Insmed Inc. Registered Shares D",
        "long_name": "Insmed Incorporated",
        "summary": "Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Bridgewater"
    },
    "IMAB": {
        "short_name": "I-MAB",
        "long_name": "I-Mab",
        "summary": "I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin (TJ101), a long-acting human growth hormone that has completed Phase II clinical trials to treat pediatric growth hormone deficiency; and Olamkicept (TJ301), a IL-6 blocker, which is in Phase II clinical trials for the treatment of ulcerative colitis and autoimmune diseases. The company's product candidates also include Enoblituzumab, a humanized B7-H3 antibody that has completed Phase I clinical trials to treat head and neck cancer and other oncology diseases; Efineptakin (TJ107), a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme (GBM) patients with lymphopenia; and Plonmarlimab (TJM2), a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies. In Addition, it is developing Lemzoparlimab (TJC4), a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Uliledlimab (TJD5), a CD73 antibody, which is in Phase I clinical trials for treating solid tumors and oncology. Its product candidates in pre-clinical development comprise TJ210, a monoclonal antibody against human C5aR1 for the treatment of cancers and potentially autoimmune diseases; TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM and TJ-CLDN4B antibodies for treating oncology diseases. I-Mab has a strategic collaboration agreement with AbbVie Ireland Unlimited Company to develop and commercialize Lemzoparlimab. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "city": "Shanghai"
    },
    "IMC.AX": {
        "short_name": "IMMURON FPO",
        "long_name": "Immuron Limited",
        "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Carlton"
    },
    "IMGN": {
        "short_name": "ImmunoGen, Inc.",
        "long_name": "ImmunoGen, Inc.",
        "summary": "ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "IMGN.MX": {
        "short_name": "IMMUNOGEN INC",
        "long_name": "ImmunoGen, Inc.",
        "summary": "ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Waltham"
    },
    "IMM.AX": {
        "short_name": "IMMUTEP FPO",
        "long_name": "Immutep Limited",
        "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as \u00c2\u0091eftilagimod alpha' or \u00c2\u0091efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "IMM.L": {
        "short_name": "IMMUPHARMA PLC ORD 10P",
        "long_name": "ImmuPharma plc",
        "summary": "ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "IMMP": {
        "short_name": "Immutep Limited",
        "long_name": "Immutep Limited",
        "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as \u00c2\u0091eftilagimod alpha' or \u00c2\u0091efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "IMNM": {
        "short_name": "Immunome, Inc.",
        "long_name": "Immunome, Inc.",
        "summary": "Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Exton"
    },
    "IMNPQ": {
        "short_name": "IMMUNE PHARMACEUTICALS INC",
        "long_name": "Immune Pharmaceuticals, Inc.",
        "summary": "Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Fort Lee"
    },
    "IMR.F": {
        "short_name": "AC IMMUNE SA  SF-,02",
        "long_name": "AC Immune SA",
        "summary": "AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Switzerland",
        "city": "Lausanne"
    },
    "IMRA": {
        "short_name": "IMARA Inc.",
        "long_name": "IMARA Inc.",
        "summary": "Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "IMRN": {
        "short_name": "Immuron Limited",
        "long_name": "Immuron Limited",
        "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Australia",
        "city": "Carlton"
    },
    "IMTX": {
        "short_name": "Immatics N.V.",
        "long_name": "Immatics N.V.",
        "summary": "Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in T\u00c3\u00bcbingen, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "T\u00c3\u00bcbingen"
    },
    "IMU.AX": {
        "short_name": "IMUGENE FPO",
        "long_name": "Imugene Limited",
        "summary": "Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "IMUC": {
        "short_name": "IMMUNOCELLULAR THERAPEUTICS LTD",
        "long_name": "ImmunoCellular Therapeutics, Ltd.",
        "summary": "ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Westlake Village"
    },
    "IMUN": {
        "short_name": "IMMUNE THERAPEUTICS INC FLA",
        "long_name": "Immune Therapeutics, Inc.",
        "summary": "Immune Therapeutics, Inc., a late development-stage biopharmaceutical company, focuses on the development, commercialization, and licensing of prescription medications for humans, animals, and pets worldwide. It develops low dose naltrexone and methionine encephalin therapies for human immunodeficiency virus (HIV) infections, autoimmune diseases, immune disorders, or cancer. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in December 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Winter Park"
    },
    "IMUX": {
        "short_name": "Immunic, Inc.",
        "long_name": "Immunic, Inc.",
        "summary": "Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in Phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in Phase 2 trial to treat Crohn's disease. The company is also developing IMU-935, an inverse agonist of RORgt; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "IMV": {
        "short_name": "IMV Inc.",
        "long_name": "IMV Inc.",
        "summary": "IMV Inc. operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma). DPX-Survivac is evaluated in multiple Phase 2 clinical trials across six cancer indications and also in combination with Merck's Keytruda in two clinical trials. The company is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts. In addition, it is developing DPX-RSV, a DPX-based vaccine candidate targeting the respiratory syncytial virus strain A. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Dartmouth"
    },
    "IMV.TO": {
        "short_name": "IMV INC",
        "long_name": "IMV Inc.",
        "summary": "IMV Inc. operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma). DPX-Survivac is evaluated in multiple Phase 2 clinical trials across six cancer indications and also in combination with Merck's Keytruda in two clinical trials. The company is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts. In addition, it is developing DPX-RSV, a DPX-based vaccine candidate targeting the respiratory syncytial virus strain A. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Dartmouth"
    },
    "IMVT": {
        "short_name": "Immunovant, Inc.",
        "long_name": "Immunovant, Inc.",
        "summary": "Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "IN.TO": {
        "short_name": "INMED PHARMACEUTICALS INC",
        "long_name": "InMed Pharmaceuticals Inc.",
        "summary": "InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "INBX": {
        "short_name": "Inhibrx, Inc.",
        "long_name": "Inhibrx, Inc.",
        "summary": "Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "La Jolla"
    },
    "INCY": {
        "short_name": "Incyte Corporation",
        "long_name": "Incyte Corporation",
        "summary": "Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat na\u00c3\u00afve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Wilmington"
    },
    "INCY.MX": {
        "short_name": "INCYTE CORPORATION",
        "long_name": "Incyte Corporation",
        "summary": "Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat na\u00c3\u00afve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Wilmington"
    },
    "INCY.VI": {
        "short_name": "INCYTE CORP",
        "long_name": "Incyte Corporation",
        "summary": "Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat na\u00c3\u00afve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "city": "Wilmington"
    },
    "INFI": {
        "short_name": "Infinity Pharmaceuticals, Inc.",
        "long_name": "Infinity Pharmaceuticals, Inc.",
        "summary": "Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "INM": {
        "short_name": "InMed Pharmaceuticals Inc.",
        "long_name": "InMed Pharmaceuticals Inc.",
        "summary": "InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "INMB": {
        "short_name": "INmune Bio Inc.",
        "long_name": "INmune Bio, Inc.",
        "summary": "INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; and LivNate to treat patients with non-alcoholic steatohepatitis. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was founded in 2015 and is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "La Jolla"
    },
    "INNMF": {
        "short_name": "AMPLIA THERAPEUTICS LTD",
        "long_name": "Amplia Therapeutics Limited",
        "summary": "Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "INO": {
        "short_name": "Inovio Pharmaceuticals, Inc.",
        "long_name": "Inovio Pharmaceuticals, Inc.",
        "summary": "Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Plymouth Meeting"
    },
    "INO.MX": {
        "short_name": "INOVIO PHARMACEUTICALS INC",
        "long_name": "Inovio Pharmaceuticals, Inc.",
        "summary": "Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Plymouth Meeting"
    },
    "INRLF": {
        "short_name": "VALNEVA SE",
        "long_name": "Valneva SE",
        "summary": "Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease and single-shot vaccine against chikungunya. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company has collaboration with Dynavax Technologies Corporation to advance vaccine development for COVID-19. Valneva SE was incorporated in 1999 and is headquartered in Nantes, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Nantes"
    },
    "INSM": {
        "short_name": "Insmed, Inc.",
        "long_name": "Insmed Incorporated",
        "summary": "Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Bridgewater"
    },
    "INTI": {
        "short_name": "INHIBITOR THERAPEUTICS INC",
        "long_name": "Inhibitor Therapeutics, Inc.",
        "summary": "Inhibitor Therapeutics Inc. operates as a pharmaceutical development company that discovers, develops, and plans to commercialize therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders in the United States. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity, and cell proliferation. It focuses on developing its lead product, SUBA-Itraconazole, a patented oral formulation for prostate and lung cancer. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics Inc. in August 2019. Inhibitor Therapeutics Inc. was founded in 1992 and is based in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Tampa"
    },
    "INVA": {
        "short_name": "Innoviva, Inc.",
        "long_name": "Innoviva, Inc.",
        "summary": "Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Burlingame"
    },
    "INZY": {
        "short_name": "Inozyme Pharma, Inc.",
        "long_name": "Inozyme Pharma, Inc.",
        "summary": "Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "IONS": {
        "short_name": "Ionis Pharmaceuticals, Inc.",
        "long_name": "Ionis Pharmaceuticals, Inc.",
        "summary": "Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson's disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with AstraZeneca; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Carlsbad"
    },
    "IONS.MX": {
        "short_name": "IONIS PHARMACEUTICALS INC",
        "long_name": "Ionis Pharmaceuticals, Inc.",
        "summary": "Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson's disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with AstraZeneca; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Carlsbad"
    },
    "IOT.V": {
        "short_name": "INNOVOTECH INC.",
        "long_name": "Innovotech Inc.",
        "summary": "Innovotech Inc. provides solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada, the United States, and internationally. The company offers InnovoSIL, an antimicrobial agents for coating onto or incorporation into medical devices; MBEC Assay, a screening assay used to determine the efficacy of antimicrobials against biofilms of various microorganisms; and Agress/AgreGuard, an environmentally friendly seed treatments and plant sprays to protect crops against both bacterial and fungal infections. It also provides implant medical devices; antibiotic, antimicrobial, and biocide resistance; bacteriophage, cytotoxicity, and in vitro antimicrobial testing; and analytical services. It serves customers in the areas of biofilm issues, including catheter and implant medical devices, antibiotic drug development, wound healing, paint and specialized coatings, water system antimicrobial agents, dental treatments and water line antimicrobial agents, and bacterial and fungal agricultural crop diseases, as well as disinfectants in food safety, transportation, and healthcare. Innovotech Inc. was incorporated in 2001 is headquartered in Edmonton, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Edmonton"
    },
    "IOVA": {
        "short_name": "Iovance Biotherapeutics, Inc.",
        "long_name": "Iovance Biotherapeutics, Inc.",
        "summary": "Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Carlos"
    },
    "IP-R.BK": {
        "short_name": "INTER PHARMA PUBLIC COMPANY LIM",
        "long_name": "Inter Pharma Public Company Limited",
        "summary": "Inter Pharma Public Company Limited develops, produces, and sells healthcare products in Thailand. It operates through two segments, Human Healthcare and Animal Healthcare. The company offers human beauty products, such as medical supplies, nutrition therapy, cosmetics, supplementary foods, probiotic and prebiotic products, health food products, general food products, medical equipment, etc.; a range of wellness and anti-aging products; aesthetic products, such as anti-wrinkle creams, hyaluronic fillers, and EGF cosmeceuticals; and diagnostic products, including blood group tests and cool box systems. It also provides pet healthcare and livestock products comprising medical supplies, nutrition therapy, vaccines, supplementary foods, probiotic and prebiotic products, animal health food products, premium grade animal foods, general formula animal foods, etc., as well as medical equipment related to pet and livestock care products. In addition, the company imports and distributes dietary supplement products for humans and animals. The company was founded in 2006 and is headquartered in Bangkok, Thailand.",
        "currency": "THB",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SET",
        "market": "th_market",
        "country": "Thailand",
        "city": "Bangkok"
    },
    "IPA": {
        "short_name": "ImmunoPrecise Antibodies Ltd.",
        "long_name": "ImmunoPrecise Antibodies Ltd.",
        "summary": "ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Fargo"
    },
    "IPA.V": {
        "short_name": "IMMUNOPRECISE ANTIBODIES LTD",
        "long_name": "ImmunoPrecise Antibodies Ltd.",
        "summary": "ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "United States",
        "city": "Fargo"
    },
    "IPCI.TO": {
        "short_name": "INTELLIPHARMACEUTICS INTERNATIO",
        "long_name": "Intellipharmaceutics International Inc.",
        "summary": "Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "IPCIF": {
        "short_name": "INTELLIPHARMACEUTICS INTL INC",
        "long_name": "Intellipharmaceutics International Inc.",
        "summary": "Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "IPH.PA": {
        "short_name": "INNATE PHARMA",
        "long_name": "Innate Pharma S.A.",
        "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Marseille"
    },
    "IPHA": {
        "short_name": "Innate Pharma S.A.",
        "long_name": "Innate Pharma S.A.",
        "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Marseille"
    },
    "IPHYF": {
        "short_name": "INNATE PHARMA",
        "long_name": "Innate Pharma S.A.",
        "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Marseille"
    },
    "IPIX": {
        "short_name": "INNOVATION PHARMACEUTICALS INC",
        "long_name": "Innovation Pharmaceuticals Inc.",
        "summary": "Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Wakefield"
    },
    "IRLAB-A.ST": {
        "short_name": "IRLAB Therapeutics AB ser. A",
        "long_name": "IRLAB Therapeutics AB (publ)",
        "summary": "IRLAB Therapeutics AB (publ), a research and development company, develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam, a dopamine D3 receptor antagonist that has completed Phase IIa clinical trial for the treatment of dyskinesia; IRL752 that has completed Phase IIa clinical trial to treat postural dysfunction; and IRL942 and 1009, a research program for the treatment of neurodegenerative disorders and ageing. It also develops P001, a research project for neurodegenerative disorders and aging; P003, a research project aiming at developing drugs that can substitute levodopa as the treatment of Parkinson's disease; and IRL448/IRL555, a follow\u00c2\u0096up to Parkinson's disease program. The company is based in Gothenburg, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Gothenburg"
    },
    "ISCO": {
        "short_name": "INTERNATIONAL STEM CELL CORPORA",
        "long_name": "International Stem Cell Corporation",
        "summary": "International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Carlsbad"
    },
    "ISEE": {
        "short_name": "IVERIC bio, Inc.",
        "long_name": "IVERIC bio, Inc.",
        "summary": "IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration. It is also developing High temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company has a license agreement with the University of Florida Research Foundation and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and Best disease and other BEST1-related inherited retinal diseases. It also has a research agreement with the University of Massachusetts Medical School to develop gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and autosomal recessive Stargardt disease; and IRDs associated with mutations in the USH2A gene. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "ISI.F": {
        "short_name": "IONIS PHARMACEUT.  DL-001",
        "long_name": "Ionis Pharmaceuticals, Inc.",
        "summary": "Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson's disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with AstraZeneca; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Carlsbad"
    },
    "ISKJ.ME": {
        "short_name": "HUMAN STEM CELLS",
        "long_name": "Public Joint-Stock Company \"Human Stem Cells Institute\"",
        "summary": "Public Joint-Stock Company \u00c2\u0091Human Stem Cells Institute' operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation. The company also offers Neovasculgen, a gene-therapy drug for treatment of peripheral arterial disease, including critical limb ischemia; and SPRS-therapy (service for personal regeneration of skin), a set of personalized diagnostics and treatment procedures for repairing skin damages. In addition, it operates GENETICO, a medical genetics center and molecular diagnostic lab that provides a range of genetic analysis and counseling services for the early detection, prediction, and prophylactic treatment of genetic disorders, including reproductive system diseases; and provides preimplantation genetic diagnosis and screening that includes testing of developing embryos for monogenic inherited diseases and chromosome abnormalities during an in vitro fertilization cycle. Further, the company offers non-invasive prenatal testing of fetal chromosome abnormalities; and develops Gemacell, a cell-based drug candidate for treatment of myocardial infarction. Additionally, it provides range of diagnostic services for identification of genetic predisposition to oncological diseases; and distributes cell processing equipment. The company was founded in 2003 and is based in Moscow, Russia. Public Joint-Stock Company \u00c2\u0091Human Stem Cells Institute' is a subsidiary of PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy.",
        "currency": "RUB",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MCX",
        "market": "ru_market",
        "country": "Russia",
        "city": "Moscow"
    },
    "ISOFOL.ST": {
        "short_name": "Isofol Medical AB",
        "long_name": "Isofol Medical AB (publ)",
        "summary": "Isofol Medical AB (publ), a biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops Arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was founded in 2008 and is headquartered in Gothenburg, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Gothenburg"
    },
    "ISR.ST": {
        "short_name": "ISR Immune System Regulation Ho",
        "long_name": "ISR Immune System Regulation Holding AB (publ)",
        "summary": "ISR Immune System Regulation Holding AB (publ) researches and develops drugs for the treatment of viral infections in Sweden. The company's product candidates include ISR048 that has completed Phase I/IIa clinical trial for the treatment of human immunodeficiency virus infection (HIV); and ISR049, which is in the development stage to treat HIV. It is also developing a second line of chemical entities, including ISR050 that has immunostimulatory properties. The company is headquartered in Stockholm, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "ITCI": {
        "short_name": "Intra-Cellular Therapies Inc.",
        "long_name": "Intra-Cellular Therapies, Inc.",
        "summary": "Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "ITECH.ST": {
        "short_name": "I-Tech AB",
        "long_name": "I-Tech AB",
        "summary": "I-Tech AB, a bio-technology company, develops and commercializes fouling prevention products in Sweden. The company offers Selektope, a bio-repellent ingredient for marine coatings that provide hard fouling prevention for ships. It serves marine coatings manufacturers. The company was founded in 2000 and is based in M\u00c3\u00b6lndal, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "M\u00c3\u00b6lndal"
    },
    "ITH.F": {
        "short_name": "NEKTAR THERAPEUTICS",
        "long_name": "Nektar Therapeutics",
        "summary": "Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "ITMC": {
        "short_name": "ITOCO INC",
        "long_name": "Itoco Inc.",
        "summary": "Itoco Inc. engages in the processing, production, and distribution of medical cannabis products. The company was formerly known as Itoco Mining Corporation and changed its name to Itoco Inc. in May 2018. Itoco Inc. is based in Reno, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Reno"
    },
    "ITOS": {
        "short_name": "iTeos Therapeutics, Inc.",
        "long_name": "iTeos Therapeutics, Inc.",
        "summary": "Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "ITRM": {
        "short_name": "Iterum Therapeutics plc",
        "long_name": "Iterum Therapeutics plc",
        "summary": "Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "IUGNF": {
        "short_name": "IMUGENE LIMITED",
        "long_name": "Imugene Limited",
        "summary": "Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "IUL.F": {
        "short_name": "IMMUCELL CORP.  DL-,10",
        "long_name": "ImmuCell Corporation",
        "summary": "ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Portland"
    },
    "IVA": {
        "short_name": "Inventiva S.A. - American Depos",
        "long_name": "Inventiva S.A.",
        "summary": "Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Daix"
    },
    "IVA.PA": {
        "short_name": "INVENTIVA",
        "long_name": "Inventiva S.A.",
        "summary": "Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Daix"
    },
    "IVACC.ST": {
        "short_name": "Intervacc AB",
        "long_name": "Intervacc AB (publ)",
        "summary": "Intervacc AB (publ), a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. It offers vaccines, pharmaceuticals, and vitamins for horses, piglets, and cows. The company also provides veterinary bacteriological and mycological analyses for veterinarians and animal hospitals. It serves customers in Nordic countries and the Baltic states. Intervacc AB (publ) holds an agreement with the Swedish University of Agricultural Sciences, SLU for the development of animal health vaccines. The company is based in H\u00c3\u00a4gersten, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "H\u00c3\u00a4gersten"
    },
    "IXC.AX": {
        "short_name": "INVEX THER FPO",
        "long_name": "Invex Therapeutics Ltd",
        "summary": "Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Subiaco, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Subiaco"
    },
    "IXI.L": {
        "short_name": "IXICO PLC ORD 1P",
        "long_name": "IXICO plc",
        "summary": "IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. It provides collection, analysis, management, and reporting services on data generated in the course of a clinical study. The company's technologies include Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, QC, and reading/analysis to reporting and data transfer. The company offers end-to-end imaging services, primarily in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases; and engages in the data collection and analysis of neurological diseases. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was incorporated in 1995 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "J7Z.F": {
        "short_name": "JAZZ PHARMACEUT. DL-,0001",
        "long_name": "Jazz Pharmaceuticals plc",
        "summary": "Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "JAGX": {
        "short_name": "Jaguar Health, Inc.",
        "long_name": "Jaguar Health, Inc.",
        "summary": "Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "JAZZ": {
        "short_name": "Jazz Pharmaceuticals plc",
        "long_name": "Jazz Pharmaceuticals plc",
        "summary": "Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "JEH.F": {
        "short_name": "GENOWAY S.A. INH.  EO-,60",
        "long_name": "genOway S.A.",
        "summary": "genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company provides technological solutions for transgenesis and model design. It produces custom mouse models, such as knockout (KO) and knockin (KI) mouse models; custom rat models; custom cell models; catalog models; and phenotyping for in vivo or in vitro studies. The company also provides patented homologous recombination technology for the generation of genetically modified rodent models; CRISPR/Cas9 nuclease systems for the KO and KI model creation; and FLEx, an inducible point mutation technology that allows scientists to induce the expression of a mutated gene or a reporter gene during the lifetime of the animal model. In addition, it offers tetracycline on/off systems to control gene expression; and internal ribosome entry site technology to generate multigenic-based disease models, reporter models, cell lineage tracking models, and tissue-specific Cre driver lines, as well as to monitor cell expression patterns in KO models. Further, the company provides recombinase-mediated cassette exchange technology to enable the swapping of genomic regions; and Quick Knockin technology, such as Rosa26, Hprt, and AAVS1. It serves pharmaceutical and life science companies, and academic institutes. genOway S.A. has a strategic alliance with Merck to develop and validate new CRISPR/Cas9-related products and solutions. The company was founded in 1999 and is based in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lyon"
    },
    "JNCE": {
        "short_name": "Jounce Therapeutics, Inc.",
        "long_name": "Jounce Therapeutics, Inc.",
        "summary": "Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "JSS.F": {
        "short_name": "SOSEI GROUP CORP",
        "long_name": "Sosei Group Corporation",
        "summary": "Sosei Group Corporation discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of AZD4635, an adenosine A2a antagonist, which is in Phase II clinical trial for the treatment of solid tumors and metastatic castration resistant prostate cancer; HTL0016878, a muscarinic M4 agonist, which is in Phase I clinical trial for the treatment of Alzheimer's disease; and dual muscarinic M1/M4 agonist, which is in pre-clinical stage for the treatment of Alzheimer's disease. It also develops HTL0014242, a mGlu5 small molecule negative-allosteric modulator, which is in Phase I clinical trial for the treatment of certain neurological order; SSTR agonist, a novel somatostatin peptide agonist, which is in Phase I clinical trial for the treatment of endocrine disorders; HTL0022562, a calcitonin gene related peptide antagonist, which is in pre-clinical stage for the treatment of migraine and other severe headaches; GLP-1 antagonist, a potent glucagon-like peptide-1 antagonist, which is in pre-clinical stage for the treatment of severe hypoglycaemia in rare diseases; and GLP-2 agonist, a potent glucagon-like peptide-2 agonist, which is in pre-clinical stage for the treatment of intestinal disorders. In addition, the company's pipeline products include OX-1 antagonist to treat cocaine-use disorders; Apelin agonist for pulmonary arterial hypertension; GPR35 agonist to treat inflammatory bowel disease; H4 antagonist and PAR2 mAb for atopic dermatitis. Sosei Group Corporation has a strategic collaboration with Kymab, PeptiDream Inc., Pfizer, MorphoSys, Genentech, Takeda Pharmaceutical Company Limited, and Captor Therapeutics SA. The company was founded in 1990 and is headquartered in Tokyo, Japan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "K27.F": {
        "short_name": "KODIAK SCIENCES  DL-,0001",
        "long_name": "Kodiak Sciences Inc.",
        "summary": "Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Palo Alto"
    },
    "K3P.F": {
        "short_name": "KIADIS PHARMA NV  EO -,10",
        "long_name": "Kiadis Pharma N.V.",
        "summary": "Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. The company develops K-NK002 as an adjunctive immunotherapeutic, which is in Phase II clinical trials for blood cancer patients undergoing a haploidentical HSCT with the post-transplant cyclophosphamide (PTCy) protocol; and K-NK003, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia relapse/refractory (AML R/R). The company's preclinical stage product include K-NK00X, a NK-cell therapy candidate for the treatment of various solid tumors. It has a collaboration agreement with Harbour BioMed, Utrecht University, Erasmus Medical Center, and Viroclinics-DDL for the development of a combination of a monoclonal antibody and natural killer cells as a treatment for COVID-19. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "KALA": {
        "short_name": "Kala Pharmaceuticals, Inc.",
        "long_name": "Kala Pharmaceuticals, Inc.",
        "summary": "Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Watertown"
    },
    "KALV": {
        "short_name": "KalVista Pharmaceuticals, Inc.",
        "long_name": "KalVista Pharmaceuticals, Inc.",
        "summary": "KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "KAN.ST": {
        "short_name": "Kancera AB",
        "long_name": "Kancera AB (publ)",
        "summary": "Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. It develops drugs for the treatment of inflammation and cancer. The company's drug development projects include ROR inhibitors for the treatment of leukemia and solid tumors; PFKFB3 inhibitors for reducing cancer's energy supply and inhibiting DNA repair; HDAC6 for the treatment of nerve inflammation and pain; and KAND567 and KAND145 that block the receptor for fractalkine and specific parts of the immune system, as well as for the treatment of heart injury after myocardial infarction. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "KAST": {
        "short_name": "KASTEN INC",
        "long_name": "Kasten, Inc.",
        "summary": "Kasten, Inc., doing business as DAKOTA Life Sciences, operates as a biopharmaceutical company that focuses on the acquisition, development, and commercialization of pharmaceuticals designed to prevent and treat serious conditions arising in hospital and community settings. It principally focuses on delivering solutions to those people who are affected by antimicrobial resistance and who need pharmaceutical products at affordable prices. The company was incorporated in 1986 and is based in Sioux Falls, South Dakota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Sioux Falls"
    },
    "KDEV.ST": {
        "short_name": "Karolinska Development AB ser.B",
        "long_name": "Karolinska Development AB (publ)",
        "summary": "Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "KDF.F": {
        "short_name": "KADMON HLDGS.INC. DL-,001",
        "long_name": "Kadmon Holdings, Inc.",
        "summary": "Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "KDMN": {
        "short_name": "Kadmon Holdings, Inc.",
        "long_name": "Kadmon Holdings, Inc.",
        "summary": "Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "KDNY": {
        "short_name": "Chinook Therapeutics, Inc.",
        "long_name": "Chinook Therapeutics, Inc.",
        "summary": "Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "KDS.AS": {
        "short_name": "KIADIS",
        "long_name": "Kiadis Pharma N.V.",
        "summary": "Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. The company develops K-NK002 as an adjunctive immunotherapeutic, which is in Phase II clinical trials for blood cancer patients undergoing a haploidentical HSCT with the post-transplant cyclophosphamide (PTCy) protocol; and K-NK003, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia relapse/refractory (AML R/R). The company's preclinical stage product include K-NK00X, a NK-cell therapy candidate for the treatment of various solid tumors. It has a collaboration agreement with Harbour BioMed, Utrecht University, Erasmus Medical Center, and Viroclinics-DDL for the development of a combination of a monoclonal antibody and natural killer cells as a treatment for COVID-19. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "AMS",
        "market": "nl_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "KDST.TA": {
        "short_name": "KADIMASTEM",
        "long_name": "Kadimastem Ltd",
        "summary": "Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and encapsulated islet-of-langerhans-like clusters for diabetes. The company was founded in 2009 and is based in Ness Ziona, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "KK3A.F": {
        "short_name": "CYTOKINETICS INC. DL-,001",
        "long_name": "Cytokinetics, Incorporated",
        "summary": "Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "KLDO": {
        "short_name": "Kaleido Biosciences, Inc.",
        "long_name": "Kaleido Biosciences, Inc.",
        "summary": "Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Lexington"
    },
    "KMPH": {
        "short_name": "KemPharm, Inc.",
        "long_name": "KemPharm, Inc.",
        "summary": "KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Celebration"
    },
    "KNBIF": {
        "short_name": "KANE BIOTECH INC",
        "long_name": "Kane Biotech Inc.",
        "summary": "Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms in Canada and internationally. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoos for dogs, cats, and horses under the Alosera trademark. The company was founded in 2001 and is based in Winnipeg, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Winnipeg"
    },
    "KNE.V": {
        "short_name": "KANE BIOTECH INC",
        "long_name": "Kane Biotech Inc.",
        "summary": "Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms in Canada and internationally. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoos for dogs, cats, and horses under the Alosera trademark. The company was founded in 2001 and is based in Winnipeg, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Winnipeg"
    },
    "KNSA": {
        "short_name": "Kiniksa Pharmaceuticals, Ltd.",
        "long_name": "Kiniksa Pharmaceuticals, Ltd.",
        "summary": "Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Bermuda",
        "city": "Hamilton"
    },
    "KNTE": {
        "short_name": "Kinnate Biopharma Inc.",
        "long_name": "Kinnate Biopharma Inc.",
        "summary": "Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. The company's lead product candidate is KIN002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. Its other products in preclinical stage include KIN003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. Kinnate Biopharma Inc. was founded in 2018 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "KNTPF": {
        "short_name": "KINTOR PHARMACEUTICAL LTD",
        "long_name": "Kintor Pharmaceutical Limited",
        "summary": "Kintor Pharmaceutical Limited, a biopharmaceutical company, engages in the research and development of drugs for the treatment of various cancers and other androgen receptor (AR) - related diseases in China, the United States, and Taiwan. The company's lead drug candidates include Proxalutamide, a small molecule second generation AR antagonist that is in various clinical trials for metastatic castration-resistant prostate cancer and breast cancer; and Pyrilutamide, which is in various clinical trials for androgenetic alopecia and acne vulgaris. It also develops ALK-1 for the treatment of metastatic hepatocellular carcinoma and liver cancer; Detorsertib, a second-generation mTOR inhibitor for the treatment of metastatic solid tumours; and GT1708F, for the treatment of leukaemia and basal-cell carcinoma. The company was founded in 2009 and is headquartered in Suzhou, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Suzhou"
    },
    "KOD": {
        "short_name": "Kodiak Sciences Inc",
        "long_name": "Kodiak Sciences Inc.",
        "summary": "Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Palo Alto"
    },
    "KOD.MX": {
        "short_name": "KODIAK SCIENCES INC",
        "long_name": "Kodiak Sciences Inc.",
        "summary": "Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Palo Alto"
    },
    "KPTI": {
        "short_name": "Karyopharm Therapeutics Inc.",
        "long_name": "Karyopharm Therapeutics Inc.",
        "summary": "Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma. The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of ow-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 2/3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration with PROMETRIKA, LLC to conduct the first randomized clinical trial for low-dose selinexor (XPOVIO\u00c3\u0082), an XPO1 inhibitor for hospitalized patients with COVID-19; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Newton"
    },
    "KRBP": {
        "short_name": "Kiromic BioPharma, Inc.",
        "long_name": "Kiromic BioPharma, Inc.",
        "summary": "Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. Its product portfolio include ALEXIS AIDT-1, an allogenic CAR cell product candidate targeting AIDT-1; ALEXIS AIDT-2 EOC, an allogenic CAR cell product candidate targeting AIDT-2; ALEXIS AIDT-2 MPM (malignant pleural mesothelioma), an allogenic CAR/NKT-Like cell product candidate targeting AIDT-2; and PD-1-AR, a check point inhibitor for solid tumors, as well as oral healthcare products, such as mouthwash. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Houston"
    },
    "KRON": {
        "short_name": "Kronos Bio, Inc.",
        "long_name": "Kronos Bio, Inc.",
        "summary": "Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Mateo"
    },
    "KROS": {
        "short_name": "Keros Therapeutics, Inc.",
        "long_name": "Keros Therapeutics, Inc.",
        "summary": "Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Lexington"
    },
    "KRTX": {
        "short_name": "Karuna Therapeutics, Inc.",
        "long_name": "Karuna Therapeutics, Inc.",
        "summary": "Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. Its lead product candidate is KarXT, an oral modulator that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, Alzheimer's, and pain, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "KRYS": {
        "short_name": "Krystal Biotech, Inc.",
        "long_name": "Krystal Biotech, Inc.",
        "summary": "Krystal Biotech, Inc., a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa. It is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in preclinical stage for treating aesthetic skin conditions; KB104 that is in preclinical stage for the treatment of Netherton Syndrome; and KB5xx for treating chronic skin diseases, which is in discovery stage. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Pittsburgh"
    },
    "KTRA": {
        "short_name": "Kintara Therapeutics, Inc.",
        "long_name": "Kintara Therapeutics, Inc.",
        "summary": "Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "KURA": {
        "short_name": "Kura Oncology, Inc.",
        "long_name": "Kura Oncology, Inc.",
        "summary": "Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "KURN.SW": {
        "short_name": "Kuros N",
        "long_name": "Kuros Biosciences AG",
        "summary": "Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company's orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Schlieren"
    },
    "KYMR": {
        "short_name": "Kymera Therapeutics, Inc.",
        "long_name": "Kymera Therapeutics, Inc.",
        "summary": "Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Watertown"
    },
    "KZA.AX": {
        "short_name": "KAZIA FPO",
        "long_name": "Kazia Therapeutics Limited",
        "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "KZIA": {
        "short_name": "Kazia Therapeutics Limited",
        "long_name": "Kazia Therapeutics Limited",
        "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "KZR": {
        "short_name": "Kezar Life Sciences, Inc.",
        "long_name": "Kezar Life Sciences, Inc.",
        "summary": "Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "LCAR": {
        "short_name": "LESCARDEN INC",
        "long_name": "Lescarden Inc.",
        "summary": "Lescarden Inc. researches, tests, develops, and sells medications for the control and cure of various diseases in the United States, Europe, and South Korea. Its lead product is Catrix Wound Dressing for the management of chronic lesions and burns, as well as for non-healing wounds, including decubitus ulcers, venous stasis ulcers, and diabetic ulcers. The company also offers a line of Catrix-based wound and skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, it provides nutritional supplements, such as Bio-Cartilage and Poly-NAG, a patented glucosamine polymer; and licenses its technologies for commercialization by other companies. Lescarden Inc. was founded in 1960 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "LCT.AX": {
        "short_name": "LIV CELL FPO",
        "long_name": "Living Cell Technologies Limited",
        "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "LCTX": {
        "short_name": "Lineage Cell Therapeutics, Inc.",
        "long_name": "Lineage Cell Therapeutics, Inc.",
        "summary": "Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Carlsbad"
    },
    "LEGN": {
        "short_name": "Legend Biotech Corporation",
        "long_name": "Legend Biotech Corporation",
        "summary": "Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen. The company is conducting multiple clinical trials to evaluate LCAR-B38M/JNJ-4528 as an earlier line of therapy for multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in Revlimid-refractory MM. It also has a broad portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, the company is developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL, which is currently in an investigator-initiated Phase 1 clinical trial in China. Further, it has various product candidates in early preclinical and clinical development for the treatment of solid tumors, as well as infectious diseases. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Somerset"
    },
    "LGDN.F": {
        "short_name": "LIGAND PHARMAC.NEW DL-001",
        "long_name": "Ligand Pharmaceuticals Incorporated",
        "summary": "Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "LGND": {
        "short_name": "Ligand Pharmaceuticals Incorpor",
        "long_name": "Ligand Pharmaceuticals Incorporated",
        "summary": "Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "LHI.F": {
        "short_name": "LIVING CELL TECHS",
        "long_name": "Living Cell Technologies Limited",
        "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "LIDDS.ST": {
        "short_name": "LIDDS AB",
        "long_name": "LIDDS AB (publ)",
        "summary": "LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an antibody-based immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. The company is based in Uppsala, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Uppsala"
    },
    "LIFE": {
        "short_name": "aTyr Pharma, Inc.",
        "long_name": "aTyr Pharma, Inc.",
        "summary": "aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan; and a research collaboration with the Medical University of South Carolina to develop therapeutic antibodies that selectively target specific NRP2 isoforms. The company was founded in 2005 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "LIFS": {
        "short_name": "LIFE STEM GENETICS INC",
        "long_name": "Life Stem Genetics Inc.",
        "summary": "Life Stem Genetics Inc., a development stage company, focuses on establishing stem cell therapy based clinics worldwide. Its products and services include nutraceutical and medical supplements, and IV nutritional cocktails; stem cell banking services; stem cell treatments for degenerative conditions, hyperbaric oxygen therapy, cancer treatments, and weight loss; anti-aging stem cell therapy; anti-viral therapy; and adistem stem cell treatments for orthopedics, neurological, and lung diseases. Life Stem Genetics Inc. has a strategic collaborative agreement with American CryoStem Corporation. The company was founded in 2012 and is based in Beverly Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Beverly Hills"
    },
    "LIXT": {
        "short_name": "Lixte Biotechnology Holdings, I",
        "long_name": "Lixte Biotechnology Holdings, Inc.",
        "summary": "Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and study with the National Cancer Institute. The company was founded in 2005 and is based in East Setauket, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "East Setauket"
    },
    "LJPC": {
        "short_name": "La Jolla Pharmaceutical Company",
        "long_name": "La Jolla Pharmaceutical Company",
        "summary": "La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "LJPP.F": {
        "short_name": "LA JOLLA PHARM.  DL-,0001",
        "long_name": "La Jolla Pharmaceutical Company",
        "summary": "La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "LMNL": {
        "short_name": "Liminal BioSciences Inc.",
        "long_name": "Liminal BioSciences Inc.",
        "summary": "Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and Alstr\u00c3\u00b6m Syndrome. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Canada",
        "city": "Laval"
    },
    "LO91.F": {
        "short_name": "VBI VACCINES INC.",
        "long_name": "VBI Vaccines Inc.",
        "summary": "VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome; and a partnership with Syneos Health, Inc. for the commercialization of VBI's 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "LOGC": {
        "short_name": "LogicBio Therapeutics, Inc.",
        "long_name": "LogicBio Therapeutics, Inc.",
        "summary": "LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was founded in 2014 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Lexington"
    },
    "LPCN": {
        "short_name": "Lipocine Inc.",
        "long_name": "Lipocine Inc.",
        "summary": "Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase 2b testing; LPCN 1148, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis cirrhosis (NASH); LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase 2 Clinical trial for the treatment of NASH. The company is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "LPTX": {
        "short_name": "Leap Therapeutics, Inc.",
        "long_name": "Leap Therapeutics, Inc.",
        "summary": "Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. Its clinical stage programs also include TRX518, a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "LQDA": {
        "short_name": "Liquidia Corporation",
        "long_name": "Liquidia Corporation",
        "summary": "Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Morrisville"
    },
    "LRMR": {
        "short_name": "Larimar Therapeutics, Inc.",
        "long_name": "Larimar Therapeutics, Inc.",
        "summary": "Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound is CTI-1601, a Phase 1 clinical program to treat Friedreich's ataxia, a rare and progressive genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Bala Cynwyd"
    },
    "LSRM.F": {
        "short_name": "CEL-SCI CORP. NEW  DL-,01",
        "long_name": "CEL-SCI Corporation",
        "summary": "CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Vienna"
    },
    "LTIA.F": {
        "short_name": "APTOSE BIOSCIENCES NEW",
        "long_name": "Aptose Biosciences Inc.",
        "summary": "Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "LTRN": {
        "short_name": "Lantern Pharma Inc.",
        "long_name": "Lantern Pharma Inc.",
        "summary": "Lantern Pharma Inc., a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Dallas"
    },
    "LUMO": {
        "short_name": "Lumos Pharma, Inc.",
        "long_name": "Lumos Pharma, Inc.",
        "summary": "Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "LVCLF": {
        "short_name": "LIVING CELL TECHNOLOGIES",
        "long_name": "Living Cell Technologies Limited",
        "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "LVCLY": {
        "short_name": "LIVING CELL TECHNOLOGIES",
        "long_name": "Living Cell Technologies Limited",
        "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "LWB.F": {
        "short_name": "MESOBLAST LTD.",
        "long_name": "Mesoblast Limited",
        "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Gr\u00c3\u00bcnenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "LWBA.F": {
        "short_name": "MESOBLAST SP.ADRS 144A/5",
        "long_name": "Mesoblast Limited",
        "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Gr\u00c3\u00bcnenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "LX31.F": {
        "short_name": "LEXICON PHARM.  DL-,001",
        "long_name": "Lexicon Pharmaceuticals, Inc.",
        "summary": "Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "The Woodlands"
    },
    "LX31.MU": {
        "short_name": "LEXICON PHARM.  DL-,001",
        "long_name": "Lexicon Pharmaceuticals, Inc.",
        "summary": "Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "The Woodlands"
    },
    "LXRX": {
        "short_name": "Lexicon Pharmaceuticals, Inc.",
        "long_name": "Lexicon Pharmaceuticals, Inc.",
        "summary": "Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "The Woodlands"
    },
    "LYKALABS.NS": {
        "short_name": "LYKA LABORATORIES",
        "long_name": "Lyka Labs Limited",
        "summary": "Lyka Labs Limited engages in manufacturing pharmaceutical formulations and active pharmaceutical ingredients various therapeutic segments in India. It manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. The company also provides contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, BA/BE clinical study data, etc. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. Lyka Labs Limited offers its products in various formulations, including injections, creams, ointments, foams, gels, and lotions. Further, the company exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.",
        "currency": "INR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NSI",
        "market": "in_market",
        "country": "India",
        "city": "Mumbai"
    },
    "LYRA": {
        "short_name": "Lyra Therapeutics, Inc.",
        "long_name": "Lyra Therapeutics, Inc.",
        "summary": "Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Watertown"
    },
    "LYS.PA": {
        "short_name": "LYSOGENE",
        "long_name": "Lysogene S.A.",
        "summary": "Lysogene S.A. engages in the research and clinical development of gene therapy for neurodegenerative disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was founded in 2009 and is based in Neuilly-sur-Seine, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Neuilly-sur-Seine"
    },
    "M8W.F": {
        "short_name": "MEDIWOUND LTD  IS-,01",
        "long_name": "MediWound Ltd.",
        "summary": "MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Yavne"
    },
    "MACK": {
        "short_name": "Merrimack Pharmaceuticals, Inc.",
        "long_name": "Merrimack Pharmaceuticals, Inc.",
        "summary": "Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "MAGLE.ST": {
        "short_name": "Magle Chemoswed Holding AB",
        "long_name": "Magle Chemoswed Holding AB (publ)",
        "summary": "Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacture of pharmaceutical products and technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); research, development, and production of products in the areas of wound care and diagnostics, with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical device technology products in the areas of advanced wound care, surgical and diagnostics, drug delivery, which include its marketed technology products comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; and SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company is headquartered in Malm\u00c3\u00b6, Sweden. Magle Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Malm\u00c3\u00b6"
    },
    "MAH0.F": {
        "short_name": "MEREO BIOPH. ADR  LS-,003",
        "long_name": "Mereo BioPharma Group plc",
        "summary": "Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "MAH0.SG": {
        "short_name": "Mereo Biopharma Group Ltd. Reg.",
        "long_name": "Mereo BioPharma Group plc",
        "summary": "Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "MATN": {
        "short_name": "MATEON THERAPEUTICS INC",
        "long_name": "Mateon Therapeutics, Inc.",
        "summary": "Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Agoura Hills"
    },
    "MBCI": {
        "short_name": "MABCURE INC",
        "long_name": "MabCure, Inc.",
        "summary": "MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "White Plains"
    },
    "MBG.F": {
        "short_name": "MARINOMED BIOTECH AG INH.",
        "long_name": "Marinomed Biotech AG",
        "summary": "Marinomed Biotech AG, a biopharmaceutical company, develops products for respiratory and ophthalmological diseases in Austria, other European countries, and internationally. It operates in two segments, Marinosolv and Carragelose. The company develops its products based on the Marinosolv, a technology platform that enhances the bioavailability of hardly soluble compounds for the treatment of sensitive tissues, such as nose and eyes; and Carragelose, an antiviral respiratory technology platform. It offers nasal and throat sprays, and lozenges. The company is also developing Budesolv and Tacrosolv targeting inflammatory diseases of nose and eyes. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was founded in 2006 and is headquartered in Vienna, Austria.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Austria",
        "city": "Vienna"
    },
    "MBIO": {
        "short_name": "Mustang Bio, Inc.",
        "long_name": "Mustang Bio, Inc.",
        "summary": "Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase 1/2 clinical trials. The company also develops MB-102, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; MB-106 for immunotherapy of B-cell lymphomas; MB-104, an NK cell receptor regulating immune functions; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has a license agreement with Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center, Inc. to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Worcester"
    },
    "MBRX": {
        "short_name": "Moleculin Biotech, Inc.",
        "long_name": "Moleculin Biotech, Inc.",
        "summary": "Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. The company has partnerships and collaboration agreement with The University of Texas MD Anderson Cancer Center, Emory University, Mayo Clinic Research Endeavor, The University of Iowa, Medical University of Gdansk, University of Bergen, DERMIN Sp. z o. o., and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Houston"
    },
    "MBW.F": {
        "short_name": "MEDICAL + BIOLOGIC.",
        "long_name": "Medical & Biological Laboratories Co., Ltd.",
        "summary": "Medical & Biological Laboratories Co., Ltd. researches, develops, manufactures, and sells in vitro diagnostics and research reagents worldwide. It offers in vitro diagnostics for allergies, autoimmune skin diseases, novel coronavirus, and polymyositis/dermatomyositis. The company was founded in 1969 and is headquartered in Nagoya, Japan. Medical & Biological Laboratories Co., Ltd. is a subsidiary of JSR Life Sciences, LLC.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Japan",
        "city": "Nagoya"
    },
    "MBX.TO": {
        "short_name": "MICROBIX J",
        "long_name": "Microbix Biosystems Inc.",
        "summary": "Microbix Biosystems Inc., a life science company, manufactures viral and bacterial antigens and reagents for the diagnostics industry worldwide. The company produces infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry. Its infectious disease antigens also used in controls for diagnostic assays, basic and applied research in virology, microbiology, cell biology, immunology, and pathology, or for vaccine and antiviral research and development. The company also provides quality assessment products, including PROCEEDx Verification/Validation samples, which are research use only products for use in test system IQ/OQ/PQ, verification/validation, and training; PTDx proficiency testing products; and REDx Controls, which are designed to enhance the diagnostic quality outcome by early detection of the deviations from desired assay performance. In addition, it develops Kinlytic Urokinase for injection, a thrombolytic biologic drug used to treat blood clots; and LumiSort cell-sorting, a technology for sorting of particles that could be used to enrich cell populations of interest, such as in sexing semen. The company also offers viral transport media that stabilize the organisms in patient samples. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Mississauga"
    },
    "MBXBF": {
        "short_name": "MICROBIX BIOSYSTEMS",
        "long_name": "Microbix Biosystems Inc.",
        "summary": "Microbix Biosystems Inc., a life science company, manufactures viral and bacterial antigens and reagents for the diagnostics industry worldwide. The company produces infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry. Its infectious disease antigens also used in controls for diagnostic assays, basic and applied research in virology, microbiology, cell biology, immunology, and pathology, or for vaccine and antiviral research and development. The company also provides quality assessment products, including PROCEEDx Verification/Validation samples, which are research use only products for use in test system IQ/OQ/PQ, verification/validation, and training; PTDx proficiency testing products; and REDx Controls, which are designed to enhance the diagnostic quality outcome by early detection of the deviations from desired assay performance. In addition, it develops Kinlytic Urokinase for injection, a thrombolytic biologic drug used to treat blood clots; and LumiSort cell-sorting, a technology for sorting of particles that could be used to enrich cell populations of interest, such as in sexing semen. The company also offers viral transport media that stabilize the organisms in patient samples. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Mississauga"
    },
    "MCET": {
        "short_name": "MULTICELL TECHNOLOGIES INC",
        "long_name": "MultiCell Technologies, Inc.",
        "summary": "MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Woonsocket"
    },
    "MCRB": {
        "short_name": "Seres Therapeutics, Inc.",
        "long_name": "Seres Therapeutics, Inc.",
        "summary": "Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "MCUJF": {
        "short_name": "MEDICURE INC",
        "long_name": "Medicure Inc.",
        "summary": "Medicure Inc., a pharmaceutical company, engages in the research, development, and commercialization of therapies for the cardiovascular market in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia; and ReDS, a non-invasive medical device that provides measurement of lung fluid for the management of congestive heart failure, as well as Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. The company was founded in 1997 and is headquartered in Winnipeg, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Winnipeg"
    },
    "MCUR.CN": {
        "short_name": "MindCureHealth",
        "long_name": "Mind Cure Health Inc.",
        "summary": "Mind Cure Health Inc. engages in the development, manufacture, and distribution of a branded line of organic and functional mushroom powders. It also operates Mind Cure Health Center, which offers psychedelic-assisted mental health therapy to patients, as well as training to therapists. The company sells its products through online and retail stores in North America. Mind Cure Health Inc. was incorporated in 2020 and is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "MCURF": {
        "short_name": "MIND CURE HEALTH INC",
        "long_name": "Mind Cure Health Inc.",
        "summary": "Mind Cure Health Inc. engages in the development, manufacture, and distribution of a branded line of organic and functional mushroom powders. It also operates Mind Cure Health Center, which offers psychedelic-assisted mental health therapy to patients, as well as training to therapists. The company sells its products through online and retail stores in North America. Mind Cure Health Inc. was incorporated in 2020 and is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "MDC.AX": {
        "short_name": "MEDLAB FPO",
        "long_name": "Medlab Clinical Limited",
        "summary": "Medlab Clinical Limited, a medical research and development facility, engages in the nutraceutical products and pharmaceutical research businesses in Australia. The company develops bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, musculoskeletal muscle loss associated with ageing, and non-opioid pain management. It also provides nutraceuticals for anti-inflammatory, cardiovascular support, endocrine support, gastrointestinal support, immunological support, infants and toddlers, metabolic support, musculoskeletal support, neurological support, sports performance, urogenital support, and weight management, as well as for men, pregnancy, seniors, teenagers, and women support. Medlab Clinical Limited was founded in 2012 and is headquartered in Botany, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Alexandria"
    },
    "MDCLF": {
        "short_name": "MEDINCELL SA",
        "long_name": "MedinCell S.A.",
        "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Jacou"
    },
    "MDFZF": {
        "short_name": "MEDIFOCUS INC",
        "long_name": "Medifocus Inc.",
        "summary": "Medifocus, Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States. The company owns technology platforms, including Endo-thermotherapy platform, a catheter-based focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites; and Adaptive Phased Array (APA) Microwave Focusing platform, which directs focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It also offers Prolieve Thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia. In addition, the company is developing APA 1000, a minimally invasive breast cancer treatment system, which is in pivotal Phase-III clinical trials. The company has a license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy technology for the treatment of cancers and other diseases. Medifocus, Inc. is based in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "MDG1.DE": {
        "short_name": "MEDIGENE AG NA O.N.",
        "long_name": "Medigene AG",
        "summary": "Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development. It also focuses on DC vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Universit\u00c3\u00a9 de Montr\u00c3\u00a9al and Institute for Research in Immunology and Cancer \u00c2\u0097 Commercialization of Research, Canada; and with Cytovant Sciences Co. Ltd. and PHIO Pharmaceuticals Corp. It has operations in Europe, the United States, Greater China, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Munich"
    },
    "MDG1.F": {
        "short_name": "MEDIGENE AG NA O.N.",
        "long_name": "Medigene AG",
        "summary": "Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development. It also focuses on DC vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Universit\u00c3\u00a9 de Montr\u00c3\u00a9al and Institute for Research in Immunology and Cancer \u00c2\u0097 Commercialization of Research, Canada; and with Cytovant Sciences Co. Ltd. and PHIO Pharmaceuticals Corp. It has operations in Europe, the United States, Greater China, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Munich"
    },
    "MDG1.VI": {
        "short_name": "MEDIGENE AG",
        "long_name": "Medigene AG",
        "summary": "Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development. It also focuses on DC vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Universit\u00c3\u00a9 de Montr\u00c3\u00a9al and Institute for Research in Immunology and Cancer \u00c2\u0097 Commercialization of Research, Canada; and with Cytovant Sciences Co. Ltd. and PHIO Pharmaceuticals Corp. It has operations in Europe, the United States, Greater China, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "Munich"
    },
    "MDGEF": {
        "short_name": "MEDIGENE AG",
        "long_name": "Medigene AG",
        "summary": "Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development. It also focuses on DC vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Universit\u00c3\u00a9 de Montr\u00c3\u00a9al and Institute for Research in Immunology and Cancer \u00c2\u0097 Commercialization of Research, Canada; and with Cytovant Sciences Co. Ltd. and PHIO Pharmaceuticals Corp. It has operations in Europe, the United States, Greater China, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Munich"
    },
    "MDGL": {
        "short_name": "Madrigal Pharmaceuticals, Inc.",
        "long_name": "Madrigal Pharmaceuticals, Inc.",
        "summary": "Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) \u00c3\u009f-selective agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). It is also developing MGL-3745, a THR-\u00c3\u009f-selective small molecule that is in preclinical trials for the treatment of NASH and hyperlipidemia. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "West Conshohocken"
    },
    "MDKM": {
        "short_name": "MDECHEM INC",
        "long_name": "MDEChem, Inc.",
        "summary": "MDEChem, Inc. provides pharmaceutical and chemical products. The company offers MaxHeal skin restoration gel, a non-steroidal and anti-inflammatory compound that provides instant relief to minor cuts, scrapes, minor burns, sunburn, and abrasions, as well as soothe itchy bites from chiggers, mosquitoes, sand fleas, black flies, and other biting insects. It also provides SANDKLENE 950, a non-toxic chemical composition, which is used in the recovery of oil from tar/oil sands. The company was founded in 1996 and is based in Floresville, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Floresville"
    },
    "MDNA": {
        "short_name": "Medicenna Therapeutics Corp.",
        "long_name": "Medicenna Therapeutics Corp.",
        "summary": "Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "MDNA.TO": {
        "short_name": "MEDICENNA THERAPEUTICS CORP",
        "long_name": "Medicenna Therapeutics Corp.",
        "summary": "Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "MDWD": {
        "short_name": "MediWound Ltd.",
        "long_name": "MediWound Ltd.",
        "summary": "MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Yavne"
    },
    "MEB.F": {
        "short_name": "MEDINCELL S.A.  EO-,01",
        "long_name": "MedinCell S.A.",
        "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Jacou"
    },
    "MEDCL.PA": {
        "short_name": "MEDINCELL",
        "long_name": "MedinCell S.A.",
        "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Jacou"
    },
    "MEIP": {
        "short_name": "MEI Pharma, Inc.",
        "long_name": "MEI Pharma, Inc.",
        "summary": "MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "MEM.AX": {
        "short_name": "MEMPHASYS FPO",
        "long_name": "Memphasys Limited",
        "summary": "Memphasys Limited, a bio-separations company, develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that uses high quality sperm cells from semen samples for human assisted reproductive technologies for treating male factor infertility; hydrogels; and other polymer membranes to separate cells from fluids. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited was incorporated in 2006 and is headquartered in Homebush, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Homebush"
    },
    "MEOBF": {
        "short_name": "MESOBLAST LTD",
        "long_name": "Mesoblast Limited",
        "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Gr\u00c3\u00bcnenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "MESO": {
        "short_name": "Mesoblast Limited",
        "long_name": "Mesoblast Limited",
        "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Gr\u00c3\u00bcnenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "MFJ.F": {
        "short_name": "POLYNOVO LTD",
        "long_name": "PolyNovo Limited",
        "summary": "Polynovo Limited develops medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; breast devices in partnership with Establishment Labs; NovoSorb dermal beta cell implant in collaboration with BetaCell Technologies Pty Ltd; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is based in Port Melbourne, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Port Melbourne"
    },
    "MGNX": {
        "short_name": "MacroGenics, Inc.",
        "long_name": "MacroGenics, Inc.",
        "summary": "MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. MacroGenics, Inc. has strategic collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was founded in 2000 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Rockville"
    },
    "MGTA": {
        "short_name": "Magenta Therapeutics, Inc.",
        "long_name": "Magenta Therapeutics, Inc.",
        "summary": "Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies; and clinical trial collaboration with bluebird bio, Inc. to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "MGTX": {
        "short_name": "MeiraGTx Holdings plc",
        "long_name": "MeiraGTx Holdings plc",
        "summary": "MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "MINA.F": {
        "short_name": "SYNLOGIC INC.  DL-,001",
        "long_name": "Synlogic, Inc.",
        "summary": "Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "MIR.V": {
        "short_name": "MEDMIRA INC",
        "long_name": "MedMira Inc.",
        "summary": "MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America, the Caribbean, Europe, and the Asia Pacific. The company's research is focused on specific areas of the diagnostics market, such as rapid, point-of-care, and in vitro sectors. It offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. The company also provides Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis; and REVEALCOVID-19, an antibody test. In addition, it offers Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics. MedMira Inc. sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Halifax"
    },
    "MIRM": {
        "short_name": "Mirum Pharmaceuticals, Inc.",
        "long_name": "Mirum Pharmaceuticals, Inc.",
        "summary": "Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Foster City"
    },
    "MIST": {
        "short_name": "Milestone Pharmaceuticals Inc.",
        "long_name": "Milestone Pharmaceuticals Inc.",
        "summary": "Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montr\u00c3\u00a9al, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Montreal"
    },
    "MITO": {
        "short_name": "Stealth BioTherapeutics Corp.",
        "long_name": "Stealth BioTherapeutics Corp",
        "summary": "Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Cayman Islands",
        "city": "George Town"
    },
    "MLC.IR": {
        "short_name": "MALIN CORP. PLC",
        "long_name": "Malin Corporation plc",
        "summary": "Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Spain, rest of European Union, and internationally. It offers life-saving cell therapeutics for patients with high unmet medical need; biological therapies, which focuses on oncology, infectious, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health and onychomycosis. The company also develops, manufactures, and markets injectable drugs; discovers and develops drugs for protein misfolding diseases, such as Alzheimer's and Parkinson's diseases. In addition, it focuses on the therapeutics areas of autoimmune and inflammatory disease, immuno-oncology, haematology, and infectious diseases; and platform to eliminate disease-causing bacteria in the gut microbiota. Further, the company provides company secretarial services. Malin Corporation plc was incorporated in 2014 and is based in Dublin, Ireland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ISE",
        "market": "ie_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "MLLCF": {
        "short_name": "MOLECULAR PARTNERS AG",
        "long_name": "Molecular Partners AG",
        "summary": "Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Schlieren"
    },
    "MLND": {
        "short_name": "Millendo Therapeutics, Inc.",
        "long_name": "Millendo Therapeutics, Inc.",
        "summary": "Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Ann Arbor"
    },
    "MLPH": {
        "short_name": "MOLECULAR PHARMACOLOGY LIMITED",
        "long_name": "Molecular Pharmacology (USA), Ltd.",
        "summary": "Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in various dosage forms, formulations, line extensions, and package configurations. The company focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies in the United States and Europe. It also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmecutical products based on the ThermaLIFE product range and its active ingredient. The company is based in Perth, Australia. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Perth"
    },
    "MMED.NE": {
        "short_name": "MIND MEDICINE (MINDMED) INC.",
        "long_name": "Mind Medicine (MindMed) Inc.",
        "summary": "Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NEO",
        "market": "ca_market",
        "country": "United States",
        "city": "New York"
    },
    "MMEDF": {
        "short_name": "MIND MEDICINE (MINDMED) INC",
        "long_name": "Mind Medicine (MindMed) Inc.",
        "summary": "Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "MMIA.F": {
        "short_name": "MEI PHARMA INC.",
        "long_name": "MEI Pharma, Inc.",
        "summary": "MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "MNKD": {
        "short_name": "MannKind Corporation",
        "long_name": "MannKind Corporation",
        "summary": "MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Westlake Village"
    },
    "MNOV": {
        "short_name": "MediciNova, Inc.",
        "long_name": "MediciNova, Inc.",
        "summary": "MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "La Jolla"
    },
    "MNPR": {
        "short_name": "Monopar Therapeutics Inc.",
        "long_name": "Monopar Therapeutics Inc.",
        "summary": "Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Espa\u00c3\u00b1ol de Investigaci\u00c3\u00b3n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Wilmette"
    },
    "MOLN.SW": {
        "short_name": "MOLECULAR PARTNERS N",
        "long_name": "Molecular Partners AG",
        "summary": "Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Schlieren"
    },
    "MOR": {
        "short_name": "MorphoSys AG",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MOR.DE": {
        "short_name": "MORPHOSYS AG O.N.",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MOR.F": {
        "short_name": "MORPHOSYS AG O.N.",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MOR.VI": {
        "short_name": "MORPHOSYS AG",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MOR2.F": {
        "short_name": "MORPHOSYS AG SP.ADR(TEMP)",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MORF": {
        "short_name": "Morphic Holding, Inc.",
        "long_name": "Morphic Holding, Inc.",
        "summary": "Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral av\u00c3\u009f6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4\u00c3\u009f7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD). The company is also developing MR \u00c3\u009f6 #2, a selective av\u00c3\u009f6 specific integrin inhibitor to treat IPF and PSC; and av\u00c3\u009f1 integrin for the treatment of fibrosis. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schr\u00c3\u00b6dinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics; and drug discovery research collaboration with HitGen Inc. to identify small molecule leads against targets specified by the company. The company was founded in 2014 and is based in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "MPHMF": {
        "short_name": "CALLITAS HEALTH INC",
        "long_name": "Callitas Health Inc.",
        "summary": "Callitas Health Inc. provides over the counter consumer health and wellness products in the United States and Canada. It offers C-103, a reformulation of Orlistat for the treatment of obesity; ToConceive, a fertility enhancing moisturizer; and Extrinsa for female sexual dysfunction solutions, as well as focuses on developing cannabinoid delivery technologies. The company was formerly known as M Pharmaceutical Inc. and changed its name to Callitas Health Inc. in September 2017. Callitas Health Inc. was founded in 2003 and is headquartered in Newport, Kentucky.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Newport"
    },
    "MPSYF": {
        "short_name": "MORPHOSYS",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MREO": {
        "short_name": "Mereo BioPharma Group plc",
        "long_name": "Mereo BioPharma Group plc",
        "summary": "Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "MRES": {
        "short_name": "INSTITUTE BIOMEDICAL RESH CORP",
        "long_name": "Institute of Biomedical Research Corp.",
        "summary": "Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internationally. Its services include regulatory control of industrial activities and products; scientific surveillance of the living environment; research and development of biomedical products and technologies; regulatory evaluation and certification of biomedical products; fundamental scientific research; and development of new diagnostic methods and experimental medical treatments. The company also researchers and develops new biomedical and food products; provides programs for graduate research studies in biomedical and environmental fields; offers two channel analog NMS, digital muscle stimulator, digital TENS, interferential, elite combination, portable four channel digital, portable ultra sound, and other healthcare devices; and provides photon red light for beauty, electric pain relief products, microcurrent electrical nerve stimulators, and high volt pulsed stimulators. In addition, it develops and commercializes microbicidal agents; disinfectant products; bandages for large burns, hard surface disinfection, microbicidal treatment of fabrics and textile products, insecticides against bed bugs and other textile goods, microbicidal towels, and mouthwash products; Purilair, an appliance that sterilizes compressed air circulating within medical instruments; colloidal silver and electro medical devices; and BioStim INF that is used for edema reduction, pain relief, and total treatment. Further, the company provides quality control, regulatory, healthcare, environmental services, environmental analysis, building decontamination, and environmental protection and management services; and regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was founded in 2010 and is based in Podgorica, Montenegro with a representative office in Montreal, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Montenegro",
        "city": "Podgorica"
    },
    "MRKR": {
        "short_name": "Marker Therapeutics, Inc.",
        "long_name": "Marker Therapeutics, Inc.",
        "summary": "Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Houston"
    },
    "MRNA": {
        "short_name": "Moderna, Inc.",
        "long_name": "Moderna, Inc.",
        "summary": "Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "MRNA.MX": {
        "short_name": "MODERNA INC",
        "long_name": "Moderna, Inc.",
        "summary": "Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "MRNS": {
        "short_name": "Marinus Pharmaceuticals, Inc.",
        "long_name": "Marinus Pharmaceuticals, Inc.",
        "summary": "Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti seizure, antidepressant, and anxiolytic actions through its effects on. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment resistant depression. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Radnor"
    },
    "MRNS.MX": {
        "short_name": "MARINUS PHARMACEUTICALS INC",
        "long_name": "Marinus Pharmaceuticals, Inc.",
        "summary": "Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti seizure, antidepressant, and anxiolytic actions through its effects on. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment resistant depression. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Radnor"
    },
    "MRPI": {
        "short_name": "MERA PHARMACEUTICALS INC",
        "long_name": "Mera Pharmaceuticals, Inc.",
        "summary": "Mera Pharmaceuticals, Inc. primarily develops and commercializes natural products derived principally from microalgae using its patented photobioreactor technology. It produces various substances and bioactive compounds that have applications in a range of commercial areas, including human nutrition, pharmaceuticals, and other commodities, such as bio-diesel. The company's products include ASTAFACTOR, a nutraceutical and source of natural astaxanthin; SALMON ESSENTIALS, a combination of astaxanthin and omega-3 fatty acids; and KONA SEA SALT. It markets its products to mass retail outlets in Hawaii through distribution arrangements with companies. The company also operates a chain of professional martial arts studios. Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Pembroke Pines, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Pembroke Pines"
    },
    "MRSN": {
        "short_name": "Mersana Therapeutics, Inc.",
        "long_name": "Mersana Therapeutics, Inc.",
        "summary": "Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "MRTX": {
        "short_name": "Mirati Therapeutics, Inc.",
        "long_name": "Mirati Therapeutics, Inc.",
        "summary": "Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "MRUS": {
        "short_name": "Merus N.V.",
        "long_name": "Merus N.V.",
        "summary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations with Caris Life Sciences to detect NRG1 fusions in cancer patients; and Loxo Oncology at Lilly to discover novel T-Cell Re-directing bispecific antibodies. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Utrecht"
    },
    "MRVI": {
        "short_name": "Maravai LifeSciences Holdings, ",
        "long_name": "Maravai LifeSciences Holdings, Inc.",
        "summary": "Maravai LifeSciences Holdings, Inc. operates as a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products used in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry. The company serves biopharmaceutical companies, and other emerging biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "MRZM": {
        "short_name": "MARIZYME INC",
        "long_name": "Marizyme, Inc.",
        "summary": "Marizyme, Inc., a development stage company, focuses on life sciences or biotechnology businesses. It focuses on commercializing therapies that address the urgent needs relating to acute care space. The company was formerly known as GBS Enterprises Incorporated. Marizyme, Inc. was incorporated in 2007 and is based in Davenport, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Davenport"
    },
    "MSB.AX": {
        "short_name": "MESOBLAST FPO",
        "long_name": "Mesoblast Limited",
        "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Gr\u00c3\u00bcnenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "MSET.CN": {
        "short_name": "MindsetPharma",
        "long_name": "Mindset Pharma Inc.",
        "summary": "Mindset Pharma Inc. operates as a neuro-pharmaceutical drug discovery and development platform company. It offers psychedelic compounds for treatment-resistant neurological and psychiatric disorders. The company is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "MTCR": {
        "short_name": "Metacrine, Inc.",
        "long_name": "Metacrine, Inc.",
        "summary": "Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases in the United States. It is developing MET409, a therapy that is in a Phase Ib proof-of-concept clinical trial for the treatment of non-alcoholic steatohepatitis patients; and MET642, a candidate, which is in Phase 1 clinical trial for the treatment of non-alcoholic steatohepatitis patients. The company has a research collaboration with Novo Nordisk A/S to perform research activities related to fibroblast growth factor 1. Metacrine, Inc. was founded in 2014 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "MTEM": {
        "short_name": "Molecular Templates, Inc.",
        "long_name": "Molecular Templates, Inc.",
        "summary": "Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies. The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted conditioning regimens to enhance the hematopoietic stem cell transplant process. Molecular Templates, Inc. is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "MTNB": {
        "short_name": "Matinas Biopharma Holdings, Inc",
        "long_name": "Matinas BioPharma Holdings, Inc.",
        "summary": "Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Bedminster"
    },
    "MTP": {
        "short_name": "Midatech Pharma PLC",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "MTPH.L": {
        "short_name": "MIDATECH PHARMA PLC ORD 0.1P",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "MTST": {
        "short_name": "METASTAT INC",
        "long_name": "MetaStat, Inc.",
        "summary": "MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company's therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "MVIR-B.ST": {
        "short_name": "Medivir AB ser. B",
        "long_name": "Medivir AB (publ)",
        "summary": "Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; MIV-828, a candidate drug for treating blood cancer; MIV-711, which is in phase II clinical trial for treating osteoarthritis; and MIV-802, a nucleotide-based drug candidate for treating hepatitis C infections. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform and SciLifeLab for the discovery of antivirals for SARS CoV-2. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Huddinge"
    },
    "MVR.F": {
        "short_name": "MEDIVIR AB B  SK 10",
        "long_name": "Medivir AB (publ)",
        "summary": "Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; MIV-828, a candidate drug for treating blood cancer; MIV-711, which is in phase II clinical trial for treating osteoarthritis; and MIV-802, a nucleotide-based drug candidate for treating hepatitis C infections. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform and SciLifeLab for the discovery of antivirals for SARS CoV-2. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Huddinge"
    },
    "MWG.F": {
        "short_name": "INMED PHARMACEUT.",
        "long_name": "InMed Pharmaceuticals Inc.",
        "summary": "InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "MYMX": {
        "short_name": "MYMETICS CORPORATION",
        "long_name": "Mymetics Corporation",
        "summary": "Mymetics Corporation, a vaccine company, focuses on research and developing vaccines for infectious diseases in Switzerland. The company's product pipeline includes vaccine candidates, such as HIV-1/AIDS, intra nasal influenza, malaria, and chikungunya. It has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative; the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; RSV Corporation for developing the RSV vaccine; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Epalinges"
    },
    "MYOV": {
        "short_name": "Myovant Sciences Ltd.",
        "long_name": "Myovant Sciences Ltd.",
        "summary": "Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "N04A.F": {
        "short_name": "NUCANA  SP.ADR 1/ LS-,04",
        "long_name": "NuCana plc",
        "summary": "NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Edinburgh"
    },
    "N4CN.F": {
        "short_name": "PARATEK PHARMAC.  DL-,001",
        "long_name": "Paratek Pharmaceuticals, Inc.",
        "summary": "Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boston"
    },
    "NANO.PA": {
        "short_name": "NANOBIOTIX",
        "long_name": "Nanobiotix S.A.",
        "summary": "Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "NANOFS.ST": {
        "short_name": "Nanoform Finland Oyj",
        "long_name": "Nanoform Finland Oyj",
        "summary": "Nanoform Finland Oy provides nanotechnology and drug particle engineering services for the pharmaceutical and biotechnology industries in Finland and internationally. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients in the creation of active pharmaceutical ingredients nanoparticles directly from solution. Its technology and services help in increasing the bioavailability of drug molecules and developing new drugs. The company was founded in 2015 and is headquartered in Helsinki, Finland.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Finland",
        "city": "Helsinki"
    },
    "NAVB": {
        "short_name": "Navidea Biopharmaceuticals, Inc",
        "long_name": "Navidea Biopharmaceuticals, Inc.",
        "summary": "Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a collaboration agreement with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Dublin"
    },
    "NB11.DE": {
        "short_name": "VAXART INC.  DL-,10",
        "long_name": "Vaxart, Inc.",
        "summary": "Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. Vaxart, Inc. is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "NB11.F": {
        "short_name": "VAXART INC.  DL-,10",
        "long_name": "Vaxart, Inc.",
        "summary": "Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. Vaxart, Inc. is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "NBCO": {
        "short_name": "NEON BLOOM INC",
        "long_name": "Neon Bloom, Inc.",
        "summary": "Neon Bloom, Inc. is a principal investment firm specializing in acquisitions. The firm primarily invests in innovative agriculture and ancillary technology products and services across the globe. Neon Bloom, Inc was founded in 2015 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "NBIO": {
        "short_name": "NASCENT BIOTECH INC",
        "long_name": "Nascent Biotech, Inc.",
        "summary": "Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer. The company has a research collaboration agreement with Manhattan BioSolutions, Inc. to initiate a vaccine program for the prevention of COVID-19 or other viral infections; and a collaboration with Hoag Family Cancer Institute and Pickup Family Neurosciences Institute for the testing of antibody brain cancer drug. The company is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "NBIX": {
        "short_name": "Neurocrine Biosciences, Inc.",
        "long_name": "Neurocrine Biosciences, Inc.",
        "summary": "Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL \u00c2\u0096 Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "NBRV": {
        "short_name": "Nabriva Therapeutics plc",
        "long_name": "Nabriva Therapeutics plc",
        "summary": "Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "NBSE": {
        "short_name": "NeuBase Therapeutics, Inc.",
        "long_name": "NeuBase Therapeutics, Inc.",
        "summary": "NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Pittsburgh"
    },
    "NBTX": {
        "short_name": "Nanobiotix S.A.",
        "long_name": "Nanobiotix S.A.",
        "summary": "Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "NBY": {
        "short_name": "NovaBay Pharmaceuticals, Inc.",
        "long_name": "NovaBay Pharmaceuticals, Inc.",
        "summary": "NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "EmeryVille"
    },
    "NBYB.SG": {
        "short_name": "Northwest Biotherapeutics Inc.R",
        "long_name": "Northwest Biotherapeutics, Inc.",
        "summary": "Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L that is in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, which is in Phase I/II clinical trials to treat various inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Bethesda"
    },
    "NC6.AX": {
        "short_name": "NANOLLOSE FPO",
        "long_name": "Nanollose Limited",
        "summary": "Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. It focuses on the development of Nullarbor, a plant-free viscose-rayon fibre. The company's products are used in textiles, nonwoven fabric, and other industries. Nanollose Limited was founded in 2014 and is based in Nedlands, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Nedlands"
    },
    "NCNA": {
        "short_name": "NuCana plc",
        "long_name": "NuCana plc",
        "summary": "NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Edinburgh"
    },
    "NEON.CN": {
        "short_name": "NeonmindBio",
        "long_name": "NeonMind Biosciences Inc.",
        "summary": "NeonMind Biosciences Inc. engages in the discovery, development, and commercialization of medicinal and psychedelic mushrooms for mental illnesses. It is developing psilocybin based products comprising mushroom-infused beverages and other mushroom-infused products to treat weight loss and management, depression, cardiovascular, obesity, diabetes, and heart diseases. The company was formerly known as Flourish Mushroom Labs Inc. and changed its name to NeonMind Biosciences Inc. in April 2020. NeonMind Biosciences Inc. was incorporated in 2019 and is headquartered in Vancouver, Canada. NeonMind Biosciences Inc. is a subsidiary of The Yield Growth Corp.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "NERV": {
        "short_name": "Minerva Neurosciences, Inc",
        "long_name": "Minerva Neurosciences, Inc.",
        "summary": "Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "NEU.AX": {
        "short_name": "NEUREN FPO NZ",
        "long_name": "Neuren Pharmaceuticals Limited",
        "summary": "Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Camberwell"
    },
    "NFX.L": {
        "short_name": "NUFORMIX PLC ORD 0.1P",
        "long_name": "Nuformix plc",
        "summary": "Nuformix plc, a pharmaceutical development company, develops drugs using cocrystal technology in the United Kingdom. Its lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. The company is also developing NXP004, which is under the pre-clinical stage for the treatment of multiple forms of fibrosis in various human tissues. It has an agreement with VistaGen Therapeutics, Inc. to develop co-crystal-based formulations of AV-101 for the treatment of various central nervous system conditions. The company also has an option agreement with Oxilio Ltd. to provide consultancy services for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "NGEN.V": {
        "short_name": "NERVGEN PHARMA CORP",
        "long_name": "NervGen Pharma Corp.",
        "summary": "NervGen Pharma Corp., a biotech company, discovers and develops treatments for patients suffering from medical conditions related to nerve damage. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "NGENF": {
        "short_name": "NERVGEN PHARMA CORP",
        "long_name": "NervGen Pharma Corp.",
        "summary": "NervGen Pharma Corp., a biotech company, discovers and develops treatments for patients suffering from medical conditions related to nerve damage. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "NGM": {
        "short_name": "NGM Biopharmaceuticals, Inc.",
        "long_name": "NGM Biopharmaceuticals, Inc.",
        "summary": "NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "NGQ1.F": {
        "short_name": "MEDICURE INC.",
        "long_name": "Medicure Inc.",
        "summary": "Medicure Inc., a pharmaceutical company, engages in the research, development, and commercialization of therapies for the cardiovascular market in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia; and ReDS, a non-invasive medical device that provides measurement of lung fluid for the management of congestive heart failure, as well as Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. The company was founded in 1997 and is headquartered in Winnipeg, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Winnipeg"
    },
    "NGRC": {
        "short_name": "NATIONAL GRAPHITE CORP",
        "long_name": "National Graphite Corp.",
        "summary": "National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications. National Graphite Corp. has a collaboration agreement with Proteo Inc. for developing ELAFIN. The company was formerly known as Lucky Boy Silver Corporation and changed its name to National Graphite Corp. in May 2012. National Graphite Corp. was founded in 2006 and is based in Duesseldorf, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Duesseldorf"
    },
    "NICXF": {
        "short_name": "NICOX SA",
        "long_name": "Nicox S.A.",
        "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Valbonne"
    },
    "NJTC.F": {
        "short_name": "POLARITYTE INC.  DL-,001",
        "long_name": "PolarityTE, Inc.",
        "summary": "PolarityTE, Inc., a biotechnology and regenerative biomaterials company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "NK": {
        "short_name": "NantKwest, Inc.",
        "long_name": "NantKwest, Inc.",
        "summary": "NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "NKB2.F": {
        "short_name": "TG THERAPEUTICS  DL -,001",
        "long_name": "TG Therapeutics, Inc.",
        "summary": "TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL); and Ublituximab, an investigational glycoengineered monoclonal antibody that targets a epitope on CD20-expressing B cells for patients with NHL, CLL, and relapsing forms of multiple sclerosis. In addition, the company develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. It is also has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "NKTR": {
        "short_name": "Nektar Therapeutics",
        "long_name": "Nektar Therapeutics",
        "summary": "Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "NKTX": {
        "short_name": "Nkarta, Inc.",
        "long_name": "Nkarta, Inc.",
        "summary": "Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "NMTR": {
        "short_name": "9 Meters Biopharma, Inc.",
        "long_name": "9 Meters Biopharma, Inc.",
        "summary": "9 Meters Biopharma, Inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Raleigh"
    },
    "NNBP": {
        "short_name": "NANOBAC PHARMACEUTICALS INC",
        "long_name": "Nanobac Pharmaceuticals, Incorporated",
        "summary": "Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as cardiovascular diseases. Nanobac Pharmaceuticals, Incorporated was formerly known as HealthCentrics Inc. and changed its name to Nanobac Pharmaceuticals, Incorporated in December 2002. The company was founded in 1994 and is based in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Tampa"
    },
    "NNFN.F": {
        "short_name": "MANNKIND CORP. NEW DL-,01",
        "long_name": "MannKind Corporation",
        "summary": "MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Westlake Village"
    },
    "NNLX": {
        "short_name": "NANOLOGIX INC",
        "long_name": "NanoLogix, Inc.",
        "summary": "NanoLogix, Inc., a biotechnology company, provides live cell and rapid diagnostics test kits that detects viable bacteria and other microorganisms. The company's products include BioNanoPore kit, which employs a water permeable membrane that works with organic and inorganic molecules, as well as proteins; and FlatPack Petri Plates that are used for the isolation and cultivation of various fastidious and non-fastidious microorganisms, as well as displays growth of aerobic and anaerobic microorganisms. Its products are used in medical, national defense, homeland security, pharmaceutical, industrial, veterinary, and environmental testing applications. The company sells its products to established medical and scientific entities, including laboratories, medical institutions, universities, businesses, and research establishments. NanoLogix, Inc. is based in Hubbard, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Hubbard"
    },
    "NNOR.VI": {
        "short_name": "NOVO-NORDISK AS",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "NNVC": {
        "short_name": "NanoViricides, Inc.",
        "long_name": "NanoViricides, Inc.",
        "summary": "NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of all types of Dengue viruses; and HIVCide that is an escape-resistant anti-HIV nanoviricide. In addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Shelton"
    },
    "NO1A.F": {
        "short_name": "NAVIDEA BIOPHARM. DL-,001",
        "long_name": "Navidea Biopharmaceuticals, Inc.",
        "summary": "Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a collaboration agreement with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Dublin"
    },
    "NONOF": {
        "short_name": "NOVO NORDISK A/S",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "NOVC.F": {
        "short_name": "NOVO-NORDISK NAM.B DK-,20",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "NOVN": {
        "short_name": "Novan, Inc.",
        "long_name": "Novan, Inc.",
        "summary": "Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, a topical anti-viral product candidate. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was founded in 2006 and is headquartered in Morrisville, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Morrisville"
    },
    "NOVO-B.CO": {
        "short_name": "Novo Nordisk B A/S",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "NOX.AX": {
        "short_name": "NOXOPHARM FPO",
        "long_name": "Noxopharm Limited",
        "summary": "Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors; and LuPIN for the combined therapy of Veyonda and 177Lu-PSMA-617. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock. The company was incorporated in 2015 and is based in Gordon, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Gordon"
    },
    "NOXOF": {
        "short_name": "NOXOPHARM LTD",
        "long_name": "Noxopharm Limited",
        "summary": "Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors; and LuPIN for the combined therapy of Veyonda and 177Lu-PSMA-617. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock. The company was incorporated in 2015 and is based in Gordon, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Gordon"
    },
    "NP5.F": {
        "short_name": "NEWRON PHARMACEUT. EO-,20",
        "long_name": "Newron Pharmaceuticals S.p.A.",
        "summary": "Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Italy",
        "city": "Bresso"
    },
    "NPAU.F": {
        "short_name": "BETTERLIFE PHARMA INC.",
        "long_name": "BetterLife Pharma Inc.",
        "summary": "BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumours to treat various types of cancer. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was founded in 2002 and is headquartered in Vancouver, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "NPHC": {
        "short_name": "NUTRA PHARMA CORP",
        "long_name": "Nutra Pharma Corp.",
        "summary": "Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia, as well as a topical gel for treating joint pain, neck pain, arthritis pain, and pain associated with repetitive stress; Pet Pain-Away, an over-the-counter pain reliever to treat pain in cats and dogs; Luxury Feet, an over-the-counter pain reliever to treat foot pain from high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Nyloxin, a topical therapy for chronic pain in horses. It is also developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases, including human immunodeficiency virus/AIDS and herpes; RPI-78 for pain and arthritis; and RPI-70 for pain. The company has a collaboration agreement with the International Security Group to develop nerve agent counter measures. Nutra Pharma Corp. was founded in 2000 and is based in Coral Springs, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Coral Springs"
    },
    "NPTX": {
        "short_name": "NEUROPATHIX INC",
        "long_name": "Neuropathix, Inc.",
        "summary": "Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary cannabinoid product platform. It engages in the research and development of chemical entities, such as KLS-13019, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of overt hepatic encephalopathy, chronic traumatic encephalopathy, and chemotherapy induced peripheral neuropathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Doylestown"
    },
    "NRBO": {
        "short_name": "NeuroBo Pharmaceuticals, Inc.",
        "long_name": "NeuroBo Pharmaceuticals, Inc.",
        "summary": "NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "NRIX": {
        "short_name": "Nurix Therapeutics, Inc.",
        "long_name": "Nurix Therapeutics, Inc.",
        "summary": "Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "NSB.AX": {
        "short_name": "NEUROSCIEN FPO",
        "long_name": "NeuroScientific Biopharmaceuticals Limited",
        "summary": "NeuroScientific Biopharmaceuticals Limited develops diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Cottesloe, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Nedlands"
    },
    "NSCI.L": {
        "short_name": "NETSCIENTIFIC PLC ORD 5P",
        "long_name": "NetScientific plc",
        "summary": "NetScientific plc is a venture capital firm specializing in seed, early and mid stage investments. The firm focuses to invest in transformative biomedical and healthcare technologies focusing on digital health, diagnostics, and therapeutics sectors. It also prefers to invest in companies that significantly improve the health and well-being of people with chronic diseases. Within digital health it focuses on data analytics, wearable technologies, and devices. The firm seeks to invest in companies based in European developed markets and in the United States. It typically invests up to $15 million, but may consider larger amounts. It prefers to hold a controlling interest in all principal subsidiaries. The firm prefers to invest through its balance sheet investments. NetScientific plc was founded in 2008 and is based in London, United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "NSHS.CN": {
        "short_name": "NanoSphereHlth",
        "long_name": "NanoSphere Health Sciences Inc.",
        "summary": "Nanosphere Health Sciences Inc., a nano-biotechnology company, focuses on providing next generation delivery of biologically active compounds in the United States. Its nanoencapsulation technology delivers nutritive elements and medicants through licensing arrangements. The company was incorporated in 2005 is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "NSP.V": {
        "short_name": "NATURALLY SPLENDID ENTERPRISES ",
        "long_name": "Naturally Splendid Enterprises Ltd.",
        "summary": "Naturally Splendid Enterprises Ltd., a biotechnology and consumer products company, develops, produces, commercializes, sells, and licenses plant-derived, bio-active ingredients, nutrient dense foods, and related products in Canada, Japan, South Korea, Thailand, and Western Europe. The company offers nutrition for athletes under the Natera Sport brand; food energy bars under the WOODS WILD BAR; healthy snack bars under the ELEVATE ME brand; hemp for health under the CHII brand; products for dogs under the PawsitiveFX brand; and hemp and plant-based natural health products under the Natera FX brand. It also provides hemp processing, manufacturing, private label, and CBD extraction services; and distributes lifestyle and healthy meal replacement products. The company sells food and ingredients to commercial processors and consumers through grocery stores, health and nutrition stores, and online. Naturally Splendid Enterprises Ltd. was incorporated in 2010 and is headquartered in Pitt Meadows, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Pitt Meadows"
    },
    "NSPDF": {
        "short_name": "NATURALLY SPLENDID ENTERPRISES ",
        "long_name": "Naturally Splendid Enterprises Ltd.",
        "summary": "Naturally Splendid Enterprises Ltd., a biotechnology and consumer products company, develops, produces, commercializes, sells, and licenses plant-derived, bio-active ingredients, nutrient dense foods, and related products in Canada, Japan, South Korea, Thailand, and Western Europe. The company offers nutrition for athletes under the Natera Sport brand; food energy bars under the WOODS WILD BAR; healthy snack bars under the ELEVATE ME brand; hemp for health under the CHII brand; products for dogs under the PawsitiveFX brand; and hemp and plant-based natural health products under the Natera FX brand. It also provides hemp processing, manufacturing, private label, and CBD extraction services; and distributes lifestyle and healthy meal replacement products. The company sells food and ingredients to commercial processors and consumers through grocery stores, health and nutrition stores, and online. Naturally Splendid Enterprises Ltd. was incorporated in 2010 and is headquartered in Pitt Meadows, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Pitt Meadows"
    },
    "NSPX": {
        "short_name": "INSPYR THERAPEUTIC",
        "long_name": "Inspyr Therapeutics, Inc.",
        "summary": "Inspyr Therapeutics, Inc., clinical-stage pharmaceutical company, focuses on the development of therapeutics for the treatment of diseases. It focuses on a pipeline of small molecule adenosine receptor modulators, such as A2B antagonists, dual A2A/A2B antagonists, and A2A agonists. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Westlake Village"
    },
    "NSTG": {
        "short_name": "NanoString Technologies, Inc.",
        "long_name": "NanoString Technologies, Inc.",
        "summary": "NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and pan cancer and 360 gene expression, CAR-T characterization, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, miRNA expression, human organ transplant, human and mouse metabolic pathway, and human and mouse fibrosis panels. Further, the company offers nCounter based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics; and Hyb & Seq molecular profiling system to determine and analyze gene sequences within biological samples. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; Astellas Pharma, Inc.; and Oregon Health & Science University for the development of novel GeoMx\u00c2\u00ae Digital Spatial Profiler protein assays to spatially profile breast cancer. NanoString Technologies, Inc. was founded in 2003 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "NTEC": {
        "short_name": "Intec Pharma Ltd.",
        "long_name": "Intec Pharma Ltd",
        "summary": "Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program; and a feasibility agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Israel",
        "city": "Jerusalem"
    },
    "NTII": {
        "short_name": "NEUROBIOLOGICAL TECHNOLOGIES IN",
        "long_name": "Neurobiological Technologies, Inc.",
        "summary": "Neurobiological Technologies, Inc. operates under a plan of liquidation and dissolution approved by stockholders in October 2009. Previously, it focused on developing investigational drugs for the treatment of human diseases. The company was founded in 1987 and is based in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Emeryville"
    },
    "NTLA": {
        "short_name": "Intellia Therapeutics, Inc.",
        "long_name": "Intellia Therapeutics, Inc.",
        "summary": "Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "NTRB": {
        "short_name": "NUTRIBAND INC",
        "long_name": "Nutriband Inc.",
        "summary": "Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. Its product line consists of an energy patch line; a weight management patch line; a multivitamin patch line; a children's multivitamin patch line; an amino acid patch line; an anti-wrinkle patch line; an insect repellant patch line; a detox patch line; a PMS patch line; a sleep patch line; and a nausea and motion sickness patch line. The company was incorporated in 2016 and is headquartered in Orlando, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Orlando"
    },
    "NTRR": {
        "short_name": "NEUTRA CORP",
        "long_name": "Neutra Corp.",
        "summary": "Neutra Corp., through its subsidiaries, provides hemp-based health and nutritional products. It offers CBD tincture, lotion, and salve. The company was founded in 2011 and is based in Sugar Land, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Sugar Land"
    },
    "NURPF": {
        "short_name": "NEUREN PHARMACEUTICALS LTD",
        "long_name": "Neuren Pharmaceuticals Limited",
        "summary": "Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Camberwell"
    },
    "NV4P.F": {
        "short_name": "CELLECTAR BIOSC.DL-,00001",
        "long_name": "Cellectar Biosciences, Inc.",
        "summary": "Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Florham Park"
    },
    "NV9.F": {
        "short_name": "KAZIA THERAPEUTICS",
        "long_name": "Kazia Therapeutics Limited",
        "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "NV9M.F": {
        "short_name": "KAZIA THER.LTD.ADR 10 NEW",
        "long_name": "Kazia Therapeutics Limited",
        "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "NVAX": {
        "short_name": "Novavax, Inc.",
        "long_name": "Novavax, Inc.",
        "summary": "Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Gaithersburg"
    },
    "NVAX.MX": {
        "short_name": "NOVAVAX INC",
        "long_name": "Novavax, Inc.",
        "summary": "Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Gaithersburg"
    },
    "NVIV": {
        "short_name": "InVivo Therapeutics Holdings Co",
        "long_name": "InVivo Therapeutics Holdings Corp.",
        "summary": "InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "NVO": {
        "short_name": "Novo Nordisk A/S",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "NVON.MX": {
        "short_name": "NOVO NORDISK A/S",
        "long_name": "Novo Nordisk A/S",
        "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "Denmark",
        "city": "Bagsvaerd"
    },
    "NVV1.F": {
        "short_name": "NOVAVAX INC.  DL-,01",
        "long_name": "Novavax, Inc.",
        "summary": "Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Gaithersburg"
    },
    "NWBO": {
        "short_name": "NORTHWEST BIOTHERAPEUTICS INC",
        "long_name": "Northwest Biotherapeutics, Inc.",
        "summary": "Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L that is in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, which is in Phase I/II clinical trials to treat various inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Bethesda"
    },
    "NWPHF": {
        "short_name": "NEWRON PHARMACEUTICALS S.P.A.",
        "long_name": "Newron Pharmaceuticals S.p.A.",
        "summary": "Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Italy",
        "city": "Bresso"
    },
    "NWRN.SW": {
        "short_name": "NEWRON PHARMA N",
        "long_name": "Newron Pharmaceuticals S.p.A.",
        "summary": "Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Italy",
        "city": "Bresso"
    },
    "NXEN.F": {
        "short_name": "SEELOS THERAPEUT. DL-,001",
        "long_name": "Seelos Therapeutics, Inc.",
        "summary": "Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "NXOA.F": {
        "short_name": "NICOX SA INH.  EO 1",
        "long_name": "Nicox S.A.",
        "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Valbonne"
    },
    "NXTC": {
        "short_name": "NextCure, Inc.",
        "long_name": "NextCure, Inc.",
        "summary": "NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Beltsville"
    },
    "NXTCL.ST": {
        "short_name": "NextCell Pharma AB",
        "long_name": "NextCell Pharma AB",
        "summary": "NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases, as well as for use in kidney transplants. It also provides a service under the Cellaviva brand name, which is a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. The company has a partnership with Bonzun Health Information AB. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Huddinge"
    },
    "NYM.F": {
        "short_name": "NYMOX PHARMACEUT.",
        "long_name": "Nymox Pharmaceutical Corporation",
        "summary": "Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company operates in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Bahamas",
        "city": "Nassau"
    },
    "NYMX": {
        "short_name": "Nymox Pharmaceutical Corporatio",
        "long_name": "Nymox Pharmaceutical Corporation",
        "summary": "Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company operates in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Bahamas",
        "city": "Nassau"
    },
    "NYR.AX": {
        "short_name": "NYRADA CDI FORUS",
        "long_name": "Nyrada Inc.",
        "summary": "Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. The company was founded in 2017 and is based in Gordon, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Gordon"
    },
    "NZW2.F": {
        "short_name": "MOLECULAR TEMPLAT.DL-,001",
        "long_name": "Molecular Templates, Inc.",
        "summary": "Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies. The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted conditioning regimens to enhance the hematopoietic stem cell transplant process. Molecular Templates, Inc. is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Austin"
    },
    "O1P.F": {
        "short_name": "OSMOTICA PHARMAC.  DL-,01",
        "long_name": "Osmotica Pharmaceuticals plc",
        "summary": "Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Bridgewater"
    },
    "O2T.F": {
        "short_name": "IVERIC BIO INC.  DL-,001",
        "long_name": "IVERIC bio, Inc.",
        "summary": "IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration. It is also developing High temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company has a license agreement with the University of Florida Research Foundation and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and Best disease and other BEST1-related inherited retinal diseases. It also has a research agreement with the University of Massachusetts Medical School to develop gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and autosomal recessive Stargardt disease; and IRDs associated with mutations in the USH2A gene. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "O7PA.F": {
        "short_name": "NEUBASE THERAPEUT. DL-,01",
        "long_name": "NeuBase Therapeutics, Inc.",
        "summary": "NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Pittsburgh"
    },
    "OB3.F": {
        "short_name": "OPTIBIOTIX HLTH PLC LS-02",
        "long_name": "OptiBiotix Health Plc",
        "summary": "Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that ID used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food products and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. Optibiotix Health Plc has an agreement with Fondazione Edmund Mach - Centro Ricerca e Innovazione to jointly fund and carry out a research project examining the role of its microbiome products to improve sleep, stress, and anxiety. The company was founded in 2012 and is headquartered in York, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "York"
    },
    "OBD.L": {
        "short_name": "OXFORD BIODYNAMICS PLC ORD GBP0",
        "long_name": "Oxford BioDynamics Plc",
        "summary": "Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use within the pharmaceutical and biotechnology industry primarily in the United Kingdom and Malaysia. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures. It has collaboration agreements with Holos Life Sciences Pte. Ltd. to develop non-invasive epigenetic biomarkers associated with sports-related concussions; and Casa Sollievo della Sofferenza to identify EpiSwitch biomarkers for the blood-based diagnosis of Autism Spectrum Disorder. The company also has a strategic partnership with Boca Biolistics LLC to provide a range of blood samples from COVID-19 patients with clinical information on disease severity. Oxford BioDynamics Plc was founded in 2007 and is headquartered in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "OBMP": {
        "short_name": "ONCBIOMUNE PHARMACEUTICALS INC",
        "long_name": "Theralink Technologies, Inc.",
        "summary": "Theralink Technologies, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapy products. The company has proprietary rights to immunotherapy platform focusing on prostate and breast cancers. The company's lead product is ProscaVax, which is in phase 2 clinical trials for the treatment of prostate cancer. It is also developing targeted therapies. Theralink Technologies, Inc. has a partnership with Perthera, Inc. to facilitate and enhance access to Theralink's 32 phosphoprotein panel, the Theralink assay, for breast cancer patients. The company was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. Theralink Technologies, Inc. is based in Baton Rouge, Louisiana.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Golden"
    },
    "OBSN.SW": {
        "short_name": "OBSEVA N",
        "long_name": "ObsEva SA",
        "summary": "ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Geneva"
    },
    "OBSV": {
        "short_name": "ObsEva SA",
        "long_name": "ObsEva SA",
        "summary": "ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Geneva"
    },
    "OBSVN.MX": {
        "short_name": "OBSEVA SA",
        "long_name": "ObsEva SA",
        "summary": "ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "Switzerland",
        "city": "Geneva"
    },
    "OCC.AX": {
        "short_name": "ORTHOCELL FPO",
        "long_name": "Orthocell Limited",
        "summary": "Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. Orthocell Limited was founded in 2006 and is based in Murdoch, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Murdoch"
    },
    "OCD1.F": {
        "short_name": "CHROMADEX CORP.  DL -,001",
        "long_name": "ChromaDex Corporation",
        "summary": "ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "OCGN": {
        "short_name": "Ocugen, Inc.",
        "long_name": "Ocugen, Inc.",
        "summary": "Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Malvern"
    },
    "OCUL": {
        "short_name": "Ocular Therapeutix, Inc.",
        "long_name": "Ocular Therapeutix, Inc.",
        "summary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert), which has completed two Phase III clinical trials for the treatment of post-surgical ocular pain and inflammation, and allergic conjunctivitis; and DEXTENZA, which is in Phase III clinical trials for the treatment of dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert), which is in Phase III clinical trials for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant, which is in Phase I clinical trials for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant, which is in Phase I clinical trials for the treatment of wet age-related macular degeneration(AMD). Its various preclinical programs include OTX- BPI for the treatment of acute ocular pain; OTX-BDI to treat post-operative Pain, and inflammation and bacterial infection; OTX-CSI to treat dry-eye disease; and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Bedford"
    },
    "OCUP": {
        "short_name": "Ocuphire Pharma, Inc.",
        "long_name": "Ocuphire Pharma, Inc.",
        "summary": "Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing various therapies for the treatment of various eye disorders. The company's pipeline includes small-molecule product candidates for front and back of the eye indications. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate to reduce pupil size that is entering into Phase 3 clinical development for dim light or night vision disturbances, and reversal pharmacologically-induced mydriasis indications, as well as into Phase 2 for presbyopia. The company's products also comprise APX3330, a twice-a-day oral tablet, which is entering into Phase 2 clinical development to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009, a second generation preclinical product candidate analog of APX3330 is being investigated for use in wet age-related macular degeneration. Ocuphire Pharma, Inc. is based in Farmington Hills, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Farmington Hills"
    },
    "OCX": {
        "short_name": "OncoCyte Corporation",
        "long_name": "OncoCyte Corporation",
        "summary": "OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Irvine"
    },
    "OCY.SG": {
        "short_name": "Oncimmune Holdings PLC Register",
        "long_name": "Oncimmune Holdings plc",
        "summary": "Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers that can help stratify patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID disease-specific stratification panels. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Nottingham"
    },
    "ODT": {
        "short_name": "Odonate Therapeutics, Inc.",
        "long_name": "Odonate Therapeutics, Inc.",
        "summary": "Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "OEZ.F": {
        "short_name": "AVECHO BIOTECHN. LTD",
        "long_name": "Avecho Biotechnology Limited",
        "summary": "Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. The company operates through Production, Human Health, and Animal Health and Nutrition segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company serves customers in Australia, Switzerland, the United States, India, Japan, China, Singapore, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited is based in Melbourne, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "OGEN": {
        "short_name": "Oragenics Inc.",
        "long_name": "Oragenics, Inc.",
        "summary": "Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against dental caries, or tooth decay. Oragenics, Inc. has collaboration agreements with Precigen, Inc. and its subsidiary, Intrexon Actobiotics NV to develop AG013; and a license agreement with LPThera LLC to develop LPT3-04. It also has a process development and drug substance manufacturing agreement with Avid Bioservices, Inc. for coronavirus vaccine. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Tampa"
    },
    "OJU1.F": {
        "short_name": "ORAMED PHARMA.NEW DL-,001",
        "long_name": "Oramed Pharmaceuticals Inc.",
        "summary": "Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "OKYO.L": {
        "short_name": "OKYO PHARMA LIMITED ORD NPV",
        "long_name": "OKYO Pharma Limited",
        "summary": "OKYO Pharma Limited operates as a life sciences and biopharmaceutical company in the United Kingdom. Its pre-clinical development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM8, a non-opioid analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "OLMA": {
        "short_name": "Olema Pharmaceuticals, Inc.",
        "long_name": "Olema Pharmaceuticals, Inc.",
        "summary": "Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "OMER": {
        "short_name": "Omeros Corporation",
        "long_name": "Omeros Corporation",
        "summary": "Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "OMMH": {
        "short_name": "OMNIMMUNE HLDGS INC",
        "long_name": "Omnimmune Holdings, Inc.",
        "summary": "Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin. In addition, the company plans to conduct a Phase I trial with its lead candidate anti-human chorionic gonadotropin beta subunit monoclonal antibodies based upon the results of the diagnostic trial. Omnimmune Holdings, Inc. is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Houston"
    },
    "OMY.SG": {
        "short_name": "Synairgen PLC Registered Shares",
        "long_name": "Synairgen plc",
        "summary": "Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-\u00c3\u009f), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-\u00c3\u009f that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Southampton"
    },
    "ONBI": {
        "short_name": "ONE BIO CORP",
        "long_name": "ONE Bio Corp.",
        "summary": "ONE Bio Corp., an agritech company, together with its subsidiaries, utilizes green process manufacturing to produce raw chemicals and herbal extracts, natural supplements, and organic products. The company operates through two business units, Chemical and Herbal Extracts (CHE) and Organic Products (OP). The CHE business unit engages in the development, manufacture, and commercialization of bio-ecological products and over-the-counter products utilizing the extractions of tobacco leaves and various other plant materials. It produces chemical and herbal extracts for use in a range of health and wellness products, including chemical extracts comprising Solanesol and Coenzyme Q10; and herabal extracts, such as Resveratrol, 5-Hydroxytryptophan, Ganoderma Tea, and powdered and particulate fertilizers. This business unit distributes its products through independent third party distributors, universities, and hospital research centers to the bio-health industry and raw chemical intermediates industry in the People's Republic of China. The OP business unit manufactures various consumer and commercial use health and energy drinks, organic food products, and fertilizers primarily based on bamboo in the People's Republic of China. Its products include boiled bamboo shoot cans, boiled bamboo shoot cans with vacuum packing, boiled mixed vegetables, and boiled seasoned vegetables, as well as Kamameshi, a Japanese rice dish. This segment distributes its products directly to supermarket chains, hotels, hospitals, and restaurants, as well as through a network of independent third party distributors. ONE Bio Corp. exports its products to Japan, southeast Asia, Europe, and North America. The company was formerly known as ONE Holdings, Corp. and changed its name to ONE Bio Corp. in November 2009. ONE Bio Corp. was incorporated in 2000 and is headquartered in Aventura, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Aventura"
    },
    "ONC.L": {
        "short_name": "ONCIMMUNE HOLDINGS PLC ORD 1P",
        "long_name": "Oncimmune Holdings plc",
        "summary": "Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers that can help stratify patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID disease-specific stratification panels. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Nottingham"
    },
    "ONCO.ST": {
        "short_name": "Oncopeptides AB",
        "long_name": "Oncopeptides AB (publ)",
        "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "ONCR": {
        "short_name": "Oncorus, Inc.",
        "long_name": "Oncorus, Inc.",
        "summary": "Oncorus, Inc., a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "ONCS": {
        "short_name": "OncoSec Medical Incorporated",
        "long_name": "OncoSec Medical Incorporated",
        "summary": "OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Pennington"
    },
    "ONCT": {
        "short_name": "Oncternal Therapeutics, Inc.",
        "long_name": "Oncternal Therapeutics, Inc.",
        "summary": "Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ROR1) that is in Phase I/II clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in Phase Ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. It also develops TK-216, a small-molecule that is designed to inhibit E26 transformation specific family of oncoproteins, which is in Phase I clinical trial to treat patients with Ewing sarcoma and in combination with vincristine chemotherapy. In addition, the company develops a chimeric antigen receptor-T product candidate that targets ROR1, which is in preclinical development for treating hematologic cancers and solid tumors. Oncternal Therapeutics, Inc. has a research and development collaboration with Karolinska Institutet to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK cells. The company is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "ONCY": {
        "short_name": "Oncolytics Biotech Inc.",
        "long_name": "Oncolytics Biotech Inc.",
        "summary": "Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Canada",
        "city": "Calgary"
    },
    "OND.F": {
        "short_name": "ONCOPEPTIDES AB O.N.",
        "long_name": "Oncopeptides AB (publ)",
        "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "ONM2.F": {
        "short_name": "ONCOSEC MEDICAL  DL-,001",
        "long_name": "OncoSec Medical Incorporated",
        "summary": "OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Pennington"
    },
    "ONPH": {
        "short_name": "ONCOLOGY PHARMA INC",
        "long_name": "Oncology Pharma Inc.",
        "summary": "Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "ONPPF": {
        "short_name": "ONCOPEPTIDES AB",
        "long_name": "Oncopeptides AB (publ)",
        "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "ONTX": {
        "short_name": "Onconova Therapeutics, Inc.",
        "long_name": "Onconova Therapeutics, Inc.",
        "summary": "Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. The company has a license agreement with SymBio Pharmaceuticals Limited; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of ON 123300 in Greater China. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Newtown"
    },
    "ONXEO.CO": {
        "short_name": "Onxeo SA",
        "long_name": "Onxeo SA",
        "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "France",
        "city": "Paris"
    },
    "ONYN.F": {
        "short_name": "ONCOLYTICS BIOTECH",
        "long_name": "Oncolytics Biotech Inc.",
        "summary": "Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Calgary"
    },
    "OPNT": {
        "short_name": "Opiant Pharmaceuticals, Inc.",
        "long_name": "Opiant Pharmaceuticals, Inc.",
        "summary": "Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Santa Monica"
    },
    "OPT": {
        "short_name": "Opthea Limited",
        "long_name": "Opthea Limited",
        "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Australia",
        "city": "South Yarra"
    },
    "OPT.AX": {
        "short_name": "OPTHEA FPO",
        "long_name": "Opthea Limited",
        "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "South Yarra"
    },
    "OPTI.L": {
        "short_name": "OPTIBIOTIX HEALTH PLC ORD 2P",
        "long_name": "OptiBiotix Health Plc",
        "summary": "Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that ID used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food products and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. Optibiotix Health Plc has an agreement with Fondazione Edmund Mach - Centro Ricerca e Innovazione to jointly fund and carry out a research project examining the role of its microbiome products to improve sleep, stress, and anxiety. The company was founded in 2012 and is headquartered in York, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "York"
    },
    "ORGS": {
        "short_name": "Orgenesis Inc.",
        "long_name": "Orgenesis Inc.",
        "summary": "Orgenesis Inc. offers biotechnology solutions focusing on cell and gene therapies (CGTs). The company's Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on identification of new therapies and leverages its POCare platform to provide a pathway for these therapies to treat patients. Additionally, the company's Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies. Orgenesis Inc. was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. The company was founded in 2008 and is based in Germantown, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Germantown"
    },
    "ORIC": {
        "short_name": "Oric Pharmaceuticals, Inc.",
        "long_name": "ORIC Pharmaceuticals, Inc.",
        "summary": "ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "ORMP": {
        "short_name": "Oramed Pharmaceuticals Inc.",
        "long_name": "Oramed Pharmaceuticals Inc.",
        "summary": "Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "ORN.F": {
        "short_name": "ORYZON GENOMICS SA EO-,05",
        "long_name": "Oryzon Genomics S.A.",
        "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in Cornell\u00c3\u00a0 de Llobregat, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Spain",
        "city": "Cornell\u00c3\u00a0 de Llobregat"
    },
    "ORPH": {
        "short_name": "Orphazyme A/S",
        "long_name": "Orphazyme A/S",
        "summary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "ORPH.L": {
        "short_name": "OPEN ORPHAN PLC ORD 0.1P",
        "long_name": "Open Orphan plc",
        "summary": "Open Orphan plc operates as a clinical research organization pharmaceutical services company with a focus on virology, vaccine studies, and orphan drugs in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. It operates a virtual rep, a pharmaceutical commercialization platform for rare/orphan disease space; and develops Genomic Health Data platform, a collection of infectious disease progression data. The company also provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations. In addition, it offers hVIVO COVID Clear Test, an antibody test for employers in the United Kingdom and Ireland. The company is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "ORPHA.CO": {
        "short_name": "Orphazyme A/S",
        "long_name": "Orphazyme A/S",
        "summary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "ORTX": {
        "short_name": "Orchard Therapeutics plc",
        "long_name": "Orchard Therapeutics plc",
        "summary": "Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "ORY.MC": {
        "short_name": "ORYZON GENOMICS, S.A.",
        "long_name": "Oryzon Genomics S.A.",
        "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in Cornell\u00c3\u00a0 de Llobregat, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MCE",
        "market": "es_market",
        "country": "Spain",
        "city": "Cornell\u00c3\u00a0 de Llobregat"
    },
    "ORYZF": {
        "short_name": "ORYZON GENOMICS SA",
        "long_name": "Oryzon Genomics S.A.",
        "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in Cornell\u00c3\u00a0 de Llobregat, Spain.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Spain",
        "city": "Cornell\u00c3\u00a0 de Llobregat"
    },
    "OSMT": {
        "short_name": "Osmotica Pharmaceuticals plc",
        "long_name": "Osmotica Pharmaceuticals plc",
        "summary": "Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Bridgewater"
    },
    "OT1A.F": {
        "short_name": "ORCHARD THERAP.SP.ADRS/1",
        "long_name": "Orchard Therapeutics plc",
        "summary": "Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "OTIC": {
        "short_name": "Otonomy, Inc.",
        "long_name": "Otonomy, Inc.",
        "summary": "Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of M\u00c3\u00a9ni\u00c3\u00a8re's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "OTLK": {
        "short_name": "Outlook Therapeutics, Inc.",
        "long_name": "Outlook Therapeutics, Inc.",
        "summary": "Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cranbury, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cranbury"
    },
    "OVB.L": {
        "short_name": "OVOCA BIO PLC EUR0.125",
        "long_name": "Ovoca Bio plc",
        "summary": "Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was founded in 1985 and is based in Dublin, Ireland.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "OVID": {
        "short_name": "Ovid Therapeutics Inc.",
        "long_name": "Ovid Therapeutics Inc.",
        "summary": "Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which is in a Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; and OV881 as a microRNA gene therapy for the treatment of angelman syndrome. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop, manufacture and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was founded in 2014 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "OVIT": {
        "short_name": "ONCOVISTA INNOVATIVE THERAPIES ",
        "long_name": "OncoVista Innovative Therapies, Inc.",
        "summary": "OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Antonio"
    },
    "OVXA.IR": {
        "short_name": "OVOCA BIO PLC",
        "long_name": "Ovoca Bio plc",
        "summary": "Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was founded in 1985 and is based in Dublin, Ireland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ISE",
        "market": "ie_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "OXB.L": {
        "short_name": "OXFORD BIOMEDICA PLC ORD 50P",
        "long_name": "Oxford Biomedica plc",
        "summary": "Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-202 for the treatment of corneal graft rejection; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, Microsoft Research, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "OXBDF": {
        "short_name": "OXFORD BIOMEDICA",
        "long_name": "Oxford Biomedica plc",
        "summary": "Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-202 for the treatment of corneal graft rejection; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, Microsoft Research, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "OXOA.F": {
        "short_name": "OXFORD BIOMEDICA  LS-,50",
        "long_name": "Oxford Biomedica plc",
        "summary": "Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-202 for the treatment of corneal graft rejection; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, Microsoft Research, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "OXUR.BR": {
        "short_name": "OXURION",
        "long_name": "Oxurion NV",
        "summary": "Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases and cancer in Belgium and internationally. Its lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of DME that has completed phase 1 clinical trial; THR-687 an integrin antagonist to treat patients with a diabetic eye disease that has completed phase 1 clinical trial; and TB-403, an anti- placental growth factor for the treatment of medulloblastoma, a pediatric malignant brain tumor. It has collaboration agreements with BioInvent International AB, Bicycle Therapeutics, Parexel, INC Research, and Galapagos. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Belgium",
        "city": "Leuven"
    },
    "OYST": {
        "short_name": "Oyster Point Pharma, Inc.",
        "long_name": "Oyster Point Pharma, Inc.",
        "summary": "Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Princeton"
    },
    "OZYMF": {
        "short_name": "ORPHAZYME A/S",
        "long_name": "Orphazyme A/S",
        "summary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Copenhagen"
    },
    "P0F.F": {
        "short_name": "EGETIS THERAPEUTICS AB",
        "long_name": "Egetis Therapeutics AB (publ)",
        "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. It engages in developing PledOx, which is in Phase III clinical trial to protect patients from nerve damage caused by chemotherapy without reducing its anticancer effects; Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling; and Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. The company was founded in 2006 and is headquartered in Stockholm, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "P0F.SG": {
        "short_name": "EGETIS THERAPEUTICS AB",
        "long_name": "Egetis Therapeutics AB (publ)",
        "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. It engages in developing PledOx, which is in Phase III clinical trial to protect patients from nerve damage caused by chemotherapy without reducing its anticancer effects; Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling; and Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. The company was founded in 2006 and is headquartered in Stockholm, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "P0X.SG": {
        "short_name": "Pharnext Actions Nom. EO-,01",
        "long_name": "Pharnext SA",
        "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "France",
        "city": "Issy-les-Moulineaux"
    },
    "PA8.DE": {
        "short_name": "PAION O.N",
        "long_name": "Paion AG",
        "summary": "Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Aachen"
    },
    "PA8.F": {
        "short_name": "PAION O.N",
        "long_name": "Paion AG",
        "summary": "Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Aachen"
    },
    "PAB.AX": {
        "short_name": "PATRYS FPO",
        "long_name": "Patrys Limited",
        "summary": "Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates live cell nuclei and inhibits mechanisms of DNA repair in target cancer cells. The company also focuses on developing PAT-DX1 as a treatment for metastatic triple negative breast cancer and glioblastoma. In addition, it engages in developing PAT-SC1's target/antigen CD55PAT-SC1, an isoform of the membrane-bound CD55 for the treatment of gastric cancer. Patrys Limited was founded in 2006 and is based in South Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "PANACEABIO.NS": {
        "short_name": "PANACEA BIOTEC LTD",
        "long_name": "Panacea Biotec Limited",
        "summary": "Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilar in India. The company operates through Vaccines, Formulations, and Real Estate segments. Its product portfolio includes prescription products in various therapeutic areas, including pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. The company also engages in the real estate business. In addition, it exports its products to approximately 30 countries worldwide. The company has a collaboration agreement with Refana Inc. for the development, manufacturing, and distribution of the Covid-19 vaccine. Panacea Biotec Limited was founded in 1984 and is based in New Delhi, India.",
        "currency": "INR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NSI",
        "market": "in_market",
        "country": "India",
        "city": "New Delhi"
    },
    "PAND": {
        "short_name": "Pandion Therapeutics Inc.",
        "long_name": "Pandion Therapeutics, Inc.",
        "summary": "Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a bifunctional molecule combining its IL-2 mutein effector with a tether module that binds to MAdCAM to drive tissue-selective immunomodulation in the gastrointestinal tract. It has a collaboration with Astellas Pharma Inc. to develop locally acting immunomodulators for autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Watertown"
    },
    "PARD": {
        "short_name": "PONIARD PHARMACEUT",
        "long_name": "Poniard Pharmaceuticals, Inc.",
        "summary": "Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "PAS.V": {
        "short_name": "PASCAL BIOSCIENCES INC",
        "long_name": "Pascal Biosciences Inc.",
        "summary": "Pascal Biosciences Inc., a biopharmaceutical company, researches and develops products for the treatment of cancer, and for the enhancement of immune system. Its development portfolio includes PAS-403, a small molecule therapeutic advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory molecule to enhance the efficacy of checkpoint inhibitors. The company is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was founded in 2013 and is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "PASG": {
        "short_name": "Passage Bio, Inc.",
        "long_name": "Passage Bio, Inc.",
        "summary": "Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (\u00c3\u009f-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin for the treatment of FTD caused by a deficiency of progranulin; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase, for infantile Krabbe disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Philadelphia"
    },
    "PBDA.F": {
        "short_name": "PROTALIX BIOTHERAP.DL-,01",
        "long_name": "Protalix BioTherapeutics, Inc.",
        "summary": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Funda\u00c3\u00a7\u00c3\u00a3o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Karmiel"
    },
    "PBIGF": {
        "short_name": "PARADIGM BIOPHARMACEUTICALS LTD",
        "long_name": "Paradigm Biopharmaceuticals Limited",
        "summary": "Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "PBLA": {
        "short_name": "Panbela Therapeutics, Inc.",
        "long_name": "Panbela Therapeutics Inc.",
        "summary": "Panbela Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics Inc. in December 2020. Panbela Therapeutics Inc. was founded in 2011 and is based in Waconia, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Waconia"
    },
    "PBT-U.CN": {
        "short_name": "PortageBiotech",
        "long_name": "Portage Biotech Inc.",
        "summary": "Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "British Virgin Islands",
        "city": "Tortola"
    },
    "PBYI": {
        "short_name": "Puma Biotechnology Inc",
        "long_name": "Puma Biotechnology, Inc.",
        "summary": "Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "PCBK.F": {
        "short_name": "SESEN BIO INC.",
        "long_name": "Sesen Bio, Inc.",
        "summary": "Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in phase 3 clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate for use in the treatment of various types of EpCAM-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "PCIB.OL": {
        "short_name": "PCI BIOTECH HLDG",
        "long_name": "PCI Biotech Holding ASA",
        "summary": "PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's lead product candidate is Amphinex, a photosensitiser fimaporfin. Its PCI technology is applied to three distinct anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer, which in Phase Ib clinical study in bile duct cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination; and fimaNAc, a nucleic acid therapeutics delivery technology. The company has collaborative research programs with AstraZeneca, Bavarian Nordic, BioNTech, eTheRNA immunotherapies, IMV, and Phio Pharmaceuticals. PCI Biotech Holding ASA is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "PCJP.F": {
        "short_name": "ABEONA THERAPEUT.  DL-,01",
        "long_name": "Abeona Therapeutics Inc.",
        "summary": "Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "PCNT": {
        "short_name": "POINT OF CARE NANO-TECHNOLOGY I",
        "long_name": "Point of Care Nano-Technology, Inc.",
        "summary": "Point of Care Nano-Technology, Inc. focuses on developing and manufacturing saliva-based medical diagnosis products in the United States. Point of Care Nano-Technology, Inc. has a license agreement with Lamina Equities Corporation to diagnose illness in humans via a saliva test. The company was formerly known as Unique Growing Solutions, Inc. and changed its name to Point of Care Nano-Technology, Inc. in April 2015. The company was founded in 2010 and is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Las Vegas"
    },
    "PCSA": {
        "short_name": "Processa Pharmaceuticals, Inc.",
        "long_name": "Processa Pharmaceuticals, Inc.",
        "summary": "Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of post-operative ileus; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It also has license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was founded in 2015 and is based in Hanover, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Hanover"
    },
    "PCVX": {
        "short_name": "Vaxcyte, Inc.",
        "long_name": "Vaxcyte, Inc.",
        "summary": "Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Foster City"
    },
    "PDSB": {
        "short_name": "PDS Biotechnology Corporation",
        "long_name": "PDS Biotechnology Corporation",
        "summary": "PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial, a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104 (TRP2) for the treatment of melanoma. The company has a collaboration agreement with Merck & Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer; and an agreement with Farmacore Biotechnology for the development of Versamune-based vaccine to prevent COVID-19 infection. The company is based in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Princeton"
    },
    "PFND": {
        "short_name": "PATHFINDER CELL THERAPY INC",
        "long_name": "Pathfinder Cell Therapy, Inc.",
        "summary": "Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "PGEN": {
        "short_name": "Precigen, Inc.",
        "long_name": "Precigen, Inc.",
        "summary": "Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Germantown"
    },
    "PH4.F": {
        "short_name": "CSTONE PHARMAC.  DL-,0001",
        "long_name": "CStone Pharmaceuticals",
        "summary": "CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment worldwide. The company's late-stage clinical products include CS1001, a monoclonal antibody against programmed death ligand 1; CS1003, a monoclonal antibody against programmed death receptor; ivosidenib, a potent inhibitor of the mutated isocitrate dehydrogenase-1 enzyme for the treatment of cancer; avapritinib, an inhibitor for the treatment of gastrointestinal stromal tumors and systematic mastocytosis; and Pralsetinib for the treatment of medullary thyroid cancer and other advanced solid tumors. Its products also comprise CS1002, CS3002, CS3003, CS3005, and CS3006 for solid tumors; Fisogatinib that is used for the treatment of hepatocellular carcinoma; and CS3004, CS1009, and CS2004 for other indications. CStone Pharmaceuticals has a licensing agreement with Numab Therapeutics AG for the development and commercialization of NM21-1480, a potential monovalent tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin; a clinical collaboration with Bayer HealthCare LLC to evaluate CS1001 in combination with Bayer's oral multi-kinase inhibitor Stivarga, as a treatment for various types of cancer, including gastric cancer; and a strategic partnership with Burning Rock Biotech Limited to co-develop and commercialize companion diagnostics for pralsetinib, an investigational treatment for the detection of RET alterations in cancer patients. The company was founded in 2015 in Cayman Islands, and is headquartered in Shanghai, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "city": "Shanghai"
    },
    "PHAR": {
        "short_name": "Pharming Group N.V.",
        "long_name": "Pharming Group N.V.",
        "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Leiden"
    },
    "PHAS": {
        "short_name": "PhaseBio Pharmaceuticals, Inc.",
        "long_name": "PhaseBio Pharmaceuticals, Inc.",
        "summary": "PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Malvern"
    },
    "PHAT": {
        "short_name": "Phathom Pharmaceuticals, Inc.",
        "long_name": "Phathom Pharmaceuticals, Inc.",
        "summary": "Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Florham Park"
    },
    "PHGE": {
        "short_name": "BiomX Inc.",
        "long_name": "BiomX Inc.",
        "summary": "BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "PHGE.TA": {
        "short_name": "BIOMX INC",
        "long_name": "BiomX Inc.",
        "summary": "BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "PHGN.F": {
        "short_name": "PHARMING GRP  EO-,01",
        "long_name": "Pharming Group N.V.",
        "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Netherlands",
        "city": "Leiden"
    },
    "PHGUF": {
        "short_name": "PHARMING GROUP NV",
        "long_name": "Pharming Group N.V.",
        "summary": "Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Leiden"
    },
    "PHIO": {
        "short_name": "Phio Pharmaceuticals Corp.",
        "long_name": "Phio Pharmaceuticals Corp.",
        "summary": "Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum M\u00c3\u00bcnchen. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Marlborough"
    },
    "PHM.MC": {
        "short_name": "PHARMA MAR, S.A.",
        "long_name": "Pharma Mar, S.A.",
        "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MCE",
        "market": "es_market",
        "country": "Spain",
        "city": "Madrid"
    },
    "PHMMF": {
        "short_name": "PHARMA MAR SA",
        "long_name": "Pharma Mar, S.A.",
        "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Spain",
        "city": "Madrid"
    },
    "PHPN.F": {
        "short_name": "GALECTIN THERA.  DL-,01",
        "long_name": "Galectin Therapeutics, Inc.",
        "summary": "Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate is GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. The company was founded in 2000 and is based in Norcross, Georgia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Norcross"
    },
    "PHRM.CN": {
        "short_name": "NewscopeCap",
        "long_name": "Newscope Capital Corporation",
        "summary": "PharmaTher Inc., pharmaceutical company, engages in repurposing psychedelic-derived drugs using artificial intelligence platform. The company was incorporated in 2020 and is based in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "None"
    },
    "PHRRF": {
        "short_name": "NEWSCOPE CAPITAL CORPORATION",
        "long_name": "Newscope Capital Corporation",
        "summary": "PharmaTher Inc., pharmaceutical company, engages in repurposing psychedelic-derived drugs using artificial intelligence platform. The company was incorporated in 2020 and is based in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "None"
    },
    "PI6.F": {
        "short_name": "PIERIS PHARMACEUT. DL-001",
        "long_name": "Pieris Pharmaceuticals, Inc.",
        "summary": "Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boston"
    },
    "PIQ.AX": {
        "short_name": "PROTEOMICS FPO",
        "long_name": "Proteomics International Laboratories Limited",
        "summary": "Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research, analytical, and consultancy. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute to enhance diagnosis and treatment of lung conditions, such as asthma and chronic obstructive pulmonary disease; the Janssen Research & Development, LLC for the research of diabetic kidney and heart disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma, the primary common form of oesophageal cancer in Australia. The company was founded in 2001 and is based in Perth, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Perth"
    },
    "PIRS": {
        "short_name": "Pieris Pharmaceuticals, Inc.",
        "long_name": "Pieris Pharmaceuticals, Inc.",
        "summary": "Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "PJT.F": {
        "short_name": "PLURISTEM THERAPEUTICS",
        "long_name": "Pluristem Therapeutics Inc.",
        "summary": "Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Haifa"
    },
    "PKPH": {
        "short_name": "PEAK PHARMACEUTICALS INC",
        "long_name": "Peak Pharmaceuticals, Inc.",
        "summary": "Peak Pharmaceuticals, Inc. operates as a bio\u00c2\u00adpharmaceutical and nutraceutical company in the United States. The company focuses to develop, manufacture, market, and sell medicinal products based on extracts from hemp. It is involved in the development of over-the-counter, THC\u00c2\u00adfree, hemp based products for human market for the prevention and alleviation of symptoms associated with inflammatory and auto-immune diseases. The company was formerly known as Cannabis Therapy Corporation and changed its name to Peak Pharmaceuticals, Inc. in December 2014. Peak Pharmaceuticals, Inc. was incorporated in 2007 and is based in Scottsdale, Arizona.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Scottsdale"
    },
    "PKTX": {
        "short_name": "PROTOKINETIX INC",
        "long_name": "ProtoKinetix, Incorporated",
        "summary": "ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in food and crop preservation at freezing temperatures. Its AAGPs have commercial applications in the harvesting, storage, and transplantation of cells, tissues, and organs; and treatments for conditions and diseases caused by stress factors, including UV radiation, oxidation, and inflammation. The company has collaboration agreement with the University of British Columbia to test neuronal retinal cells in living tissue for the treatment of macular degeneration; and research agreement with the University of Dalhousie to examine the effects of AAGP in transplant medicine. It develops AAGP to treat Dry Eye Disease therapy. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was founded in 1999 and is based in Marietta, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Marietta"
    },
    "PLNT.TA": {
        "short_name": "PLANTARC BIO LTD",
        "long_name": "PlantArc Bio Ltd.",
        "summary": "PlantArcBio Ltd. operates as a biotechnology company for the enhancement of crop productivity and performance for food security. The company has developed a Direct In Plant gene discovery platform. It focuses on yield and abiotic stresses, insect resistance, herbicide tolerance, and disease control market segments. The company was founded in 2014 and is based in Giv'at Hen, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Giv\u00e2\u0080\u0099at Hen"
    },
    "PLPL": {
        "short_name": "PLANDAI BIOTECHNOLOGY INC",
        "long_name": "Planda\u00ed Biotechnology, Inc.",
        "summary": "Planda\u00c3\u00ad Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. It is developing Phytofare Catechin Complex, a botanical extract derived from green tea harvested in the Senteeko Tea Estate in Mpumalanga, South Africa; and Phytofare citrus complex, a citrus extract, as well as extracts from tomato fruit, Artemisia, and cannabis. The company also produces and sells timber and agricultural products from its farm and tea estate holdings in South Africa. Planda\u00c3\u00ad Biotechnology, Inc. is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "PLRX": {
        "short_name": "Pliant Therapeutics, Inc.",
        "long_name": "Pliant Therapeutics, Inc.",
        "summary": "Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of av\u00c3\u009f6 and av\u00c3\u009f1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of av\u00c3\u009f1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "PLX": {
        "short_name": "Protalix BioTherapeutics, Inc. ",
        "long_name": "Protalix BioTherapeutics, Inc.",
        "summary": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Funda\u00c3\u00a7\u00c3\u00a3o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "Israel",
        "city": "Karmiel"
    },
    "PLX.TA": {
        "short_name": "PROTALIX BIOTHERAP",
        "long_name": "Protalix BioTherapeutics, Inc.",
        "summary": "Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Funda\u00c3\u00a7\u00c3\u00a3o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Karmiel"
    },
    "PMCB": {
        "short_name": "PHARMACYTE BIOTECH INC",
        "long_name": "PharmaCyte Biotech, Inc.",
        "summary": "PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. PharmaCyte Biotech, Inc. has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and a research agreement with the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Laguna Hills"
    },
    "PMN.TO": {
        "short_name": "PROMIS NEUROSCIENCES INC",
        "long_name": "ProMIS Neurosciences, Inc.",
        "summary": "ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform\u00c2\u0097ProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (A\u00c3\u009fO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of A\u00c3\u009fO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company has a collaboration with BC Neuroimmunology to develop and commercialize proprietary diagnostic assays; and BC Neuroimmunology to develop and offer blood-based diagnostic tests for Alzheimer's diseases. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "PMRA.F": {
        "short_name": "PHARMA MAR S.A. EO -,60",
        "long_name": "Pharma Mar, S.A.",
        "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Spain",
        "city": "Madrid"
    },
    "PMVP": {
        "short_name": "PMV Pharmaceuticals, Inc.",
        "long_name": "PMV Pharmaceuticals, Inc.",
        "summary": "PMV Pharmaceuticals, Inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cranbury"
    },
    "PNEXF": {
        "short_name": "PHARNEXT",
        "long_name": "Pharnext SA",
        "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Issy-les-Moulineaux"
    },
    "PNV.AX": {
        "short_name": "POLYNOVO FPO",
        "long_name": "PolyNovo Limited",
        "summary": "Polynovo Limited develops medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; breast devices in partnership with Establishment Labs; NovoSorb dermal beta cell implant in collaboration with BetaCell Technologies Pty Ltd; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is based in Port Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Port Melbourne"
    },
    "POLN.SW": {
        "short_name": "Polyphor N",
        "long_name": "Polyphor AG",
        "summary": "Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. Its lead drug candidates include Balixafortide (POL6326), an antagonist of the chemokine receptor CXCR4, which is in Phase III for combination treatment in oncology; POL6014, an inhaled inhibitor of neutrophil elastase, which is in Phase Ib clinical trial for the treatment of cystic fibrosis and other neutrophilic lung diseases; and outer membrane protein targeting antibiotics (OMPTA) platform. The company is also developing POL7306, targeting the most resistant MDR strains of all Gram-negative ESKAPE, including enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa, and enterobacter species pathogens; and inhaled murepavadin (POL7080), a precision outer membrane protein targeting antibiotic for the treatment of pseudomonas aeruginosa. Polyphor AG was founded in 1996 and is headquartered in Allschwil, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Allschwil"
    },
    "POLXF": {
        "short_name": "POLYDEX PHARMACEUTICALS INC",
        "long_name": "Polydex Pharmaceuticals Limited",
        "summary": "Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. The company also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. It primarily offers dextran and derivative products, including iron dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product to treat cystic fibrosis, a genetic disease. Further, it supplies ferric hydroxide and hydrogenated dextran solutions. Polydex Pharmaceuticals Limited sells its products through independent distributors and wholesalers, as well as directly to companies. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was incorporated in 1979 and is based in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "POXEL.PA": {
        "short_name": "POXEL",
        "long_name": "Poxel S.A.",
        "summary": "Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lyon"
    },
    "PPBT": {
        "short_name": "Purple Biotech Ltd.",
        "long_name": "Purple Biotech Ltd.",
        "summary": "Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "PPBT.TA": {
        "short_name": "PURPLE BIOTECH",
        "long_name": "Purple Biotech Ltd.",
        "summary": "Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "PPCB": {
        "short_name": "PROPANC BIOPHARMA INC",
        "long_name": "Propanc Biopharma, Inc.",
        "summary": "Propanc Biopharma, Inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Ja\u00c3\u00a9n to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was founded in 2007 and is based in Camberwell, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Camberwell"
    },
    "PPMD": {
        "short_name": "PROTIDE PHARMACEUTICALS  INC",
        "long_name": "Protide Pharmaceuticals, Inc.",
        "summary": "Protide Pharmaceuticals, Inc. discovers, develops, and commercializes technologies and processes in the areas of clinical cell therapy, regenerative medicine, transfusion medicine, cell engineering, and transplantation in the United States and internationally. It offers serum reducers, cell culture and processing products, stem cell cryopreservatives, and stem cell and regenerative research products. The company is based in Lake Zurich, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Lake Zurich"
    },
    "PPTDF": {
        "short_name": "PEPTIDREAM INC",
        "long_name": "PeptiDream Inc.",
        "summary": "PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company uses its Peptide Discovery Platform System platform for the development of peptides. PeptiDream Inc. has a collaboration with Merck & Co. Inc. for the discovery and development of peptide therapeutics capable of neutralizing the SARS-CoV-2 virus (COVID19) and potential coronavirus outbreaks; and a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was founded in 2006 and is headquartered in Kawasaki, Japan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Japan",
        "city": "Kawasaki"
    },
    "PQ6.F": {
        "short_name": "STARPHARMA HOLDINGS LTD.",
        "long_name": "Starpharma Holdings Limited",
        "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Abbotsford"
    },
    "PQB.SG": {
        "short_name": "Pure Biologics S.A. Inhaber-Akt",
        "long_name": "Pure Biologics Sp\u00f3lka Akcyjna",
        "summary": "Pure Biologics Sp\u00c3\u00b3lka Akcyjna, a biopharmaceutical company, engages in the research and development of new therapies and diagnostic methods in the field of immuno-oncology and rare diseases. It is also involved in the production, purification, analysis, and characterization of recombinant proteins and antibodies, protein engineering and formulation, genome sequencing, proteomic analysis, and bioinformatics; development and validation of assays; development of measurement methods and the derivation of stable cell lines; and provision of contract research service related to lead identification from antibody and aptamer libraries. In addition, the company offers medical devices; cancer diagnostics products; PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use; and Pure Select2, a platform for in vitro selection of recombinant human antibody fragments that recognize a chosen molecular target, including whole cells. Further, it undertakes partnership projects in cooperation with various institutions, which include Molecular Analytical Robotics Assays (MARA), which focuses on the development of modern nanotechnologies in the diagnosis and treatment of bacterial infections; MAGBBRIS project that investigate growth factors secreted by endothelial progenitor cells; and APIFAG project, a bacteriophage preparation intended for the prevention and treatment of American Foulbrood and European Foulbrood in honeybees, as well as various other projects funded by the European Union. The company was founded in 2010 and is based in Wroclaw, Poland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Poland",
        "city": "Wroclaw"
    },
    "PRAX": {
        "short_name": "Praxis Precision Medicines, Inc",
        "long_name": "Praxis Precision Medicines, Inc.",
        "summary": "Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "PREV.CN": {
        "short_name": "PreveCeuticalMe",
        "long_name": "PreveCeutical Medical Inc.",
        "summary": "PreveCeutical Medical Inc., a health sciences company, develops options for preventive and curative therapies utilizing organic and nature identical products in the United States and Canada. It has research and development programs, including dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a soluble gel drug delivery program, which provide relief from pain, inflammation, seizures, and neurological disorders; Nature Identical peptide therapeutic applications; non-addictive analgesic peptides as a replacement to the addictive analgesics, such as morphine, fentanyl, and oxycodone; and a therapeutic product for treating athletes who suffer from concussions. It also provides medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "PRLD": {
        "short_name": "Prelude Therapeutics Incorporat",
        "long_name": "Prelude Therapeutics Incorporated",
        "summary": "Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Wilmington"
    },
    "PRNAF": {
        "short_name": "ALTERITY THERAPEUTICS LIMITED",
        "long_name": "Alterity Therapeutics Limited",
        "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "PROG": {
        "short_name": "Progenity, Inc.",
        "long_name": "Progenity, Inc.",
        "summary": "Progenity, Inc., a biotechnology company, provides complex molecular and specialized testing services to physicians, clinicians, and their patients in the United States. It offers testing services for common hereditary disorders, cystic fibrosis, spinal muscular atrophy, fragile X syndrome, and Jewish genetic diseases; pan-ethnic carrier screening services; non-invasive prenatal, miscarriage, and pharmacogenetic testing services; and ovarian assessment reports for women. The company also provides pediatric testing services. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November, 2013. The company was incorporated in 2012 and is based in San Diego, California with a laboratory in Ann Arbor, Michigan. It has a bill payment location in Detroit, Michigan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "PROMO.ST": {
        "short_name": "Promore Pharma AB",
        "long_name": "Promore Pharma AB (publ)",
        "summary": "Promore Pharma AB (publ), a biopharmaceutical company, develops therapeutic peptides for the bio-active wound care market in Sweden and internationally. Its product candidates include PXL01 for the prevention of post-surgical adhesions and scars, as well as for tendon repair surgery in the hand; and LL-37 that is in Phase IIb clinical studies for treating patients with venous leg ulcers. The company is also developing drugs for the prevention of dermal scars and treatment of diabetic foot ulcers. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is based in Solna, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "PROT": {
        "short_name": "PROTEONOMIX INC",
        "long_name": "Proteonomix, Inc.",
        "summary": "Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Hawthorne"
    },
    "PRQR": {
        "short_name": "ProQR Therapeutics N.V.",
        "long_name": "ProQR Therapeutics N.V.",
        "summary": "ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Leiden"
    },
    "PRRUF": {
        "short_name": "IMMUTEP LTD",
        "long_name": "Immutep Limited",
        "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as \u00c2\u0091eftilagimod alpha' or \u00c2\u0091efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "PRTA": {
        "short_name": "Prothena Corporation plc",
        "long_name": "Prothena Corporation plc",
        "summary": "Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; A\u00c3\u009f, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Ireland",
        "city": "Dublin"
    },
    "PRTC": {
        "short_name": "PureTech Health plc",
        "long_name": "PureTech Health plc",
        "summary": "PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a digital therapeutics to treat cognitive dysfunction associated with neurology and psychiatry conditions; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a immunomodulation platform to treat chronic and acute inflammatory disorders. It also provides hematopoietic stem cell based therapies to treat hematologic malignancies; a vocal biomarker technology to monitor and diagnose psychological and physical medical conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate which is in Phase 1 clinical trial to treat lymphedema, and other lymphatic and fibrotic disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "PRTC.L": {
        "short_name": "PURETECH HEALTH PLC ORD 1P",
        "long_name": "PureTech Health plc",
        "summary": "PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a digital therapeutics to treat cognitive dysfunction associated with neurology and psychiatry conditions; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a immunomodulation platform to treat chronic and acute inflammatory disorders. It also provides hematopoietic stem cell based therapies to treat hematologic malignancies; a vocal biomarker technology to monitor and diagnose psychological and physical medical conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate which is in Phase 1 clinical trial to treat lymphedema, and other lymphatic and fibrotic disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United States",
        "city": "Boston"
    },
    "PRTK": {
        "short_name": "Paratek Pharmaceuticals, Inc.",
        "long_name": "Paratek Pharmaceuticals, Inc.",
        "summary": "Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "PRVB": {
        "short_name": "Provention Bio, Inc.",
        "long_name": "Provention Bio, Inc.",
        "summary": "Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Oldwick"
    },
    "PRVCF": {
        "short_name": "PREVECEUTICAL MEDICAL INC",
        "long_name": "PreveCeutical Medical Inc.",
        "summary": "PreveCeutical Medical Inc., a health sciences company, develops options for preventive and curative therapies utilizing organic and nature identical products in the United States and Canada. It has research and development programs, including dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a soluble gel drug delivery program, which provide relief from pain, inflammation, seizures, and neurological disorders; Nature Identical peptide therapeutic applications; non-addictive analgesic peptides as a replacement to the addictive analgesics, such as morphine, fentanyl, and oxycodone; and a therapeutic product for treating athletes who suffer from concussions. It also provides medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "PSTI": {
        "short_name": "Pluristem Therapeutics, Inc.",
        "long_name": "Pluristem Therapeutics Inc.",
        "summary": "Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Haifa"
    },
    "PSTI.TA": {
        "short_name": "PLURISTEM THERAPEU",
        "long_name": "Pluristem Therapeutics Inc.",
        "summary": "Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Haifa"
    },
    "PSTV": {
        "short_name": "PLUS THERAPEUTICS, Inc.",
        "long_name": "Plus Therapeutics, Inc.",
        "summary": "Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "PSTX": {
        "short_name": "Poseida Therapeutics, Inc.",
        "long_name": "Poseida Therapeutics, Inc.",
        "summary": "Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "PTCHF": {
        "short_name": "PURETECH HEALTH PLC",
        "long_name": "PureTech Health plc",
        "summary": "PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a digital therapeutics to treat cognitive dysfunction associated with neurology and psychiatry conditions; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a immunomodulation platform to treat chronic and acute inflammatory disorders. It also provides hematopoietic stem cell based therapies to treat hematologic malignancies; a vocal biomarker technology to monitor and diagnose psychological and physical medical conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate which is in Phase 1 clinical trial to treat lymphedema, and other lymphatic and fibrotic disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "PTCT": {
        "short_name": "PTC Therapeutics, Inc.",
        "long_name": "PTC Therapeutics, Inc.",
        "summary": "PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South Plainfield"
    },
    "PTE": {
        "short_name": "PolarityTE, Inc.",
        "long_name": "PolarityTE, Inc.",
        "summary": "PolarityTE, Inc., a biotechnology and regenerative biomaterials company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Salt Lake City"
    },
    "PTGEF": {
        "short_name": "PORTAGE BIOTECH INC",
        "long_name": "Portage Biotech Inc.",
        "summary": "Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "British Virgin Islands",
        "city": "Tortola"
    },
    "PTGX": {
        "short_name": "Protagonist Therapeutics, Inc.",
        "long_name": "Protagonist Therapeutics, Inc.",
        "summary": "Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat patients with moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating inflammatory bowel disease. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Newark"
    },
    "PTIX": {
        "short_name": "PROTAGENIC THERAPEUTICS INC",
        "long_name": "Protagenic Therapeutics, Inc.",
        "summary": "Protagenic Therapeutics, Inc. engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "PTN": {
        "short_name": "Palatin Technologies, Inc.",
        "long_name": "Palatin Technologies, Inc.",
        "summary": "Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Cranbury"
    },
    "PTNA.F": {
        "short_name": "PALATIN TECHS  DL-,01",
        "long_name": "Palatin Technologies, Inc.",
        "summary": "Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cranbury"
    },
    "PTPI": {
        "short_name": "Petros Pharmaceuticals, Inc.",
        "long_name": "Petros Pharmaceuticals, Inc.",
        "summary": "Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues. The company operates through two segments, Prescription Medications and Medical Devices. It focuses on erectile dysfunction, peyronie's disease, endothelial dysfunction, and prostate cancer; and hormone health, and products enhancing overall health and wellness in men. The company offers prescription medication, such as Stendra for the treatment of erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "PTX.AX": {
        "short_name": "PRESCIENT FPO",
        "long_name": "Prescient Therapeutics Limited",
        "summary": "Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in South Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "PUL.F": {
        "short_name": "BIOSEARCH S.A.INH. EO-,24",
        "long_name": "Biosearch, S.A.",
        "summary": "Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Spain",
        "city": "Granada"
    },
    "PULM": {
        "short_name": "Pulmatrix, Inc.",
        "long_name": "Pulmatrix, Inc.",
        "summary": "Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and Cipla Technologies LLC for the development and commercialization of Pulmazole. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Lexington"
    },
    "PV3B.F": {
        "short_name": "EYEPOINT PHARMAC.  DL-,01",
        "long_name": "EyePoint Pharmaceuticals, Inc.",
        "summary": "EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Watertown"
    },
    "PVCT": {
        "short_name": "PROVECTUS BIOPHARMACEUTICALS IN",
        "long_name": "Provectus Biopharmaceuticals, Inc.",
        "summary": "Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing drugs based on halogenated xanthenes for oncology, hematology, and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase Ib/II study for metastatic melanoma; Phase I study for hepatocellular carcinoma and other solid tumors metastatic to the liver; and non-clinical assessment of pediatric cancer tumor cell. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Knoxville"
    },
    "PX91.F": {
        "short_name": "CASSAVA SCIENCES  DL-,001",
        "long_name": "Cassava Sciences, Inc.",
        "summary": "Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Austin"
    },
    "PXY.SG": {
        "short_name": "Provectus Biopharmaceutic.Inc.R",
        "long_name": "Provectus Biopharmaceuticals, Inc.",
        "summary": "Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing drugs based on halogenated xanthenes for oncology, hematology, and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase Ib/II study for metastatic melanoma; Phase I study for hepatocellular carcinoma and other solid tumors metastatic to the liver; and non-clinical assessment of pediatric cancer tumor cell. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Knoxville"
    },
    "PYC.L": {
        "short_name": "PHYSIOMICS PLC ORD 0.4P",
        "long_name": "Physiomics Plc",
        "summary": "Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the European Union, and the United States. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "PYPB.F": {
        "short_name": "IXICO PLC  LS -,01",
        "long_name": "IXICO plc",
        "summary": "IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. It provides collection, analysis, management, and reporting services on data generated in the course of a clinical study. The company's technologies include Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, QC, and reading/analysis to reporting and data transfer. The company offers end-to-end imaging services, primarily in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases; and engages in the data collection and analysis of neurological diseases. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was incorporated in 1995 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "PYPD": {
        "short_name": "PolyPid Ltd.",
        "long_name": "PolyPid Ltd.",
        "summary": "PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting \u00c3\u009f tri-calcium phosphate granule for bone related infections applications; and BONYPID\u00c2\u0096500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Israel",
        "city": "Petah Tikva"
    },
    "PZRXQ": {
        "short_name": "PHASERX INC",
        "long_name": "PhaseRx, Inc.",
        "summary": "PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "QBI.HM": {
        "short_name": "Q2M MGMT.BERAT.AG",
        "long_name": "Q2M Managementberatung AG",
        "summary": "Q2M Managementberatung AG provides provides management consultancy services. It offers succession planning, interim management, and operational implementation services. The company is based in Mannheim, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HAM",
        "market": "dr_market",
        "country": "Germany",
        "city": "Mannheim"
    },
    "QBIO": {
        "short_name": "Q BIOMED INC",
        "long_name": "Q BioMed Inc.",
        "summary": "Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and Metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research for the development of novel Covid-19 therapeutics. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was founded in 2013 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "QLGN": {
        "short_name": "Qualigen Therapeutics, Inc.",
        "long_name": "Qualigen Therapeutics, Inc.",
        "summary": "Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Carlsbad"
    },
    "QPT.V": {
        "short_name": "QUEST PHARMATECH INC.",
        "long_name": "Quest PharmaTech Inc.",
        "summary": "Quest PharmaTech Inc., a biotechnology company, develops and commercializes antibody based immunotherapeutic products for cancer. The company focuses on combinatorial immunotherapeutic approaches to cancer by using monoclonal antibodies of the immunoglobulin G or E subclass in combination with chemotherapy/immune-adjuvant. Its lead product candidate is Oregovomab, a monoclonal antibody, which has completed Phase II clinical trial for the treatment of ovarian cancer. The company also owns the Photodynamic therapy technology for oncology and dermatology applications; and develops Mab AR 9.6 against truncated O-glycan on MUC16 for targeted cancer therapy applications. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Edmonton"
    },
    "QRON": {
        "short_name": "QRONS INC",
        "long_name": "Qrons Inc.",
        "summary": "Qrons Inc., a preclinical stage biotechnology company, engages in developing stem cell synthetic hydrogel-based solutions to combat neuronal injuries, primarily focusing on traumatic brain injuries. Its products candidates include QS100, an injury specific, 3D printable, implantable modified mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries. Qrons Inc. has a license and research funding agreement with Ariel University R&D Co., Ltd. for the development and commercialization of products for neuronal tissue regeneration and repair. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. Qrons Inc. was founded in 2016 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "QSAM": {
        "short_name": "QSAM BIOSCIENCES INC",
        "long_name": "QSAM Biosciences, Inc.",
        "summary": "QSAM Biosciences, Inc., together with its subsidiary, engages in the manufacture and sale of compost and engineered soils from waste resources in the United States. Its products are used in the agriculture, horticulture, construction, landscape, site restoration, sod and turf, Silviculture and land reclamation, and infrastructure sectors. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Palm Beach, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Palm Beach"
    },
    "QSOA.F": {
        "short_name": "SURFACE ONCOLOGY DL-,0001",
        "long_name": "Surface Oncology, Inc.",
        "summary": "Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDA\u00c3\u0082 (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "QUIA.ST": {
        "short_name": "QuiaPEG Pharmaceuticals Holding",
        "long_name": "QuiaPEG Pharmaceuticals Holding AB (publ)",
        "summary": "QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "QURE": {
        "short_name": "uniQure N.V.",
        "long_name": "uniQure N.V.",
        "summary": "uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Netherlands",
        "city": "Amsterdam"
    },
    "R3X1.F": {
        "short_name": "OCUPHIRE PHARMA DL-,0001",
        "long_name": "Ocuphire Pharma, Inc.",
        "summary": "Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing various therapies for the treatment of various eye disorders. The company's pipeline includes small-molecule product candidates for front and back of the eye indications. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate to reduce pupil size that is entering into Phase 3 clinical development for dim light or night vision disturbances, and reversal pharmacologically-induced mydriasis indications, as well as into Phase 2 for presbyopia. The company's products also comprise APX3330, a twice-a-day oral tablet, which is entering into Phase 2 clinical development to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009, a second generation preclinical product candidate analog of APX3330 is being investigated for use in wet age-related macular degeneration. Ocuphire Pharma, Inc. is based in Farmington Hills, Michigan.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Farmington Hills"
    },
    "R7E1.F": {
        "short_name": "CYBIN INC.",
        "long_name": "Cybin Inc.",
        "summary": "Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "R9Q.F": {
        "short_name": "RECCE PHARMACEUTICALS LTD",
        "long_name": "Recce Pharmaceuticals Ltd",
        "summary": "Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotics. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "RAC.AX": {
        "short_name": "RACEONCO FPO",
        "long_name": "Race Oncology Limited",
        "summary": "Race Oncology Limited operates as a specialty pharmaceutical company in Australia. It is developing Bisantrene, a small molecule cancer chemotherapy drug that is used for the treatment of acute myeloid leukaemia. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "RAPT": {
        "short_name": "RAPT Therapeutics, Inc.",
        "long_name": "RAPT Therapeutics, Inc.",
        "summary": "RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "RARE": {
        "short_name": "Ultragenyx Pharmaceutical Inc.",
        "long_name": "Ultragenyx Pharmaceutical Inc.",
        "summary": "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Novato"
    },
    "RASP": {
        "short_name": "RASNA THERAPEUTICS INC",
        "long_name": "Rasna Therapeutics, Inc.",
        "summary": "Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia. It focuses on developing molecule drug candidates targeting NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. The company is developing RASP-201 (LSD1), an enzyme that demethylates lysine side chain of histones; and RASP-301, an NPM1 gene that provides instructions for making nucleophosmin protein. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "RCAR": {
        "short_name": "RENOVACARE INC",
        "long_name": "RenovaCare, Inc.",
        "summary": "RenovaCare, Inc., a development-stage company, focuses on the acquisition, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in Roseland, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Roseland"
    },
    "RCE.AX": {
        "short_name": "RECCE LTD FPO",
        "long_name": "Recce Pharmaceuticals Ltd",
        "summary": "Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotics. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "RCHA": {
        "short_name": "RICH PHARMACEUTICALS INC",
        "long_name": "Rich Pharmaceuticals, Inc.",
        "summary": "Rich Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies in oncology. It is developing RP-323 for the treatment of Hodgkin's lymphoma, acute myelogenous leukemia, and to cause elevation of white blood cells. The company was formerly known as Nepia Inc. and changed its name to Rich Pharmaceuticals, Inc., in August 2013. Rich Pharmaceuticals, Inc. was incorporated in 2010 and is based in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "RCKT": {
        "short_name": "Rocket Pharmaceuticals, Inc.",
        "long_name": "Rocket Pharmaceuticals, Inc.",
        "summary": "Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energ\u00c3\u00a9ticas, Medioambientales y Tecnol\u00c3\u00b3gicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "RCPIQ": {
        "short_name": "ROCK CREEK PHARMACEUTICALS INC",
        "long_name": "Rock Creek Pharmaceuticals, Inc.",
        "summary": "Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida. On September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Sarasota"
    },
    "RCUS": {
        "short_name": "Arcus Biosciences, Inc.",
        "long_name": "Arcus Biosciences, Inc.",
        "summary": "Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab (AB154), its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; license agreements with Taiho Pharmaceutical Co., Ltd and Abmuno Therapeutics LLC; and strategic relationship with WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was founded in 2015 and is based in Hayward, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Hayward"
    },
    "RECI-B.ST": {
        "short_name": "Recipharm AB ser. B",
        "long_name": "Recipharm AB (publ)",
        "summary": "Recipharm AB (publ) provides contract development and manufacturing solutions to the pharmaceutical industry in Sweden, Italy, France, India, Spain, Portugal, Germany, and internationally. It operates through three segments: Manufacturing Steriles & Inhalation, Manufacturing Solids and Others, and Development and Technology. The company manufactures liquid vials and ampoules, lyophilisates, and blow-fill-seal products and inhalation; and tablets, capsules, semi-solids, and non-sterile liquids on behalf of pharmaceutical companies. It also provides supplementary services, such as regulatory, supply chain, active life cycle management, and stability studies and analytical method development services, as well as gateway release and testing services. In addition, the company offers pharmaceutical development services based on various technologies, such as drug substance, drug product, and clinical services to pharmaceutical companies in the drug development phase for new pharmaceuticals; and access to a range of proprietary technologies and intellectual property. Further, it supplies medical devices and veterinary products; and solid, semi-solid, liquid, injectable, and ophthalmic products, as well as serialization services. The company serves various pharma, and research and development companies. The company was founded in 1995 and is headquartered in Stockholm, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Stockholm"
    },
    "REDX.L": {
        "short_name": "REDX PHARMA PLC ORD 1P",
        "long_name": "Redx Pharma Plc",
        "summary": "Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company is developing RXC004, a porcupine inhibitor, which has completed Phase I clinical development for the treatment of colorectal, pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory intestinal fibrosis; RXC007, a Rho-associated protein kinase 2 inhibitors for the treatment of orphan disease, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, and other systemic fibrotic conditions; and Porcupine (RXC006), which is in Phase I for the treatment of lung fibrosis. Redx Pharma Plc has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. The company was founded in 2010 and is based in Macclesfield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Macclesfield"
    },
    "REGMF": {
        "short_name": "REMEGEN CO LTD",
        "long_name": "RemeGen Co., Ltd.",
        "summary": "RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in the People's Republic of China and internationally. The company's products in various stages of development include Telitacicept (RC18) for use in the treatment of autoimmune diseases, such as systemic lupus erythematosus, neuromyelitis optica spectrum disorder, rheumatoid arthritis, IgA nephritis, Sj\u00c3\u00b6gren's syndrome, multiple sclerosis, and myasthenia gravis; and Disitamab Vedotin (RC48) and RC98 for use in the treatment of various cancers. It is also developing RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; and RC88, which is in Phase 1 clinical trials for use in the treatment of diabetic macular edema, as well as pre-clinical products, such as RC108, RC118, RC138, RC148, and RC158 to treat various solid tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Yantai"
    },
    "REGN": {
        "short_name": "Regeneron Pharmaceuticals, Inc.",
        "long_name": "Regeneron Pharmaceuticals, Inc.",
        "summary": "Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Tarrytown"
    },
    "REGN.MX": {
        "short_name": "REGENERON PHARMACEUTICALS INC",
        "long_name": "Regeneron Pharmaceuticals, Inc.",
        "summary": "Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Tarrytown"
    },
    "REGN.VI": {
        "short_name": "REGENERON PHARMACEUTICALS",
        "long_name": "Regeneron Pharmaceuticals, Inc.",
        "summary": "Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "city": "Tarrytown"
    },
    "REGN34.SA": {
        "short_name": "REGENERON PHDRN",
        "long_name": "Regeneron Pharmaceuticals, Inc.",
        "summary": "Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "city": "Tarrytown"
    },
    "RENE.L": {
        "short_name": "RENEURON GROUP PLC ORD 1P",
        "long_name": "ReNeuron Group plc",
        "summary": "ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Pencoed"
    },
    "REPCF": {
        "short_name": "REPLICEL LIFE SCIENCES INC",
        "long_name": "RepliCel Life Sciences Inc.",
        "summary": "RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that has completed Phase I clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase II clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "REPL": {
        "short_name": "Replimune Group, Inc.",
        "long_name": "Replimune Group, Inc.",
        "summary": "Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Woburn"
    },
    "RETA": {
        "short_name": "Reata Pharmaceuticals, Inc.",
        "long_name": "Reata Pharmaceuticals, Inc.",
        "summary": "Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Plano"
    },
    "RFL": {
        "short_name": "Rafael Holdings, Inc.",
        "long_name": "Rafael Holdings, Inc.",
        "summary": "Rafael Holdings, Inc. owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Newark"
    },
    "RFL.F": {
        "short_name": "TYME TECHNOLOGIES DL-0001",
        "long_name": "Tyme Technologies, Inc.",
        "summary": "Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "RFL.SG": {
        "short_name": "Tyme Technologies Inc. Register",
        "long_name": "Tyme Technologies, Inc.",
        "summary": "Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "RFM.SG": {
        "short_name": "Sensorion S.A. Actions au Porte",
        "long_name": "Sensorion SA",
        "summary": "Sensorion SA, a biopharmaceutical company, develops therapies for the treatment of inner ear disorders. The company develops SENS-111, which is in phase II clinical trials to treat acute unilateral vestibulopathy; and SENS-401 that is in phase I clinical trials to treat sudden sensorineural hearing loss. It also develops SENS-300, which is under the pre-clinical stage for use in inner ear toxicity treatment. The company has a strategic collaboration with Cochlear Limited to study combination therapies for cochlear implant patients. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "France",
        "city": "Montpellier"
    },
    "RFS.F": {
        "short_name": "RESVERLOGIX CORP",
        "long_name": "Resverlogix Corp.",
        "summary": "Resverlogix Corp. operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. Resverlogix Corp. is headquartered in Calgary, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Calgary"
    },
    "RGBP": {
        "short_name": "REGEN BIOPHARMA INC",
        "long_name": "Regen BioPharma, Inc.",
        "summary": "Regen BioPharma, Inc. focuses on the development of small molecule therapies for treating cancer and autoimmune disorders in the United States. The company intends to develop small molecule NR2F6 that activates to immune cell for oncology and autoimmune diseases. The company was founded in 2012 and is based in La Mesa, California. Regen BioPharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "La Mesa"
    },
    "RGBPP": {
        "short_name": "REGEN BIOPHARMA INC",
        "long_name": "Regen BioPharma, Inc.",
        "summary": "Regen BioPharma, Inc. focuses on the development of small molecule therapies for treating cancer and autoimmune disorders in the United States. The company intends to develop small molecule NR2F6 that activates to immune cell for oncology and autoimmune diseases. The company was founded in 2012 and is based in La Mesa, California. Regen BioPharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "La Mesa"
    },
    "RGLS": {
        "short_name": "Regulus Therapeutics Inc.",
        "long_name": "Regulus Therapeutics Inc.",
        "summary": "Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "RGNX": {
        "short_name": "REGENXBIO Inc.",
        "long_name": "REGENXBIO Inc.",
        "summary": "REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Rockville"
    },
    "RGRX": {
        "short_name": "REGENERX BIOPHARMACEUTICALS",
        "long_name": "RegeneRx Biopharmaceuticals, Inc.",
        "summary": "RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. It is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is based in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Rockville"
    },
    "RI2A.F": {
        "short_name": "RIGEL PHARMACEUT. DL-,001",
        "long_name": "Rigel Pharmaceuticals, Inc.",
        "summary": "Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trials for warm autoimmune hemolytic anemia; R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trials for autoimmune and inflammatory diseases; and R552, a receptor-interacting protein kinase Inhibitor that is in phase I clinical trials for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "RIGL": {
        "short_name": "Rigel Pharmaceuticals, Inc.",
        "long_name": "Rigel Pharmaceuticals, Inc.",
        "summary": "Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trials for warm autoimmune hemolytic anemia; R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trials for autoimmune and inflammatory diseases; and R552, a receptor-interacting protein kinase Inhibitor that is in phase I clinical trials for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "RLAY": {
        "short_name": "Relay Therapeutics, Inc.",
        "long_name": "Relay Therapeutics, Inc.",
        "summary": "Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "RLF.SW": {
        "short_name": "RELIEF THERAPEUTICS N",
        "long_name": "Relief Therapeutics Holding AG",
        "summary": "Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief in serious diseases with high unmet medical need. The company focuses on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases. Relief Therapeutics Holding AG is based in Geneva, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Geneva"
    },
    "RLFTF": {
        "short_name": "RELIEF THERAPEUTICS HOLDING AG",
        "long_name": "Relief Therapeutics Holding AG",
        "summary": "Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief in serious diseases with high unmet medical need. The company focuses on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases. Relief Therapeutics Holding AG is based in Geneva, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Geneva"
    },
    "RMN.F": {
        "short_name": "MEDICINOVA  NEW  DL-,001",
        "long_name": "MediciNova, Inc.",
        "summary": "MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "La Jolla"
    },
    "RNA": {
        "short_name": "Avidity Biosciences, Inc.",
        "long_name": "Avidity Biosciences, Inc.",
        "summary": "Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "La Jolla"
    },
    "RNUGF": {
        "short_name": "RENEURON GROUP",
        "long_name": "ReNeuron Group plc",
        "summary": "ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Pencoed"
    },
    "ROVI.MC": {
        "short_name": "LABORATORIOS FARMACEUTICOS ROVI",
        "long_name": "Laboratorios Farmaceuticos Rovi, S.A.",
        "summary": "Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company also distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent thromboembolic disease; Enoxaparin biosimilar, a low-molecular-weight heparin; Neparvis for the treatment of symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for the treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebr\u00c3\u00a1n that are prescription medicines for treatment of attention deficit hyperactivity disorder in children and adolescents. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Expr\u00c3\u00a8s that are contrast injection systems and compatible disposable material. In addition, it provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing COVID-19 vaccine candidate. Laboratorios Farmaceuticos Rovi, S.A. was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmace\u00c3\u00baticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MCE",
        "market": "es_market",
        "country": "Spain",
        "city": "Madrid"
    },
    "RP.V": {
        "short_name": "REPLICEL LIFE SCIENCES INC",
        "long_name": "RepliCel Life Sciences Inc.",
        "summary": "RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that has completed Phase I clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase II clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "RPD.MU": {
        "short_name": "ROYALTY PHARMA OA DL-0001",
        "long_name": "Royalty Pharma plc",
        "summary": "Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. The company has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. Royalty Pharma plc was founded in 1996 and is based in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "RPRX": {
        "short_name": "Royalty Pharma plc",
        "long_name": "Royalty Pharma plc",
        "summary": "Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. The company has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. Royalty Pharma plc was founded in 1996 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "RPTX": {
        "short_name": "Repare Therapeutics Inc.",
        "long_name": "Repare Therapeutics Inc.",
        "summary": "Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing CCNE1-SL inhibitor, a proprietary drug discovery program for tumors with amplification of CCNE1; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was founded in 2016 and is headquartered in Montr\u00c3\u00a9al, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Canada",
        "city": "Montreal"
    },
    "RQE1.F": {
        "short_name": "RENEURON GRP PLC  LS-,01",
        "long_name": "ReNeuron Group plc",
        "summary": "ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Pencoed"
    },
    "RSPID": {
        "short_name": "RESPIRERX PHARMACEUTICALS INC",
        "long_name": "RespireRx Pharmaceuticals Inc.",
        "summary": "RespireRx Pharmaceuticals Inc. engages in the discovery and development of pharmaceuticals for the treatment of respiratory disorders. It has two drug platforms comprising ampakines, which are small molecule compounds to enhance the excitatory actions of the neurotransmitter glutamate at the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor complex; and cannabinoids, primarily dronabinol, a synthetic derivative for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS. The company's lead ampakine, CX1739, which is in Phase II clinical studies for drug-induced respiratory depression (RD), as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven respiratory disorders, neurobehavioral disorders, spinal cord injury, neurological diseases, and orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was founded in 1987 and is headquartered in Glen Rock, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Glen Rock"
    },
    "RTALB.IS": {
        "short_name": "RTA LABORATUVARLARI",
        "long_name": "RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S.",
        "summary": "RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of molecular diagnostic kits, industrial products, and biomedical instruments in Turkey. It offers microbiology products, including petri dish, tube and bottle, chromogenic media, blood culture bottle, tuberculosis diagnostic, rapid test, microbiological stain, hygislide, surcheck media, membrane, and swab products; and molecular biology products, such as nucleic acid isolation kits, real time PCR kits, and voltran viral load detection systems. The company was founded in 1996 and is based in Kocaeli, Turkey.",
        "currency": "TRY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "IST",
        "market": "tr_market",
        "country": "Turkey",
        "city": "Kocaeli"
    },
    "RTI.F": {
        "short_name": "REVANCE THERAPEUT.DL-,001",
        "long_name": "Revance Therapeutics, Inc.",
        "summary": "Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Newark"
    },
    "RTQ1.F": {
        "short_name": "AVACTA GROUP PLC  LS-,10",
        "long_name": "Avacta Group Plc",
        "summary": "Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in Diagnostics, Therapeutics, and Animal Health segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Wetherby"
    },
    "RTRA.F": {
        "short_name": "TIZIANA LI.ADR /2 LS-,03",
        "long_name": "Tiziana Life Sciences PLC",
        "summary": "Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "RUBY": {
        "short_name": "Rubius Therapeutics, Inc.",
        "long_name": "Rubius Therapeutics, Inc.",
        "summary": "Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "RV41.F": {
        "short_name": "FENNEC PHARMACEUT.",
        "long_name": "Fennec Pharmaceuticals Inc.",
        "summary": "Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Research Triangle Park"
    },
    "RV7.F": {
        "short_name": "HALOZYME THERAPEU.DL-,001",
        "long_name": "Halozyme Therapeutics, Inc.",
        "summary": "Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "RVMD": {
        "short_name": "Revolution Medicines, Inc.",
        "long_name": "Revolution Medicines, Inc.",
        "summary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "RVNC": {
        "short_name": "Revance Therapeutics, Inc.",
        "long_name": "Revance Therapeutics, Inc.",
        "summary": "Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Newark"
    },
    "RVPH": {
        "short_name": "Reviva Pharmaceuticals Holdings",
        "long_name": "Reviva Pharmaceuticals Holdings, Inc.",
        "summary": "Reviva Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, as well as for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. The company is based in Cupertino, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cupertino"
    },
    "RVW1.F": {
        "short_name": "PHYSIOMICS PLC  LS -,004",
        "long_name": "Physiomics Plc",
        "summary": "Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the European Union, and the United States. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "RVX.TO": {
        "short_name": "RESVERLOGIX CORP.",
        "long_name": "Resverlogix Corp.",
        "summary": "Resverlogix Corp. operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. Resverlogix Corp. is headquartered in Calgary, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Calgary"
    },
    "RVXCF": {
        "short_name": "RESVERLOGIX CORP",
        "long_name": "Resverlogix Corp.",
        "summary": "Resverlogix Corp. operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. Resverlogix Corp. is headquartered in Calgary, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Calgary"
    },
    "RXK3.F": {
        "short_name": "SELLAS LIFE SCIENCES GRP",
        "long_name": "SELLAS Life Sciences Group, Inc.",
        "summary": "SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials for the treatment of breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "New York"
    },
    "RYIS.F": {
        "short_name": "SUNESIS PHARMAC. DL-,0001",
        "long_name": "Sunesis Pharmaceuticals, Inc.",
        "summary": "Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "RYTM": {
        "short_name": "Rhythm Pharmaceuticals, Inc.",
        "long_name": "Rhythm Pharmaceuticals, Inc.",
        "summary": "Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alstr\u00c3\u00b6m syndrome; and is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "RYTM.MX": {
        "short_name": "RHYTHM PHARMACEUTICALS INC",
        "long_name": "Rhythm Pharmaceuticals, Inc.",
        "summary": "Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alstr\u00c3\u00b6m syndrome; and is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Boston"
    },
    "RZLT": {
        "short_name": "Rezolute, Inc.",
        "long_name": "Rezolute, Inc.",
        "summary": "Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "S09.F": {
        "short_name": "SUTRO BIOPHARMA  DL-,001",
        "long_name": "Sutro Biopharma, Inc.",
        "summary": "Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "S1BA.F": {
        "short_name": "STEALTH BIOTH. SP.ADR/12",
        "long_name": "Stealth BioTherapeutics Corp",
        "summary": "Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Cayman Islands",
        "city": "George Town"
    },
    "S1GE34.SA": {
        "short_name": "SEAGEN      DRN",
        "long_name": "Seagen Inc.",
        "summary": "Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "city": "Bothell"
    },
    "S1RP34.SA": {
        "short_name": "SAREPTA THERDRN",
        "long_name": "Sarepta Therapeutics, Inc.",
        "summary": "Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "S4BA.F": {
        "short_name": "F-STAR THERAPEUT.DL-,0001",
        "long_name": "F-star Therapeutics, Inc.",
        "summary": "F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "SAGE": {
        "short_name": "Sage Therapeutics, Inc.",
        "long_name": "Sage Therapeutics, Inc.",
        "summary": "Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217; Biogen Inc. to develop and commercialize zuranolone (SAGE-217) for various depressive disorder, postpartum depression, and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders; and Biogen MA Inc. and Biogen International GmbH for the development, manufacture, and commercialization of products containing SAGE-217 molecule and products containing the SAGE-324 molecule. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "SANION.ST": {
        "short_name": "Saniona AB",
        "long_name": "Saniona AB (publ)",
        "summary": "Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The company's products include Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase III clinical trials to treat obesity; Tesomet, a fix-dose combination of tesofensine and metoprolol that is in Phase II clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; NS2359, a triple monoamine reuptake inhibitor that is in Phase II clinical trial for cocaine addiction; and CAD-1883 that is in Phase II clinical trial for tremor and spinocerebellar ataxia. It is also developing SAN711 for chronic itching and neuropathic pain; Boehringer Ingelheim program for schizophrenia; IK program for inflammatory bowel diseases; Nicotinic-a6 program for parkinson's diseases; Kv7 program for pain, epilepsy, and urinary incontinence; and SAN903 for autoimmune disorders. Saniona AB (publ) was founded in 2011 and is headquartered in Ballerup, Denmark.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Denmark",
        "city": "Ballerup"
    },
    "SANN.SW": {
        "short_name": "SANTHERA N",
        "long_name": "Santhera Pharmaceuticals Holding AG",
        "summary": "Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. It is developing Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage, or age. The company's late stage drug candidates include Puldysa (idebenone) and vamorolone, which are being developed as treatments for DMD. Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies. The company also out-licenses ex-North American rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. It had collaboration agreement with Cold Spring Harbor Laboratory to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase, as a therapeutic intervention for COVID-19-related acute respiratory distress syndrome. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Switzerland",
        "city": "Pratteln"
    },
    "SAR.L": {
        "short_name": "SAREUM HOLDINGS PLC ORD 0.025P",
        "long_name": "Sareum Holdings plc",
        "summary": "Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "SAVA": {
        "short_name": "Cassava Sciences, Inc.",
        "long_name": "Cassava Sciences, Inc.",
        "summary": "Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "SBBP": {
        "short_name": "Strongbridge Biopharma plc",
        "long_name": "Strongbridge Biopharma plc",
        "summary": "Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Trevose"
    },
    "SBH.HM": {
        "short_name": "SANGUI BIOTECH INTL",
        "long_name": "Sangui Biotech International, Inc.",
        "summary": "Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HAM",
        "market": "dr_market",
        "country": "Germany",
        "city": "Hamburg"
    },
    "SBHMY": {
        "short_name": "SINO BIOPHARMACEUTICAL",
        "long_name": "Sino Biopharmaceutical Limited",
        "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Hong Kong",
        "city": "Wan Chai"
    },
    "SBM.V": {
        "short_name": "SIRONA BIOCHEM CORP.",
        "long_name": "Sirona Biochem Corp.",
        "summary": "Sirona Biochem Corp. develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. The company develops programs in the areas of diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "SBMFF": {
        "short_name": "SINO BIOPHARMACEUTICAL",
        "long_name": "Sino Biopharmaceutical Limited",
        "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Hong Kong",
        "city": "Wan Chai"
    },
    "SBTX": {
        "short_name": "Silverback Therapeutics, Inc.",
        "long_name": "Silverback Therapeutics, Inc.",
        "summary": "Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was founded in 2016 and is headquartered in Seattle, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Seattle"
    },
    "SBTX.L": {
        "short_name": "SKINBIOTHERAPEUTICS PLC ORD 1P",
        "long_name": "SkinBioTherapeutics Plc",
        "summary": "SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. The company focuses on the development of SkinBiotix technology for use in cosmetic, infection control, and eczema applications. It has an agreement with Croda International Plc for the design and manufacture of a new active cosmetic skincare ingredient based on its SkinBiotix skin microbiome technology. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Macclesfield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Macclesfield"
    },
    "SCLP.L": {
        "short_name": "SCANCELL HOLDINGS PLC ORD 0.1P",
        "long_name": "Scancell Holdings plc",
        "summary": "Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "SCP.F": {
        "short_name": "SCANCELL HLDGS  LS -,001",
        "long_name": "Scancell Holdings plc",
        "summary": "Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "SCPH": {
        "short_name": "scPharmaceuticals Inc.",
        "long_name": "scPharmaceuticals Inc.",
        "summary": "scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Burlington"
    },
    "SCPS": {
        "short_name": "Scopus BioPharma Inc.",
        "long_name": "Scopus BioPharma Inc.",
        "summary": "Scopus BioPharma Inc. develops therapeutics drugs targeting the endocannabinoid system. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December, 2017. The company was incorporated in 2017 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "SEEL": {
        "short_name": "Seelos Therapeutics, Inc.",
        "long_name": "Seelos Therapeutics, Inc.",
        "summary": "Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "SEER": {
        "short_name": "Seer, Inc.",
        "long_name": "Seer, Inc.",
        "summary": "Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration program agreement with Discovery Life Sciences, LLC; and commercial agreements with Bruker Scientific LLC and Thermo Electron North America LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Redwood City"
    },
    "SELB": {
        "short_name": "Selecta Biosciences, Inc.",
        "long_name": "Selecta Biosciences, Inc.",
        "summary": "Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; BIND Therapeutics, Inc.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Watertown"
    },
    "SESN": {
        "short_name": "Sesen Bio, Inc.",
        "long_name": "Sesen Bio, Inc.",
        "summary": "Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in phase 3 clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate for use in the treatment of various types of EpCAM-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "SFYC.F": {
        "short_name": "SYNTHETIC BIOLOG.DL -,001",
        "long_name": "Synthetic Biologics, Inc.",
        "summary": "Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Rockville"
    },
    "SGBI": {
        "short_name": "SANGUI BIOTECH INTERNATIONAL",
        "long_name": "Sangui Biotech International, Inc.",
        "summary": "Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Hamburg"
    },
    "SGEN": {
        "short_name": "Seagen Inc.",
        "long_name": "Seagen Inc.",
        "summary": "Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Bothell"
    },
    "SGMO": {
        "short_name": "Sangamo Therapeutics, Inc.",
        "long_name": "Sangamo Therapeutics, Inc.",
        "summary": "Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression. Its therapeutic products that are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; ST-920 gene therapy for Fabry disease; ST-101 gene therapy for phenylketonuria; ST-400 and BIVV-003 for the treatment of hemoglobinopathies; SB-913 for the treatment of Mucopolysaccharidosis type II; SB-318 for the treatment of Mucopolysaccharidosis type I; and SB-FIX for the treatment of hemophilia B. The company has collaborative and strategic partnerships with Biogen Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Brisbane"
    },
    "SGT.F": {
        "short_name": "SEAGEN INC.  DL-,001",
        "long_name": "Seagen Inc.",
        "summary": "Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Bothell"
    },
    "SGTX": {
        "short_name": "Sigilon Therapeutics, Inc.",
        "long_name": "Sigilon Therapeutics, Inc.",
        "summary": "Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "SIGA": {
        "short_name": "SIGA Technologies Inc.",
        "long_name": "SIGA Technologies, Inc.",
        "summary": "SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "SIGHT.PA": {
        "short_name": "GENSIGHT BIOLOGICS",
        "long_name": "GenSight Biologics S.A.",
        "summary": "GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery and development of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial target sequence and optogenetics technology platforms. Its lead product candidates include GS010, an AAV2 based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by mutation of the ND4 gene; and GS030 that is in Phase I/II trial for the treatment of retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "SIGY": {
        "short_name": "SIGYN THERAPEUTICS INC",
        "long_name": "Sigyn Therapeutics, Inc.",
        "summary": "Sigyn Therapeutics, Inc. operates as a therapeutic technology company that treats inflammatory conditions by cytokine storm syndrome. It offers Sigyn Therapy, a blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Sigyn Therapeutics, Inc. was incorporated in 2019 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "SILO": {
        "short_name": "SILO PHARMA INC",
        "long_name": "Silo Pharma Inc.",
        "summary": "Silo Pharma Inc. operates as an early stage biopharmaceutical company. It focuses on the use of psychedelic therapeutics for patients suffering from various indications, such as depression, PTSD, Alzheimer's, and other rare neurological disorders. The company was formerly known as Uppercut Brands Inc. and changed its name to Silo Pharma Inc. in September 2020. Silo Pharma Inc. was incorporated in 2010 and is based in Teaneck, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Teaneck"
    },
    "SIMRIS-B.ST": {
        "short_name": "Simris Alg AB ser. B",
        "long_name": "Simris Alg AB (publ)",
        "summary": "Simris Alg AB (publ) manufactures and sells dietary supplements and algae-based foods in Sweden and internationally. It offers Simris Algae Omega-3, a plant-based marine omega-3 EPA and DHA line; and a line of algae-based products, such as finest chlorella, spirulina sprinkles, boosting astaxanthin, flower power algae tea, and sun candy algae tea under the Simris Select brand. The company was founded in 2010 and is headquartered in Hammenh\u00c3\u00b6g, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Hammenh\u00c3\u00b6g"
    },
    "SIOX": {
        "short_name": "Sio Gene Therapies Inc.",
        "long_name": "Sio Gene Therapies, Inc.",
        "summary": "Sio Gene Therapies, Inc., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was founded in 2014 and is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "SKIN.SW": {
        "short_name": "CASSIOPEA N",
        "long_name": "Cassiopea S.p.A.",
        "summary": "Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Italy",
        "city": "Lainate"
    },
    "SKYE": {
        "short_name": "SKYE BIOSCIENCE INC",
        "long_name": "Skye Bioscience, Inc.",
        "summary": "Skye Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "SLGL": {
        "short_name": "Sol-Gel Technologies Ltd.",
        "long_name": "Sol-Gel Technologies Ltd.",
        "summary": "Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, which has completed Phase II clinical trials for the treatment of acne vulgaris; Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea; SGT-210, a epidermal growth factor receptor inhibitor, which is in development for the treatment of palmoplantar keratoderma and non-melanoma skin cancer; and tapinarof and roflumilast to treat psoriasis and other dermatological indications. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Ness Ziona"
    },
    "SLGN.TA": {
        "short_name": "SOLEGREEN LTD",
        "long_name": "Solegreen Ltd",
        "summary": "Solegreen Ltd engages in the renewable energy business in Israel. It operates and maintains solar energy facilities. The company was formerly known as Procognia (Israel) Ltd. and changed its name to Solegreen Ltd in January 2015. Solegreen Ltd was founded in 2000 and is based in Herzliya, Israel. As per the transaction announced on September 3, 2018, Solegreen Ltd operates as a subsidiary of Lahav Green Mountains Ltd.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TLV",
        "market": "il_market",
        "country": "Israel",
        "city": "Tel Aviv"
    },
    "SLN": {
        "short_name": "Silence Therapeutics Plc - Amer",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "SLN.L": {
        "short_name": "SILENCE THERAPEUTICS PLC ORD 5P",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "SLNCF": {
        "short_name": "SILENCE THERAPEUTICS PLC",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "SLRX": {
        "short_name": "Salarius Pharmaceuticals, Inc.",
        "long_name": "Salarius Pharmaceuticals, Inc.",
        "summary": "Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Houston"
    },
    "SLS": {
        "short_name": "SELLAS Life Sciences Group, Inc",
        "long_name": "SELLAS Life Sciences Group, Inc.",
        "summary": "SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials for the treatment of breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "SLZ.F": {
        "short_name": "ENVERIC BIOSCI.INC.DL-,01",
        "long_name": "Enveric Biosciences, Inc.",
        "summary": "Jay Pharma Inc. develops evidence-based cannabinoid products and combination therapies cure effects of cancer treatment. The company was incorporated in 2017 and is based in Toronto, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "SMMT": {
        "short_name": "Summit Therapeutics Inc.",
        "long_name": "Summit Therapeutics Inc.",
        "summary": "Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. Summit Therapeutics Inc. was founded in 2003 and is based in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "SMSLIFE.NS": {
        "short_name": "SMS LIFESCIENCES",
        "long_name": "SMS Lifesciences India Limited",
        "summary": "SMS Lifesciences India Limited researches, develops, manufactures, buys, imports, and sells active pharmaceutical ingredients (API) and its intermediates, organic and inorganic chemicals, and pharmaceuticals in India and internationally. The company offers APIs in various therapeutic areas, such as antiulcer, antifungal, and erectile dysfunction. It also provides consultancy services; and contract manufacturing services for APIs and intermediates. In addition, the company exports its products. The company was founded in 1990 and is based in Hyderabad, India.",
        "currency": "INR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NSI",
        "market": "in_market",
        "country": "India",
        "city": "Hyderabad"
    },
    "SMZ1.F": {
        "short_name": "SINO BIOPH.SUBDIV.HD-,025",
        "long_name": "Sino Biopharmaceutical Limited",
        "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Hong Kong",
        "city": "Wan Chai"
    },
    "SMZU.F": {
        "short_name": "SINO BIOPHARM. UNS.ADR/20",
        "long_name": "Sino Biopharmaceutical Limited",
        "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Hong Kong",
        "city": "Wan Chai"
    },
    "SNCA": {
        "short_name": "Seneca Biopharma, Inc.",
        "long_name": "Seneca Biopharma, Inc.",
        "summary": "Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been completed Phase II clinical trials for the treatment of major depressive disorder; and NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Germantown"
    },
    "SNDX": {
        "short_name": "Syndax Pharmaceuticals, Inc.",
        "long_name": "Syndax Pharmaceuticals, Inc.",
        "summary": "Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Waltham"
    },
    "SNG.L": {
        "short_name": "SYNAIRGEN PLC ORD 1P",
        "long_name": "Synairgen plc",
        "summary": "Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-\u00c3\u009f), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-\u00c3\u009f that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Southampton"
    },
    "SNGX": {
        "short_name": "Soligenix, Inc.",
        "long_name": "Soligenix, Inc.",
        "summary": "Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Princeton"
    },
    "SNNAQ": {
        "short_name": "SIENNA BIOPHARMACEUTICALS INC",
        "long_name": "Sienna Biopharmaceuticals, Inc.",
        "summary": "Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Westlake Village"
    },
    "SNPX": {
        "short_name": "SYNAPTOGENIX INC",
        "long_name": "Synaptogenix",
        "summary": "Neurotrope Bioscience, Inc. operates in the healthcare industry focusing on pharmaceutical business. The company engages in the research and development of bryostatin-1 in the treatment of alzheimer's disease. The company was incorporated in 2012 and is headquartered in New York, New York. Neurotrope Bioscience, Inc. operates independently of Neurotrope, Inc. as of December 2, 2020.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "SNSS": {
        "short_name": "Sunesis Pharmaceuticals, Inc.",
        "long_name": "Sunesis Pharmaceuticals, Inc.",
        "summary": "Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "SOAN": {
        "short_name": "ANGIOSOMA INC",
        "long_name": "AngioSoma, Inc.",
        "summary": "AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Houston"
    },
    "SOFTX.OL": {
        "short_name": "SOFTOX SOLUTIONS",
        "long_name": "SoftOx Solutions AS",
        "summary": "SoftOx Solutions AS, together with its subsidiaries, operates as a medtech company in Norway. Its SoftOx technology kills the microorganisms in biofilms by acting on various microbial components. The company engages in the development of SoftOx Wound Irrigation Solution that is under preclinical studies for the prevention and treatment of infections on breached or compromised skin, including acute wounds and skin lesions in patients with eczema; and SoftOx Biofilm Eradicator, which is in preclinical studies to treat biofilm infections in non-healing chronic wounds. The company was founded in 2012 and is headquartered in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "SOLTF": {
        "short_name": "SOSEI GROUP CORP",
        "long_name": "Sosei Group Corporation",
        "summary": "Sosei Group Corporation discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of AZD4635, an adenosine A2a antagonist, which is in Phase II clinical trial for the treatment of solid tumors and metastatic castration resistant prostate cancer; HTL0016878, a muscarinic M4 agonist, which is in Phase I clinical trial for the treatment of Alzheimer's disease; and dual muscarinic M1/M4 agonist, which is in pre-clinical stage for the treatment of Alzheimer's disease. It also develops HTL0014242, a mGlu5 small molecule negative-allosteric modulator, which is in Phase I clinical trial for the treatment of certain neurological order; SSTR agonist, a novel somatostatin peptide agonist, which is in Phase I clinical trial for the treatment of endocrine disorders; HTL0022562, a calcitonin gene related peptide antagonist, which is in pre-clinical stage for the treatment of migraine and other severe headaches; GLP-1 antagonist, a potent glucagon-like peptide-1 antagonist, which is in pre-clinical stage for the treatment of severe hypoglycaemia in rare diseases; and GLP-2 agonist, a potent glucagon-like peptide-2 agonist, which is in pre-clinical stage for the treatment of intestinal disorders. In addition, the company's pipeline products include OX-1 antagonist to treat cocaine-use disorders; Apelin agonist for pulmonary arterial hypertension; GPR35 agonist to treat inflammatory bowel disease; H4 antagonist and PAR2 mAb for atopic dermatitis. Sosei Group Corporation has a strategic collaboration with Kymab, PeptiDream Inc., Pfizer, MorphoSys, Genentech, Takeda Pharmaceutical Company Limited, and Captor Therapeutics SA. The company was founded in 1990 and is headquartered in Tokyo, Japan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Japan",
        "city": "Tokyo"
    },
    "SONN": {
        "short_name": "Sonnet BioTherapeutics Holdings",
        "long_name": "Sonnet BioTherapeutics Holdings, Inc.",
        "summary": "Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Princeton"
    },
    "SPHDF": {
        "short_name": "SANTHERA PHARMACEUTICALS HOLDIN",
        "long_name": "Santhera Pharmaceuticals Holding AG",
        "summary": "Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. It is developing Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage, or age. The company's late stage drug candidates include Puldysa (idebenone) and vamorolone, which are being developed as treatments for DMD. Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies. The company also out-licenses ex-North American rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. It had collaboration agreement with Cold Spring Harbor Laboratory to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase, as a therapeutic intervention for COVID-19-related acute respiratory distress syndrome. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Pratteln"
    },
    "SPHRF": {
        "short_name": "STARPHARMA HOLDINGS LIMITED",
        "long_name": "Starpharma Holdings Limited",
        "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Abbotsford"
    },
    "SPHRY": {
        "short_name": "STARPHARMA HOLDINGS LIMITED",
        "long_name": "Starpharma Holdings Limited",
        "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Australia",
        "city": "Abbotsford"
    },
    "SPHS": {
        "short_name": "SOPHIRIS BIO INC",
        "long_name": "Sophiris Bio, Inc.",
        "summary": "Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "La Jolla"
    },
    "SPL.AX": {
        "short_name": "STARPHARMA FPO",
        "long_name": "Starpharma Holdings Limited",
        "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Abbotsford"
    },
    "SPPI": {
        "short_name": "Spectrum Pharmaceuticals, Inc.",
        "long_name": "Spectrum Pharmaceuticals, Inc.",
        "summary": "Spectrum Pharmaceuticals, Inc., a biopharma company, develops and commercializes oncology and hematology drug products. The company is developing ROLONTIS, a novel long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFN\u00c3\u00a1, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of relapsed or refractory non-Hodgkin's lymphoma patients, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. for interferon therapeutics drug delivery platform. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Henderson"
    },
    "SPRB": {
        "short_name": "Spruce Biosciences, Inc.",
        "long_name": "Spruce Biosciences, Inc.",
        "summary": "Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Daly City"
    },
    "SPRO": {
        "short_name": "Spero Therapeutics, Inc.",
        "long_name": "Spero Therapeutics, Inc.",
        "summary": "Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "SQZ": {
        "short_name": "SQZ Biotechnologies Company",
        "long_name": "SQZ Biotechnologies Company",
        "summary": "SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company's lead product candidate, SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United States",
        "city": "Watertown"
    },
    "SRBCF": {
        "short_name": "SIRONA BIOCHEM CORPORATION",
        "long_name": "Sirona Biochem Corp.",
        "summary": "Sirona Biochem Corp. develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. The company develops programs in the areas of diabetes, anti-inflammatories, and anti-infectives for therapeutics; anti-aging and depigmenting agents in cosmeceuticals; and biological ingredients, such as inducers and adjuvants for the biological development and preservation. It develops a sodium glucose co-transporter inhibitor for the treatment of diabetes, as well as cosmetic skin lightening agents and compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "SRNE": {
        "short_name": "Sorrento Therapeutics, Inc.",
        "long_name": "Sorrento Therapeutics, Inc.",
        "summary": "Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "SRPT": {
        "short_name": "Sarepta Therapeutics, Inc.",
        "long_name": "Sarepta Therapeutics, Inc.",
        "summary": "Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "SRRA": {
        "short_name": "Sierra Oncology, Inc.",
        "long_name": "Sierra Oncology, Inc.",
        "summary": "Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor Checkpoint kinase 1 is being investigated in two Phase 1/2 clinical trials; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "SRRK": {
        "short_name": "Scholar Rock Holding Corporatio",
        "long_name": "Scholar Rock Holding Corporation",
        "summary": "Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, a novel inhibitor of the activation of myostatin, which is in Phase II clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "STABL.ST": {
        "short_name": "Stayble Therapeutics AB",
        "long_name": "Stayble Therapeutics AB (publ)",
        "summary": "Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) is based in Gothenburg, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Gothenburg"
    },
    "STOK": {
        "short_name": "Stoke Therapeutics, Inc.",
        "long_name": "Stoke Therapeutics, Inc.",
        "summary": "Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Bedford"
    },
    "STRO": {
        "short_name": "Sutro Biopharma, Inc.",
        "long_name": "Sutro Biopharma, Inc.",
        "summary": "Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "STSA": {
        "short_name": "Satsuma Pharmaceuticals, Inc.",
        "long_name": "Satsuma Pharmaceuticals, Inc.",
        "summary": "Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "STTK": {
        "short_name": "Shattuck Labs, Inc.",
        "long_name": "Shattuck Labs, Inc.",
        "summary": "Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "SUD.AX": {
        "short_name": "SUDA FPO",
        "long_name": "Suda Pharmaceuticals Ltd",
        "summary": "Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Osborne Park"
    },
    "SURF": {
        "short_name": "Surface Oncology, Inc.",
        "long_name": "Surface Oncology, Inc.",
        "summary": "Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDA\u00c3\u0082 (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "SVRA": {
        "short_name": "Savara, Inc.",
        "long_name": "Savara Inc.",
        "summary": "Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; Phase IIa development stage for treating nontuberculous mycobacterial (NTM) lung infection; and in Phase IIa development stage for the treatment of NTM lung infection in people living with cystic fibrosis. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III development stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "SWTX": {
        "short_name": "SpringWorks Therapeutics, Inc.",
        "long_name": "SpringWorks Therapeutics, Inc.",
        "summary": "SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in preclinical trials for the treatment of RRMM. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase Ib clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Stamford"
    },
    "SYBX": {
        "short_name": "Synlogic, Inc.",
        "long_name": "Synlogic, Inc.",
        "summary": "Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "SYGGF": {
        "short_name": "SYNAIRGEN",
        "long_name": "Synairgen plc",
        "summary": "Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-\u00c3\u009f), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-\u00c3\u009f that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Southampton"
    },
    "SYN": {
        "short_name": "Synthetic Biologics, Inc.",
        "long_name": "Synthetic Biologics, Inc.",
        "summary": "Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Rockville"
    },
    "SYNGENE.NS": {
        "short_name": "SYNGENE INTERNATIO",
        "long_name": "Syngene International Limited",
        "summary": "Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India and internationally. The company offers discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and discovery analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also provides development services in biologics; and carries out exploratory/discovery, In Vitro and Genetic toxicology, and developmental and reproductive, as well as acute, sub-chronic, and chronic toxicity studies. In addition, the company offers chemical and formulation development, polymer research, and analytical services. Further, it provides target identification and validation, lead generation and optimization, lead selection, preclinical development, API, and drug product development services. Additionally, the company offers clinical trial management, PK analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. It also provides bioinformatics research, antibody drug conjugate discovery and development, and oligonucleotide synthesis services. The company serves start-up companies, pharma/biotech, agrochemical, chemical, nutrition, and animal health companies. It has partnerships with Bristol-Myers Squibb Co.; Baxter International Inc.; Amgen Inc.; Zoetis Inc.; GSK; Merck KGaA; Artelo Biosciences, Inc.; PharmAust Limited; HiMedia Laboratories; and Zumutor Biologics. The company was incorporated in 1993 and is based in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.",
        "currency": "INR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NSI",
        "market": "in_market",
        "country": "India",
        "city": "Bengaluru"
    },
    "SYRS": {
        "short_name": "Syros Pharmaceuticals, Inc.",
        "long_name": "Syros Pharmaceuticals, Inc.",
        "summary": "Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "T051.F": {
        "short_name": "TRACON PHARMACEUT.DL-,001",
        "long_name": "TRACON Pharmaceuticals, Inc.",
        "summary": "TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead clinical stage products include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include DE-122, which is in randomized Phase IIa study for the treatment of wet AMD; TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I/II to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in a Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Santen Pharmaceutical Co. Ltd. for the development of carotuximab products for ophthalmology indications; Roswell Park Cancer Institute and Health Research Inc.; Case Western Reserve University; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "San Diego"
    },
    "TA5.F": {
        "short_name": "TARGOVAX ASA  NK -,10",
        "long_name": "Targovax ASA",
        "summary": "Targovax ASA, a clinical stage immuno-oncology company, engages in the development of oncolytic viruses to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102 that is in Phase I/II clinical studies for the treatment of mesothelioma, melanoma, peritoneal disease, and prostate cancer. It also develops neoantigen cancer vaccines targeting tumors with oncogenic RAS\u00c2\u0096mutations. The company has collaboration agreements with Cancer Research Institute, Ludwig Cancer Research, and AstraZeneca to develop ONCOS-102 for peritoneal disease; Sotio to develop ONCOS-102 for prostate cancer; Valo Therapeutics to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Merck & Co., Inc. to evaluate ONCOS-102 in combination with KEYTRUDA in mesothelioma. Targovax ASA is based in Oslo, Norway.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "TAKE.NS": {
        "short_name": "TAKE SOLUTIONS",
        "long_name": "TAKE Solutions Limited",
        "summary": "TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services and solutions in life sciences and supply chain management in the United States, Asia Pacific, and Europe. It offers IP-driven and technology backed solutions, consulting, technology, and functional services across clinical, regulatory, and safety for life sciences industry. The company also provides software solutions related to enterprise mobility, material tracking, value chain collaboration, business services sourcing, trade management, and engineering design for the technology, consumer packaged goods, oil and gas, and automotive sectors. It offers its supply chain management services through a cloud platform, on premise, and through hand-held devices; and engineering services, including engineering, sourcing, and technology services. The company's IP-led approach enables its clients to automate supply chain processes; track, trace, and control at item level; mandate supplier compliance; and streamline material and shipment movement. The company was founded in 2000 and is headquartered in Chennai, India. TAKE Solutions Limited is a subsidiary of TAKE Solutions Pte Ltd.",
        "currency": "INR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NSI",
        "market": "in_market",
        "country": "India",
        "city": "Chennai"
    },
    "TARA": {
        "short_name": "Protara Therapeutics, Inc.",
        "long_name": "Protara Therapeutics, Inc.",
        "summary": "Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "TARS": {
        "short_name": "Tarsus Pharmaceuticals, Inc.",
        "long_name": "Tarsus Pharmaceuticals, Inc.",
        "summary": "Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Irvine"
    },
    "TAUG": {
        "short_name": "TAURIGA SCIENCES INC",
        "long_name": "Tauriga Sciences, Inc.",
        "summary": "Tauriga Sciences, Inc. produces and sells cannabidiol infused chewing gum under the Tauri-Gum brand name. It also develops anti-nausea product. The company sells its products through e-commerce, distributors, and wholesale channels. It has a collaboration agreement with Aegea Biotechnologies, Inc. to develop a rapid, multiplexed COVID-19 (novel coronavirus) test. Tauriga Sciences, Inc. was founded in 2001 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "TBGNF": {
        "short_name": "OXURION",
        "long_name": "Oxurion NV",
        "summary": "Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases and cancer in Belgium and internationally. Its lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of DME that has completed phase 1 clinical trial; THR-687 an integrin antagonist to treat patients with a diabetic eye disease that has completed phase 1 clinical trial; and TB-403, an anti- placental growth factor for the treatment of medulloblastoma, a pediatric malignant brain tumor. It has collaboration agreements with BioInvent International AB, Bicycle Therapeutics, Parexel, INC Research, and Galapagos. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Belgium",
        "city": "Leuven"
    },
    "TBIO": {
        "short_name": "Translate Bio, Inc.",
        "long_name": "Translate Bio, Inc.",
        "summary": "Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Lexington"
    },
    "TBP.TO": {
        "short_name": "TETRA BIO PHARMA INC",
        "long_name": "Tetra Bio-Pharma Inc.",
        "summary": "Tetra Bio-Pharma Inc., a development stage biopharmaceutical company, engages development of cannabinoid-based medicines. It develops drugs for chronic pain, which includes SERENITY for cancer cachexia, which is clinical phase 2; REBORN, drug for breakthrough pain, which is in clinical phase 2; and PLENITUDE for advanced cancer pain, which is clinical phase 1. The company also develops PPP003, drug for painful dry eye and uveitis pain, which is in clinical phase 1; and HCC011 for hepatocellular carcinoma.It has collaboration agreements with Aphria Inc.; IntelGenx Corp.; Panag Pharma Inc.; the University of New Brunswick; and Ovensa Inc. The company also has a co-development partnership with Storz & Bickel for the treatment of fibromyalgia. The company was formerly known as GrowPros Cannabis Ventures Inc. and changed its name to Tetra Bio-Pharma Inc. in September 2016. Tetra Bio-Pharma Inc. is headquartered in Orleans, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Orl\u00c3\u00a9ans"
    },
    "TBPH": {
        "short_name": "Theravance Biopharma, Inc.",
        "long_name": "Theravance Biopharma, Inc.",
        "summary": "Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Cayman Islands",
        "city": "George Town"
    },
    "TBPMF": {
        "short_name": "TETRA BIO PHARMA INC",
        "long_name": "Tetra Bio-Pharma Inc.",
        "summary": "Tetra Bio-Pharma Inc., a development stage biopharmaceutical company, engages development of cannabinoid-based medicines. It develops drugs for chronic pain, which includes SERENITY for cancer cachexia, which is clinical phase 2; REBORN, drug for breakthrough pain, which is in clinical phase 2; and PLENITUDE for advanced cancer pain, which is clinical phase 1. The company also develops PPP003, drug for painful dry eye and uveitis pain, which is in clinical phase 1; and HCC011 for hepatocellular carcinoma.It has collaboration agreements with Aphria Inc.; IntelGenx Corp.; Panag Pharma Inc.; the University of New Brunswick; and Ovensa Inc. The company also has a co-development partnership with Storz & Bickel for the treatment of fibromyalgia. The company was formerly known as GrowPros Cannabis Ventures Inc. and changed its name to Tetra Bio-Pharma Inc. in September 2016. Tetra Bio-Pharma Inc. is headquartered in Orleans, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Orl\u00c3\u00a9ans"
    },
    "TCCR": {
        "short_name": "TRICCAR INC",
        "long_name": "TRICCAR, Inc.",
        "summary": "TRICCAR, Inc. operates as an integrated biomedical research, development, and marketing company. The company develops bioceutical and pharmaceutical products to support the well-being of humans and animals that have common diseases. It is involved in the research, development, and clinical testing of 38 bioceutical formulations designed to support illnesses and diseases, including formulae built around a patented fruit-based calcium supplement; a weight loss and obesity supplement; a formula that helps relieve the symptoms of menopause; a fast-acting blood performance product that separates white and red blood cells; a mental focus formula to enhance attention and recall of information and beneficial to children diagnosed with attention deficit disorder; a mental acuity formula to enhance memory recall and aid in the formation of new memories; and others. The company is based in Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Las Vegas"
    },
    "TCE2.F": {
        "short_name": "CELLDEX THER.  DL-,001",
        "long_name": "Celldex Therapeutics, Inc.",
        "summary": "Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Hampton"
    },
    "TCON": {
        "short_name": "TRACON Pharmaceuticals, Inc.",
        "long_name": "TRACON Pharmaceuticals, Inc.",
        "summary": "TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead clinical stage products include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include DE-122, which is in randomized Phase IIa study for the treatment of wet AMD; TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I/II to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in a Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Santen Pharmaceutical Co. Ltd. for the development of carotuximab products for ophthalmology indications; Roswell Park Cancer Institute and Health Research Inc.; Case Western Reserve University; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "TCRR": {
        "short_name": "TCR2 Therapeutics Inc.",
        "long_name": "TCR2 Therapeutics Inc.",
        "summary": "TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "TECH": {
        "short_name": "Bio-Techne Corp",
        "long_name": "Bio-Techne Corporation",
        "summary": "Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Minneapolis"
    },
    "TENX": {
        "short_name": "Tenax Therapeutics, Inc.",
        "long_name": "Tenax Therapeutics, Inc.",
        "summary": "Tenax Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Morrisville"
    },
    "TF2.F": {
        "short_name": "TAKARA BIO INC.",
        "long_name": "Takara Bio Inc.",
        "summary": "Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Japan",
        "city": "Kusatsu"
    },
    "TFFP": {
        "short_name": "TFF Pharmaceuticals, Inc.",
        "long_name": "TFF Pharmaceuticals, Inc.",
        "summary": "TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company has a research collaboration with the University of Georgia's Center for Vaccines and Immunology (CVI), along with the University of Texas at Austin (UT Austin), to evaluate the immunogenicity of universal influenza vaccines; and cooperative research and development agreement with United States Army Medical Research Institute of Infectious Diseases for use of its thin film freezing technology platform. TFF Pharmaceuticals, Inc. also has a joint development and collaboration agreement with Augmenta Bioworks, Inc. to develop commercial products incorporating Augmenta's human-derived monoclonal antibodies for COVID-19 therapeutics. The company was founded in 2018 and is based in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "TG1N.F": {
        "short_name": "ARMATA PHARMACEUT.",
        "long_name": "Armata Pharmaceuticals Inc.",
        "summary": "Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Marina del Rey"
    },
    "TG4.F": {
        "short_name": "OXURION N.V.",
        "long_name": "Oxurion NV",
        "summary": "Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases and cancer in Belgium and internationally. Its lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of DME that has completed phase 1 clinical trial; THR-687 an integrin antagonist to treat patients with a diabetic eye disease that has completed phase 1 clinical trial; and TB-403, an anti- placental growth factor for the treatment of medulloblastoma, a pediatric malignant brain tumor. It has collaboration agreements with BioInvent International AB, Bicycle Therapeutics, Parexel, INC Research, and Galapagos. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Leuven"
    },
    "TGNA.F": {
        "short_name": "TRANSGENE SA  EO 0,50",
        "long_name": "Transgene SA",
        "summary": "Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. It also has a collaborative research and license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Illkirch-Graffenstaden"
    },
    "TGTX": {
        "short_name": "TG Therapeutics, Inc.",
        "long_name": "TG Therapeutics, Inc.",
        "summary": "TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL); and Ublituximab, an investigational glycoengineered monoclonal antibody that targets a epitope on CD20-expressing B cells for patients with NHL, CLL, and relapsing forms of multiple sclerosis. In addition, the company develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. It is also has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "TILS.L": {
        "short_name": "TIZIANA LIFE SCIENCES PLC ORD 3",
        "long_name": "Tiziana Life Sciences PLC",
        "summary": "Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "TLC": {
        "short_name": "Taiwan Liposome Company, Ltd.",
        "long_name": "Taiwan Liposome Company, Ltd.",
        "summary": "Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III trial for knee osteoarthritis pain. The company's product candidates also comprises TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that is in Phase II clinical trial for post-surgical pain management; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; and TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Taiwan",
        "city": "Taipei"
    },
    "TLOG": {
        "short_name": "TETRALOGIC PHARMACEUTICALS CORP",
        "long_name": "TetraLogic Pharmaceuticals Corporation",
        "summary": "TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Malvern"
    },
    "TLSA": {
        "short_name": "Tiziana Life Sciences plc - Ame",
        "long_name": "Tiziana Life Sciences PLC",
        "summary": "Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "TLX.AX": {
        "short_name": "TELIXPHARM FPO",
        "long_name": "Telix Pharmaceuticals Limited",
        "summary": "Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a development collaboration agreement with ARTMS Products Inc. for the manufacture of its prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET). Telix Pharmaceuticals Limited has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "North Melbourne"
    },
    "TMBR": {
        "short_name": "Timber Pharmaceuticals, Inc.",
        "long_name": "Timber Pharmaceuticals, Inc.",
        "summary": "Timber Pharmaceuticals LLC, a clinical-stage medical dermatology company, focuses on the development and commercialization of pharmaceuticals for treatment of orphan dermatologic diseases. The company was founded in 2019 and is based in Woodcliff Lake, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASE",
        "market": "us_market",
        "country": "United States",
        "city": "Woodcliff Lake"
    },
    "TNG.PA": {
        "short_name": "TRANSGENE",
        "long_name": "Transgene SA",
        "summary": "Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. It also has a collaborative research and license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Illkirch-Graffenstaden"
    },
    "TNGNQ": {
        "short_name": "TENGION INC",
        "long_name": "Tengion, Inc.",
        "summary": "Tengion, Inc. operates as a regenerative medicine company. The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Its product portfolio includes Neo-Kidney Augment to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease; and Neo-Urinary Conduit, which is in Phase I clinical trial and used to replace the use of bowel tissue in bladder cancer patients requiring a non-continent urinary diversion after bladder removal surgery. The company has a license agreement with Children's Medical Center Corporation (CMCC) for the license of certain patent rights and intellectual property rights owned or controlled by CMCC related to tissue engineering technology. Tengion, Inc. was founded in 2003 and is headquartered in Winston-Salem, North Carolina. On December 29, 2014, Tengion, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Winston-Salem"
    },
    "TNXP": {
        "short_name": "Tonix Pharmaceuticals Holding C",
        "long_name": "Tonix Pharmaceuticals Holding Corp.",
        "summary": "Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, manufacturing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 and TNX-2600, which are live replicating attenuated vaccine candidates for the prevention of COVID-19. In addition, the company's lead CNS candidate is TNX-102 SL, a sublingual formulation of cyclobenzaprine, which is in Phase 3 development for fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer's disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR for depression; and TNX-1900 for migraine and cranio-facial pain treatment. Additionally, its preclinical pipeline includes TNX-1600 for posttraumatic stress disorder, depression, and attention deficit hyperactivity disorder; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500 for transplant organ rejection and autoimmune conditions; and TNX-1700 for gastric and pancreatic cancers. The company is headquartered in Chatham, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Chatham"
    },
    "TOMDF": {
        "short_name": "TODOS MEDICAL LIMITED",
        "long_name": "Todos Medical Ltd.",
        "summary": "Todos Medical Ltd., a clinical-stage medical diagnostics company, develops and commercializes blood tests for the detection of immune-related diseases in Israel and internationally. The company develops Total Biochemical Infrared Analysis method, a proprietary method for screening of solid tumors using peripheral blood spectroscopy analysis; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis product includes TM-B1 and TM-B2 for breast cancer blood tests; and TM-C1 for testing of colorectal cancer. The company also imports and distributes personal protective equipment, test kits, and medical devices, such as ventilators. Todos Medical Ltd. has partnership with Moto-Para and Meridian HSN to provide a complete turnkey solution for on-site COVID testing. Todos Medical Ltd. was founded in 2010 and is headquartered in Rehovot, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Rehovot"
    },
    "TPMR.F": {
        "short_name": "TONIX PHARMA.  DL-,001",
        "long_name": "Tonix Pharmaceuticals Holding Corp.",
        "summary": "Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, manufacturing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 and TNX-2600, which are live replicating attenuated vaccine candidates for the prevention of COVID-19. In addition, the company's lead CNS candidate is TNX-102 SL, a sublingual formulation of cyclobenzaprine, which is in Phase 3 development for fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer's disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR for depression; and TNX-1900 for migraine and cranio-facial pain treatment. Additionally, its preclinical pipeline includes TNX-1600 for posttraumatic stress disorder, depression, and attention deficit hyperactivity disorder; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500 for transplant organ rejection and autoimmune conditions; and TNX-1700 for gastric and pancreatic cancers. The company is headquartered in Chatham, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Chatham"
    },
    "TPTX": {
        "short_name": "Turning Point Therapeutics, Inc",
        "long_name": "Turning Point Therapeutics, Inc.",
        "summary": "Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-na\u00c3\u00afve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "TQB.F": {
        "short_name": "IMMUNOPRECISE ANTIBOD.",
        "long_name": "ImmunoPrecise Antibodies Ltd.",
        "summary": "ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Fargo"
    },
    "TRGNF": {
        "short_name": "TRANSGENE",
        "long_name": "Transgene SA",
        "summary": "Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. It also has a collaborative research and license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Illkirch-Graffenstaden"
    },
    "TRIL": {
        "short_name": "Trillium Therapeutics Inc.",
        "long_name": "Trillium Therapeutics Inc.",
        "summary": "Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "Canada",
        "city": "Mississauga"
    },
    "TRIL.TO": {
        "short_name": "TRILLIUM THERAPEUTICS INC",
        "long_name": "Trillium Therapeutics Inc.",
        "summary": "Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "TOR",
        "market": "ca_market",
        "country": "Canada",
        "city": "Mississauga"
    },
    "TRPXY": {
        "short_name": "THERAPIX BIOSCIENCES LTD SPON A",
        "long_name": "SciSparc Ltd.",
        "summary": "Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. Therapix Biosciences Ltd. has a collaboration with The University of Calgary to evaluate the analgesic effect of Therapix's CB2R agonist proprietary drug candidate, THX-160. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Givatayim"
    },
    "TRVI": {
        "short_name": "Trevi Therapeutics, Inc.",
        "long_name": "Trevi Therapeutics, Inc.",
        "summary": "Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Its Haduvio (nalbuphine ER), which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. The company was founded in 2011 and is headquartered in New Haven, Connecticut.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New Haven"
    },
    "TRVN": {
        "short_name": "Trevena, Inc.",
        "long_name": "Trevena, Inc.",
        "summary": "Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Chesterbrook"
    },
    "TRVX.OL": {
        "short_name": "TARGOVAX ASA",
        "long_name": "Targovax ASA",
        "summary": "Targovax ASA, a clinical stage immuno-oncology company, engages in the development of oncolytic viruses to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102 that is in Phase I/II clinical studies for the treatment of mesothelioma, melanoma, peritoneal disease, and prostate cancer. It also develops neoantigen cancer vaccines targeting tumors with oncogenic RAS\u00c2\u0096mutations. The company has collaboration agreements with Cancer Research Institute, Ludwig Cancer Research, and AstraZeneca to develop ONCOS-102 for peritoneal disease; Sotio to develop ONCOS-102 for prostate cancer; Valo Therapeutics to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Merck & Co., Inc. to evaluate ONCOS-102 in combination with KEYTRUDA in mesothelioma. Targovax ASA is based in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "TRX.L": {
        "short_name": "TISSUE REGENIX GROUP PLC ORD 0.",
        "long_name": "Tissue Regenix Group plc",
        "summary": "Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, Cardiac, and GBM-V divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from biological tissues, the patient's cells can repopulate and colonise, creating new, like-for-like tissue, which is recognized and accepted by the body by reducing the risk of rejection, and stimulating a natural healing process. It also offers BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for orthopaedics, trauma, and woundcare; and SurgiPure XD, a Decellularised xenograft tissue for the repair of hernias and/or body wall defects, which require the use of reinforcing or buttressing material to obtain the desired surgical outcome. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; and develops CardioPure product. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Garforth"
    },
    "TRYP.CN": {
        "short_name": "TrypTherapeutic",
        "long_name": "Tryp Therapeutics Inc.",
        "summary": "Tryp Therapeutics Inc., a pharmaceutical company, focuses on developing compounds with known activity and/or safety profiles for the treatment of rare or orphan diseases and other diseases with high unmet medical needs. The company's lead development program is psilocybin-for-neuropsychiatry, or PFN, which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its program candidates include TRP-8802 that has indication for fibromyalgia, a condition characterized by pain that is chronic and widespread; and TRP-1001, an oral formulation of razoxane evaluating for the treatment of soft tissue sarcoma. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was founded in 2019 and is headquartered in Kelowna, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Kelowna"
    },
    "TSHA": {
        "short_name": "Taysha Gene Therapies, Inc.",
        "long_name": "Taysha Gene Therapies, Inc.",
        "summary": "Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Dallas"
    },
    "TTNP": {
        "short_name": "Titan Pharmaceuticals, Inc.",
        "long_name": "Titan Pharmaceuticals, Inc.",
        "summary": "Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "TUB.BR": {
        "short_name": "TUBIZE-FIN",
        "long_name": "Financi\u00e8re de Tubize SA",
        "summary": "Financi\u00c3\u00a8re de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financi\u00c3\u00a8re de Tubize S.A. is based in Brussels, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Belgium",
        "city": "Brussels"
    },
    "TXTM": {
        "short_name": "PROTEXT MOBILITY INC",
        "long_name": "ProText Mobility, Inc.",
        "summary": "ProText Mobility, Inc., a biotech company, engages in the development of pharmaceutical botanical medicines. Its medicines are formulated with highly-bioavailable plant extracts. The company is based in Boca Raton, Florida. ProText Mobility, Inc. is a subsidiary of Planda\u00c3\u00ad Biotechnology, Inc.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Boca Raton"
    },
    "TYME": {
        "short_name": "Tyme Technologies, Inc.",
        "long_name": "Tyme Technologies, Inc.",
        "summary": "Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "UAVP.F": {
        "short_name": "ORAGENICS INC.  DL-,001",
        "long_name": "Oragenics, Inc.",
        "summary": "Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against dental caries, or tooth decay. Oragenics, Inc. has collaboration agreements with Precigen, Inc. and its subsidiary, Intrexon Actobiotics NV to develop AG013; and a license agreement with LPThera LLC to develop LPT3-04. It also has a process development and drug substance manufacturing agreement with Avid Bioservices, Inc. for coronavirus vaccine. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Tampa"
    },
    "UBX": {
        "short_name": "Unity Biotechnology, Inc.",
        "long_name": "Unity Biotechnology, Inc.",
        "summary": "Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase II clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee; UBX1325, which is Phase I clinical trial for the treatment of diabetic macular edema; and UBX1967 for the treatment of ophthalmologic diseases. It is also developing programs in pulmonary disorders and neurological disorders, as well as kidney and liver diseases. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "UCB.BR": {
        "short_name": "UCB",
        "long_name": "UCB SA",
        "summary": "UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company offers Evenity for the treatment of osteoporosis; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 for immunology; and UCB0599 for neurology; and UCB0107 for progressive supranuclear palsy. Additionally, the company engages in contract manufacturing activities. It has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company was founded in 1928 and is headquartered in Brussels, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "Belgium",
        "city": "Brussels"
    },
    "UCB.VI": {
        "short_name": "UCB",
        "long_name": "UCB SA",
        "summary": "UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company offers Evenity for the treatment of osteoporosis; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 for immunology; and UCB0599 for neurology; and UCB0107 for progressive supranuclear palsy. Additionally, the company engages in contract manufacturing activities. It has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company was founded in 1928 and is headquartered in Brussels, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Belgium",
        "city": "Brussels"
    },
    "UCBJF": {
        "short_name": "UCB S.A.",
        "long_name": "UCB SA",
        "summary": "UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company offers Evenity for the treatment of osteoporosis; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 for immunology; and UCB0599 for neurology; and UCB0107 for progressive supranuclear palsy. Additionally, the company engages in contract manufacturing activities. It has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company was founded in 1928 and is headquartered in Brussels, Belgium.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Belgium",
        "city": "Brussels"
    },
    "UCBJY": {
        "short_name": "UCB S.A.",
        "long_name": "UCB SA",
        "summary": "UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company offers Evenity for the treatment of osteoporosis; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 for immunology; and UCB0599 for neurology; and UCB0107 for progressive supranuclear palsy. Additionally, the company engages in contract manufacturing activities. It has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company was founded in 1928 and is headquartered in Brussels, Belgium.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Belgium",
        "city": "Brussels"
    },
    "UKJ.F": {
        "short_name": "OPTHEA LTD",
        "long_name": "Opthea Limited",
        "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "South Yarra"
    },
    "UKJ2.F": {
        "short_name": "OPTHEA LTD (SP.ADR/8)",
        "long_name": "Opthea Limited",
        "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "South Yarra"
    },
    "UNC.F": {
        "short_name": "UCB S.A.",
        "long_name": "UCB SA",
        "summary": "UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company offers Evenity for the treatment of osteoporosis; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 for immunology; and UCB0599 for neurology; and UCB0107 for progressive supranuclear palsy. Additionally, the company engages in contract manufacturing activities. It has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company was founded in 1928 and is headquartered in Brussels, Belgium.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Belgium",
        "city": "Brussels"
    },
    "UR8.F": {
        "short_name": "UROGEN PHARMA LTD IS -,01",
        "long_name": "UroGen Pharma Ltd.",
        "summary": "UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Princeton"
    },
    "UR9.F": {
        "short_name": "CLINUVEL PHARMACEUTICALS",
        "long_name": "Clinuvel Pharmaceuticals Limited",
        "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PR\u00c3\u0089NUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "UR9A.F": {
        "short_name": "CLINUVEL PHARMAC.ADRS1",
        "long_name": "Clinuvel Pharmaceuticals Limited",
        "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PR\u00c3\u0089NUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Melbourne"
    },
    "URGN": {
        "short_name": "UroGen Pharma Ltd.",
        "long_name": "UroGen Pharma Ltd.",
        "summary": "UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Princeton"
    },
    "UROV": {
        "short_name": "Urovant Sciences Ltd.",
        "long_name": "Urovant Sciences Ltd.",
        "summary": "Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "USRM": {
        "short_name": "U S STEM CELL INC",
        "long_name": "U.S. Stem Cell, Inc.",
        "summary": "U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is based in Sunrise, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Sunrise"
    },
    "UTH.F": {
        "short_name": "UTD THERAP. (DEL.) DL-,01",
        "long_name": "United Therapeutics Corporation",
        "summary": "United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Silver Spring"
    },
    "UTHR": {
        "short_name": "United Therapeutics Corporation",
        "long_name": "United Therapeutics Corporation",
        "summary": "United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Silver Spring"
    },
    "UXI4.F": {
        "short_name": "CYCLACEL PHARM.  DL-,001",
        "long_name": "Cyclacel Pharmaceuticals, Inc.",
        "summary": "Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Berkeley Heights"
    },
    "V7B1.F": {
        "short_name": "ASSEMBLY BIOSCIENCES",
        "long_name": "Assembly Biosciences, Inc.",
        "summary": "Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs; and a collaboration and option agreement with Door Pharmaceuticals, LLC focused on the development of a hepatitis B virus core protein modulators. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "V7B1.SG": {
        "short_name": "Assembly Biosciences Inc. Regis",
        "long_name": "Assembly Biosciences, Inc.",
        "summary": "Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs; and a collaboration and option agreement with Door Pharmaceuticals, LLC focused on the development of a hepatitis B virus core protein modulators. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "VACC.OL": {
        "short_name": "VACCIBODY AS",
        "long_name": "Vaccibody AS",
        "summary": "Vaccibody AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of melanoma, lung, head and neck, renal, and bladder; and VB10.16, a therapeutic DNA vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. The company has clinical collaboration agreements with Roche and Nektar Therapeutics. Vaccibody AS was founded in 2007 and is based in Oslo, Norway.",
        "currency": "NOK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "OSL",
        "market": "no_market",
        "country": "Norway",
        "city": "Oslo"
    },
    "VAL.L": {
        "short_name": "VALIRX PLC ORD 0.1P",
        "long_name": "ValiRx plc",
        "summary": "ValiRx plc, a biotechnology oncology focused company, engages in developing novel therapeutics and associated biomarkers for cancer in the United Kingdom. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the treatment of women with endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a candidate produced by GeneICE technology platform to modulate BCl2 expression \u00c2\u0096 implicated in cancers. ValiRx plc has collaboration agreement with Oncolytika Limited and Black Cat Bio Limited to develop and evaluate BC201 for patients suffering a hyperimmune response to Coronavirus SARS-CoV2 infection. The company was incorporated in 2000 and is based in Hatfield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Hatfield"
    },
    "VBIO": {
        "short_name": "VITALITY BIOPHARMA INC",
        "long_name": "Vitality Biopharma, Inc.",
        "summary": "Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of inflammatory disorders in the United States. The company is developing tetrahydrocannabinol glycoside (VBX-100), an oral cannabinoid prodrug for inflammatory bowel disease and irritable bowel syndromes. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. was founded in 2007 and is headquartered in Los Angeles, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Los Angeles"
    },
    "VBIV": {
        "short_name": "VBI Vaccines, Inc.",
        "long_name": "VBI Vaccines Inc.",
        "summary": "VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome; and a partnership with Syneos Health, Inc. for the commercialization of VBI's 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "VBIZF": {
        "short_name": "VIVA BIOTECH HOLDINGS",
        "long_name": "Viva Biotech Holdings",
        "summary": "Viva Biotech Holdings provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company develops structure based drug discovery, fragment based drug discovery, affinity selection mass spectrometry screening, and membrane protein targeted drug discovery platforms. The company's products include cell lines, crystal structures, GPCR proteins, antibodies, and proteins. It also offers EFS, gene-to-protein and gene-to-structure, viva engine for lead discovery, medicinal chemistry, in vitro pharmacology, and antibody discovery services. Viva Biotech Holdings was founded in 2008 and is headquartered in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Shanghai"
    },
    "VBLT": {
        "short_name": "Vascular Biogenics Ltd.",
        "long_name": "Vascular Biogenics Ltd.",
        "summary": "Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase 3 clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase 1/2 clinical trials for recurrent platinum-resistant ovarian cancer, as well as in Phase 2 clinical trials to treat GI tumors and has completed phase 2 clinical trial for the treatment of thyroid cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. Further, the company is developing VB-201, a Lecinoxoid-based compound used to treat atherosclerosis that has completed phase II clinical, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 and 611 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Israel",
        "city": "Hevel Modi'in"
    },
    "VBS.AX": {
        "short_name": "VECTUS BIO FPO",
        "long_name": "Vectus Biosystems Limited",
        "summary": "Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that improves speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was founded in 2005 and is based in Rosebery, Australia.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ASX",
        "market": "au_market",
        "country": "Australia",
        "city": "Rosebery"
    },
    "VCC2.F": {
        "short_name": "BRICKELL BIOTECH  DL-,01",
        "long_name": "Brickell Biotech, Inc.",
        "summary": "Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boulder"
    },
    "VCEL": {
        "short_name": "Vericel Corporation",
        "long_name": "Vericel Corporation",
        "summary": "Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "VCNX": {
        "short_name": "Vaccinex, Inc.",
        "long_name": "Vaccinex, Inc.",
        "summary": "Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Rochester"
    },
    "VCYT": {
        "short_name": "Veracyte, Inc.",
        "long_name": "Veracyte, Inc.",
        "summary": "Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and a collaboration with Johnson & Johnson Services, Inc. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "VERU": {
        "short_name": "Veru Inc.",
        "long_name": "Veru Inc.",
        "summary": "Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. In addition, the company's drug candidates include Enobosarm, an oral selective androgen receptor agonist that targets the androgen receptor positive, estrogen receptor positive, and human epidermal growth factor receptor 2 metastatic breast cancer without the unwanted virilizing side effects. Further, it is advancing a new drug formulation in its specialty pharmaceutical pipeline addressing unmet medical needs in urology, such as Tadalafil and Finasteride Combination. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Miami"
    },
    "VGLS": {
        "short_name": "VG LIFE SCIENCES INC",
        "long_name": "VG Life Sciences Inc.",
        "summary": "VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Santa Barbara"
    },
    "VIAP": {
        "short_name": "VIA PHARMACEUTICALS INC",
        "long_name": "VIA Pharmaceuticals, Inc.",
        "summary": "VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company's drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases. VIA Pharmaceuticals, Inc. has two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonist; and multiple compounds from preclinical DGAT1 metabolic disorders program. The company was founded in 2004 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "VIBI": {
        "short_name": "VILACTO BIO INC",
        "long_name": "Vilacto Bio Inc.",
        "summary": "Vilacto Bio Inc. operates as a biotech company in Denmark. The company holds a patented molecule license, known as the Lactoactive molecule for the treatment of inflammatory diseases, diabetics, psoriasis, and skin issues in various levels. It markets a line of skin care products, including lotions, skin care creams and gels, lip balms, foot creams and oils, and other items through its Website, vilacto.com. The company was formerly known as Zlato, Inc. and changed its name to Vilacto Bio Inc. in April 2017. Vilacto Bio Inc. was founded in 2013 and is headquartered in Naestved, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "N\u00c3\u00a6stved"
    },
    "VICO.ST": {
        "short_name": "Vicore Pharma Holding AB",
        "long_name": "Vicore Pharma Holding AB (publ)",
        "summary": "Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), diffuse systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; and license agreement with Nanologica AB (publ). The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Gothenburg"
    },
    "VIE": {
        "short_name": "Viela Bio, Inc.",
        "long_name": "Viela Bio, Inc.",
        "summary": "Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sj\u00c3\u00b6gren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Gaithersburg"
    },
    "VINC": {
        "short_name": "Vincerx Pharma, Inc.",
        "long_name": "Vincera Pharma, Inc.",
        "summary": "Vincera Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in clinical trials. Its drug candidates are in development for the treatment of solid tumors, leukemia, B-cell malignancies, lymphomas, and myelodysplastic syndrome. Vincera Pharma, Inc. is based in Santa Clara, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Palo Alto"
    },
    "VINCU": {
        "short_name": "Vincerx Pharma, Inc.",
        "long_name": "Vincera Pharma, Inc.",
        "summary": "Vincera Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in clinical trials. Its drug candidates are in development for the treatment of solid tumors, leukemia, B-cell malignancies, lymphomas, and myelodysplastic syndrome. Vincera Pharma, Inc. is based in Santa Clara, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Palo Alto"
    },
    "VIR": {
        "short_name": "Vir Biotechnology, Inc.",
        "long_name": "Vir Biotechnology, Inc.",
        "summary": "Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "San Francisco"
    },
    "VIRI": {
        "short_name": "Virios Therapeutics, Inc.",
        "long_name": "Virios Therapeutics, LLC",
        "summary": "Virios Therapeutics, LLC, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, LLC in July 2020. Virios Therapeutics, LLC was founded in 2012 and is headquartered in Alpharetta, Georgia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Alpharetta"
    },
    "VIU1.SG": {
        "short_name": "Vivus Inc. Registered Shares o.",
        "long_name": "VIVUS, Inc.",
        "summary": "VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Campbell"
    },
    "VKTX": {
        "short_name": "Viking Therapeutics, Inc.",
        "long_name": "Viking Therapeutics, Inc.",
        "summary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "San Diego"
    },
    "VLA.PA": {
        "short_name": "VALNEVA",
        "long_name": "Valneva SE",
        "summary": "Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease and single-shot vaccine against chikungunya. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company has collaboration with Dynavax Technologies Corporation to advance vaccine development for COVID-19. Valneva SE was incorporated in 1999 and is headquartered in Nantes, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Nantes"
    },
    "VM4.F": {
        "short_name": "VANDA PHARMAC.INC.DL-,001",
        "long_name": "Vanda Pharmaceuticals Inc.",
        "summary": "Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt\u00c2\u00ae (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Washington"
    },
    "VNDA": {
        "short_name": "Vanda Pharmaceuticals Inc.",
        "long_name": "Vanda Pharmaceuticals Inc.",
        "summary": "Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt\u00c2\u00ae (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "Washington"
    },
    "VNTA": {
        "short_name": "VENTANA BIOTECH INC",
        "long_name": "Ventana Biotech, Inc.",
        "summary": "Ventana Biotech, Inc., a development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. The company focuses in the areas of anti-obesity and related illnesses. The company holds rights for the formula for a medicament containing chewing gum with a composition of the extract of hoodia gordonii and 2-hydroxyoleic acid for the treatment of obesity, hypertension, and other metabolic disorders. The company develops appetite suppressant chewing gums, including the low dosage product for the over-the-counter market and the high dosage product for distribution by pharmacists. It intends to market low dosage product though drug and health food stores. The company was formerly known as Personalica, Inc. and changed its name to Ventana Biotech, Inc. in October 2008. Ventana Biotech, Inc. was founded in 1989 and is based in Butschwil, Switzerland.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Switzerland",
        "city": "Butschwil"
    },
    "VOQP": {
        "short_name": "VIOQUEST PHARMACEUTICALS INC",
        "long_name": "VioQuest Pharmaceuticals, Inc.",
        "summary": "VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company's products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors. VioQuest Pharmaceuticals also provides chiral products, technology, and custom synthesis development services to pharmaceutical and fine chemical companies in various stages of a products' lifecycle. The company was founded in 2000 and is headquartered in Basking Ridge, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Basking Ridge"
    },
    "VPA1.F": {
        "short_name": "AVEO PHARMA.NEW DL-,001",
        "long_name": "AVEO Pharmaceuticals, Inc.",
        "summary": "AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. AVEO Pharmaceuticals, Inc. has collaboration and license agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Kirin Co., Ltd. It has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "VPRO": {
        "short_name": "VIROPRO INC",
        "long_name": "Viropro Inc.",
        "summary": "Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis. It manufactures biologics drugs, including bio-similars for pre-clinical, and Phase I, II, and III clinical trials; offers its clients with supply of mammalian cell proteins, such as monoclonal antibodies or recombinant proteins, or other cell-derived products; owns three clones that include two in insulin therapy and one for cancer therapy; and provides contractual research and manufacturing services to biotech and biopharmaceutical companies. The company's contractual work activities include cloning, sequencing, purifying, developing, validating, and producing biopharmaceutical products and sub-products. It has operations in Canada, the United Kingdom, and Malaysia. Viropro Inc. has collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products. The company is based in San Jose, California. Viropro Inc. is a subsidiary of Alpha Biologics Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "San Jose"
    },
    "VRCA": {
        "short_name": "Verrica Pharmaceuticals Inc.",
        "long_name": "Verrica Pharmaceuticals Inc.",
        "summary": "Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica Pharmaceuticals Inc. was founded in 2013 and is headquartered in West Chester, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United States",
        "city": "West Chester"
    },
    "VRCI": {
        "short_name": "VERDE SCIENCE INC",
        "long_name": "Verde Science, Inc.",
        "summary": "Verde Science, Inc., a pharmaceutical research and development company, focuses on developing a portfolio of cannabinoid based prescription medicines for various medical conditions. The company was formerly known as Rango Energy, Inc. and changed its name to Verde Science, Inc. in May 2014. Verde Science, Inc. was founded in 2007 and is based in Dallas, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Dallas"
    },
    "VRDN": {
        "short_name": "Viridian Therapeutics, Inc.",
        "long_name": "Viridian Therapeutics, Inc.",
        "summary": "Viridian Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boulder"
    },
    "VRNA": {
        "short_name": "Verona Pharma plc",
        "long_name": "Verona Pharma plc",
        "summary": "Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "VRTX": {
        "short_name": "Vertex Pharmaceuticals Incorpor",
        "long_name": "Vertex Pharmaceuticals Incorporated",
        "summary": "Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "VRTX.MX": {
        "short_name": "VERTEX PHARMACEUTICAL",
        "long_name": "Vertex Pharmaceuticals Incorporated",
        "summary": "Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United States",
        "city": "Boston"
    },
    "VRTX.VI": {
        "short_name": "VERTEX PHARMACEUTICALS INC",
        "long_name": "Vertex Pharmaceuticals Incorporated",
        "summary": "Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "United States",
        "city": "Boston"
    },
    "VRTX34.SA": {
        "short_name": "VERTEX PHARMDRN",
        "long_name": "Vertex Pharmaceuticals Incorporated",
        "summary": "Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",
        "currency": "BRL",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SAO",
        "market": "br_market",
        "country": "United States",
        "city": "Boston"
    },
    "VSBC": {
        "short_name": "VITASPRING BIOMEDICAL CO LTD",
        "long_name": "VitaSpring Biomedical Co. Ltd.",
        "summary": "VitaSpring Biomedical Co. Ltd. focuses on the development of drugs of cell medicine. The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. in February 17, 2020. VitaSpring Biomedical Co. Ltd. Was incorporated in 2016 and is headquartered in Irvine, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Irvine"
    },
    "VSTM": {
        "short_name": "Verastem, Inc.",
        "long_name": "Verastem, Inc.",
        "summary": "Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is based in Needham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Needham"
    },
    "VTGN": {
        "short_name": "VistaGen Therapeutics, Inc.",
        "long_name": "VistaGen Therapeutics, Inc.",
        "summary": "VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "VTVT": {
        "short_name": "vTv Therapeutics Inc.",
        "long_name": "vTv Therapeutics Inc.",
        "summary": "vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "High Point"
    },
    "VVY.AS": {
        "short_name": "VIVORYON",
        "long_name": "Vivoryon Therapeutics N.V.",
        "summary": "Vivoryon Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development products is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics AG has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology. The company was formerly known as Probiodrug AG and changed its name to Vivoryon Therapeutics AG in June 2019. Vivoryon Therapeutics AG was founded in 1997 and is headquartered in Halle, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "AMS",
        "market": "nl_market",
        "country": "Germany",
        "city": "Halle"
    },
    "VX1.F": {
        "short_name": "VERTEX PHARMAC.  DL-,01",
        "long_name": "Vertex Pharmaceuticals Incorporated",
        "summary": "Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boston"
    },
    "VXL.V": {
        "short_name": "VAXIL BIO LTD",
        "long_name": "Vaxil Bio Ltd.",
        "summary": "Vaxil Bio Ltd., an immunotherapy biotech company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "VXLLF": {
        "short_name": "VAXIL BIO LTD (CA)",
        "long_name": "Vaxil Bio Ltd.",
        "summary": "Vaxil Bio Ltd., an immunotherapy biotech company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Toronto"
    },
    "VXRT": {
        "short_name": "Vaxart, Inc. - Common Stock",
        "long_name": "Vaxart, Inc.",
        "summary": "Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. Vaxart, Inc. is headquartered in South San Francisco, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "South San Francisco"
    },
    "VYGR": {
        "short_name": "Voyager Therapeutics, Inc.",
        "long_name": "Voyager Therapeutics, Inc.",
        "summary": "Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "VYNE": {
        "short_name": "VYNE Therapeutics Inc.",
        "long_name": "VYNE Therapeutics Inc.",
        "summary": "VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is headquartered in Bridgewater, New Jersey.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Bridgewater"
    },
    "WBIO.CN": {
        "short_name": "WPDPharma",
        "long_name": "WPD Pharmaceuticals Inc.",
        "summary": "WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious disease. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat CNS tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of GBM, melanoma, and other cancers that is in the pre-clinical trial; and Annamycin to treat AML and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is based in Vancouver, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Vancouver"
    },
    "WEK.F": {
        "short_name": "ZIOPHARM ONCOLOGY DL-,001",
        "long_name": "ZIOPHARM Oncology, Inc.",
        "summary": "ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Boston"
    },
    "WINT": {
        "short_name": "Windtree Therapeutics, Inc.",
        "long_name": "Windtree Therapeutics, Inc.",
        "summary": "Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Warrington"
    },
    "WIZP": {
        "short_name": "WIZE PHARMA INC",
        "long_name": "Wize Pharma, Inc.",
        "summary": "Wize Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the treatment of ophthalmic disorders. It has in-license rights to purchase, market, sell, and distribute LO2A for the treatment of dry eye syndrome (DES) and other ophthalmological illnesses, including Conjunctivochalasis and Sj\u00c3\u00b6gren's syndrome (Sj\u00c3\u00b6gren's) in the United States and other territories. The company is also conducting a Phase IV study for LO2A for DES in patients with Sj\u00c3\u00b6gren's. The company was formerly known as Star Night Technologies Ltd. and changed its name to Wize Pharma, Inc. in July 2015. Wize Pharma, Inc. was founded in 1982 and is headquartered in Hod Hasharon, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Israel",
        "city": "Hod HaSharon"
    },
    "WVE": {
        "short_name": "Wave Life Sciences Ltd.",
        "long_name": "Wave Life Sciences Ltd.",
        "summary": "Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Singapore",
        "city": "Singapore"
    },
    "WWHC": {
        "short_name": "W WORLD CORP",
        "long_name": "W World Corp.",
        "summary": "W World Corp., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat a range of metabolic and nervous system disorders. The company focuses on the disorders of the brain-gut axis, pain/inflammation, and autoimmune, as well as gout disorders. Its lead compounds under clinically development include Levotofisopam, a non-sedating agent for the treatment of Gout; and Dextofisopam, a non-serotonergic agent, which has completed Phase IIa and Phase IIb clinical trials for the treatment of irritable bowel syndrome. The company was founded in 1990 and is headquartered in North Las Vegas, Nevada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "North Las Vegas"
    },
    "WXIBF": {
        "short_name": "WUXI BIOLOGICS (CAYMAN) INC",
        "long_name": "WuXi Biologics (Cayman) Inc.",
        "summary": "WuXi Biologics (Cayman) Inc., an investment holding company, operates as an open-access technology platform company that provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology; international sales contracting services; testing and development of testing technologies; provision of biologics clinical and manufacturing services provision of sales and marketing services in the United States; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. In addition, it provides clinical and commercial manufacturing, assay, formulation and process development, process validation, lot release testing, stability studies, drug product formulation, fill and finish, and regulatory support services for recombinant protein, monoclonal antibodies, and antibody drug conjugates. The company serves pharmaceutical and biotechnology companies. It has strategic partnerships with Amicus Therapeutics; ABL Bio; NBE-Therapeutics; I-Mab Biopharma; NovoCodex Biopharmaceuticals Co., Ltd.; Almirall; Antengene Corporation; and Arcus Biosciences, Inc. The company was founded in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Wuxi"
    },
    "WXXWY": {
        "short_name": "WUXI BIOLOGICS (CAYMAN) INC",
        "long_name": "WuXi Biologics (Cayman) Inc.",
        "summary": "WuXi Biologics (Cayman) Inc., an investment holding company, operates as an open-access technology platform company that provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology; international sales contracting services; testing and development of testing technologies; provision of biologics clinical and manufacturing services provision of sales and marketing services in the United States; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. In addition, it provides clinical and commercial manufacturing, assay, formulation and process development, process validation, lot release testing, stability studies, drug product formulation, fill and finish, and regulatory support services for recombinant protein, monoclonal antibodies, and antibody drug conjugates. The company serves pharmaceutical and biotechnology companies. It has strategic partnerships with Amicus Therapeutics; ABL Bio; NBE-Therapeutics; I-Mab Biopharma; NovoCodex Biopharmaceuticals Co., Ltd.; Almirall; Antengene Corporation; and Arcus Biosciences, Inc. The company was founded in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Wuxi"
    },
    "X0M1.F": {
        "short_name": "XOMA CORP.  DL -,0005",
        "long_name": "XOMA Corporation",
        "summary": "XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "EmeryVille"
    },
    "XBIO": {
        "short_name": "Xenetic Biosciences, Inc.",
        "long_name": "Xenetic Biosciences, Inc.",
        "summary": "Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Framingham"
    },
    "XBIT": {
        "short_name": "XBiotech Inc.",
        "long_name": "XBiotech Inc.",
        "summary": "XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. Its product candidates include 514G3, an anti-infective antibody that is in Phase II clinical trial for the treatment of Staphylococcus Aureus infections; and other anti-infectious disease antibodies, which are in pre-clinical development to treat Clostridium Difficile, influenza, Ebola, and Herpes Varicella Zoster (Chickenpox). XBiotech Inc. has a collaboration with BioBridge Global for the development of potential COVID 19 treatment based on natural antibodies from recovered patients. The company was founded in 2005 and is headquartered in Austin, Texas.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Austin"
    },
    "XBRANE.ST": {
        "short_name": "Xbrane Biopharma AB",
        "long_name": "Xbrane Biopharma AB (publ)",
        "summary": "Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and neck, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars and additional biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "XCUR": {
        "short_name": "Exicure, Inc.",
        "long_name": "Exicure, Inc.",
        "summary": "Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes AST-008 that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA\u00c2\u0096based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; and XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is based in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Chicago"
    },
    "XE9.F": {
        "short_name": "XENCOR INC.  DL-,01",
        "long_name": "Xencor, Inc.",
        "summary": "Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; Amgen Inc.; Catalent Pharma Solutions LLC.; Janssen Biotech, Inc.; MorphoSys AG; Incyte Corporation; and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Monrovia"
    },
    "XENE": {
        "short_name": "Xenon Pharmaceuticals Inc.",
        "long_name": "Xenon Pharmaceuticals Inc.",
        "summary": "Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Canada",
        "city": "Burnaby"
    },
    "XENO": {
        "short_name": "XENO TRANSPLANTS CORPORATION",
        "long_name": "Xeno Transplants Corporation",
        "summary": "Xeno Transplants Corporation operates as a bio-technology research and development company. The company, through a license agreement with Massachusetts General Hospital, intends to develop, manufacture, distribute, and use products and processes for public use with regard to xenotransplantation. The Xenotransplantation is intended to address the problems arising from the limited supply of available human cells, tissues, and organs for transplantation by developing technologies to permit the transplantation of cells, tissues, and organs from other species into humans, such as swine. Xeno Transplants Corporation was incorporated in 2004 and is based in Brookline, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Brookline"
    },
    "XERS": {
        "short_name": "Xeris Pharmaceuticals, Inc.",
        "long_name": "Xeris Pharmaceuticals, Inc.",
        "summary": "Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Chicago"
    },
    "XFOR": {
        "short_name": "X4 Pharmaceuticals, Inc.",
        "long_name": "X4 Pharmaceuticals, Inc.",
        "summary": "X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenstr\u00c3\u00b6m macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "XINT.ST": {
        "short_name": "Xintela AB",
        "long_name": "Xintela AB (publ)",
        "summary": "Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing Xintela Assay for Cell Therapy (XACT), an analytical test for cell therapy. It also offers XSTEM-OA, a stem cell-based product for the treatment of osteoarthritis in humans. In addition, the company develops stem cell-based products for animals. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Lund"
    },
    "XLRN": {
        "short_name": "Acceleron Pharma Inc.",
        "long_name": "Acceleron Pharma Inc.",
        "summary": "Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Cambridge"
    },
    "XLS.F": {
        "short_name": "XLIFE SCIENCES AG  SF 1",
        "long_name": "Xlife Sciences AG",
        "summary": "Xlife Sciences AG focuses on the development of life sciences technologies. The company's projects and pipeline include biotech/therapies and technology platforms for antibody therapy, including obesity, acute myeloid leukemia, and acute lymphocytic leukemia; nanovesikel therapy comprising arthritis, MS, and ALS; painkiller solution; screening technology of antibodies; and modification of antibodies and breakdown of polygeny (genetics). Its projects and pipeline also include medical technology and artificial intelligence comprising 3D bioprinting for life; medical technology comprising reprocessing of instruments of surgical robots; medical devices for the early detection of dementia and Parkinson's disease; development of bile duct implants; and analysis software (AI) for the diagnosis/evaluation of X-ray and MRI images for early detection of prostate cancer. The company is headquartered in Zurich, Switzerland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Switzerland",
        "city": "Z\u00c3\u00bcrich"
    },
    "XLS.MU": {
        "short_name": "XLIFE SCIENCES AG  SF 1",
        "long_name": "Xlife Sciences AG",
        "summary": "Xlife Sciences AG focuses on the development of life sciences technologies. The company's projects and pipeline include biotech/therapies and technology platforms for antibody therapy, including obesity, acute myeloid leukemia, and acute lymphocytic leukemia; nanovesikel therapy comprising arthritis, MS, and ALS; painkiller solution; screening technology of antibodies; and modification of antibodies and breakdown of polygeny (genetics). Its projects and pipeline also include medical technology and artificial intelligence comprising 3D bioprinting for life; medical technology comprising reprocessing of instruments of surgical robots; medical devices for the early detection of dementia and Parkinson's disease; development of bile duct implants; and analysis software (AI) for the diagnosis/evaluation of X-ray and MRI images for early detection of prostate cancer. The company is headquartered in Zurich, Switzerland.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "Switzerland",
        "city": "Z\u00c3\u00bcrich"
    },
    "XMPA.F": {
        "short_name": "PLUS THERAPEUTICS",
        "long_name": "Plus Therapeutics, Inc.",
        "summary": "Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Austin"
    },
    "XNCR": {
        "short_name": "Xencor, Inc.",
        "long_name": "Xencor, Inc.",
        "summary": "Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; Amgen Inc.; Catalent Pharma Solutions LLC.; Janssen Biotech, Inc.; MorphoSys AG; Incyte Corporation; and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Monrovia"
    },
    "XOMA": {
        "short_name": "XOMA Corporation",
        "long_name": "XOMA Corporation",
        "summary": "XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "EmeryVille"
    },
    "XP0.F": {
        "short_name": "XENON PHARMACEUTICALS",
        "long_name": "Xenon Pharmaceuticals Inc.",
        "summary": "Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Canada",
        "city": "Burnaby"
    },
    "XRP1.F": {
        "short_name": "SILENCE THERAPEUT. LS-,05",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "XRP2.F": {
        "short_name": "SILENCE THERAP. SP.ADR/1",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "XRTXF": {
        "short_name": "XORTX THERAPEUTICS INC",
        "long_name": "XORTX Therapeutics Inc.",
        "summary": "XORTX Therapeutics Inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. It has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. The company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. In addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. The company has a strategic alliance with Teijin Pharma Limited to develop TMX-049, a xanthine oxidoreductase; and a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Calgary, Canada.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Canada",
        "city": "Calgary"
    },
    "XRX.CN": {
        "short_name": "XORTXTherap",
        "long_name": "XORTX Therapeutics Inc.",
        "summary": "XORTX Therapeutics Inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. It has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. The company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. In addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. The company has a strategic alliance with Teijin Pharma Limited to develop TMX-049, a xanthine oxidoreductase; and a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Calgary, Canada.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CNQ",
        "market": "ca_market",
        "country": "Canada",
        "city": "Calgary"
    },
    "XSNX": {
        "short_name": "NOVACCESS GLOBAL INC",
        "long_name": "NovAccess Global Inc.",
        "summary": "NovAccess Global Inc. engages in the design, sale, and installation of solar photovoltaic (PV) power generation, energy storage, and energy use management technologies in the United States. It company provides project assessment and installation services, including technology selection, system engineering, procurement, permission, construction, grid connection, warranty, system monitoring, and maintenance. The company also offers various energy production and management technologies, and energy storage systems. It serves commercial and residential solar PV markets. The company was formerly known as XsunX, Inc. and changed its name to NovAccess Global Inc. in August 2020. NovAccess Global Inc. was founded in 1997 and is based in Chesterland, Ohio.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United States",
        "city": "Chesterland"
    },
    "XSPRAY.ST": {
        "short_name": "Xspray Pharma AB",
        "long_name": "Xspray Pharma AB (publ)",
        "summary": "Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was founded in 2003 and is based in Solna, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "city": "Solna"
    },
    "XTLB": {
        "short_name": "XTL Biopharmaceuticals Ltd.",
        "long_name": "XTL Biopharmaceuticals Ltd.",
        "summary": "XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Israel",
        "city": "Ramat Gan"
    },
    "XUP.F": {
        "short_name": "GENFIT S.A.  EO -,25",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Loos"
    },
    "XUP.SG": {
        "short_name": "Genfit S.A. Actions au Port. EO",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "France",
        "city": "Loos"
    },
    "XUPB.MU": {
        "short_name": "GENFIT S.A.  ADR/1 EO-,25",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "France",
        "city": "Loos"
    },
    "XYNO": {
        "short_name": "XYNOMIC PHARMACEUTICALS HLDGS I",
        "long_name": "Xynomic Pharmaceuticals Holdings, Inc.",
        "summary": "Xynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "city": "Shanghai"
    },
    "YAG2.F": {
        "short_name": "ATOSSA THERAPEU. DL -,015",
        "long_name": "Atossa Therapeutics, Inc.",
        "summary": "Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Seattle"
    },
    "YAG2.SG": {
        "short_name": "Atossa Genetics Inc. Registered",
        "long_name": "Atossa Therapeutics, Inc.",
        "summary": "Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United States",
        "city": "Seattle"
    },
    "YB4P.F": {
        "short_name": "SAVARA INC.  DL-,001",
        "long_name": "Savara Inc.",
        "summary": "Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; Phase IIa development stage for treating nontuberculous mycobacterial (NTM) lung infection; and in Phase IIa development stage for the treatment of NTM lung infection in people living with cystic fibrosis. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III development stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Austin"
    },
    "YBOC.F": {
        "short_name": "TENAX THERAPEUTICS DL-,01",
        "long_name": "Tenax Therapeutics, Inc.",
        "summary": "Tenax Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "Morrisville"
    },
    "YDO1.F": {
        "short_name": "MADRIGAL PHARMAC.  DL-,01",
        "long_name": "Madrigal Pharmaceuticals, Inc.",
        "summary": "Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) \u00c3\u009f-selective agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). It is also developing MGL-3745, a THR-\u00c3\u009f-selective small molecule that is in preclinical trials for the treatment of NASH and hyperlipidemia. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United States",
        "city": "West Conshohocken"
    },
    "YMAB": {
        "short_name": "Y-mAbs Therapeutics, Inc.",
        "long_name": "Y-mAbs Therapeutics, Inc.",
        "summary": "Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "New York"
    },
    "YMTX": {
        "short_name": "Yumanity Therapeutics, Inc.",
        "long_name": "Yumanity Therapeutics, Inc.",
        "summary": "Yumanity Therapeutics Inc. discovers and develops disease-modifying therapies for neurodegenerative diseases. It focuses on discovering disease-modifying therapies for patients with Parkinson's, amyotrophic lateral sclerosis, and Alzheimer's diseases. The company concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding. Yumanity Therapeutics Inc. has a strategic research collaboration and license agreement with Merck. The company was founded in 2014 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "YP1A.F": {
        "short_name": "IMMUTEP LTD ADRS II/10",
        "long_name": "Immutep Limited",
        "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as \u00c2\u0091eftilagimod alpha' or \u00c2\u0091efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "YP1B.F": {
        "short_name": "IMMUTEP LTD",
        "long_name": "Immutep Limited",
        "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as \u00c2\u0091eftilagimod alpha' or \u00c2\u0091efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Australia",
        "city": "Sydney"
    },
    "YP2A.F": {
        "short_name": "BIOLIN.RX S.ADR 15 IL-,01",
        "long_name": "BioLineRx Ltd.",
        "summary": "BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's TECENTRIQ (Atezolizumab) in Phase 1b/2 studies for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Israel",
        "city": "Hevel Modi'in"
    },
    "ZIOP": {
        "short_name": "ZIOPHARM Oncology Inc",
        "long_name": "ZIOPHARM Oncology, Inc.",
        "summary": "ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United States",
        "city": "Boston"
    },
    "ZVA.F": {
        "short_name": "CELLECTIS NOM.  EO-,05",
        "long_name": "Cellectis S.A.",
        "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "ZVAA.F": {
        "short_name": "CELLECTIS SP.ADR 1 EO-,05",
        "long_name": "Cellectis S.A.",
        "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    }
}